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X 
  ﻠﺨﺺﺴﺘاﻟﻤ
  اﻟﺨﻠﻔﻴﺔ 
 اﻟﻘﻠﺐ هﻮ اﻟﺘﻨﺒﺆ ﺑﺨﻄﻮرة اﻣѧﺮاض اﻟﻘﻠѧﺐ اﻟﻤﺆدﻳѧﺔ اﻟѧﻲ اﻟﻤѧﻮت ﻗﺎتﺳﺮﻋﺔ دﻳﻌﺘﺒﺮ اﻻﺳﺘﻌﻤﺎل اﻻآﺜﺮ ﺷﻴﻮﻋًﺎ ﻟﺘﻐﻴﺮات 
 وﻟﻜﻦ ﺑﺪأ اﺳﺘﻌﻤﺎل هѧﺬا اﻟﻔﺤѧﺺ ﻓѧﻲ اﻟѧﺴﻨﻮات اﻻﺧﻴѧﺮة ﻟﻤﻌﺮﻓѧﺔ اﺳѧﺒﺎب اﻟﺘﻌﻠѧﻞ اﻟﻤﺮﺗﺒﻄѧﺔ ﺑѧﺎﺧﺘﻼل ﻘﻠﺒﻴﻪﺑﺤﺔ اﻟ ﺬﻣﺜﻞ اﻟ 
 اﻟﻘﻠѧﺐ  اﻟﺪراﺳﺎت اﻟﺘѧﻲ اﺟﺮﻳѧﺖ ﻓѧﻲ ﻣѧﺮض اﻟﺮﺑѧﻮ  اﻟѧﺸﻌﺒﻲ  و اﻟﻤﺮﺗﺒﻄѧﺔ ﺑﺘﻐﻴѧﺮات ﻧﻈѧﻢ .اﻟﺠﻬﺎز اﻟﻌﺼﺒﻲ اﻟﻼ ارادي 
ﺎﻳﺔ وذات ﻧﺘﺎﺋﺞ ﻣﺘﺒﺎﻳﻨﺔ ﻳﻤﻜﻦ ﺗﻔﺴﻴﺮهﺎ ﺑﺈﺧﺘﻼف اﻟﺘﺤﻜﻢ اﻟﻌѧﺼﺒﻲ اﻟѧﻼاردي ﻟﻤﺨﺘﻠѧﻒ ﻣﺮﺿѧﻲ اﻟﺮﺑѧﻮ اﻟѧﺸﻌﺒﻲ ﻐﻗﻠﻴﻠﺔ ﻟﻠ 
  .أو اﺧﺘﻼف ﻃﺮق اﻟﺒﺤﺚ ﻟﺘﻠﻚ اﻟﺪراﺳﺎت 
  اﻻهﺪاف 
 ﻣﺮﺿѧﻲ ﺰﻴﻴﺣﺴﺎب ﻣﻌﺪل ﻣﻌﺘﻤﺪ ﻋﻠﻲ ﻗﻴﺎﺳﺎت وﻇﺎﺋﻒ اﻟﺮﺋﺔ ﻳﻤﻜﻨﻪ ﻋﻜﺲ اﻟﺘﻬﻮﻳﺔ اﻟﺮﺋﻮﻳﺔ ﺑﺼﻮرة ﻣﻤﺘﺎزة و ﺗﻤ  .1
  . ﻣﻦ ﻏﻴﺮهﻢاﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ
و ﺗѧﺼﻨﻴﻒ اﻟﺒﺮﻧѧﺎﻣﺞ اﻟﻘѧﻮﻣﻲ ﻟﻠﻮﻗﺎﻳѧﺔ ﻣѧﻦ اﻟﺮﺑѧﻮ  ( TCA)ﻣﻌﺮﻓﺔ ﻗﺪرة وﺻﻼﺣﻴﺔ اﺧﺘﺒѧﺎر ﺗﺤﻜѧﻢ اﻟﺮﺑѧﻮ اﻟѧﺸﻌﺒﻲ  .2
   .ﻓﻲ اﻟﺘﻨﺒﺆ ﺑﺤﺪة اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ اﻋﺘﻤﺎدًا ﻋﻠﻲ اﻟﻤﻌﺪل اﻟﻤﺬآﻮر اﻋﻼﻩ( PPEAN)اﻟﺸﻌﺒﻲ 
 ﻬﻮﻳѧﺔ اﻟﺮﺋﻮﻳѧﺔ و ﻣѧﻊ ﻣﻘѧﺎﻳﻴﺲ اﻟﺘ ( PPEAN & TCA) اﻟﺮﺑѧﻮ اﻟѧﺸﻌﺒﻲ اﻟﻤѧﺬآﻮرة ﺪةﺷѧ ﻣﻌﺮﻓѧﺔ ارﺗﺒѧﺎط ﻣﻌѧﺎﻳﻴﺮ  .3
  . اﻟﺘﺤﻜﻢ اﻟﻌﺼﺒﻲ اﻟﻼاراديﻣﺆﺷﺮات
 اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ ﻓﻴﻤﺎ ﻳﺘﻌﻠﻖ ﺑﺒﻌﺾ اﻟﻤﻌﺎﻳﻴﺮ اﻟﺘѧﻲ ﻳѧﺘﺤﻜﻢ ﻓﻴﻬѧﺎ ﻰﻣﻌﺮﻓﺔ ﻃﺮق اﻟﺘﺤﻜﻢ اﻟﻌﺼﺒﻲ اﻟﻼاردي ﻓﻲ ﻣﺮﺿ  .4
  .اﻟﺠﻬﺎز اﻟﻮدي وﺟﺎر اﻟﻮدي ﻣﺜﻞ ﺿﻐﻂ اﻟﺪم و ﺗﺮآﻴﺰ اﻟﺴﻜﺮ ﻓﻲ اﻟﺪم
  اﻟﻄﺮق
ﺗﻢ ﺗﻘѧﺴﻴﻢ ﻣﺮﺿѧﻲ اﻟﺮﺑѧﻮ . ﺒﻲ ﻣﻦ ﻧﻔﺲ اﻟﻌﻤﺮ و اﻟﺠﻨﺲ  ﻣﺮﻳﺾ رﺑﻮ ﺷﻌ 001 ﺻﺤﻴﺢ و 65اﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻓﻲ 
ﺗﻢ ﻗﻴﺎس ﺿﻐﻂ اﻟﺪم، اﻻﻧﺜﺮوﺑѧﻮﻣﻴﺘﺮي ، وﻇѧﺎﺋﻒ اﻟﺮﺋѧﺔ . PPEAN & TCA ﻋﻠﻲ ًااﻟﺸﻌﺒﻲ اﻟﻲ ﻣﺠﻤﻮﻋﺎت اﻋﺘﻤﺎد
، ﺗﻐﻴѧﺮات ﻧﻈѧѧﻢ اﻟﻘﻠѧѧﺐ، اﻧѧѧﻮاع اﻟﻌﻘѧѧﺎرات ، ﻣﻌѧѧﺪل اﻟﻬﻴﻤѧѧﻮﻗﻠﺒﻴﻦ و اﻟﺠﻠﻜѧѧﻮز و اﻻﻟﻜﺘﺮوﻟﻴѧѧﺖ ﻓѧѧﻲ اﻟѧѧﺪم ﻟﻜѧѧﻞ ﻓѧѧﺮد ﺗﺤѧѧﺖ 
ﺑﺈﺳѧﺘﺨﺪام اﻟﺪاﻟѧﺔ  ( SAD )ﻢ آﻞ ﻣﻘﺎﻳﻴﺲ وﻇﺎﺋﻒ اﻟﺮﺋﺔ ﻓﻲ ﻣﻌﺪل واﺣﺪ ﻣﻤﺜѧﻞ ﻟﻬѧ ﻜﺪﻳﺲﺎء ﻟﺘ اﺳﺘﺨﺪم اﻻﺣﺼ . اﻟﺪراﺳﺔ
ﻲ ﻨѧ  و ﻣﻘﺎﻳﻴﺲ وﻇﺎﺋﻒ اﻟﺮﺋﺔ اﻻﺧѧﺮي ﺑﻮاﺳѧﻄﺔ اﺧﺘﺒѧﺎر اﻟﺤѧﺴﺎﺳﻴﺔ و اﻟﺨѧﺼﻮﺻﻴﺔ و ﻣﻨﺤ SADﻓﺤﺺ ال . اﻟﺘﻤﻴﻴﺰﻳﺔ
ﺎل  اﺧﺘﺒѧﺮت ﻣﺨﺘﻠѧﻒ اﻟﻤﺘﻐﻴѧﺮات ﺗﺤѧﺖ ﻣﺠѧ . ﻟﻤﻌﺮﻓﺔ ﻣﻘﺪرة هﺬﻩ اﻟﻤﻌﺎﻳﻴﺮ ﻓﻲ ﺗﺸﺨﻴﺺ ﻣﺮﺿѧﻲ اﻟﺮﺑѧﻮ اﻟѧﺸﻌﺒﻲ COR
اﻟﺪراﺳﺔ ﻟﻮﺟﻮد ارﺗﺒﺎﻃﺎت أو إﺧﺘﻼﻓﺎت وﺳﻄﻴﺔ ﻣﻬﻤﺔ ﺑﻴﻦ ﻣﺮﺿﻲ اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ و اﻻﺻﺤﺎء ﻣﻊ اﻻﺧﺬ ﻓﻲ اﻻﻋﺘﺒѧﺎر 
  .ﻋﻮاﻣﻞ اﻻﻋﻼل اﻟﺘﻲ ﻗﺪ ﺗﺆﺛﺮ ﻋﻠﻲ ﺗﻠﻚ اﻟﻌﻼﻗﺎت
  اﻟﻨﺘﺎﺋﺞ
ﻋﻨѧﺪ ﻣﻘﺎرﻧѧﺔ (.  ﻟﻠﻜѧﻞ 000.0 = P )SADوﺟѧﺪت ارﺗﺒﺎﻃѧﺎت ﻣﻬﻤѧﺔ ﺑѧﻴﻦ ﻣﻘѧﺎﻳﻴﺲ وﻇѧﺎﺋﻒ اﻟﺮﺋѧﺔ و  :وﻇѧﺎﺋﻒ اﻟﺮﺋѧﻪ 
آﻤﻘﻴѧﺎس ﻟﺤѧﺪة اﻟﺮﺑѧﻮ اﻟѧﺸﻌﺒﻲ وﺟѧﺪ أن  ( %1VEF) ﻓѧﻲ اﻟﺜﺎﻧﻴѧﺔ اﻻوﻟѧﻲ ي اﻻﻗѧﺼﻰ ﺮﻴѧ ﻓﺰﺤﺠѧﻢ اﻟ اﻟ  ﻣﻊ ﻧѧﺴﺒﺔ SAD
 و SAD ل% 41.49)و ﺧѧѧﺼﻮﺻﻴﺔ    ( %1VEFل % 17 و SAD ل% 18)اﻻول أآﺜѧѧﺮ ﺣѧѧﺴﺎﺳﻴﺔ هѧѧﻲ 
ﻟﻠﻤﺰﻳѧѧﺪ ﻣѧѧﻦ اﻟﺘﺄآѧѧﺪ ﺗѧѧﻢ ﻓﺤѧѧﺺ . %1VEF( ل 58.87 و SADل % 45.68)وﺻѧѧﺤﺔ  ( %1VEFل % 68.29
 أآﺜﺮ ﺣﺴﺎﺳﻴﺔ ﻣѧﻦ ﺑѧﺎﻗﻲ ﻣﻘѧﺎﻳﻴﺲ وﻇѧﺎﺋﻒ اﻟﺮﺋѧﺔ ﻓѧﻲ ﺗѧﺸﺨﻴﺺ SADﺣﻴﺚ وﺟﺪ أن  COR ﺑﻮاﺳﻄﺔ ﻣﻨﺤﻨﻲ  SAD
  (.179.0 -798.0 و ﺣﺪود ﺛﻘﺔ 91-E77.2 = P ،   339.0اﻟﻤﺴﺎﺣﺔ ﺗﺤﺖ اﻟﻤﻨﺤﻲ )ﻣﺮض اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ 
IX 
ﻏﻴﺮ ﻣﺘﺤﻜﻤѧﻴﻦ ﺗﻤﺎﻣѧًﺎ % 14 ﺑﺪون اﻋﺮاض ﻣﻦ ذوي اﻟﺘﺤﻜﻢ اﻟﻀﻌﻴﻒ ﻟﻠﺮﺑﻮ اﻟﺸﻌﺒﻲ و ﻣﻦ اﻟﻤﺮﺿﻲ % 43وﺟﺪ أن 
ﺮﺿﻲ ﺑѧѧﺪون ـﻤѧѧـ ﻓѧѧﻲ اﻟPPEANو ﺗѧѧﺪﻧﻲ ( TCA) اﻟѧѧﻲ ارﺗﻔѧѧﺎع ﻣﻌѧѧﺪل اﺧﺘﺒѧѧﺎر ﺗﺤﻜѧѧﻢ اﻟﺮﺋѧѧﺔ ﻬѧѧﺬا اﻟﻤѧѧﺮض إﺿѧѧﺎﻓﺔ ﺑ
 SAD(.  ﻋﻠѧﻲ اﻟﺘѧﻮاﻟﻲ500.0 & 000.0 = P)ﺮﺿﻲ ذوي اﻻﻋѧﺮاض اﻟﺮﺑﻮﻳѧﺔ ـѧـﻤـﺎرﻧﺔ ﻣѧﻊ اﻟـѧـﺮاض ﻣﻘـѧـاﻋ
  (. ﻟﻼﺛﻨﻴﻦ000.0 = P )PPEAN و TCAﻮرة ﺟﻴﺪة ﻣﻊ ﻣﻌﺪل ـــﻣﺮﺗﺒﻂ ﺑﺼ
ﺒѧﻴﻂ اﻟﺠـѧـﻬﺎز ﺜذوي اﻻﻋﺮاض اﻟﺨﻔﻴﻔﺔ ﺑﻨﺸﺎط اﻟﺠـﻬﺎز ﺟѧﺎر اﻟѧﻮدي و ﺗ  اﻟﻤﺮﺿﻲ ﺰ ﻳﺘﻤﻴ : اﻟﻘﻠﺐ ﺳﺮﻋﺔ دﻗﺎت ﺗﻐﻴﺮات 
ﺑﻴﻨﻤﺎ ﻻﻳﻮﺟﺪ اﺧﺘﻼف ﻳﺬآﺮ ﺑﻴﻦ اﻟﻤﺮﺿﻲ (  ﻋﻠﻲ اﻟﺘﻮاﻟﻲ 510.0 & 020.0 = P)اﻟﻮدي ﻣﻘﺎرﻧﺔ ﻣﻊ ﻋﻴﻨﺔ اﻟﺘﺤﻜـــﻢ 
 ﻣѧﻦ (.  ﻋﻠѧﻲ اﻟﺘѧﻮاﻟﻲ 998.0 & 797.0 = P)اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ اﻟﺸﺪﻳﺪ و اﻻﺻﺤﺎء ﻓﻴﻤﺎ ﻳﺨﺘﺺ ﺑﻨﺸﺎط هﺬﻳﻦ اﻟﺠﻬﺎزﻳﻦ 
ﺑѧﺼﻮرة ﺿѧﻌﻴﻔﺔ ﻣѧﻊ ﻣﺆﺷѧﺮي اﻟﺠﻬѧﺎز اﻟѧﻮدي و ﺟѧﺎر ( TCA) ﺟﻬﺔ اﺧﺮي ﻳﺮﺗﺒﻂ اﻟﺘﺤﻜﻢ ﻓﻲ ﻣﺮض اﻟﺮﺑѧﻮ اﻟѧﺸﻌﺒﻲ 
  .(200 .0 , 300.0 = P  & 903.0 ,292.0 = CC)اﻟﻮدي 
 اﻟѧﺪم ﻣﺘﻮﺳѧﻂ ﺿѧﻐﻂ ﻌﻜﺲ ﻣﺘﻮﺳﻂ ﺿﻐﻂ اﻟﺪم و ﺿﻐﻂ اﻟﺪم اﻻﻧﻘﺒﺎﺿѧﻲ ﻓѧﺈن ﺑ :ﺿﻐﻂ اﻟﺪم و ﺗﺮآﻴﺰ اﻟﺠﻠﻜﻮز ﻓﻲ اﻟﺪم 
ﺑﻴﻨﻤѧﺎ ﻳﻮﺟѧﺪ ارﺗﺒѧﺎط ﻣﻮﺟѧﺐ ﺑѧﻴﻦ ( 200.0 = P)ﻟﺮﺑѧﻮ اﻟѧﺸﻌﺒﻲ ﻣﻘﺎرﻧѧﺔ ﺑﻌﻴﻨѧﺔ اﻟѧﺘﺤﻜﻢ اﻻﻧﺒﺴﺎﻃﻲ اآﺜѧﺮ ﻓѧﻲ ﻣﺮﺿѧﻲ ا 
ﻓѧﻲ (  ﻟﻠﻜѧﻞ 50.0 < P) ﻣﻊ ﻣﺆﺷﺮ ﻧﺸﺎط اﻟﺠﻬﺎز ﺟﺎر اﻟﻮدي وارﺗﺒﺎط ﺳﺎﻟﺐ اﻟﻮدي ﻧﺸﺎط اﻟﺠﻬﺎزﺿﻐﻂ اﻟﺪم وﻣﺆﺷﺮ 
  .اﻟﺸﻌﺒﻲاﻻﺻﺤﺎء و ﻟﻴﺲ ﻣﺮﺿﻲ اﻟﺮﺑﻮ 
وﻳѧﺮﺗﺒﻂ  ﺳѧﻠﺒًﺎ ﻣѧﻊ ( 000.0 = P)ﻲ اﻻﺻѧﺤﺎء ﺗﺮآﻴﺰ اﻟﺠﻠﻜﻮز ﻓﻲ اﻟﺪم ﻟﻤﺮﺿﻲ اﻟﺮﺑﻮ اﻟѧﺸﻌﺒﻲ اآﺒѧﺮ ﻣѧﻦ ﺗﺮآﻴѧﺰﻩ ﻓѧ 
ﻣﺆﺷѧﺮ ﻧѧﺸﺎط اﻟﺠﻬѧﺎز اﻟѧﻮدي و اﻳﺠﺎﺑѧًﺎ ﻣѧﻊ ﻣﺆﺷѧﺮ ﻧѧﺸﺎط اﻟﺠﻬѧﺎز ﺟѧﺎر اﻟѧﻮدي ﻓѧﻲ اﻻﺻѧﺤﺎء و ﻟѧﻴﺲ ﻣﺮﺿѧﻲ اﻟﺮﺑѧﻮ 
  . اﻟﺸﻌﺒﻲ 
  اﻟﺨﻼﺻﺔ
 أآﺜѧѧﺮ ﺣѧѧﺴﺎﺳﻴﺔ و ﺧѧѧﺼﻮﺻﻴﺔ و ﺻѧѧﺤﺔ ﻣﻘﺎرﻧѧѧﺔ ﻣѧѧﻊ ﺑѧѧﺎﻗﻲ ﻣﻘѧѧﺎﻳﻴﺲ وﻇѧѧﺎﺋﻒ اﻟﺮﺋѧѧﺔ وﻟﻜﻨѧѧﻪ آﺒѧѧﺎﻗﻲ SADﻳﻌﺘﺒѧѧﺮ  .1
  .ﺳﻴﺔ و ﺧﺼﻮﺻﻴﺔ ﻓﻴﻤﺎ ﻳﺘﻌﻠﻖ ﺑﺘﺸﺨﻴﺺ اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲﺣﺴﺎ% 001اﻟﻤﻘﺎﻳﻴﺲ ﻟﻢ ﻳﺤﻘﻖ 
ة ﺪﺷѧ وﺟﻮد أو إﺧﺘﻔﺎء أﻋѧﺮاض اﻻزﻣѧﺔ ﻻ ﻳﻌﻜѧﺲ اﻟѧﺘﺤﻜﻢ ﻓѧﻲ اﻟﻤѧﺮض اﻟѧﺸﺊ اﻟѧﺬي ﻳﺠѧﺐ اﻋﺘﺒѧﺎرﻩ ﻓѧﻲ ﺗѧﺼﻨﻴﻒ  .2
 . اﻟﺸﻌﺒﻰﻮاﻟﺮﺑ
زﻳﺎدة ﻧﺸﺎط اﻟﺠﻬﺎز ﺟﺎر اﻟﻮدي و ﻧﻘﺼﺎن ﻧѧﺸﺎط اﻟﺠﻬѧﺎز )اﻟﺘﺤﻜﻢ اﻟﻌﺼﺒﻲ اﻟﻼارادي ﻓﻲ ﺣﺎﻻت اﻻزﻣﺔ اﻟﺨﻔﻴﻔﺔ  .3
 (.  ﻟﻠﺠﻬﺎز اﻟﻮدي و ﺟﺎر اﻟﻮديﻃﺒﻴﻌﻲﻧﺸﺎط )ﻋﻦ ﺣﺎﻻت اﻻزﻣﺔ اﻟﺸﺪﻳﺪة ﻳﺨﺘﻠﻒ ( اﻟﻮدي
 . أﻋﺮاض اﻟﺮﺑﻮ اﻟﺸﻌﺒﻲ وﻟﻴﺲ ﻋﻠﻲ اﻟﺘﻬﻮﻳﺔ اﻟﺮﺋﻮﻳﺔﺪةﺷﻗﺪ ﻳﺆﺛﺮ اﻟﺘﺤﻜﻢ اﻟﻌﺼﺒﻲ اﻟﻼارادي ﻋﻠﻲ  .4
 ﻋﻠѧﻲ ﺗﻐﻴﻴѧﺮ ﻧﻤѧﻂ ﺗﺤﻜѧﻢ اﻟﺠﻬѧﺎز اﻟﻌѧﺼﺒﻲ ( ﺿѧﻐﻂ اﻟѧﺪم اﻻﻧﺒѧﺴﺎﻃﻲ و ﺗﺮآﻴѧﺰ اﻟﺠﻠﻜѧﻮز )هﻨﺎﻟѧﻚ ﻋѧﺪة ﻣﺆﺷѧﺮات .5
  .ﻟﺮﺑﻮ اﻰاﻟﻼارادي ﻓﻲ ﻣﺮﺿ
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ABSTRACT 
Background 
HRV is widely accepted to have prognostic significance in patients with 
cardiovascular diseases especially after acute myocardial infarction. However, 
recently, interest has grown in relating some pathologies with abnormal autonomic 
activity based on HRV studies. Although asthmatics are known to have enhanced 
cholinergic activity, little HRV studies were done on asthma patients. Moreover, the 
results of these studies are not reproducible, probably due to inter-individual 
differences of autonomic balance in test group or inadequately designed methods.  
Objectives 
1. To develop an effective spirometric score that can faithfully reflect ventilatory 
functions of the lungs and efficiently discriminating asthmatics from non-
asthmatics  
2. To detect reliability and validity of Asthma Control Test (ACT) and National 
Asthma Education and Prevention Program (NAEPP) in the classification of 
studied asthmatic patients based on above-mentioned spirometric score. 
3. To correlate asthma control (using ACT and NAEPP) and ventilatory function 
with parameters of autonomic balance.  
4. To detect the pattern of autonomic balance in asthmatics using a parameter known 
to be influenced by sympathetic and parasympathetic e.g. airways narrowing 
indicated by spirometry, blood pressure and blood glucose concentration.  
Methods 
The study involved 56 apparently healthy subjects and gender and an age matched 
group of 100 asthma patients classified into subgroups according to asthma severity 
using ACT and NAEPP classifications. Blood pressure, anthropometric, spirometric, 
HRV measurements together with drug therapy, blood level of glucose, hemoglobin 
and electrolytes were assessed for every subject. All spirometric measurements were 
condensed into one representative score (discrimination analysis score (DAS)) using 
discrimination analysis. Sensitivity and specifity of DAS were tested using 
conditional ratios and Receiver Operating Characteristic (ROC) curve. Screening of 
studied variables for significant correlations and mean differences among different 
groups with adjustment for possible confounding factors was performed using 
appropriate statistical techniques. 
 XIII
Results   
Spirometry: Correlations between all spirometric measurements and DAS were 
highly significant (P = 0.000 for all correlations). DAS when compared with FEV1% 
(at the most accurate cutoff equal to 80%) as a predictive measurement for presence 
of asthma, is proved to be more sensitive (81.00% for DAS and 71.00% for FEV1%), 
specific (94.14% for DAS and 92.86% for FEV1%) and accurate (86.54% for DAS 
and 78.85% for FEV1%). For further verification, accuracy of DAS was compared 
with the remaining of spirometric measurements using ROC curves. DAS is proved to 
be the most sensitive measure in diagnosing asthma (area under the curve = 0.933, P = 
2.77E-19 and 95% confidence interval 0.897 - 0.971).  
Of asymptomatic asthma patients, 34.0 % were labeled poorly controlled and 41.5% 
were labeled uncontrolled. ACT score was higher while NAEPP class was lower in 
symptoms free compared with symptomatic asthmatic patients (P = 0.000 and 0.005 
respectively). DAS correlate significantly, but moderately, with ACT score and 
NAEPP class (P = 0.000 for both, CC = 0.38 and -0.49 respectively).  
Heart Rate Variability: Sympathetic tone (LF Norm) of mild asthmatics was 
significantly lower while parasympathetic tone (HF Norm) was significantly higher 
compared with apparently healthy subjects (P = 0.016 and 0.017 respectively). This 
was also true when mild asthmatics are compared with severe asthma patients (P = 
0.020 and 0.015 respectively). ACT state of asthmatics correlate significantly, but 
weakly, with LF Norm (CC = 0.292, P = 0.003) and HF Norm (CC = 0.309, P = 
0.002). 
Blood Pressure and Blood Glucose Concentration: In contrast to systolic and mean 
arterial blood pressures, diastolic blood pressure was significantly higher in 
asthmatics compared with non-asthmatics (P = 0.002). Blood pressures correlate 
positively with sympathetic and negatively with parasympathetic activity in non-
asthmatics (P < 0.05 for all). However, these correlations are lost in asthmatics.  
Blood glucose concentrations in asthmatic patients were significantly higher as 
compared with healthy subjects (P = 0.000). Blood glucose concentrations correlate 
positively with parasympathetic and negatively with sympathetic in non-asthmatics (P 
< 0.05 for all). Nevertheless, these correlations are lost in asthmatic patients. 
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Conclusions 
1. DAS is more sensitive, specific and accurate compared with other spirometric 
measurements, but like other indicators it fails to reach 100% sensitivity and 
specifity on asthma diagnosis. 
2. Presence or absence of symptoms did not correlate with asthma control which 
draws attention to asthma classification criteria. 
3. The autonomic balance of mild asthma (showing high parasympathetic and low 
sympathetic activities) is different compared to the severe form of the disease 
(which showed normal parasympathetic and sympathetic activities).  
4. Autonomic balance might influence symptomatology but not ventilatory function 
5. Many signs of functional impairment (control of blood pressure and blood glucose 
concentrations) of the autonomic nervous system are noted in asthmatic patients.  
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CHAPTER ONE  
INTRODUCTION 
Over the past three decades, significant advances were made in the research, 
diagnosis, and treatment of cardiovascular diseases. Such progress was in every 
sphere of cardiology including non-invasive technologies. Interpretive 
electrocardiography is one of the areas where the progress has been significant. This 
involves digital recording of cardiac signals at the body surface and subsequent 
computerized analysis. One such non-invasive field is heart rate variability (HRV), 
which is widely accepted to have prognostic significance in patients with 
cardiovascular diseases especially after acute myocardial infarction (Bigger et al 1993 
and Malik et al 1990). This is because HRV represents one of the most helpful 
markers of autonomic balance and hence can predict the tendency to develop fatal 
arrhythmias (Task Force of the ESC and NASPE 1996).  
Recently, interest has grown in relating some pathologies with abnormal autonomic 
nervous system (ANS) activity based on HRV studies, for example: hypertension 
(Schroede et al 2003 and Pikkujämsä et al 1998), diabetes mellitus (Bernardi et al 
1992 and Ewing et al 1984), tetraplegia (Guzzetti  et al 1994 and Inoue et al 1990), 
renal failure (Ranpuria et al 2008, Wen1 et al  2007 and Tsai et al 2002), irritable 
bowel syndrome (Heitkemper et al 2001) and anxiety (Gehi et al  2005).  
Although enhanced cholinergic activity of asthmatics has been established at least 
four decades ago (Simonsson et al 1967 and Molfino et al 1993), little HRV studies 
were done on asthma patients (Garrard et al 2005, Du et al 2001 and Kazuma et al 
1997). Moreover, the results of these studies are not reproducible, probably due to 
inter-individual differences of autonomic balance in test groups or inadequacy of 
methods. This study will take into account careful classification of asthma severity, its 
control and duration as well as the duration of HRV recording. 
Previous researches on HRV of asthmatics considered asthma severity at the time of 
the studies without special concern for the disease control. The present study consider 
asthma activity over the last month prior to patients evaluations using internationally 
valid and reliable tests, namely Asthma Control Test (ACT) score and National 
Asthma Education and Prevention Program (NAEPP) classification (Eleftherios et al 
2008, Schatz et al 2007, NAEPP Expert Panel report III 2007 and Schatz et al 2003).  
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Almost all previous studies relied on comparison between healthy controls and 
asthmatics divided into groups according to the asthma severity. The results were 
based on t-test and/or analysis of variance (ANOVA). None of these studies 
correlated HRV parameters with spirometric measurements. Therefore, in the present 
study, an especially designed score that can effectively reflect ventilatory function is 
derived to test for significant correlations between airways narrowing and activities of 
the sympathetic and parasympathetic systems. This will clarify the effect of enhanced 
cholinergic activity in asthmatics and whether it directly worsens asthma by 
increasing airways resistance. Furthermore, the relationship between asthma severity 
and HRV will be elucidated without being hampered by the subjectivity of symptoms 
as measure of asthma activity (Apter1994, Kikuchi 1994, Blanc 1993 and Bailey et al 
1992). 
Most studies on HRV of asthmatics were based on 24-hour HRV recordings. 
Although long-term HRV looks more attractive, it may be less effective in 
determining the relation between autonomic balance and asthma activity. This is 
because asthma activity is extremely labile and can change throughout the day 
(Toungoussova et al 2007, Graziani et al 2004 and Hetzel 1998). Other determinants 
of heart rhythm are similarly not constant during the day e.g. respiratory rate (Hirsch 
and Bishop 1981) and blood pressures (Schroeder et al 2003, Lucini et al 2002 and 
Fagard et al 2001). Therefore, it seems more logical to study short-term HRV under 
similar conditions where these parameters are less likely to change significantly 
(Furlan et al 1990). Several studies confirm that short-term correlate very well with 
long-term HRV (Min et al 2008).  Desok et al demonstrate that fifteen to thirty second 
heartbeat measurements were long enough to produce reliable long-term patterns of 
HRV features. Thus, short and intermittent recordings of heartbeats could be used to 
detect long term HRV patterns (Desok et al 2008). This is especially true for power 
spectral measures of RR variability calculated from short (2 to 15 minutes) ECG 
recordings (Bigger et al 1993).  Another advantage of short-term HRV is that it is 
more practical and less expensive when needed for the purpose of follow up in 
outpatient clinics.  
This study aims to develop an effective spirometric score that can faithfully reflect 
ventilatory functions of the lungs to be used in evaluating the relationship between 
autonomic balance and measures of asthma severity and other  parameters known to 
 3
be influenced by sympathetic and parasympathetic e.g. blood pressure and blood 
glucose concentration. 
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LITERATURE REVIEW 
1. Asthma 
Asthma is a disorder defined by its clinical, physiological, and pathological 
characteristics. The predominant feature of the clinical history is episodic shortness of 
breath, particularly at night, often accompanied by cough. Wheezing heard on 
auscultation of the chest is the most common physical finding. The main 
physiological feature of asthma is episodic airway obstruction characterized by 
expiratory airflow limitation. The dominant pathological feature is airway 
inflammation, sometimes associated with airway structural changes. 
Asthma has significant genetic and environmental components, but since its 
pathogenesis is not clear, much of its definition is descriptive. Based on the functional 
consequences of airway inflammation, asthma is defined by GINA (2008) as: 
"A chronic inflammatory disorder of the airways in which many cells and cellular 
elements play a role. The chronic inflammation is associated with airway 
hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, 
chest tightness, and coughing, particularly at night or in the early morning. These 
episodes are usually associated with widespread, but variable, airflow obstruction 
within the lung that is often reversible either spontaneously or with treatment". 
Because there is no clear definition of the asthma phenotype, researchers studying the 
development of this complex disease turn to characteristics that can be measured, 
such as atopy and airway hyperresponsiveness.  
1.1.Astma Etiology  
Factors that influence the risk of asthma can be divided into those that cause the 
development of asthma and those that trigger asthma symptoms; some do both. 
1.1.1. Host Factors 
1.1.1.1. Genetic Factors  
Asthma has a heritable component, but it is not simple. Multiple genes may be 
involved in the pathogenesis of asthma. The search for genes linked to the 
development of asthma has focused on four major areas: production of allergen-
specific IgE antibodies (atopy); expression of airway hyperresponsiveness; generation 
of inflammatory mediators, such as cytokines, chemokines, and growth factors; and 
determination of the ratio between Th1 and Th2 immune responses (LeSouëf 1998 
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and Strachan 1989). In addition to genes that predispose to asthma, there are genes 
that are associated with the response to asthma treatment. For example, variations in 
the gene encoding the beta-adrenoreceptor have been linked to differences in subjects' 
responses to beta-2 agonists (Israel et al 2004).  
1.1.1.2. Obesity 
Certain mediators such as leptins may affect airway function and increase the 
likelihood of asthma development (Beuther et al 2006 and Shore et al 2005). 
1.1.1.3. Gender 
Male sex is a risk factor for asthma in children. Prior to the age of 14, the prevalence 
of asthma is nearly twice as great in boys as in girls. As children get older the 
difference between the genders becomes narrower, and by adulthood the prevalence 
of asthma is greater in women than in men (Horwood et al 1985). The reasons for this 
sex-related difference are not clear.  
1.1.2. Environmental Factors 
There is some overlap between environmental factors that influence the risk of 
developing asthma, and factors that cause asthma symptoms, for example, 
occupational sensitizers belong to both categories. However, there are some important 
causes of asthma symptoms, such as air pollution and some allergens, which have not 
been clearly linked to the development of asthma.  
1.1.2.1. Allergens 
Indoor and outdoor allergens are well known to cause asthma exacerbations. The 
relationship between allergen exposure and sensitization in children is not 
straightforward. It depends on the allergen, the dose, the time of exposure, age, and 
probably genetics as well (Wahn et al 1997). 
1.1.2.2. Infections 
A number of viruses have been associated with the initiation of the asthma. 
Respiratory syncytial virus (RSV) and parainfluenza virus produce a pattern of 
symptoms including bronchiolitis that parallel many features of childhood asthma 
(Gern et al 2002 and Stein et al 1999). On the other hand, evidence also indicates that 
certain respiratory infections early in life, including measles and sometimes even 
RSV, may protect against the development of asthma (Gern et al 2002 and Shaheen et 
al 1996). The “hygiene hypothesis” of asthma suggests that exposure to infections 
early in life influences the development of a child's immune system leading to a 
reduced risk of asthma and other allergic diseases (Ramsey et al 2005). 
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1.1.2.3. Occupational sensitizers   
Occupational asthma is defined as asthma caused by exposure to an agent encountered 
in the work environment. The substances include highly reactive small molecules 
such as isocyanates, irritants that may cause an alteration in airway responsiveness, 
known immunogens such as platinum salts, and complex plant and animal biological 
products that stimulate the production of IgE (Malo et al 2004). 
1.1.2.4. Diet 
The role of diet, particularly breast-feeding, in relation to the development of asthma 
has been extensively studied. Data reveal that infants fed formulas of intact cow's 
milk or soy protein have a higher incidence of wheezing illnesses in early childhood 
compared with those fed breast milk (Friedman et al 2005). 
Some data also suggest that certain characteristics of Western diets, such as increased 
use of processed foods and decreased antioxidant (in the form of fruits and 
vegetables), increased n-6 polyunsaturated fatty acids (found in margarine and 
vegetable oil), and decreased n-3 polyunsaturated fatty acids (found in oily fish) 
intakes have contributed to the recent increases in asthma and atopic disease 
(Devereux et al 2005). Further research may determine whether dietary intervention 
can reduce the risk of asthma and atopic disease. 
Low electrolytes concentrations in asthma patients can be attributed to low intake 
(Britton et al 1994, Landon et al 1993 and Burney et al 1989) or secondary to asthma 
medication (Whyte et al 1988, Haalboom et al 1985, Prince et al 1988 and Bos et al 
1988 and Gustafson et al 1996). Association between sodium intake and asthma is 
consistent with some previous studies (Carey et al 1993 and Burney et al 1989) but 
not others (Britton et al 1994 and Lieberman et al 1992). Possible mechanisms that 
may lead to airway reactivity include direct effect of sodium and potassium on 
bronchial smooth muscle contractility (Chideckel et al 1987) as well as potential 
enhancement of the release of mast cell-derived inflammatory mediators, possibly 
through airway osmolarity changes (Mickleborough et al 2001 and Eggleston et al 
1984).  
1.2. Asthma Pathology and Pathophysiology 
1.2.1. Gross Features  
Most of the classic descriptions of the pathologic patterns of asthma have been 
derived from autopsy studies (Dunnill 1960 and Messer et al 1960). These studies, 
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based on individuals who died in status asthmaticus, describe overinflation of the 
lungs and mucus plugs occluding medium-sized bronchi, small bronchi, and 
bronchioles. In more recent articles, however, there are descriptions derived from 
bronchoscopic biopsies (Vignola et al 1998, Grootendorst et al 1997 and Wenzel et al 
1997). Bronchoscopic studies can provide pathologic description of early and mild 
forms of the disease. Overinflation is seen in individuals who die in status 
asthmaticus, but the lungs may appear normal between attacks. The lungs fill the 
chest cavity during status asthmaticus and do not collapse when the pleural space is 
opened (Dunnill 1960 and Messer et al 1960). 
1.2.2. Microscopic Features  
Airways of asthmatic patients may be normal or they may show only mild histological 
changes between asthmatic attacks. Mucous plugs made of heavily viscous mucus fill 
both bronchi and bronchioles. These plugs appear to be produced by both submucosal 
gland hypertrophy and goblet cell hyperplasia. It has been reported that the proportion 
of both mucin and goblet cells in the epithelium may be up to 3 times higher in 
asthmatic patients than in controls (Ordonez et al 2001). 
Although transbronchial biopsies traditionally have not been considered essential in 
the diagnosis and management of asthmatic patients, some researches support the 
belief that morphometric studies and immunohistochemistry may help to understand 
the natural history and response to treatment of this disease in the future (Ordonez et 
al 2001 and Grootendorst et al 1997). 
1.2.2.1. Airway Remodeling 
A series of progressive structural changes of the airways is known as airway 
remodeling. These changes most likely occur because of repeated episodes of 
inflammation with production of matrix proteins and growth factors by inflammatory 
cells (Calhoun et al 1991). It is also possible that repeated damage to the epithelium, 
with subsequent repair, may lead to airway remodeling (Holgate et al 1999).  
1.2.2.2. Airway Epithelium 
Goblet cell hyperplasia is a common histopathologic finding, although not specific for 
asthma (Salvato 1968). Other common findings are the presence of mucus plugs and 
squamous metaplasia (Aikawa et al 1992). Areas of uncovered epithelium are seen 
occasionally. It has been proposed that patients with significant epithelial 
desquamation present with persistent rather than intermittent asthma (Vignola et al 
1998) because of direct exposure of nerve endings to factors that would trigger the 
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inflammatory response (Djukanovic et al 1990). The airway wall can be thickened 
from edema, an increase in smooth muscle, and an increase in the size of the 
submucosal mucous glands. 
1.2.2.3.  Reticular Basement Membrane 
Light microscopy has revealed that what has been interpreted in the old literature as 
basement membranes are usually thicker in asthmatic individuals than in non-
asthmatic individuals (Djukanovic et al 1990 and Dunnill 1960). What light 
microscopic studies refer to as “basement membrane thickening” has been determined 
by ultrastructural and immunohistochemical studies to be deposition of types III and 
V collagen as well as fibronectin beneath the true basement membrane, which usually 
retains its normal thickness (Djukanovic et al 1990). The mechanism of production of 
this reticular basement membrane is controversial; but it has been suggested that 
activated eosinophils are involved through the production of cytokines such as 
transforming fibroblast growth factor (TGF-β), which is a potent profibrotic cytokine 
(Minshall 1997). 
1.2.2.4.  Bronchial Submucosal Glands 
Bronchial submucosal glands are increased in size in individuals with asthma, but at 
some stage, patients with chronic bronchitis also show increased bronchial 
submucosal glands. The results of Carroll et al (2002) show increased mucous gland 
area and that degranulation of mast cells may contribute to secretion of mucus into the 
lumen in cases of fatal asthma. 
1.2.2.5. Smooth Muscle 
Patients dying of status asthmaticus have a 2-fold to 3-fold increase in the amount of 
airway smooth muscle, especially in the medium-sized bronchi (Kuwano et al 1993 
and Saetta et al 1991). Smooth muscle thickness in asthmatic patients appears to 
increase with age (Bai et al 2000). It has been proposed that myofibroblasts play a 
role in this smooth muscle thickening and in the reticular basement membrane 
thickening because of the production and deposition of fibronectin in the bronchial 
mucosa. Presence of myofibroblasts has been associated with local expression of 
TGF-β produced by eosinophils and fibroblasts (Redington et al 1997). 
1.2.2.6. Lung Elastic Recoil 
The lung elastic recoil provides the major source of load against which the airway 
smooth muscle (ASM) has to shorten. To be effective against ASM shortening, the 
force exerted by lung parenchyma must be properly transmitted to the external wall of 
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the airways and from here across all tissues separating it from ASM. Tissues softened 
by inflammatory changes may loose their ability to limit ASM shortening, especially 
at low lung volume (Lambert et al 1997). Increased adventitial thickness was found to 
increase constriction by reducing parenchymal interdependence (Lambert et al 1993). 
In addition, fluid accumulation around the airways would uncouple them from lung 
parenchyma, thus possibly impeding the transmission of lung elastic recoil force to 
airways (Brusasco et al 2003).  
1.2.3. Neural Mechanism of Asthma 
For many years, asthma has been classified as a neural disease, with an imbalance 
between constrictor and dilator nerves being responsible for the symptomatology. 
Although asthma now is recognized as an inflammatory disorder of the airways, 
neural mechanisms remain very important (Verleden 1996). 
Acetylcholine receptors are classified into nicotinic and muscarinic receptors. There 
are at least five muscarinic receptors and they are designated M1-M5 (Fryer and 
Jacoby 1998). Muscarinic receptors in human airways are almost certainly either M2 
or M3 (Van Koppen et al 1985). Although M3 muscarinic receptors have been linked 
to airway smooth muscle contraction, the functional role of M2 subtype in ASM has 
been unclear. M2 muscarinic receptors do not play a direct role in smooth muscle 
contraction; they appear to inhibit the activity of the ß2-adrenergic receptor-induced 
bronchodilation. (Fernandes et al 1992) (Figure 1-1). Although patients with asthma 
are hyperresponsive to cholinergic agonists, there is no evidence that the M3 receptors 
mediating contraction of the airway smooth muscle have been altered by disease. In 
vitro studies showed that exogenous cholinergic agonists produced no greater 
contraction of muscle fibers taken from subjects with asthma compared with muscle 
from subjects with no asthma (Emala et al 1995).  
In contrast, there is clearly increased release of the neurotransmitter acetylcholine in 
animal models of hyperactivity and in asthma. Release of acetylcholine is controlled 
by inhibitory M2 muscarinic receptors, and it appears that it is these M2 receptors that 
are dysfunctional in animal models of hyperresponsiveness (Larsen et al 1994). 
Allergen-induced M2 receptor dysfunction is largely dependent upon an influx of 
eosinophils into the airways. Activated eosinophils release a major basic protein, 
which binds to M2 receptors and prevents binding of acetylcholine (Jacoby et al 
1993). Thus, the normal negative feedback control of acetylcholine release is lost, and 
acetylcholine release is increased. In conclusion, loss of function of inhibitory M2 
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muscarinic receptors on the airway parasympathetic nerves causes vagally mediated 
bronchoconstriction and hyperresponsiveness following antigen challenge (Fryer and 
Jacoby 1998).  
Figure (1-1): Autonomic control of airway smooth muscle (adapted from 
Proskocil and Fryer 2005). 
 
Muscarinic (M2 and M3) and adrenergic receptors (β2) are expressed in airway 
smooth muscle and in the nerves supplying smooth muscle. Receptors that cause 
enhance neurotransmitter release are marked with a (+) receptors that inhibit release 
have a (–). PKC = protein kinase C, ACh = acetylcholine, Gi/o = inhibitory G protein, 
cAMP = 3',5'adenosine monophosphate, Gs = stimulatory G protein coupled to β2-
adrenergic receptor, Gq = stimulatory G protein coupled to M3-muscarinic receptor. 
 
1.2.4. Airway Hyperresponsiveness 
Airway hyperresponsiveness results in airway narrowing in a patient with asthma in 
response to a stimulus that would be innocuous in a normal person. In turn, this 
airway narrowing leads to variable airflow limitation and intermittent symptoms. In 
addition to the neural mechanism discussed above airway hyperresponsiveness is 
linked to both inflammation and repair of the airways. Its mechanisms are 
incompletely understood; however, the followings are suggested: 
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1. In normal individuals, deep inspiration (DI) produce "plastic" deformation that 
keeps the airways well dilated. In asthmatics, "elastic" deformation takes place, 
which causes the airway smooth muscle to return to its original length after DI and 
therefore maintaining the narrowing of airways (Fernandes 2003). 
2. Excessive contraction of airway smooth muscle may result from increased volume 
and/or contractility of airway smooth muscle cells (Black 2004). 
3. Thickening of the airway wall by edema and structural changes amplifies airway 
narrowing due to contraction of airway smooth muscle (Wang et al 2003). 
4. Sensory nerves may be sensitized by inflammation, leading to exaggerated 
bronchoconstriction in response to sensory stimuli (Djukanovic et al 1990). 
1.3. Clinical Diagnosis 
1.3.1. Medical History 
A clinical diagnosis of asthma is often suggested by symptoms such as episodic 
breathlessness, wheezing, cough, and chest tightness. Episodic symptoms after an 
incidental allergen exposure, seasonal variability of symptoms and a positive family 
history of asthma and atopic disease are also helpful diagnostic indicators. Asthma 
associated with rhinitis may occur intermittently, with the patient being entirely 
asymptomatic between seasons or it may involve seasonal worsening of asthma 
symptoms or a background of persistent asthma. The patterns of these symptoms that 
strongly suggest an asthma diagnosis are variability; precipitation by non-specific 
irritants, such as smoke, fumes, strong smells, or exercise; worsening at night; and 
responding to appropriate asthma therapy. 
1.3.2. Physical Examination 
The physical examination of the respiratory system may be normal. The most usual 
abnormal physical finding is wheezing on auscultation, a finding that confirms the 
presence of airflow limitation. However, in some people with asthma, wheezing may 
be absent or only detected when the person exhales forcibly, even in the presence of 
significant airflow limitation. Occasionally, in severe asthma exacerbations, wheezing 
may be absent owing to severely reduced airflow and ventilation. However, patients 
in this state usually have other physical signs reflecting the exacerbation and its 
severity, such as cyanosis, drowsiness, difficulty speaking, tachycardia, hyperinflated 
chest, use of accessory muscles, and intercostal recession. Other clinical signs are 
only likely to be present if patients are examined during symptomatic periods. 
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Features of hyperinflation result from patients breathing at a higher lung volume in 
order to increase outward retraction of the airways and maintain the patency of 
smaller airways (which are narrowed by a combination of airway smooth muscle 
contraction, edema, and mucus hypersecretion).  
1.3.3. Tests for Diagnosis and Monitoring 
1.3.3.1. Measurements of lung function 
Measurement of lung function provides an assessment of the severity and reversibility 
of airflow limitation; however, it does not correlate strongly with symptoms or other 
measures of disease control (Kikuchi 1994, Apter1994, Blanc 1993 and Bailey et al 
1992).  
Various methods are available to assess airflow limitation, however, spirometry has 
gained widespread acceptance for use in asthma patients. The terms reversibility and 
variability refer to changes in symptoms accompanied by changes in airflow 
limitation that occur spontaneously or in response to treatment. The term reversibility 
is generally applied to rapid improvements in FEV1 (or PEF), measured within 
minutes after inhalation of a rapid-acting bronchodilator or more sustained 
improvement over days or weeks after the introduction of effective controller 
treatment such as inhaled glucocorticosteroids. Variability refers to improvement or 
deterioration in symptoms and lung function occurring over time. Variability may be 
experienced over the course of one day (when it is called diurnal variability), from 
day to day, from month to month, or seasonally. Obtaining a history of variability is 
an essential component of the diagnosis of asthma. In addition, variability represents 
part of the assessment of asthma control. 
Spirometry is the recommended method of measuring airflow limitation; and 
reversibility is assumed to establish a diagnosis of asthma. Spirometry will be 
reviewed separately late in this chapter.  
1.3.3.2. Measurement of airway responsiveness 
For patients with symptoms consistent with asthma, but normal lung function, 
measurements of airway responsiveness to direct airway challenges such as inhaled 
methacholine and histamine or indirect airway challenges such as inhaled mannitol or 
exercise challenge may help to establish a diagnosis of asthma. Measurements of 
airway responsiveness reflect the “sensitivity” of the airways to factors that can cause 
asthma symptoms, sometimes called “triggers,” and the test results are usually 
expressed as the provocative concentration (or dose) of the agonist causing a given 
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fall (often 20%) in FEV1. These tests are sensitive for a diagnosis of asthma, but have 
limited specificity (Cockcroft 1992). This is because airway hyperresponsiveness has 
been described in patients with allergic rhinitis and in those with airflow limitation 
caused by conditions other than asthma e.g. bronchiectasis, and chronic obstructive 
pulmonary disease (Ramsdale et al 1985 and Ramsdale et al 1984). 
1.3.3.3. Non-invasive markers of airway inflammation 
The evaluation of airway inflammation associated with asthma may be undertaken by 
examining spontaneously produced or hypertonic saline-induced sputum for 
eosinophilic or neutrophilic inflammation (Green et al 2002). In addition, levels of 
exhaled nitric oxide (Kharitonov et al 1997) and carbon monoxide (Horvath et al 
1999) have been suggested as non-invasive markers of airway inflammation in 
asthma. This is because mediators produced by activated inflammatory cells may lead 
to induction of nitric oxide synthase producing nitric oxide and heme oxygenase 
releasing carbon monoxide in the airways. Both nitric oxide and carbon monoxide are 
present in exhaled air and their levels are elevated in asthma reflecting airway 
inflammation. The methods for measurements of these gases is not at present used in 
routine evaluation of asthma. 
1.3.3.4. Measurements of allergic status  
The presence of allergies in asthma patients (identified by skin testing or 
measurement of specific IgE in serum) can help to identify risk factors that cause 
asthma symptoms in individual patients. Deliberate provocation of the airways with a 
suspected allergen or sensitizing agent may be helpful in the occupational setting, but 
is not routinely recommended, because it is rarely useful in establishing a diagnosis, 
requires considerable expertise and can result in life-threatening bronchospasm 
(GINA 2007). 
1.4. Asthma Classifications 
The reasons for classifying asthma are wide ranging. From a research perspective, 
classification is needed to select appropriate and comparable patient populations for 
inclusion in clinical trials, and to facilitate understanding and evaluation of clinical 
outcomes after intervention. From a social perspective, the cost and burden of illness 
need to be investigated; from a clinical perspective, appropriate pharmacotherapy 
needs to be determined. Based on these varied requirements, there is utility for 
classifying asthma. However, it is important that any clinical tool for classifying 
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asthma should be reliable, valid and can be applied easily to a range of clinical 
situations and patient groups. Therefore, classifying asthma into different patient 
groups with different needs for management has been a key component of guideline 
development.  
1.4.1. The National Asthma Education and Prevention Program (NAEPP) 
Classification of Asthma  
NAEPP guidelines adopted a "stepped-care" approach to pharmacotherapy: increasing 
treatment intensity with asthma severity (table 1-1). This approach also forms the 
basis of the Global Initiative for Asthma (GINA) guidelines.  
 
Table 1-1: NAEPP Guidelines Severity Classification and Recommended Therapy  
Asthma 
Classification 
Days 
Symptoms 
Nights 
Symptoms FEV1%
Recommended 
Pharmacotherapy 
Severe 
persistent Continual Frequent <60% 
As-needed short-acting ß2-
agonist; high-dose ICS plus long-
acting bronchodilator plus oral 
corticosteroids 
Moderate 
persistent Daily 
≥ 5 
times/month 
60 % to 
80% 
As-needed short-acting ß2-
agonist; medium-dose ICS or 
low-dose inhalation steroid plus 
long-acting bronchodilator; 
increase inhalation steroid dose 
and add long-acting broncho-
dilator if needed 
Mild 
persistent 
> 2 
times 
/week 
3-4 
times/month ≥80% 
As-needed short-acting ß2-
agonist; low-dose inhalation 
steroid or other anti-inflammatory 
Mild 
intermittent 
≤2 
times 
/week 
≤ 2 
times/month ≥80% 
No daily medication; as-needed 
short-acting ß2-agonist 
 
To apply the stepped-care approach, clear determinants are required for where the 
patient "steps" for initial therapy and the criteria for stepping-up or stepping-down 
therapy. The expert panel recommended using a severity classification, determined by 
symptoms and pulmonary function, which was used to direct pharmacotherapy. 
Despite widespread awareness of the NAEPP guidelines, severity classification still 
provides many challenges to practicing physicians, which may lead to poor adherence 
to or poor understanding of treatment guidelines (Graham 2006 and Baker et al 2003). 
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1.4.2. Asthma Control Test (ACT) 
Despite guidelines that enumerate the goals of asthma control and define management 
strategies, asthma imposes a growing burden on society in terms of morbidity, quality 
of life, and healthcare costs (Fuhlbrigge et al 2002). The lack of a clinical gold 
standard for determining asthma control, as well as inadequate recognition of 
uncontrolled asthma by patients and physicians, may contribute to this situation 
(Prieto et al 2007). An approach to this problem has been the development of 
validated questionnaire tools to measure asthma control in the clinical setting 
(Vollmer et al 1999 and Juniper et al 1999). 
One such tool is the Asthma Control Test (ACT) which is based on a 5-item survey 
that assesses interference with activity, shortness of breath, nocturnal symptoms, 
rescue medication use, and self-rating of asthma control (table 1-2). It was developed 
using asthma specialist assessment of asthma control as the criterion measure of 
asthma control in a population of patients followed up by these specialists (Nathan et 
al 2004) and was validated in a separate sample of patients new to these specialists 
(Kennedy et al 2007 and Schatz et al 2006).  
The ACT is a 5-item patient-administered survey for assessing asthma control. Each 
of the five questions is given a score from 1 to 5. Responses from the ACT are 
summated to yield a score that ranges from 5 (no control) to 25 (complete control). A 
score of 20 or higher was found to be the most discriminating cutoff to define totally 
from poorly controlled patients while a score of 15 or lower was identified as the most 
discriminating cutoff to define asthma that was not controlled at all (Kennedy et al 
2007, Schatz et al 2006 and Nathan et al 2004). The attractiveness of the ACT score 
as a screening test lies in its ability to provide the busy physician with an accurate, 
reliable and easy to use control tool that is essential in management of asthma. 
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Table 1-2: Asthma Control Test (ACT). 
Questions Single Best Answer 
I. During the past 4 weeks, how much of the 
time did your asthma keep you from 
getting as much done at work, school or 
home? 
1. All of the time 
2. Most of the time 
3. Some of the time 
4. A little of the time 
5. None of the time 
II. During the past 4 weeks, how often have 
you had shortness of breath? 
1. More than once a day 
2. Once a day 
3. 3–6 times a week 
4. Once or twice a week 
5. Not at all 
III. During the past 4 weeks, how often did 
your asthma symptoms (wheezing, 
coughing, shortness of breath, chest 
tightness or pain) wake you up at night or 
earlier than usual in the morning? 
1. Four or more times a week 
2. 2–3 times a week 
3. Once a week 
4. Once or twice per month 
5. Not at all 
IV. During the past 4 weeks how often have 
you used your nebulizer medication (such 
as salbutamol)? 
1. Three or more times a day 
2. Once or twice a day 
3. 2–3 times a week 
4. Once a week or less 
5. Not at all 
V. How would you rate your asthma control 
during the past 4 weeks? 
1. Not controlled at all 
2. Poorly controlled 
3. Somewhat controlled 
4. Well controlled 
5. Completely controlled 
 
1.5. Management of Asthma  
Pharmacologic intervention to treat established asthma is highly effective in 
controlling symptoms and improving quality of life. However, it is equally important 
to follow measures that prevent the development of asthma by avoiding or reducing 
exposure to risk factors (Malo et al 2004, Gern et al 2002 and Stein et al 1999). 
According to GINA (2007), the goal of asthma treatment is to achieve and maintain 
clinical control. Medications to treat asthma can be classified as controllers or 
relievers. Controllers are medications taken daily on a long-term basis to keep asthma 
under clinical control chiefly through their anti-inflammatory effects. They include 
inhaled and systemic glucocorticosteroids, leukotriene modifiers, long-acting inhaled 
beta-2 agonists in combination with inhaled glucocorticosteroids, sustained-release 
theophylline, cromones, anti-IgE, and other systemic steroid-sparing therapies. 
Inhaled glucocorticosteroids are the most effective controller medications currently 
available. 
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Relievers are medications used when needed and act quickly to reverse 
bronchoconstriction and relieve its symptoms. They include rapid-acting inhaled beta-
2 agonists, inhaled anticholinergics, short-acting theophylline, and short-acting oral 
beta-2 agonists. 
Each patient should be assessed to establish his or her current treatment regimen, 
adherence to the current regimen, and level of asthma control. Some composite 
control measures e.g. Asthma Control Test and NAEPP classifications have been 
developed and had been validated for various applications, including use by health 
care providers to assess the state of control of their asthma patients. 
The patient's current level of asthma control and current treatment determine the 
selection of pharmacologic treatment as shown in table 1-1. For example, if asthma is 
not controlled on the current treatment regimen, treatment should be stepped up until 
control is achieved. If control has been maintained for at least three months, treatment 
can be stepped down with the aim of establishing the lowest step and dose of 
treatment that maintains control (GINA 2007).  
The systemic side effects of long-term treatment with glucocorticosteroids include 
easy bruising, adrenal suppression, and decreased bone mineral density, cataracts 
glaucoma and stunted growth in children. Local adverse effects from inhaled 
glucocorticosteroids include oropharyngeal candidiasis, dysphonia, and occasionally 
coughing from upper airway irritation. Therapy with inhaled beta-2 agonists causes 
fewer systemic adverse effects such as cardiovascular stimulation, skeletal muscle 
tremor, hypokalaemia and some other electrolyte disturbance (British Guideline on 
the Management of Asthma 2008, GINA 2007). 
2. Spirometry 
Spirometry is a physiological test that measures how an individual inhales or exhales 
volumes of air as a function of time. The primary signal measured in spirometry may 
be volume or flow. Spirometry is useful as a screening test of general respiratory 
health in the same way that ECG provides important informations about general 
cardiovascular health. However, on its own, spirometry does not lead clinicians 
directly to an aetiological diagnosis. Some indications for spirometry are given in 
table 1-3. 
Spirometry can be undertaken with many different types of equipment, and requires 
the cooperation of the subject with the examiner. The results obtained depend on 
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technical as well as personal factors. If the variability of the results can be diminished 
and the measurement accuracy improved, the range of normal values for populations 
can be narrowed and abnormalities more easily detected. The Snowbird workshop 
held in 1979 resulted in the first American Thoracic Society (ATS) statement on the 
standardization of spirometry (ATS 1979). This was updated in 1987 (ATS 1987), 
1994 (ATS 1994) and lastly 2005 (Miller et al 2005). For further details, the reader is 
referred to table 2-3 and the last update on the standardization of spirometry (Miller et 
al 2005). Most spirometers display the following graphs: 
1. A volume-time curve, showing volume (liters) along the Y-axis and time (seconds) 
along the X-axis. The classical example of this is vitalography.  
2. A flow-volume loop, which graphically depicts the rate of airflow on the Y-axis 
and the total volume inspired or expired on the X-axis. 
In both tests, most of the spirometric indices are derived from forced vital capacity 
and therefore interpretation of spirometry mainly depends on good understanding of 
the physiology of this manouver. 
 
Table (1-3): Indications for Spirometry (Miller et al 2005) 
Diagnostic 
To evaluate symptoms, signs or abnormal laboratory tests 
To measure the effect of disease on pulmonary function 
To screen individuals at risk of having pulmonary disease 
To assess pre-operative risk 
To assess prognosis 
To assess health status before beginning strenuous physical activity 
programmes 
Monitoring 
To assess therapeutic intervention 
To describe the course of diseases that affect lung function 
To monitor people exposed to injurious agents 
To monitor for adverse reactions to drugs with known pulmonary toxicity 
Disability/impairment evaluations 
To assess patients as part of a rehabilitation programme 
To assess risks as part of an insurance evaluation 
To assess individuals for legal reasons 
Public health 
Epidemiological surveys 
Derivation of reference equations 
Clinical research 
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2.1. Vital Capacity 
Vital capacity (VC) is the volume change of the lung between a full inspiration and a 
maximal expiration. The maneuver may be performed in different ways: 
1. The maneuver can be performed rather slowly, starting from end-tidal volume. 
The subject expires maximally and subsequently makes a full inspiration. This is 
the slow Inspiratory vital capacity (SIVC) or starting from end-tidal volume the 
subjects makes a full inspiration and subsequently exhales maximally. This 
represents the slow expiratory vital capacity (SEVC). 
2. Alternatively, the same maneuvers can be performed with maximal force to 
produce forced inspiratory vital capacity (FIVC) and forced expiratory vital 
capacity (FEVC) respectively.  
In healthy subjects the vital capacities measured according to these different 
procedures are nearly the same. In patient with obstructive lung disease, however, the 
vital capacity obtained during forced expiratory maneuvers is smaller than when 
obtained upon relaxed (slow) inspiration i.e.  FIVC > SIVC > SEVC > FEVC. 
Therefore, FEVC is the most sensitive vital capacity and is commonly used in 
assessing obstructive lung diseases (Pellegrino et al 2005). The volume assessed is the 
forced expiratory vital capacity (FEVC) is simply called forced vital capacity (FVC). 
The maneuver is usually performed in conjunction with the assessment of the FEV1 
and of maximum expiratory flow-volume curves. 
2.2. Mechanics of Forced expiration 
By taking a deep breath and then exhaling with maximal force, pleural and alveolar 
pressure increase to above barometric pressure and gas is expelled from the lung. The 
energy required to overcome resistance to flow converts into a pressure drop. In the 
simplest case (that of laminar flow) the pressure drop (dP) is proportional to airways 
resistance (Raw) and flow (V'): 
dP = V'·Raw 
Going from the alveoli to the mouth, the pressure falls steadily; it is high in the alveoli 
(Palv), falls steadily within bronchi (Pbr) to the level of mouth pressure and 
subsequently barometric pressure (Pbar). This is because the total cross sectional area 
of the airways decreases towards the trachea. The pressure outside intrathoracic 
airways is pleural pressure; the pressure outside extrathoracic airways approximates 
barometric pressure. It follows that during a forced expiration all intrathoracic airways 
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are exposed to a high pleural pressure, whilst pressure within airways drops from a 
high level near the alveoli to a low level near the thoracic outlet. The intrathoracic 
airways can be divided into three sections (figure 1-2): 
1. A section nearest the alveoli where bronchial pressure exceeds pleural pressure 
i.e. the pressure difference expands the airways.  
2. A point where intra and extra-bronchial pressures are equal (equal pressure point). 
3. A section where bronchial pressure is lower than outside pressure; the airway will 
be compressed (flow limiting segment). 
  
Figure (1-2): Mechanics of Forced Expiration (For Abbreviations and discussion 
see the text). 
 
Airway compression always occurs first in the trachea. However, the cartilaginous 
rings oppose high exrratracheal pressure giving rise to a slit-like airway. This narrow 
airway segment functions as a valve and therefore the speed of gas molecules is no 
longer governed by the pressure difference from alveoli to mouth. Expiration of air 
beyond this is said to be effort independent.  
2.3. Physiological determinants of spirometry 
2.3.1. Lung Characteristics 
The thoracic cavity expands during inspiration, due to the descent of the diaphragm, 
which passively expand the lung. When the lung inflates, the increasing elastic recoil 
pressure needs to be overcome, therefore the trans-pulmonary pressure (the pressure 
difference across the lung) is increased. It follows that pressure in the pleural space 
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(Ppl) drops relative to alveolar pressure (Palv). The pressure difference reflects the 
elastic recoil pressure of the lung (PL,el) at that lung volume: 
Palv - Ppl = PL,el 
If after a deep inspiration, the breath is held with the glottis open, then the pressure in 
all airways (Pbr) and alveolar spaces equals barometric (Pbar) and mouth pressure 
(Pmo), and gas flow is nil: 
Pbar = Pmo = Pbr = Palv 
Pbr is always higher than Ppl by value determined by PL,el. As one expires 
progressively, the lung is stretched less and PL,el diminishes. The radial traction 
exerted on the airway diminishes leading to decreased airway calibre. Therefore, 
airway diameter is greatest at high lung volume, and smallest at low lung volume. 
Similarly, airways resistance is highest at low lung volumes. Therefore, the elastic 
properties of the lung are an important determinant of airway caliber.  
In case of asthma all above-mentioned contribute to airways narrowing. Bai et al 
(1993) and Kuwano et al (1994) defined three functionally distinct layers to the wall, 
and the thickening of each can have separate effects, as shown in figure 1-3.  
1. The thickening of the inner airway wall layer , i.e. epithelium, lamina 
reticularis, and loose connective tissue between the lamina reticularis and the 
airway smooth muscle (ASM) layer, can amplify the effect of ASM shortening 
2. The thickening of the outer (or adventitial) layer could decrease the static and 
dynamic loads on the ASM. 
3.  The increase in the ASM layer thickness can increase the strength of the 
muscle. 
The remodeling of the connective tissue in the smooth muscle compartment could 
decrease the amount of radial constraint provided to the ASM. Moreover, thickening 
and fibrous connective tissue deposition in all layers could decrease airway 
dispensability and allow ASM adaptation to shorter lengths (Wang et al 2003). 
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Figure (1-3): Schematic diagram of the airway with compartments. Po = outer 
adventitial perimeter; Pe = smooth muscle perimeter; Pbm = basement 
membrane perimeter; Ao, Ae, and Abm = areas subtended by Po, Pe, and Pbm, 
respectively. Adapted from Wang et al (2003).   
 
2.3.2. Age, Gender, Anthropometry and Ethnicity  
Lung function is greatly influenced by age, gender, anthropometry and ethnicity. 
Lung volumes, especially vital capacity, increase with height and lean body mass but 
decrease with obesity. For the same weight and height, spirometric measurements are 
usually higher in males compared with females. Almost all equations for prediction of 
lung function in various populations include these parameters (Miller et al 2005, 
Bottai et al 2002, Hankinson et al 1999 and Schwartz et al 1988). 
2.3.3. Physical activity 
Significant associations between spirometric values and intensities of physical activity 
is proved by many studies (Mälkiä et al 1998 and Doherty et al1997). The results of 
Mälkiä et al (1998) show significant associations between spirometric values and 
intensities of physical activity at work and during leisure time in asthmatic men. 
Although healthier subjects may select more physically demanding activities, it is an 
equally possible hypothesis that physical activity may improve respiratory function in 
subjects with and without bronchial asthma. The study of Doherty et al (1997) show 
that swimmers have superior FEV1 independent of stature and age in comparison with 
both land based athletes and sedentary controls. When years of training are controlled 
for, the difference in FEV1 between the two groups is no longer evident. This 
suggests that the years of training may have a significant influence on subsequent 
lung function. 
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2.3.4. Altitude  
Ventilatory functions show a significant decrease during the first days on high altitude 
and improve only after several days spent in the same altitude (Pollard et al 1996). 
This support the hypothesis that at high altitude the respiratory function can be 
affected by the presence of an increased pulmonary blood volume and/or the 
development of interstitial edema (Pollard et al 1996). The observed changes in 
forced expiration curves at high altitude seem to reflect the degree of acclimatization 
that is related to the individual susceptibility, to the altitude reached and to the 
duration of the exposure. These changes are transient and resolve after returning to 
sea level (Cogo et al 1997). 
2.4. FVC-Derived Spirometric Measurements  
2.4.1. Timed Forced Expiratory Volumes (FEVx)  
The FEVx is the volume exhaled during the first x seconds of a forced expiratory 
maneuver started from the level of total lung capacity. The commonly used forced 
expiratory volumes are FEV1, FEV3 and FEV6. FEV1 is by far the most frequently 
used index for assessing airway obstruction, bronchoconstriction or bronchodilatation. 
FEV6 is sometimes used to represent forced vital capacity in detecting airways 
obstruction and restriction. This leads to misclassification when compared to results 
using ATS maneuvers of longer duration (Akpinar-Elci et al 2006 and Swanney et al 
2000). 
2.4.2. Timed Forced Expiratory Volumes Ratios (FEVx%)  
FEVx% is FEVx expressed as a percentage of the VC. The commonly used timed 
forced expiratory volumes ratios are FEV1%, FEV3% and FEV6%. FEV1% is by far 
the most frequently used index for assessing airway obstruction, bronchoconstriction 
or bronchodilatation. As   FIVC > SIVC > SEVC > FVC in patients with obstructive 
lung disease, the VC should be specified when using the FEVx/VC ratio, hence 
FEVx%FVC, FEVx%FIVC… ect. FEV1/FEV6 accurately represent FEV1% in the 
spirometric diagnosis of airway obstruction and restriction (Pedersen 2006 and 
Swanney et al 2000).    
2.4.3. Peak Expiratory Flow Rate (PEFR) 
Expiratory peak flow rate (PEFR) is the maximum flow generated during expiration 
performed with maximal force and started after a full inspiration. PEFR is appreciably 
larger if the maneuver is performed without pause immediately after the inspiration 
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than if it is performed after a pause (D’Angelo et al 1994 and Kano et al 1993). PEFR 
is not effort dependent. If the maneuver is performed sufficiently forcefully in most 
subjects, PEFR is determined by flow limitation in central, possibly also in more 
peripheral airways (Pedersen et al 1997). 
PEFR shows larger variability in asthmatics than in healthy subjects. It is used as an 
index of the activity of the disease process. For this purpose, PEFR is measured daily 
at least on getting out of bed, at noon, and at night before going to sleep. Variability is 
expressed as the ratio of the difference between the highest and lowest PEFR divided 
by the average of all measurements of that day. An improved or lower level of PEFR, 
of its variability, or both, signifies improvement or deterioration of the asthma 
(Quackenboss et al 1991 and Higgins et al 1989).  
The best reference value for a subject is the best value this subject produced when in a 
clinically good condition. In severe obstructive lung disease rapid and extensive 
dynamic airway compression during the forced maneuver contribute appreciably to 
initial maximum expiratory flow from the lungs; the severity of airway obstruction 
then tends to be underestimated from PEFR (Knudson et al 1974).  
2.4.4. Forced Expiratory Flows (FEFx%) 
FEFx% is the maximum expiratory flow when x% of the FVC has been exhaled. The 
commonly used FEFx% are FEF25%, FEF50% and FEF75%. Forced expiratory flows 
between 25% and 75% of the FVC are effort independent because they are 
determined by the flow limiting segments, which develop in the intrathoracic airways 
(Pedersen et al 1997). Variability in FVC contributes to that measured in the forced 
expiratory flow. For this reason, predicted values of FEFx% are of little value. 
2.4.5. FEFx1 -x2% 
FEFx1%-x2% is the average expiratory flow over the range of X1% to X2% of the 
FVC. The commonly used FEFx1-x2% are FEF25-75%, FEF75-85% and FEF85-95%. 
FEF25-75% is the most popular of these indices.  
The earliest change associated with airflow obstruction in small airways is believed to 
be a slowing in the terminal portion of the spirogram i.e. forced expiratory flow after 
75% of FVC. This slowing of expiratory flow is reflected in a concave shape on the 
flow–volume curve. As airway disease becomes more advanced the timed segments 
of the spirogram, such as the FEV1, will be reduced out of proportion to the reduction 
in FVC (Pellegrino 2005).  
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2.5. The Flow Volume Loops 
A normal Flow-Volume loop begins on the X-axis (Volume axis). At the start of the 
test, both flow and volume are equal to zero. Directly after this starting point the 
curve rapidly rises to peaked expiratory flow rate (PEFR). If the test is performed 
correctly, this PEFR is attained within the first 150 milliseconds of the test.  
The flow rate then quickly slows as more air is exhaled due to developing of the flow 
limiting segments. This landmark is very important in judging if the patient is giving 
maximal effort, overall quality of the test, strength of expiratory muscles, and the 
condition of the large airways, such as the trachea and main bronchi (figure 1-4). 
 
Figure (1-4): The Flow Volume Loop 
 
Forced expiratory volume after 1 second (FEV1) indicates the amount of air exhaled 
with maximum effort in the first second. The FEV1 is another very important 
landmark in assessing the overall status of the patient and quality of the test.  
Forced expiratory volume after 3 seconds (FEV3) indicates the amount of air exhaled 
with maximum effort in the first three seconds While forced expiratory volume after 6 
seconds (FEV6) indicates the amount of air exhaled with maximum effort in the first 
six seconds (not shown in figure 1-4). This parameter is primarily used to ensure 
expiratory efforts meet or exceed 6 seconds.  
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Another important result of a flow volume loop is the FVC. Many of the other results 
depend on this measurement. 
The FEF25% is the flow rate at the 25% point of the total volume (FVC) exhaled. 
Assuming maximal effort this flow rate is still indicative of the condition of fairly 
large to medium size bronchi. This landmark is used in calculations, with the 
FEF75%, to give FEF25-75% i.e. the middle half of the FVC. FEF25-75% is not 
dependent on patient effort. Many physicians look at FEF25-75% as an indicator for 
obstruction in the small airways. FEF25-75% value is largely dependent on the total 
volume exhaled (FVC) and tends to be highly variable from test to test.  
The FEF50% is the flow rate at the 50% point of the total volume (FVC) exhaled. 
This landmark is at the midpoint of the FVC and indicates the status of medium to 
small airways, it's sometimes looked at instead of the FEF25-75%.  
The FEF75% is the flow rate at the 75% point of the total volume (FVC) exhaled. 
This landmark indicates the status of small airways and is used in the FEF25-75% 
calculation. The damage done by most chronic pulmonary diseases show up in the 
smallest airways first and early indications of this damage begin to appear toward the 
end of the expiratory part of the flow volume loop. FEF75-85% (not shown in figure 
1-4) gives results comparable with FEF75%. 
When the flow reaches zero, the FVC is reached, it is recommended that the patient 
makes a complete and forced inspiration to obtain a closed flow-volume loop. This 
maneuver will give rise to the FIVC and its derived values, which are beyond the 
scope of this review (figure 1-4).  
The morphology of the flow-volume loop is very important. To the trained eye the 
flow-volume loop tells immediately if the test was well done and the most likely 
pattern of ventilatory defect. 
Forced Expiratory Time (FET) is time taken to exhale as much air as possible. To 
obtain reliable FVC values, the expiratory effort should be continued for at least 6 
seconds. The FET should never be less than 6 seconds unless the patient is severely 
restricted. 
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2.6. The Reference Values 
Lung diseases are associated with obstructive and/or restrictive ventilatory defects, 
which must be assessed with lung function tests. Usually results of previous 
spirometric tests are not available, so that it is difficult to judge whether the present 
results are within the normal range for that subject. In such circumstances reference 
values may be useful, i.e. equations used to predict ventilatory function of an 
apparently healthy subject of the same weight, height, age, gender and ethnic group.  
Since introduction of spirometry, a multitude of measurements, including volumes, 
flows and ratios, have evolved to assess normality and disease. Recently, the 
American Thoracic Society (ATS)/European Respiratory Society (ERS) Task Force 
suggested the need for a new Europe-wide study to derive updated reference equations 
for interpretation of spirometric tests, however, the official reference values in Europe 
are still those implemented by the European Coal and Steel Community (ECSC) and 
the ERS (Degens et al 2008 and Hansen et al 2006). 
3. Heart Rate Variability 
3.1. Background Information 
Overall visceral functions of the human body is controlled by the autonomic nervous 
system through its main two antagonistic branches – the sympathetic and 
parasympathetic nervous systems. Most of human organs are stimulated by one 
branch and inhibited by the other. Generally, when the person is in a calm state 
(relaxation, sleep, etc.), organs such as the heart, lungs, and blood vessels are under 
the dominance of parasympathetic control. When active (during physical activity, 
psycho-emotional arousal or stress) these organs are dominated by the sympathetic 
nervous system. A healthy person is capable of adjusting to external influences by 
means of quick and adequate sympathetic response. Once that factor disappears, 
parasympathetic activity increases, which balances overall autonomic activity. 
One of the most informative methods of evaluating the balance of the autonomic 
nervous system, including both branches, is heart rate variability analysis. It measures 
the time intervals between consecutive heartbeats, which vary under control of the 
autonomic nervous system. When the parasympathetic system is dominant, the 
heartbeat intervals (RR intervals) oscillate with higher frequencies. When sympathetic 
arousal occurs, lower frequency oscillations take place. 
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There is a standard mathematical procedure for short-term HRV evaluation, suggested 
by the Task Force of the European Society of Cardiology and the North American 
Society of Pacing and Electrophysiology (1996). It provides both time and frequency 
domain analysis of the RR time series. There are three important parameters of 
frequency domain analysis that reflect the levels of sympathetic and parasympathetic 
activity and their balance (see below).  
To perform the HRV analysis, an electrocardiograph (ECG) signal is usually 
measured. The RR intervals are derived from the ECG as the intervals between 
consecutive R-wave peaks. The alternative way is to use a photoplethysmograph 
(pulse wave) – pulse wave signal measurement by means of a portable and convenient 
finger or ear-clip sensor. It emits an infrared (IR) light on the skin. The emitted light 
is partially consumed by the blood flow. The degree of light consumption / reflection 
is proportional to the changes in blood flow. The pulse wave signal has periodic peaks 
that represent blood vessel pulsation. It can be also used to derive the RR intervals 
(the time between two pulse wave peaks). 
3.2. Physiology of Heart Rate Variability 
Because of continuous changes in the sympathetic-parasympathetic balance, the sinus 
rhythm exhibits fluctuations around the mean heart rate. Continuous small 
adjustments in heart rate are made by cardiovascular control mechanisms under 
steady state conditions. This results in periodic fluctuations in heart rate. The main 
periodic fluctuations found are respiratory sinus arrhythmia and baroreflex-related 
and thermoregulation-related heart rate variability (Akselrod et al 1985). Due to 
inspiratory inhibition of the vagal tone, the heart rate shows fluctuations with a 
frequency equal to the respiratory rate (McCabe et al 1985).  
Fluctuation of heart rate originates from self-oscillation in the vasomotor part of the 
baroreflex loop. These intrinsic oscillations result from the negative feedback in the 
baroreflex and are accompanied by synchronous fluctuations in blood pressure 
(Madwed et al 1989). The frequency of the fluctuations is determined by the time 
delay of the system (Rimoldi et al 1990. Pomeranz et al 1985 and Pagani et al 1984). 
Peripheral vascular resistance exhibits intrinsic oscillations with a low frequency 
which are influenced by thermal skin stimulation and are thought to arise from 
thermoregulatory peripheral blood flow adjustments. The fluctuations in peripheral 
vascular resistance are accompanied by fluctuations with the same frequency in blood 
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pressure and heart rate and are mediated by the sympathetic nervous system 
(Lindqvist et al 1989 and Kitney 1975).  
3.3. Heart Rate Variability Measurement 
There are different methods of evaluation of the variations in heart rate. Two are the 
most common and recommended by the Task Force of the European Society of 
Cardiology and the North American Society of Pacing and Electrophysiology (1996): 
1. Time Domain Methods 
2. Frequency Domain Methods 
Time domain methods are commonly used for 24-hour data recordings. However, 
according to the Task force short-term recordings (e.g. 5-min length) can also be 
analyzed. Frequency domain methods can be easily used for short-term recordings as 
well. The following heart rate variability parameters are calculated by most HRV 
machines on short-term data record (at least 5 minutes long): 
3.3.1. Time Domain Parameters 
Calculation of these indices is based on statistical operations on R-R intervals. The 
main time domain parameters are: 
3.3.1.1 Mean Heart Rate (MHR) is a mean heart rate value averaged on the entire 
recording (trial). MHR is measured in beats per minute (BPM). 
3.3.1.2. Mean NN (MNN) is a mean heart beat interval value averaged on entire 
recording (NN means normal-to-normal beats). It is used to be called the mean RR 
interval when it is derived from ECG recording (R-R interval = N-N interval). MNN is 
measured in milliseconds (ms).  
3.3.1.3. Standard deviation of the NN intervals (SDNN) is the square root of variance 
of N-N intervals. A variance is mathematically equivalent to the total power of 
spectral analysis, so it reflects all cyclic components of the variability in recorded 
series of N-N intervals. The actual values of SDNN depend on the length of recording 
i.e. the longer the recording, the higher the SDNN values are. Thus, in practice it is 
inappropriate to compare SDNN values derived from the NN recording of different 
length (Task Force ESC and NASPE 1996). SDNN is measured in milliseconds. 
3.3.1.4. Square root of the mean squared differences of successive NN intervals 
(RMSSD) is an estimate of high-frequency variations in heart rate in short-term NN 
recordings which reflects an estimate of parasympathetic regulation of the heart. 
RMSSD is measured in milliseconds. 
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3.3.2. Frequency Domain Parameters:  
Calculation of these indices is based on spectral analysis of R-R intervals. The main 
advantage of this method is the possibility to study their frequency-specific 
oscillations. Thus not only the amount of variability but also the oscillation frequency 
(number of heart rate fluctuations per second) can be obtained. Spectral analysis 
involves decomposing the series of sequential R-R intervals into a sum of sinusoidal 
functions of different amplitudes and frequencies by the Fourier transform algorithm. 
The result can be displayed (power spectrum) with the magnitude of variability as a 
function of frequency. Thus, the power spectrum reflects the amplitude of the heart 
rate fluctuations present at different oscillation frequencies (figure 1-5). The main 
time frequency parameters are:  
Figure (1-5): Frequency Domain Heart Rate Variability 
 
Top. Each point represents the instantaneous heart rate calculated from the R-R 
interval length. Bottom. Heart rate power spectrum of the heart rate trace visualized 
in the top panel. The three main components (peaks) of the power spectrum 
correspond to the main periodic fluctuations in heart rate: very-low-frequency (VLF), 
low-frequency (LF) and high-frequency (HF) fluctuations. 
 
3.3.2.1. Total Power (TP) is a short-term estimate of the total power of power spectral 
density in the range of frequencies between 0 and 0.4 Hz. This measure reflects 
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overall autonomic activity. Total Power is calculated in milliseconds squared 
(ms2/Hz). 
3.3.2.2. Very Low Frequency (VLF) is a band of power spectrum range between 
0.0033 and 0.04 Hz. Very Low Frequency band is calculated in milliseconds squared 
(ms2/Hz). The physiological explanation of the VLF component is much less defined, 
and the existence of a specific physiological process attributable to these heart period 
changes might even be questioned. The nonharmonic component, which does not 
have coherent properties, is commonly accepted as a major constituent of VLF. Thus, 
VLF assessed from short-term recordings (5 minutes) is a dubious measure and 
should be avoided when the PSD of short-term ECGs is interpreted (Task Force of the 
ESC and NASPE 1996). 
3.3.2.3. Low Frequency (LF) is a band of power spectrum range between 0.04 and 
0.15 Hz. This measure reflects primarily sympathetic activity. It is a strong indicator 
of sympathetic activity in long-term recordings. The parasympathetic influences LF 
when respiration rate is lower than 9 per minute or during taking a deep breath. Thus, 
when subject is in the state of relaxation with a slow and even breathing, the LF 
values can be very high indicating increased parasympathetic activity rather than 
increased sympathetic regulation. It is recommended to maintain a breathing rate not 
less than 9 breaths per minute during HRV recording to ensure separation of 
sympathetic and parasympathetic activities. Low Frequency band is calculated in 
milliseconds squared (ms2/Hz). 
3.3.2.4. High Frequency (HF) is a band of power spectrum range between 0.15 and 
0.4 Hz. This measurement reflects parasympathetic (vagal) activity. HF is also known 
as a ‘respiratory’ band because it corresponds to the NN variations caused by 
respiration; the respiratory sinus arrhythmia (RSA). The heart rate is increased during 
inhalation and drops during exhalation. Deep and even breathing causes an increase in 
the amplitude of HF peak on power spectrum. However if respiration rate drops below 
nine breaths per minute this peak moves into LF frequency range and still represents 
parasympathetic regulatory activity. High Frequency band is calculated in 
milliseconds squared (ms2/Hz). 
3.3.2.5. LF/HF Ratio is the ratio between the power of Low Frequency and High 
Frequency bands. This measure indicates overall balance between sympathetic and 
parasympathetic systems. Higher values reflect domination of the sympathetic system, 
while lower ones indicate domination of the parasympathetic system. However, when 
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deep and even breathing occurs at rates less than 9 breaths per minute, the elevation of 
this parameter reflects increase of parasympathetic regulation due to the effect of 
respiratory sinus arrhythemia.  
3.3.2.6. Normalized Low Frequency (LF Norm) is the ratio between absolute value of 
the Low Frequency and difference between total power and very low frequency. This 
measure minimizes an effect of changes in very low frequency power and emphasizes 
changes in sympathetic regulation. Normalized LF is calculated in percentile units. 
3.3.2.7. Normalized High Frequency (HF Norm) is the ratio between absolute value of 
the High Frequency and difference between total power and very low frequency. This 
measure minimizes an effect of changes in very low frequency power and emphasizes 
changes in parasympathetic regulation. Normalized HF is calculated in percentile 
units. 
In conclusion, the representation of LF and HF in normalized units emphasizes the 
controlled and balanced behavior of the two divisions of the autonomic nervous 
system. Moreover, the normalization tends to minimize the effect of the changes in 
total power on the values of LF and HF components. Nevertheless, normalized units 
should always be quoted with absolute values of the LF and HF power in order to 
describe completely the distribution of power in spectral components (Task Force of 
the ESC and NASPE 1996). 
3.4. Duration and Circumstances of ECG Recording  
In HRV research, the duration of recording is dictated by the nature of each 
investigation. Standardization is needed particularly in studies investigating the 
physiological and clinical potential of HRV.  Frequency domain methods should be 
preferred to the time domain methods when short-term recordings are investigated. 
The Task Force of the ESC and NASPE (1996) recommends recording time at least 
10 times the wavelength of the lower frequency band of the investigated component, 
and should not be substantially extended so as to ensure the stability of the signal. 
Thus, recording of approximately 1 minute is needed to assess the HF components of 
HRV, while approximately 2 minutes are needed to address the LF component. To 
standardize different studies investigating short-term HRV, 5-minute recordings of a 
stationary system are preferred unless the nature of the study dictates another design.  
Although the time domain methods, especially the SDNN and RMSSD methods, can 
be used to investigate recordings of short durations, the frequency methods are usually 
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able to provide results that are more easily interpretable in terms of physiological 
regulations. In general, the time domain methods are ideal for the analysis of long-
term recordings.  
A substantial part of the long-term HRV value in cardiac studies is contributed by the 
day-night differences. Thus, the long-term recording analyzed by the time domain 
methods should contain at least 18 hours of analyzable ECG data that include the 
whole night (Task Force of the ESC and NASPE 1996).  
Little is known about the effects of the environment (type and nature of physical 
activity and emotional circumstances) during long-term ECG recordings. For some 
experimental designs, environmental variables should be controlled and in each study, 
the character of the environment should always be described. The design of 
investigations also should ensure that the recording environment of individual subjects 
is similar. In physiological studies comparing HRV in different well-defined groups, 
the causes of differences between underlying heart rate also should be properly 
acknowledged. 
3.5. Determinants of Heart Rate Variability 
3.5.1. Respiratory Frequency  
Respiratory sinus arrhythmia increases when respiratory frequency approaches the 
frequency of the intrinsic baroreflex-related heart rate fluctuations. Respiratory sinus 
arrhythmia in adults is maximal at a breathing rate of 6 per minute (0.1 Hz). 
Respiratory rate greater than this frequency is negatively correlated with the amount 
of respiratory sinus arrhythmia (Hirsch and Bishop 1981). Respiratory sinus 
arrhythmia persists for all exercise intensities and increases during the highest 
intensities. Its persistence and increase are strongly linked to both the frequency and 
degree of lung inflation, suggesting a mechanical influence of breathing on respiratory 
sinus arrhythmia (Blain et al 2005). 
3.5.2. Blood Pressures 
Previous studies have reported decreased HRV among hypertensives (Mussalo et al 
2001, Singh et al 1998 and Liao et al 1996). Not only hypertension was associated 
with decreased HRV but also the association between HRV and blood pressure was 
present across the full blood pressure range (Schroeder et al 2003, Lucini et al 2002 
and Fagard et al 2001). Individuals with low HRV at baseline were at an increased 
risk of developing hypertension over 9 years of follow-up, thus indicating that 
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decreased HRV often precedes the development of hypertension (Schroeder et al 
2003). 
3.5.3. Gender and Age 
Studies of gender differences in autonomic regulation demonstrate significantly 
greater parasympathetic activity in women than do age-matched men (Kuo et al 1999 
and Rossy et al 1998). However, the results of Umetani et al (1998) revealed lower 
HRV in female compared with male subjects at age less than 30 years old, decreased 
gender differences at age between 30 – 50 years old and no gender differences at age 
above 50 years old. Therefore, previous studies examining gender differences in 
healthy populations report mixed findings possibly due to examining different age 
groups and a failure to control confounding factors that might affect cardiovascular 
control.  
3.5.4. Body Size 
It has been reported that a disordered homeostatic mechanism may promote excessive 
storage of energy by decreasing sympathetic activity, while defending against weight 
gain by decreasing parasympathetic activity (Peterson et al 1988). In contrast, another 
study reported that modest diet-induced weight gain elicits sympathetic neural 
activation in non-obese males (Gentile et al 2007). Masuo et al have reported that 
plasma norepinephrine concentrations increase following weight gain in men (Masuo 
et al 2003). The results of many studies consistently reveal higher sympathetic 
activity in obese compared with non-obese individuals (Alvarez 2002 and 
Gudbjornsdottir et al 1996). However, anthropometric measurements seem to have 
minor influences on HRV. A task force of the European society of cardiology and the 
North American society of pacing and electrophysiology suggested comprehensive 
investigations to obtain formulae of normal values of HRV in large normal 
populations based on age and gender without special consideration to anthropometry 
(Task Force of the ESC and NASPE 1996). This is probably justified by the weak 
correlations between anthropometry and HRV. 
3.5.5. Others  
HRV measures have been found to be related to several clinical, lifestyle, and 
laboratory factors e.g. short-term HRV is related inversely to LDL cholesterol and 
smoking in the population, and directly to alcohol use in women (Kupariet al 1993). 
HRV improves with physical training especially the HF and LF components. These 
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effects must therefore be addressed in investigations on autonomic balance (Molgaard 
et al 1994). 
3.6. Clinical Use of HRV   
HRV has been the subject of numerous clinical studies investigating a wide spectrum 
of cardiological and noncardiological diseases and clinical conditions (Task Force of 
the ESC and NASPE 1996). These include myocardial infarction (Casolo et al 1992), 
hypertension (Schroede et al 2003 and Pikkujämsä et al 1998), diabetes mellitus 
(Bernardi et al 1992 and Ewing et al 1984), tetraplegia (Guzzetti  et al 1994 and Inoue 
et al 1990), renal failure (Ranpuria et al 2008, Wen1 et al  2007 and Tsai et al 2002), 
irritable bowel syndrome (Heitkemper et al 2001) and anxiety (Gehi et al  2005). The 
particulars of these studies are outside the scope of this review.  
Regarding asthma, few HRV studies were done in this field (Du et al 2001, Kazuma 
et al 1998, Kazuma et al 1997, Korematsu 1995 and Garrard et al 1992). The study 
groups of most of these researches are children. Their results are not reproducible, 
probably due to inter-individual differences of autonomic balance in test group or 
inadequately designed methods. 
Garrard et al (1992) evaluate ten healthy controls, nine asymptomatic, untreated 
asthmatic subjects and ten asthmatic patients during treatment for acute asthma, by 
measurement of the variation in resting heart rate using frequency spectrum analysis. 
Spectral density of the beat-to-beat heart rate was measured with the LF and HF. 
Acute asthmatics had higher heart rates than either of the other two groups. 
Sympathetically mediated heart rate variability (LF Norm) was significantly lower in 
both asymptomatic and acute asthma subjects compared to the controls. The study fail 
to prove dominance of parasympathetic activity (HF Norm) in asthmatic groups. 
Kazuma et al (1997) analyzed the 24-hour HRV in 94 asthmatic children (ages 5-15 
years). These subjects were divided into groups according to the severity of their 
asthma. The autonomic nervous function (ANF) of asthma subjects was lower in 
comparison to the normal group. SDNN, LF and HF were lowest in the severe asthma 
group. It was concluded that even in the normal condition in which the patient is free 
of an asthma attack; the ANF of asthma sufferers differs from that of normal children.  
One year later, Kazuma and his group (1998) examined the circadian rhythm of 
parasympathetic nervous function in 80 asthmatic children, subdivided into three 
groups according to asthma severity, and 90 healthy children. All patients underwent 
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24-hours electrocardiography in normal condition. Circadian rhythm disappeared in 
nine of the 80 asthmatic children and was observed in all the individuals in the 
healthy children. There was no significant difference between the different severity or 
therapies in each group. In some asthmatic children, the circadian rhythm of 
parasympathetic nervous function disappeared, the parasympathetic nervous function 
was low in remission. It was suggested that the disorder of biologic rhythm is related 
to the pathogenesis of asthma. 
Du et al (2001) studied the changes of autonomic nervous function in 23 young 
healthy volunteers and 69 asthmatic using 24- hours HRV. Asthmatics were divided 
into three groups according to the severity of asthma. Results revealed high HF and 
low LF in asthmatics compared with the normal group, concluding autonomic nervous 
function of asthmatics differ from that of normal young adults. Similar results were 
obtained by Korematsu (1995) in children (age 2 -16 years old) with severe form of 
the disease. 
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4. Objectives 
4.1. Main Objectives 
− To detect reliability and validity of ACT and NAEPP in the classification of 
asthmatic patients based on spirometry evaluation. 
− To detect effects of asthma on short-term HRV indices. 
− To detect effects of electrolytes (Na+, K+, Ca++ and Mg ++) on lung function 
parameters and HRV. 
4.2. Specific Objectives 
− To compare the relative variability of a wide range of spirometric measurements 
in asthmatics and non-asthmatics. 
− To determine arrhythmogenic effect of asthma using indices derived from short-
term HRV recordings. 
− To use HRV indices as indicators of autonomic balance in chronic asthmatics. 
− To determine the effect of asthma on heart rate and blood pressure. 
− To evaluate the relation of  electrolytes levels and pulmonary function tests. 
− To evaluate the relation of blood glucose and electrolytes levels and HRV. 
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CHAPTER TWO 
METHODOLOGY 
1. Study Design 
Cross-sectional case control study. 
2. Study area 
Patients were selected from chest clinics of teaching hospitals in Khartoum state 
(Khartoum, El-Saab, Bashayr, Ibraheem Malik, Omdurman, Abo-Anga and Khartoum 
North teaching hospitals) and then referred to Al-Neelain University – faculty of 
medicine – department of physiology for further evaluations and investigations.  
3. Study Population and Sample Size 
The study involved two groups: a control group of 56 apparently healthy subjects and 
gender and age matched group of 100 asthma patients who satisfy selection criteria 
(table 2-1). The subjects of the control group were recruited mainly from university 
students and employees.  
Table (2-1): Gender and Age Distribution of Sample Size 
Subjects/Patients Gender Age (Years) Sample Size 
Males 20-40 28 Non-Asthmatics 
Females 20-40 28 
Males 20-40 29 Symptoms-Free Asthmatics 
Females 20-40 24 
Males 20-40 23 Asthmatics with Active Symptoms 
Females 20-40 24 
Total 156 
 
4. Criteria for Selecting the Test group 
4.1. The Inclusion Criteria 
1. Past medical history of asthma (at least for two years). 
2. Age: 20-40 years old. 
4.2. The Exclusion Criteria 
1. Past medical history suggestive of other chronic respiratory diseases apart from 
asthma. 
2. Age: less than 20 and more than 40 years old patients  
3. Past medical history of diabetes mellitus, hypertension, heart diseases or any 
illness that may alter heart rate. 
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5. Procedure of Data Collection 
Volunteers arrived at the physiology laboratory – faculty of medicine – Alneelain 
University  at morning, between 09.00 and 12.00 am. Proper history and examination 
were done guided by the data collection sheet (Appendix A) for each individual. 
Blood samples were taken in appropriate blood containers for biochemical 
investigations. After a resting period, during which each subject was familiarized with 
the testing equipments and procedures used in the study, spirometry and then HRV 
studies were done according to ATS/ERS (Miller et al 2005) and ESC/NASPE (Task 
Force of the ESC and NASPE 1996) standards respectively (see below). Studied 
variables are summarized in table (2-2). 
5.1. Procedure for Measuring Weight and Height 
GIMA scale (Professional Medical Products - Italy) was used for measuring weight 
and height simultaneously. The weight scale was placed in "zero" position, then the 
subject was asked to remove his/her shoes and stand erect on the scale with shoulders 
in the horizontal level, hands at sides, knees and thighs together, feet comfortably 
touching the centre of the platform and weight evenly distributed on both lower limbs. 
Weight was measured to the nearest decimals and recorded immediately. Then the 
head was adjusted, while the subject in the same position, so that an imaginary line 
from the lower margin of the eye socket to the notch above the tragus of the ear is 
completely horizontal and head, back, buttocks and heals touching height scale. A flat 
headpiece was placed firmly on the crown of the head and at right angle with the 
measurement surface. Height was measured to the nearest decimals and recorded 
immediately. Body mass index (BMI) was calculated using the formula: BMI (Kg/m2) 
= Weight (Kg) / (Height)2. 
5.2. Procedure for Measuring Blood Pressure 
The non-invasive ausculatory method was used for measuring the blood pressure. The 
subject sat down and relaxed his/her arm on a table so that the brachial artery was 
leveled with the heart. The cuff of sphygmomanometer (Mercury in glass 
Sphygmomanometer – GOH Industries Limited - Japan) was wrapped around the 
subject's upper arm, just above the elbow. The cuff is inflated to a pressure sufficient 
to abolish radial pulse. The corresponding blood pressure (crude systolic pressure) 
was recorded and then the cuff was deflated.  Thereafter, a stethoscope was placed on 
the hollow of the elbow, over the brachial artery, and the cuff was inflated again to a 
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pressure 30 mmHg above the crudely predetermined systolic pressure. The valve on 
the pump was loosened slowly to allow the pressure of the sphygmomanometer cuff 
to decrease. The systolic blood pressure (SBP) was determined by appearance of heart 
sounds (Korotkoff sound I) while diastolic blood pressure (DBP) was determined by 
disappearance of the sounds (Korotkoff sound V). Mean arterial blood pressure 
(MABP) was determined by the formula: MABP = DBP + [(SBP – DBP)/3]. 
Table (2-2) Studied Variables. 
History Age, gender, ACT score, NAEPP class, 
asthma duration and drug therapy. 
Examination Systolic, diastolic and mean arterial blood 
pressures. 
Anthropometry Weight, height and body mass index. 
Laboratory Investigations Concentrations of blood hemoglobin, 
glucose (random), sodium, potassium, 
calcium and magnesium. 
Pulmonary Function Tests Forced expiratory volumes (FEV1, FEV3, 
FEV6, FVC), timed forced expiratory 
ratios (FEV1%, FEV3%, FEV6%), 
FEV1/FEV6 and forced expiratory flows 
(PEFR, FEF25%, FEF50% FEF75% 
FEF25%-75%, FEF75 -85%). 
Heart Rate Variability Studies Time domain indices (MHR, MNN, 
SDNN and RMSSD), frequency domain 
indices (TP, VLF, LF and HF) and 
indicators of autonomic balance (LF 
Norm, HF Norm and LF/HF). 
 
5.3. Procedure for Measuring Pulmonary Function 
"IQ TQ Spirometer" (Version 5.18 - Clement Clarke International Limited – U. K) 
was used for measuring pulmonary function. This is a portable device, PC based and 
connected to the computer with a USB cable. Following calibration and data entering, 
FVC maneuvre was repeated until subjects were able to perform an acceptable flow 
volume loop according to ATS/ERS standardization of spirometry (Miller et al 2005). 
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For each subject, a minimum of three acceptable and reproducible maneuvers were 
performed (table 2-3). The readings of the highest FVC of the three sets of acceptable 
maneuvers was chosen and saved in the computer. All tests were done in the standing 
position. The guidelines of ATS/ERS on standardization of spirometry are 
summarized in table (2-3). Measured spirometric indices are pointed out in table (2-2) 
Table (2-3): Guidelines of ATS/ERS on Standardization of Spirometry. 
FVC  
Minimum 
Duration 
1. Fet100%φ ≥ 6 seconds, or  
2. plateau in the volume-time curve, or 
3. Subject cannot or should not continue to exhale. 
FVC  
End of Test 
(EOT)criteria 
1. Decay dv/dtζ must be less than 0.03, or 
2. Subject cannot or should not continue further exhalation, or 
3. The volume time curve shows an obvious plateau, or 
4. The forced exhalation is of reasonable duration 
Maximum 
Number of 
Maneuvers 
8 maneuvers 
FVC  
Maneuver 
Acceptability 
1. The Peak t(s)Υ should be less than 0.12 seconds. 
2. Extrap V Ψ < 5% of FVC or 150 mL, whichever is greater 
3. coughing that interferes with the measurement of FEV1 and/or 
FVC 
4. Absence of valsalva maneuvea, leak or glottis closure 
5. Maximal effort throughout the maneuvre. 
FVC and FEV1 
Reproducibility 
the largest and second largest FVC and or FEV1 must not differ by 
more than 150 mL 
φ Fet100% (total forced expiratory time) is the calculated test duration, from the extrapolated start 
to the end of test. 
ζ Decay dv/dt Is the slope of the Volume-Time graph at the end of the test. It is a measure of the 
volume that is being exhaled as a ratio of time taken at the end of test. It is indicative of less than 
0.03 litres of air being exhaled over a 1 second of time. A Decay dv/dt that does not meet the 
requirement is indicative of a premature end. 
Υ Peak t(s) is the time taken from the calculated start of the test until peak flow was reached. 
Ψ Extrapolated Volume in Litres (Extrap V (L)) is the difference in volume (in litres) between 
the first sign of exhalation as a start point and the extrapolated start position. Extrapolated 
Volume as a Percentage (Extrap V(%))  is the Extrap V(l) as a percentage of the FVC. 
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5.4. Procedure for Measuring Heart Rate Variability 
Biocom 3000 ECG recorder (Heart Rhythm Scanner - Version 2.0 - Biocom 
Technologies – U.S.A) was used for studying HRV. This is a portable device, PC 
based and connected to computer with a USB cable. The device has a standard ECG 
Y-type cable terminated with two small flat plastic pads (that embed large Ag / AgCl 
dry ECG electrodes) with two elastic wristbands. Both sensor pads marked as “Left” 
and “Right” were placed on respective wrists with electrode disks facing down so that 
wristbands secure those pads firmly. Volunteers were advised to lie down (in supine 
position) and breathe comfortably while feeding the software with their data. Ensuring 
clean ECG signals and absence of movement artifacts, ECG recording was initiated 
by pressing start button. Heart Rhythm Scanner automatically finishes the trial session 
once its time expires (5 minutes). After recording the session, the ECG data was 
reviewed for abnormal ECG readings. The software is capable of doing an automatic 
search for various types of abnormal ECG recording irrelevant to their cause. This is 
based on the standard statistical procedure of exclusion of rough artifacts from the 
data series. Abnormal ECG readings were deleted and the software were allowed to 
calculate HRV parameters from the rest of the raw data. Measured HRV parameters 
are pointed out in table (2-2).  
5.5. Blood Samples 
About 5 ml of blood was collected from each subject, mostly from median cubital 
vein although other veins on the forearm or back of the hand were sometimes used. 
Tourniquet was not used because venous stasis might lead to acidaemia and unbinding 
of calcium bound to proteins, which might result in a falsely high reading of calcium 
concentrations. 
Skin over the site of venepuncture was cleaned with an alcohol swab. Using the 
dominant hand the needle was inserted through the skin into the vein at an angle of 
15-30 degrees. Once there is enough blood, the needle was removed quickly and 
venepuncture site was pressed with a cotton wool. The collected blood was transfered 
into heparinized blood containers. The blood containers were inverted several times to 
ensure mixing. 0.02 ml of the heparinized blood was used for estimation of 
hemoglobin concentration. The remainder of blood was separated by centrifugation 
machine (Centrfic Model 228 – Fisher Scientific – U.S.A) for the rest of 
investigations.  
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5.6. Colorimetry 
Colorimetry was used for estimation of hemoglobin, glucose, calcium and magnesium 
concentrations while flame photometry was used for estimation of sodium and 
potassium concentrations.  
5.6.1. Principle of the method 
Colorimetry is used to determine the concentrations of substances that absorb light of 
a specific wavelength or color according to Lambert's law, which relates the amount 
of light absorbed to the distance traveled through the absorbing medium, and Beer's 
law, relating it to the concentration of absorbing substance in the colored solution. A 
photocell is often used to measure the amount of light transmitted through a glass tube 
containing the solution to be analyzed; the result is compared with results from a 
similar tube containing solvent alone. Concentrations of most elements and many 
compounds may be identified by colorimetry or spectrophotometry, a closely related 
technique. 
5.6.1.1. Principle of Measuring Hemoglobin Concentrations  
Whole blood when diluted with Drabkin's solution (potassium fericyanide and 
potassium cyanide), the RBCs are hemolysed and the hemoglobin will be oxidized by 
fericyanide into methemoglobin. The latter is converted by cyanide into stable 
hemoglobincyanide (HiCN). Absorbance of the HiCN solution is read in a calorimeter 
at wavelength 540nm/yellow-green filter. 
5.6.1.2. Principle of Measuring Glucose Concentrations  
Glucose present in the plasma is oxidized by the enzyme glucose oxidase to gluconic 
acid with the liberation of hydrogen peroxide, which is converted to water and oxygen 
by the enzyme peroxidase (POD). 4 aminophenazone, an oxygen acceptor, takes up 
the oxygen and together with phenol forms a pink coloured chromogen which can be 
measured at 520mm. 
5.6.1.3. Principle of Measuring Calcium Concentrations  
Calcium forms a purple-coloured complex with ortho-cresolphthalein complexone in 
an alkaline medium. The inclusion of HCl helps to release calcium bound to proteins 
and 8 hydroxy-quinoline eliminates the interference by magnesium. 2-amino, 2-
methyl, 1-propanol (AMP) provides the proper alkaline medium for the colour 
reaction. The intensity of the colour is measured at 580nm/yellow green filter. 
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5.6.1.4. Principle of Measuring Magnesium Concentrations  
This is carried out by fixing amounts of a chelatometric dye, metal cation masking 
agents, a chelating agent, an alkaline buffer and a stabilizer on a bibulous material 
covered with a semipermeable membrane, adding the test specimen, and measuring 
the amount of color change of the dye at 540nm wavelength.  
5.6.2. Procedure of Measuring Hemoglobin Concentrations 
1. Four ml of Drabkin's solution was added into each of three tubes labeled blank, 
standard and the test. 
2. 0.02 ml of well-mixed commercial standard was added to the standard tube. 
3. 0.02 ml of well-mixed heparinized blood sample was applied to the test tube. 
4. JENWAY 6051 Colorimeter (Bibby Scientific Limited – U.K)  was used to read 
the absorbance of the preparations (test and standard) after zeroing by the blank  
using the filter 540 nm 
5. The Hb concentration was estimated from the formula: Hb concentration = 
absorbance of the test X concentration of standard / absorbance of standard 
5.6.3. Procedure of Measuring Glucose Concentrations  
JENWAY 6051 Colorimeter (Bibby Scientific Limited – U.K) was used to measure 
Glucose concentration as follows: 
1. One ml of the working solution was added into each of three tubes labeled blank, 
standard and the test. 
2. 0.01 ml of a commercial standard was added to the standard tube. 
3. 0.01 ml of plasma derived from heparinized blood sample centrifugation was 
applied to the test tube. 
4. JENWAY 6051 Colorimeter (Bibby Scientific Limited – U.K) was used to read 
the absorbance of the preparations (test and standard) after zeroing by the blank  
using the filter 520 nm 
5. Blood glucose concentration was estimated from the formula: Concentration of 
test = absorbance of the test X concentration of standard / absorbance of standard. 
5.6.4. Procedure of Measuring calcium and Magnesium Concentrations  
BS-200 Chemical analyzer (Shenzhen Mindray Bio-Medical Electronics – China) was 
used in measuring calcium and magnesium concentrations. It is a kind of biochemical 
analyzer used to assay biochemical indexes of blood, urine, or other body fluids, with 
characteristics simulating manual operations to achieve a series of processes during 
biochemical analyzing, including dispensing reagents and samples, mixing, heat-
 45
preserving reaction, detecting absorbency, and calculating data results. BS-200 
Chemical analyzer mainly consists of a reaction disk having a constant temperature 
system, a sample disk (a sample delivery rack), a reagent disk, a sample dispensing 
mechanism, a reagent dispensing mechanism, a stirring mechanism, a cleaning 
mechanism for reaction cups, and a user operating system. Test samples was delivered 
to the machine after data entering. Waiting for the automated processes described 
above, the machine provided the results within nine-minute duration. Ten calcium and 
three magnesium samples were damaged and give zero results and therefore were not 
considered in data analysis (appendix table 1, 4 and 8). 
5.6.5. Measurement of Sodium and Potassium (Flame Photometry) 
5.6.5.1. Principle of the method  
When a solution of an inorganic salt such as sodium chloride is sprayed into the 
flame, the elements in the compound are partly converted into the atomic state. Due to 
the heat energy of the flame a very small proportion of these atoms is excited and the 
electrons move to a higher energy level. The proportion of the atoms that are excited 
depends upon the concentration of the particular element and on the temperature of 
the flame. In the excited state, the electrons are unstable and they rapidly revert back 
to their former lower energy level. As they change from the excited state or higher 
energy level back to the lower energy level, they emit the light in the form of a fixed 
wavelength, to produce a spectrum. Under carefully controlled conditions the amount 
of light emitted is directly proportional to the number of atoms that are excited, which 
in turn is proportional to the concentration of the substance in the sample.  
5.6.5.2. Procedure of Measuring Sodium and Potassium Concentrations 
1. Flame photometer 410 (Sherwood Scientific Limited – U. K) is Switch on. This 
should turn digital display on. 
2. Appropriate filter is selected (Na+ or K+ according to the test). 
3. Compressor is switched and checked for the air pressure (adjusted to read between 
0.4 and 0.6 k g/cm2). 
4. The gas cylinder is opened, the trapper at the rear of the flame photometer is 
removed and the flame is ignited. 
5. The atomizer is fed with distilled water and waited for at least 30 seconds. Then 
the digital display is adjusted the zero. 
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6. Lastly, the diluted test sample (1 in 100) is fed to the atomizer for at least 30 
seconds before reading Na+ or K+ concentrations.      
6. Saving the Data 
By the end of the day (during period of data collection), all data concerning each 
subject were registered in a separate row of an excel sheet (Microsoft Office Excel for 
windows; 2003). Graded categorical data were given the codes 0, 1, 2 … ect, 
according to the strength of the variable. Later upon finishing data collection, data 
were transferred and saved in its numerical form in Statistical Package Program for 
Social Science (SPSS for windows 11.5; Chicago, IL).  
7. Statistics and Analysis 
Statistical evaluation was performed using the Microsoft Office Excel and SPSS 
programs under supervision of expert statisticians from department of applied 
statistics – Al Sudan University for Science and Technology. Studied variables were 
described with bar charts, measures of central tendency (mainly means) and measures 
of dispersion (mainly standard deviations and standard errors of the means).  
In this study, an intention to classify subjects according to asthma severity (using 
ACT and NAEPP classifications and spirometry) was prearranged. Subjects are 
classified into non-asthmatics, mildly asthmatics (including symptoms free, well 
controlled and intermittent asthma) and severely asthmatics (including symptomatic, 
poorly controlled, uncontrolled and persistent asthma). Screening studied variables for 
significant differences in the means between the groups was performed using analysis 
of variance.  
When significant differences were identified, individual groups were compared using 
the Student two-tailed, unpaired T-test. Discriminant analysis technique was used to 
condense all studied spirometric measurements in to one representative score.  
To compare efficiency of different spirometric measurements on asthma diagnosis, 
conditional ratios (sensitivity, specifity, accuracy, positive predictive and negative 
predictive values) and ROC curves were used. Associations between studied variable 
were tested by bivariate correlations.  
Adjustment for possible confounding factors was performed using partial correlations 
and the general linear model. In all of these statistical tests, only P < 0.05 was 
considered significant.   
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CHPTER THREE 
RESULTS  
The main findings of this research will be presented under the following headings: 
1. Characteristics of test and control groups. 
2. Lung function parameters. 
3. Heart rate variability studies. 
4. Effects of Drug Therapy. 
5. Levels of glucose, haemoglobin & electrolytes and their relationship to above 
parameters. 
The tables show means, standard deviations and standard error of means of main 
parameters studied. The appendix shows tables of the raw data and their statistical 
analysis. 
1. Classification of Patients 
Patients were classified according to presence or absence of symptoms, the asthma 
control test (ACT) score and NAEPP classification taking into consideration duration 
of asthma. According to ACT, 41.5% of asymptomatic and 72.3% of symptomatic 
asthma patients were labeled uncontrolled. Therefore, it was decided to present data 
according to the presence or absence of symptoms at the time of examination. For 
comparison, the data of classification according to ACT are given in figures 3-1, 3-5 
__3-9 and 3-13 __ 3-15. 
Table (3-1) characterizes asthmatic patients using the above-mentioned parameters. 
ACT score was higher while NAEPP class was lower in symptoms free compared 
with symptomatic asthmatic patients (P = 0.000 and 0.005 respectively). Asthma 
duration showed no significant difference between these groups. For means, standard 
deviations and P values see appendix table 7-13 and 7-14, which can also be 
consulted for all other data. 
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Table (3-1): Characterization of Asthmatic Patients according to Asthma 
Control Test Score, NAEPP Classification and Duration of Asthma. 
Subjects and 
Patients   Gender 
Asthma 
Control Test 
Score NAEPP Class 
Duration of 
Asthma 
(Years) 
Mean 17.42 1.92 11.58 
SD 
Female 
3.99 0.78 10.15 
Mean 16.14 2.38 10.69 
SD 
Male 
4.33 0.78 8.76 
Mean 16.72 2.17 11.09 
Asthmatics without 
Symptoms 
(Females = 24, 
Males = 29) 
SD 
Total 
4.19 0.8 9.33 
Mean 11.92 2.67 10.79 
SD 
Female 
3.88 0.87 6.22 
Mean 14.61 2.61 13.48 
SD 
Male 
3.96 0.78 9.66 
Mean 13.23 2.64 12.11 
Asthmatics with 
Symptoms 
(Females = 24, 
Males = 23) 
SD 
Total 
4.11 0.82 8.11 
€ Significant Mean Difference between Asthmatics with Symptoms and Asthmatics without 
Symptoms. 
 
Figure 3-1 compares asthmatic patients according to ACT, NAEPP classification and 
duration of asthma. ACT scores were higher while NAEPP classes were lower in well 
controlled compared with both poorly controlled and uncontrolled asthmatic patients 
(P < 0.01 for all). All asthmatic patients had long-standing history of asthma (mean = 
16.6 years for controlled, 8.93 years for poorly controlled and 10.93 years for 
uncontrolled). However, Asthma duration was significantly higher in well controlled 
compared with both poorly controlled and uncontrolled asthmatic patients (P = 0.000 
for both). 
2. Characteristics of Test and Control Groups 
The study involved 100 asthmatic patients and 56 apparently healthy subjects as a 
control group. Of the total asthmatic patients, 53% were symptoms free at the time of 
data collection.  
Table (3-2) shows gender distribution, means, standard deviations and standard errors 
of means for age, weight, height, body mass index and blood pressures of different 
studied groups. The mean ages of non-asthmatics were significantly lower compared 
with asthmatics (P = 0.000). However, the difference of the means of the two groups 
was not great, constituting only 4.5 years (table 3-2). Diastolic blood pressure of non-
asthmatics were significantly lower compared with asthmatics (P = 0.002). This was 
true for both symptomatic (P = 0.014) and symptoms free asthmatics (P = 0.006) 
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(Table 3-2). Comparing males with females, height was significantly higher while 
body mass index was significantly lower in males (table 7-14 B).    
Figure (3-1): Comparisons of Asthma Patients according to (A) ACT, (B) 
NAEPP Classification and (C) Duration of Asthma. 
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Patients were Graded 0-4 according to NAEPP Classification (GINA 2007) 
0 = No Asthma, 1 = Mild Intermittent Asthma, 2 = Mild Persistent Asthma, 
3 = Moderate Persistent Asthma, 4 = Severe Persistent Asthma. 
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For details of significant mean differences (means, standard deviations and P values) see 
appendix tables 7-13 and 7-14 
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Table (3-2): Sample Characteristics 
Subjects and 
Patients   Gender
Age 
(Years) 
Weight 
(Kg) 
Height 
(Cm) 
Body 
Mass 
Index 
(Kg/m2) 
Systolic 
Blood 
Pressure 
(mmHg) 
Diastolic 
Blood 
Pressure 
(mmHg) 
Mean 
Arterial 
Blood 
Pressure 
(mmHg) 
Mean 25.14 64.87 160.16 25.35 118.64 76.86 90.78 
SD 
Female
5.37 17.21 4.77 7.12 10.19 9.68 8.64 
Mean 24.86 67.91 171.92 22.94 118 73.21 88.14 
SD 
Male 
3.79 14.63 5.44 4.59 16.67 10.11 10.48 
Mean 25.00§ 66.39 166.04 24.14 118.32 75.04§ 89.46 
Non 
Asthmatics 
(Females = 28, 
Males = 28) 
SD 
Total 
4.61 15.9 7.81 6.06 13.69 9.98 9.61 
Mean 28.48 66.03 159.13 26.07 117.5 81.35 93.4 
SD 
Female
5.37 15.75 5.77 5.95 14.33 10.45 10.75 
Mean 30.44 67.28 172.88 22.52 114.23 79.13 90.83 
SD 
Male 
5.1 12.23 7.37 4.01 12.1 9.59 9.19 
Mean 29.5 66.68 166.28 24.23 115.8 80.2 92.07 
Asthmatics 
(Females = 48, 
Males = 52) 
SD 
Total 
5.3 13.97 9.56 5.32 13.25 10.02 10 
Mean 28.29 64.18 158.31 25.63 118.13 81.04 93.4 
SD 
Female
5.51 16.21 6.75 6.24 15.38 11.42 11.76 
Mean 30.28 68.21 173.8 22.58 115.52 80 91.84 
SD 
Male 
5.03 11.77 7.56 3.68 12.2 9.64 9.08 
Mean 29.38 66.38 166.79 23.96 116.7 80.47ψ 92.55 
Asthmatics 
without 
Symptoms 
(Females = 24, 
Males = 29) 
SD 
Total 
5.3 13.96 10.56 5.18 13.66 10.39 10.3 
Mean 28.67 67.89 159.95 26.52 116.88 81.67 93.4 
SD 
Female
5.33 15.39 4.58 5.76 13.5 9.63 9.88 
Mean 30.65 66.1 171.72 22.45 112.61 78.04 89.56 
SD 
Male 
5.3 12.96 7.11 4.47 12.05 9.62 9.38 
Mean 29.64 67.01 165.71 24.53 114.79 79.89 91.52 
Asthmatics with 
Symptoms 
(Females = 24, 
Males = 23) 
SD 
Total 
5.35 14.13 8.37 5.51 12.85 9.7 9.73 
§ Significant Mean Difference between Non-Asthmatics and Asthmatics 
ψ Significant Mean Difference between Non-Asthmatics and Asthmatics without Symptoms. 
€ Significant Mean Difference between Non-Asthmatics and Asthmatics with Symptoms. 
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Figure (3-2) compares means of age, weight, height, body mass index and blood 
pressures between different groups according to ACT. Diastolic blood pressures of 
non-asthmatics were significantly higher compared with asthmatics, this is especially 
true for poorly controlled or uncontrolled (P ≤ 0.001 for all). In asthmatics, ACT 
score correlated negatively while NAEPP correlated positively with age (P=0.000 for 
both). 
Figure (3-2): Comparisons of Means of (A) Age, (B) Weight, (C) Height, (D) Body 
Mass Index (E) Systolic Blood Pressure, (F) Diastolic Blood Pressure and (G) 
Mean Arterial Blood Pressure between Different Groups. 
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Figure (3-2): Continued 
(D) 
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For details of significant mean differences (means, standard deviations and P values) see 
appendix tables 7-13 and 7-14 
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3. Lung Function Parameters 
Figures 3-3 __ 3-6 show typical spirometric reports of an apparently healthy non-
asthmatic subject, a well controlled, a poorly controlled, and an uncontrolled 
asthmatic patient respectively. Within each report, the upper right and left squares 
show repeatability criteria and the maneuver with the highest acceptable FVC 
respectively. Middle left square, opposite to manual and computer reports, shows 
volume-time quality control measures i.e. compliance with the ATS test criteria. The 
lower part shows the normal predicted values, the best test values and various 
comparisons between these, a graphical presentation of the range of the predicted 
norm, the position of the best test results and details of adjustments made to any of the 
parameters of the predicted normal equation. 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 54
        Figure (3-3): Spirometry of A Non-Asthmatic Subject 
IQ TeQ Spirometerv 5.18 3:00:09 PM18 Apr 2008Flow Volume Test
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       Figure (3-4): Spirometry of A Controlled Asthmatic Patient.  
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Figure (3-5): Spirometry of A Poorly controlled Asthmatic Patient. 
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       Figure (3-6): Spirometry of an uncontrolled Asthmatic Patient 
IQ TeQ Spirometerv 5.18 3:32:38 AM13 Jan 2008Flow Volume Test
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Table (3-3) shows means, standard deviations and standard errors of means of forced 
expiratory volumes of different studied groups. As expected, FEV1, FEV3, FEV6 and 
FVC were significantly higher in males compared with females, non-asthmatics 
compared asthmatics (P < 0.01 for all). In symptoms free asthmatics, only FEV1 (but 
none of other forced expiratory volumes) was significantly lower compared with the 
control group (P = 0.000). On the other hand all forced expiratory volumes were 
significantly lower in symptomatic asthmatics compared with the control group (P = 
0.000 for all). Comparing symptomatic with asymptomatic asthmatics, all forced 
expiratory volumes were significantly lower in symptomatic asthmatics (P = 0.000 for 
all). There was significant positive correlations between forced expiratory volumes 
and height in asthmatics and control group. (see appendix table 7-18 and 7-19 for 
correlation coefficients (CC) and P values. These tables can also be consulted for 
correlations of all subsequent data). 
Table (3-3): Comparisons of Forced Expiratory Volumes between Different Groups. 
Subjects and 
Patients   Gender FEV1 (L) FEV3 (L) FEV6 (L) FVC (L) 
Mean 2.66 2.9 2.91 2.91 
SD 
Female 
0.35 0.42 0.43 0.43 
Mean 3.82 4.26 4.28 4.28 
SD 
Male 
0.56 0.6 0.6 0.6 
Mean 3.24§ 3.58§ 3.60§ 3.60§ 
Non Asthmatics 
(Females = 28, 
Males = 28) 
SD 
Total 
0.75 0.86 0.86 0.86 
Mean 2.01 2.48 2.59 2.6 
SD 
Female 
0.61 0.6 0.57 0.57 
Mean 2.52 3.4 3.62 3.68 
SD 
Male 
0.94 1.09 1.06 1.03 
Mean 2.28 2.96 3.12 3.16 
Asthmatics 
(Females = 48, 
Males = 52) 
SD 
Total 
0.83 1 1 1 
Mean 2.35 2.76 2.84 2.85 
SD 
Female 
0.38 0.36 0.34 0.35 
Mean 2.9 3.81 4 4.01 
SD 
Male 
0.84 1.04 1.04 1.03 
Mean 2.65 ψ 3.34 3.47 3.49 
Asthmatics 
without 
Symptoms 
(Females = 24, 
Males = 29) 
SD 
Total 
0.72 0.96 0.99 0.99 
Mean 1.68 2.21 2.34 2.36 
SD 
Female 
0.63 0.66 0.65 0.65 
Mean 2.05 2.88 3.13 3.26 
SD 
Male 
0.83 0.94 0.89 0.88 
Mean 1.86€╣ 2.54€╣ 2.73€╣ 2.80€╣ 
Asthmatics with 
Symptoms 
(Females = 24, 
Males = 23) 
SD 
Total 
0.75 0.87 0.87 0.89 
ψ Significant Mean Difference between Non-Asthmatics and Asthmatics without Symptoms. 
€ Significant Mean Difference between Non-Asthmatics and Asthmatics with Symptoms. 
╣ Significant Mean Difference between Asthmatics with Symptoms and Asthmatics without Symptoms. 
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Figure (3-7) compares the means of forced expiratory volumes between different 
groups according to ACT. FEV1 is significantly lower in well controlled and poorly 
controlled asthmatics compared non-asthmatics (P = 0.008, 0.000 respectively). FEV3 
was significantly lower in poorly controlled asthmatics compared with non-asthmatics 
(P = 0.034). All forced expiratory volumes were significantly lower in uncontrolled 
compared with non-asthmatics (P < 0.01 for all). However, none of the means of 
forced expiratory volumes was significantly different when comparing well controlled 
with poorly controlled asthmatics. Comparing uncontrolled with both well controlled 
and poorly controlled asthmatics, only FEV1 was significantly lower in the first group 
(P = 0.010, 0.047 respectively). 
Figure (3-7) Comparisons of Means of Forced Expiratory Volumes 
between Different Groups (A) FEV1 (B) FEV3 (C) FEV6 (D) FVC. 
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Figure (3-7): Continued 
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For details of significant mean differences (means, standard deviations and P values) 
see appendix tables 7-13 and 7-14 
 
Table (3-4) shows means, standard deviations and standard errors of means of 
FEV1%, FEV3%, FEV6% and FEV1/FEV6 of different studied groups. As expected, 
all of these were significantly higher in non-asthmatics compared with asthmatics, 
whether symptomatic or not (P = 0.000 for all) and in males compared with females 
(P < 0.04 for all). Comparing symptomatic with asymptomatic asthmatics, FEV1%, 
FEV3%, FEV6% and FEV1/FEV6 were significantly lower in symptomatic 
asthmatics (P = 0.000 for all). 
Testing for significant correlations between FEV1%, FEV3%, FEV6%, FEV1/FEV6 
and other studied variables revealed the following: 
In non-asthmatics 
− FEV1% correlated negatively with weight and body mass index. 
− FEV1/FEV6 correlated positively with systolic blood pressure. 
In asthmatics 
− FEV1%, FEV3%, FEV6%, FEV1/FEV6 correlated positively with age. 
− FEV1% and FEV1/FEV6 correlated negatively with height. 
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Table (3-4): Comparisons of FEV1%, FEV3%, FEV6% and FEV1/FEV6 between 
Different Groups. 
Subjects and Patients   Gender FEV1% FEV3% FEV6% FEV1/FEV6 
Mean 91.65 99.67 99.67 0.92 
SD 
Female
5.75 0.69 0.69 0.06 
Mean 89.37 99.61 99.61 0.9 
SD 
Male 
5.95 0.91 0.91 0.09 
Mean 90.5§ 99.64§ 99.64§ 0.91§ 
Non Asthmatics (Females 
= 28, Males = 28) 
SD 
Total 
5.91 0.8 0.8 0.08 
Mean 76.31 95.04 95.04 0.77 
SD 
Female
13.84 6.23 6.23 0.13 
Mean 67.51 91.53 91.53 0.69 
SD 
Male 
13.51 8.93 8.93 0.12 
Mean 71.74 93.21 93.21 0.72 
Asthmatics (Females = 
48, Males = 52) 
SD 
Total 
14.3 7.91 7.91 0.13 
Mean 82.69 96.95 96.95 0.83 
SD 
Female
11.79 4.87 4.87 0.11 
Mean 72.29 94.77 94.77 0.73 
SD 
Male 
10.1 4.95 4.95 0.1 
Mean 77.00 ψ 95.76 ψ 95.76 ψ 0.77 ψ 
Asthmatics without 
Symptoms (Females = 
24, Males = 29) 
SD 
Total 
11.99 4.99 4.99 0.12 
Mean 69.94 93.13 93.13 0.7 
SD 
Female
12.94 6.93 6.93 0.12 
Mean 61.48 87.44 87.44 0.64 
SD 
Male 
14.99 11.06 11.06 0.13 
Mean 65.80€ ╣ 90.34€ ╣ 90.34€ ╣ 0.67€ ╣ 
Asthmatics with 
Symptoms (Females = 
24, Males = 23) 
SD 
Total 
14.47 9.52 9.52 0.13 
§ Significant Mean Difference between Non-Asthmatics and Asthmatics 
ψ Significant Mean Difference between Non-Asthmatics and Asthmatics without Symptoms. 
€ Significant Mean Difference between Non-Asthmatics and Asthmatics with Symptoms. 
╣ Significant Mean Difference between Asthmatics with Symptoms and Asthmatics without 
Symptoms 
 
Figure (3-8) compares means of FEV1%, FEV3%, FEV6% and FEV1/FEV6 of 
different studied groups according to ACT. All of these were significantly higher in 
non-asthmatics compared asthmatics, especially for poorly controlled or uncontrolled 
(P < 0.01 for all). This was also true when comparing uncontrolled with both well 
controlled and poorly controlled asthmatics (P < 0.02 for all).  
 
 
 
 
 
 62
Figure (3-8): Comparisons of Means of (A) FEV1%, (B) FEV3%, (C) 
FEV6% and (D) EEV1/FEV6 between Different Groups. 
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For details of significant mean differences (means, standard deviations and P values) 
see appendix tables 7-13 and 7-14 
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Table (3-5) shows means, standard deviations and standard errors of means of forced 
expiratory flows of different studied groups. All of these were significantly higher in 
non-asthmatics compared with asthmatics, whether symptomatic or not (P = 0.000 for 
all). Comparing males with females, PEFR and FEF25 were significantly higher in 
males (P = 0.000 and 0.017 respectively). Comparing symptomatic with 
asymptomatic asthmatics, forced expiratory flows were significantly lower in 
symptomatic asthmatics (P = 0.000 for all). Testing for significant correlations 
between forced expiratory flows and other studied variables revealed the following: 
In non-asthmatics 
− All forced expiratory flows correlated positively with height. 
− FEF25% correlated positively with weight. 
− FEF75%, FEF75%-85% correlated negatively with body mass index. 
− FEF25% and FEF50% correlated positively with systolic blood pressure. 
In asthmatics 
− All forced expiratory flows, except PEFR, correlated positively with age. 
− PEFR correlated positively with height. 
Figure (3-9) compares means of forced expiratory flows of different studied groups 
according to ACT. All of these were significantly higher in non-asthmatics compared 
with asthmatics, whether well controlled, poorly controlled or uncontrolled (P = 0.000 
for all). This was also true when comparing well controlled with uncontrolled 
asthmatics (P < 0.01 for all)  
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Table (3-5): Comparisons of Forced Expiratory Flows between Different Groups. 
Subjects and 
Patients   Gender 
PEFR 
(L/sec)
FEF25% 
(L/sec) 
FEF50% 
(L/sec) 
FEF75% 
(L/sec) 
FEF25%-
75% (L/sec) 
FEF85%-
75% (L/sec) 
Mean 5.98 5.66 4.16 1.95 3.71 1.49 
SD 
Female 
1.01 1.01 1 0.52 0.76 0.47 
Mean 8.68 7.81 5.58 2.56 4.87 1.98 
SD 
Male 
1.18 1.28 1.45 0.88 1.26 0.75 
Mean 7.33 6.74§ 4.87§ 2.26§ 4.29§ 1.73§ 
Non Asthmatics 
(Females = 28, 
Males = 28) 
SD 
Total 
1.75 1.58 1.43 0.78 1.18 0.67 
Mean 4.37 3.86 2.45 1.03 2.14 0.75 
SD 
Female 
1.58 1.82 1.43 0.67 1.27 0.5 
Mean 5.44 4.09 2.3 0.96 2 0.74 
SD 
Male 
2.05 2.1 1.6 0.76 1.37 0.62 
Mean 4.93 3.98 2.37 0.99 2.07 0.74 
Asthmatics 
(Females = 48, 
Males = 52) 
SD 
Total 
1.91 1.96 1.52 0.71 1.32 0.56 
Mean 5.19 4.71 3.2 1.33 2.76 0.98 
SD 
Female 
1.05 1.36 1.32 0.68 1.16 0.52 
Mean 6.27 4.81 2.81 1.18 2.43 0.92 
SD 
Male 
1.7 1.82 1.73 0.87 1.48 0.72 
Mean 5.78 ψ 4.76 ψ 2.99 ψ 1.25 ψ 2.58 ψ 0.95 ψ 
Asthmatics 
without 
Symptoms 
(Females = 24, 
Males = 29) 
SD 
Total 
1.53 1.62 1.56 0.78 1.34 0.64 
Mean 3.56 3.02 1.69 0.72 1.51 0.51 
SD 
Female 
1.61 1.86 1.11 0.52 1.07 0.33 
Mean 4.39 3.17 1.66 0.68 1.46 0.52 
SD 
Male 
2.01 2.1 1.17 0.47 1.02 0.34 
Mean 3.97€╣ 3.09€╣ 1.68€╣ 0.70€╣ 1.49€╣ 0.51€╣ 
Asthmatics with 
Symptoms 
(Females = 24, 
Males = 23) 
SD 
Total 
1.84 1.96 1.13 0.49 1.03 0.33 
§ Significant Mean Difference between Non-Asthmatics and Asthmatics  
ψ Significant Mean Difference between Non-Asthmatics and Asthmatics without Symptoms. 
€ Significant Mean Difference between Non-Asthmatics and Asthmatics with Symptoms. 
╣ Significant Mean Difference between Asthmatics with Symptoms and Asthmatics without Symptoms. 
 
Figure (3-9): Comparisons of Means of Forced Expiratory Flows between 
Different Groups. 
(A) PEFR, (B) FEF25%, (C) FEF50%, (D) EEF75%, (E) FEF25%-75% and (F) 
FEF75%-85  
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Figure (3-9): Continued 
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Figure (3-9): Continued 
(F) 
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For details of significant mean differences (means, standard deviations and P values) see 
appendix tables 7-13 and 7-14 
 
3.1. Discrimination Analysis Score (DAS) 
Since all spirometric measurements are highly correlated to each other, and in order to 
avoid multicolinearity, which may compromise some statistical analysis techniques, 
discrimination analysis was used to condense all spirometric measurements into one 
representative score. This score is called discrimination analysis score (DAS). 
Discrimination analysis is a statistical approach that can be used to analyze 
interrelationships among a large number of variables and to explain these variables 
in terms of their common underlying dimension. The statistical approach involves 
finding a way of condensing the information contained in a number of original 
variables into one dimension with a minimum loss of information. The main use of 
discriminant analysis in statistics is to predict group membership from a set of 
predictors (in this study predictors were spirometric measurements). Accordingly, 
DAS can predict presence or absence of asthma as shown in (figure 3-10). DAS can 
be expressed by the following equation (appendix table 7-12B): 
DAS = 2.581247 X [FEV1 (L)] + 0.947458 X [FEV3 (L)] - 3.59972 X [FEV6 (L)] + 
0.741176 X [FVC (L)] + 0.048703 X [FEV1%] - 0.08066 X [FEV3%] - 2.65372 X 
[FEV1/FEV6] + 0.479868 X [PEFR (L/sec)] - 0.47014 X [FEF25% (L/Sec)] - 
0.44485 X [FEF50% (L/Sec)] + 0.483335 X [FEF75% (L/Sec)] + 0.769923 X 
[FEF25%-75% (L/Sec)] - 0.6501 X [FEF75%-85% (L/Sec)] + 4.405138. 
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Figure (3-10): Comparisons of Means of Discrimination Analysis Scores between 
Different Groups. 
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For details of significant mean differences (means, standard deviations and P values) see 
appendix tables 7-13 and 7-14 
 
The standardized discriminant function coefficients (appendix table 12A) indicate the 
relative importance of the studied spirometric measurements in predicting presence of 
asthma. Accordingly, the most important spirometric measurement in discriminating 
presence of asthma (according to DAS) was FEV6 (L) followed by FEV1 (L), 
FEF25%-75% (L/Sec), FEV3 (L), PEFR (L/sec), FEF25% (L/Sec), FVC (L), 
FEF50% (L/Sec), FEV1%, FEV3%, FEF75%-85% (L/Sec), FEF75% (L/Sec) and 
lastly FEV1/FEV6 in a descending manner (appendix table 7-12A).  
Note that the standardized discriminant function coefficients for FEV6 is negative 
while that of FEV1 is positive (-3.60 and +2.58 respectively). As FEV6 and FEV1 are 
the most important discriminating coefficients, it is suggested that the DAS has come 
out on the positive side of the scale for control group while most asthmatics, whether 
controlled or uncontrolled, have come on the negative side. 
Correlations between all spirometric measurements and DAS were highly significant 
(P = 0.000 for all correlations) as shown in appendix table 7-12C. This confirms the 
fact that DAS can represent all spirometric measurements. 
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The cutoff point for DAS to predict presence of asthma was found to be 0.284 i.e. any 
subject whose DAS is less than 0.284 is most likely to be suffering from asthma. This 
test, when compared with FEV1% as a predictive measurement for presence of 
asthma, is proved to be more sensitive, specific and accurate (table 7-12D and 7-12E). 
The P value of Chi-Square test was more significant for DAS (P = 9.80E-20) when 
compared with FEV1% (P = 1.89E-14). Both positive predictive value (i.e. the 
proportion of disease positive out of whole test positive subjects) and negative 
predictive value (i.e. the proportion of disease negative out of whole test negative 
subjects) were more in case of DAS test compared with FEV1% (table 12D and 12E). 
ACT and DAS scores were significantly less in symptomatic compared with 
asymptomatic asthmatics (P = 0.000 for both) and in uncontrolled compared with both 
well controlled and poorly controlled asthmatics (P = 0.000 for all).  
Testing for significant correlations, DAS correlated positively with height and 
negatively with BMI in non-asthmatics giving results similar to results of other 
spirometric measurements.  
4. Heart rate variability studies  
Figures 3-11 __ 3-14 show four short-term HRV (5-min) reports of an apparently 
healthy non-asthmatic subject, a well controlled, a poorly controlled and an 
uncontrolled asthmatic patient respectively. Within each report, the upper part 
summarizes test values of time and frequency domain analysis of short-term HRV. 
Middle portion displays heart rate tachyegram, which shows changes in heart rate 
with time over the 5 minute of recording. The lower left and right corners give 
diagrammatic representations of autonomic balance and frequency domain indices 
(High frequency (HF) represents parasympathetic activity while low frequency (LF) 
represents sympathetic activity). 
 
 
 
 
 
 
 
 
 69
Figure (3-11): Short Term (5-min) HRV Recording of A Non-Asthmatic Subject 
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Figure (3-12): Short Term (5-min) HRV Recording of A Controlled Asthmatic Patient 
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Figure (3-13): Short Term (5-min) HRV Recording of Poorly Controlled Asthmatic Patient 
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Figure (3-14): Short Term (5-min) HRV Recording of An Uncontrolled Asthmatic Patient 
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Table (3-6) shows means, standard deviations and standard errors of means of short-
term HRV (5-min) time domain indices of different studied groups. MHR and SDNN 
were significantly higher while MNN was significantly lower in asthmatics compared 
with non-asthmatics (P = 0.016, 0.045 and 0.022 respectively). MHR, SDNN and 
RMSSD were significantly higher in symptoms free asthmatics compared with non-
asthmatics (P = 0.049, 0.030 and 0.043 respectively). MHR was significantly higher 
while MNN was significantly lower in symptomatic asthmatics compared with non-
asthmatics (P = 0.030 and 0.023 respectively). 
Comparing males with females, all short-term HRV (5-min) time domain indices were 
significantly higher in males except MHR, which was significantly higher in females 
(P ≤ 0.011 for all). 
Testing for significant correlations between short-term HRV (5-min) time domain 
indices and other studied variables revealed the following: 
In non-asthmatics 
− MNN correlated positively with height. 
− SDNN and RMSSD correlated negatively with body mass index. 
− SDNN, RMSSD correlated negatively with diastolic blood pressure. 
− SDNN, RMSSD correlated negatively with mean arterial blood pressure. 
In asthmatics 
− All time domain indices correlated positively except MHR, which correlated 
negatively with height.  
− FEV1 correlated positively with MNN and negatively with MHR. 
− FEV3, FEV6 and FVC correlated positively with MNN, SDNN, RMSSD and 
negatively with MHR. 
In physiological studies comparing HRV in different well-defined groups, the 
differences between underlying heart rate should also be properly acknowledged 
(Task Force of the ESC and NASPE 1996). Therefore, heart rate (MHR) was 
introduced as a covariate in the statistical analysis of HRV. Adjusting for MHR, all 
above correlation remain significant (table 7-14 A). 
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Table (3-6): Comparisons of Short Term Time Domain HRV (5-min) between 
Different Groups. 
Subjects and 
Patients   Gender
MHR 
(Beat/min) MNN (ms) SDNN (ms) SMSSD (ms) 
Mean 86.48 701.93 64.44 71.68 
SD 
Female
9.09 81.42 45.1 64.28 
Mean 82.34 744.22 90.62 94.99 
SD 
Male 
12.36 108.34 65.06 84.07 
Mean 84.41§ 723.08§ 77.53§ 83.34 
Non Asthmatics 
(Females = 28, 
Males = 28) 
SD 
Total 
10.95 97.32 57.02 75.07 
Mean 91.66 661.79 83.78 87.63 
SD 
Female
9.65 70.65 70.23 84.64 
Mean 86.36 708.56 117.13 129.97 
SD 
Male 
11.86 104.58 78.92 98.65 
Mean 88.91 686.11 101.12 109.64 
Asthmatics 
(Females = 48, 
Males = 52) 
SD 
Total 
11.13 92.5 76.36 94.16 
Mean 92.28 655.3 96.97 104.04 
SD 
Female
8.19 61.29 85.19 103.32 
Mean 85.71 717.39 115.86 130.65 
SD 
Male 
13.01 120.75 80.98 103.93 
Mean 88.68 ψ 689.27 ψ 107.30 ψ 118.6 
Asthmatics without 
Symptoms 
(Females = 24, 
Males = 29) 
SD 
Total 
11.48 102.4 82.65 103.52 
Mean 91.05 668.28 70.59 71.21 
SD 
Female
11.06 79.72 49.59 58.34 
Mean 87.19 697.43 118.73 129.1 
SD 
Male 
10.46 81.03 78.03 93.86 
Mean 89.16€╣ 682.54€╣ 94.14 99.54 
Asthmatics with 
Symptoms 
(Females = 24, 
Males = 23) 
SD 
Total 
10.83 80.84 68.8 82.29 
§ Significant Mean Difference between Non-Asthmatics and Asthmatics 
ψ Significant Mean Difference between Non-Asthmatics and Asthmatics without Symptoms. 
€ Significant Mean Difference between Non-Asthmatics and Asthmatics with Symptoms. 
╣ Significant Mean Difference between Asthmatics with Symptoms and Asthmatics without Symptoms. 
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Figure (3-15) compares means of short-term HRV (5-min) time domain indices of 
different studied groups according to ACT. Both SDNN and RMSSD were 
significantly higher in poorly controlled asthmatics compared with non-asthmatics (P 
= 0.008 and 0.016 respectively). This is also true when poorly controlled are 
compared with uncontrolled asthmatics (P = 0.048 for both). MHR was significantly 
higher while MNN was significantly lower in well controlled asthmatics compared 
with non-asthmatics (P = 0.025 and 0.029 respectively). Adjusting for MHR, the 
significance of all above findings remains the same. 
Figure (3-15): Comparisons of Means of Short Term Time Domain 
HRV (5-min) Indices between Different Groups. (A) MHR, (B) MNN, 
(C) SDNN and (D) SMSSD. 
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Figure (3-15): Continued. 
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For details of significant mean differences (means, standard deviations and P 
values) see appendix tables 7-13 and 7-14 
 
Table (3-7) shows means, standard deviations and standard errors of means of short-
term HRV (5-min) frequency domain indices of different studied groups. Both LF and 
HF were significantly higher in symptoms free asthmatics compared with non-
asthmatics (P = 0.034 and 0.027 respectively). This is also true for both SDNN and 
RMSSD (P = 0.030 and 0.043 respectively). Adjusting for MHR, the significance of 
all above findings remains the same except for correlations of RMSSD. In addition, 
comparing males with females of the whole sample, all HRV parameters are 
significantly higher in males (P < 0.05 for all) except for indicators of autonomic 
balance (LF Norm, HF Norm and LF/HF) which show no significant means 
differences. 
Testing for significant correlations between short-term HRV (5-min) frequency 
domain indices and other studied variables revealed the following: 
In non-asthmatics 
− TP, LF and HF correlated negatively while LF/HF correlated positively with 
diastolic blood pressure. 
− HF Norm correlated negatively while LF/HF correlated positively with mean 
arterial blood pressure. 
− No correlation between spirometric measurements and HRV indices in non-
asthmatics (appendix table18B). However, DAS correlated positively with both 
LF and HF 
In asthmatics 
− LF Norm correlated negatively while HF Norm correlated positively with height.  
− HF Norm correlated negatively while LF Norm correlated positively with body 
mass index. 
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− HF Norm correlated negatively with diastolic and mean arterial blood pressures. 
− FEV3 and FVC correlated positively with TP, LF and HF. 
− FEV6 correlated positively with TP. 
− ACT score correlated positively HF. 
− Duration of asthma correlated positively HF Norm and negatively with LF Norm. 
Adjusting for MHR, the significance of all above findings remains the same except 
for correlations of BMI and correlation between HF Norm and both DBP and MABP. 
Table (3-7): Comparisons of Short Term Frequency Domain HRV (5-min) between Different Groups. 
Subjects and 
Patients   Gender
TP 
(ms2/Hz) 
VLF 
(ms2/Hz) 
LF 
(ms2/Hz) 
HF 
(ms2/Hz) 
LF 
Norm% 
HF 
Norm% 
LF/HF 
Ratio 
Mean 1108.11 263.86 319.74 524.5 49.89 50.12 1.35 
SD 
Female
1509.83 236.46 404.41 919.69 18.05 18.06 1.09 
Mean 2771.89 893.23 820 1094.03 55.46 44.54 1.65 
SD 
Male 
3598.99 1836.1 956.44 1547.41 16.57 16.57 1.22 
Mean 1940 578.54 569.87 809.27 52.67 47.33 1.5 
Non Asthmatics 
(Females = 28, 
Males = 28) 
SD 
Total 
2860.47 1335.39 770.1 1293.54 17.39 17.4 1.15 
Mean 2350.28 448.42 753.95 1147.92 52.77 46.48 1.49 
SD 
Female
3932.19 596.69 1255.52 2222.81 16.26 16.36 1.1 
Mean 3438.91 859.36 1019.36 1541.73 47.42 52.58 1.67 
SD 
Male 
4190.79 1484 1277.9 2008.58 17.8 17.8 2.81 
Mean 2916.37 662.11 891.96 1352.7 49.99 49.65 1.58 
Asthmatics 
(Females = 48, 
Males = 52) 
SD 
Total 
4084.96 1160.21 1267.82 2112.6 17.2 17.31 2.16 
Mean 3439.17 588.77 1091.22 1759.18 52.95 47.05 1.5 
SD 
Female
5086.26 775.24 1622.62 2887.22 17.46 17.46 1.2 
Mean 3305.11 695.76 1013.31 1562.93 46.58 53.42 1.41 
SD 
Male 
4188.09 1110.71 1348.9 2135.41 18.05 18.05 1.93 
Mean 3365.82 647.31 1048.59 1651.8 ψ 49.4 ψ 50.54 1.45 
Asthmatics 
without 
Symptoms 
(Females = 24, 
Males = 29) 
SD 
Total 
4570.75 965.92 1464.87 2480.36 17.91 17.91 1.63 
Mean 1261.38 308.07 416.68 536.66 52.58 45.92 1.48 
SD 
Female
1803.34 292.32 592.38 990.31 15.34 15.55 1.02 
Mean 3607.62 1065.63 1026.99 1515 48.49 51.51 1.99 
SD 
Male 
4282.11 1858.85 1212.34 1883.48 17.83 17.83 3.65 
Mean 2409.54 678.79 715.34 1015.42 50.58 48.65 1.73 
Asthmatics with 
Symptoms 
(Females = 24, 
Males = 23) 
SD 
Total 
3435.28 1357.13 986.65 1559.28 16.55 16.76 2.64 
ψ Significant Mean Difference between Non-Asthmatics and Asthmatics without Symptoms. 
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Figure (3-16) compares means of short-term HRV (5-min) frequency domain indices 
of different studied groups according to ACT. HF Norm (i.e. parasympathetic 
activity) were significantly higher in well controlled asthmatics compared with both 
non-asthmatics (P = 0.014) and uncontrolled asthmatics (P = 0.004). LF Norm (i.e. 
sympathetic activity) was significantly lower in well controlled asthmatics compared 
with both non-asthmatics (P = 0.014) and uncontrolled asthmatics (P = 0.007). LF/HF 
(autonomic balance i.e. the ratio of sympathetic tone to parasympathetic tone) was 
significantly lower in well controlled asthmatics compared with uncontrolled 
asthmatics (P = 0.045). Global HRV (TP) especially LF and HF components are 
higher in poorly controlled asthmatics when compared with both non-asthmatics (P = 
0.006, 0.001 and 0.002 respectively) and uncontrolled asthmatics (P = 0.013, 0.003 
and 0.002 respectively). Adjusting for MHR, the significance of all above findings 
remains the same. 
 
Figure (3-16): Comparisons of Means of Short Term Frequency 
Domain HRV (5-min) Indices between Different Groups. (A) TP, (B) 
VLF, (C) LF, (D) HF, (E) LF Norm (F) LF Norm (G)LF/ HF. 
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Figure (3-16): Continued. 
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Figure (3-16): Continued. 
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For details of significant mean differences (means, standard deviations and P 
values) see appendix tables 7-13 and 7-14 
 
Table (3-8) summarizes correlations between DAS, ACT State and NAEPP class as 
indicators of asthma severity. DAS correlated negatively with ACT State and NAEPP 
class (P = 0.000 and 0.009 respectively).  
On examining the relationships with LF Norm, HF Norm and LF/HF, which reflect 
autonomic balance, DAS did not correlate well with LF Norm, HF Norm or LF/HF. 
This was not true for ACT state, which correlated positively with both LF Norm (P = 
0.003) and LF/HF (P = 0.043) and negatively with HF Norm (P = 0.002). 
There was no significant correlation between NAEPP class and LF Norm, HF Norm 
or LF/HF. However, LF Norm was significantly lower while HF Norm was 
significantly higher in those with mild intermittent asthma when compared with non-
asthmatics (P = 0.040 for both) as shown in appendix table 7-15. 
Table (3-8): Correlations between Discriminant Analysis Score (DAS), NAEPP 
Class, ACT state, Normalized Low Frequency (LF Norm), Normalized High 
Frequency (HF Norm) and LF/HF Ratio in asthmatics. 
 
  DAS NAEPP Class 
ACT 
State 
LF 
Norm 
HF 
Norm LF/HF 
CC 1.000 -0.493 -0.259 0.004 -0.004 -0.091 
DAS 
Sig. . 0.000 ψ 0.009 ψ 0.969 0.969 0.370 
CC -0.493 1.000 0.518 0.133 -0.133 0.014 
NAEPP Class 
Sig. 0.000 ψ . 0.000 ψ 0.188 0.188 0.889 
CC -0.370 0.674 1.000 0.292 -0.309 0.204 
ACT State 
Sig. 0.000 ψ 0.000 ψ . 0.003 ψ 0.002 ψ 0.043 ψ 
ψ Significant Correlation 
N.B: 
• Patients were Graded 0-4 according to NAEPP Classification; 0 = Non Asthma, 1 = Mild 
Intermittent Asthma, 2 = Mild Persistent Asthma, 3 = Moderate Persistent Asthma, 4 = 
Severe Persistent Asthma. 
• Patients were Graded 0-3 according to ACT State; 0 = No Asthma, 1 = Controlled 
Asthma, 2 = Poorly controlled Asthma, 3 = Uncontrolled Asthma. 
• CC = Correlation Coefficient 
• Sig. = Significance of the Correlation 
• The Significance of the Correlation of HRV parameters are adjusted for MHR.  
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 5. Effects of Drug Therapy 
Table (3-9) shows drug taken by asthmatics during data collection. Most of 
asthmatics (40%) were on combined steroid and beta agonist therapy. Most cough 
syrups were expectorants and most antibiotics were macrolytes. 
Table (3-9): Drug Therapy 
 
Type of Drug Used Percentage out of Total Asthmatic Patients 
Not Taking Beta Agonists 33% 
Beta Agonists Only 27% Beta Agonist 
Beta Agonists + Steroids 40% 
67% 100% 
Not Taking Steroids 53% 
Steroids Only 7% Steroid 
Beta Agonists + Steroids 40% 
47% 100% 
Not Taking Cough Syrup 83% 
Expectorants Only 14% Cough Syrup 
Expectorants + Cough Sedatives 3% 
17% 100% 
Not Taking Antibiotics 71% 
Macrolytes Only 20% Antibiotics 
Others Types of Antibiotics 9% 
29% 100% 
Others 8% 
 
Comparing off-treatment asthmatics with non-asthmatics:  
− Diastolic blood pressure and random blood glucose concentration were 
significantly higher in off-treatment asthmatics (P = 0.015, 0.023 respectively), 
for means and P values see table 7-16 and 7-17 which can also be consulted for all 
other data.  
− All spirometric measurement (except for FEV6 and FVC) were significantly lower 
in off-treatment asthmatics (P = 0.032 for FEV1 and P = 0.000 for all others).  
Comparing asthmatics treated with beta-agonist only with non-asthmatics:  
− Systolic blood pressure was significantly lower (P = 0.032) in asthmatics. 
− Random blood glucose concentration was significantly higher in asthmatics (P = 
0.005).  
− Serum calcium concentration was significantly higher in asthmatics (P = 0.000).  
− SDNN and RMSSD were significantly higher in asthmatics (P = 0.021 and 0.023 
respectively). Following adjustment for MHR, all HRV parameters except VLF 
and indicators of autonomic balance were significant.  
− All spirometric measurement (except for FEV1, FEV6 and FVC) were 
significantly lower in asthmatics (P = 0.000 for all). 
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Comparing asthmatics treated with steroid only with non-asthmatics: 
− Random blood glucose concentration was significantly higher in asthmatics (P 
= 0.016).  
− All spirometric measurements were significantly lower in asthmatics 
Comparing asthmatics treated with both steroids and beta agonists with non-
asthmatics: 
−  Systolic, mean arterial blood pressures were significantly higher in asthmatics 
(P = 0.000, 0.013 respectively).  
− Random blood glucose and serum calcium concentrations were significantly 
higher in asthmatics (P = 0.004 and 0.003  respectively) 
− All spirometric measurements were significantly lower in asthmatics (P = 
0.001 for FEV6, 0.001 for FVC, 0.000 for all other spirometric 
measurements).  
− MHR was significantly higher in asthmatics (P = 0.007).  
− MNN was significantly lower in asthmatics (P = 0.009). 
Comparing off-treatment asthmatics with asthmatics taking beta agonists only: 
− Diastolic blood pressure was significantly higher in off-treatment asthmatics 
(P = 0.048).  
Comparing off-treatment asthmatics with asthmatics taking steroid only: 
− All forced expiratory volumes were significantly higher in off-treatment 
asthmatics (P = 0.036 for FEV1, 0.028 for FEV3, 0.012 for FEV6 and 0.020 
for FVC). 
Comparing off-treatment asthmatics with asthmatics taking both beta agonists and 
steroids: 
− FEV6 and FVC were significantly higher in the first group (P = 0.042 and 
0.044 respectively). 
No significant mean differences in all studied variables when comparing asthmatics 
not taking antibiotics with asthmatics taking antibiotics and asthmatics not taking 
cough syrup with asthmatics taking cough syrup except for the fact that weight of 
asthmatics not taking cough syrup was significantly lower compared with asthmatics 
taking cough syrup (P = 0.001). 
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6. Levels of Glucose, Haemoglobin and Electrolytes 
Table (3-10) shows means, standard deviations and standard errors of means of blood 
concentration of haemoglobin and glucose, sodium, potassium, calcium and 
magnesium of different studied groups. Both random blood glucose concentrations 
and calcium concentrations of asthmatics were significantly higher compared with 
non-asthmatics (P = 0.000 and 0.002 respectively). These were true for both 
symptomatic (P = 0.000 and 0.001 respectively) and symptoms free asthmatics (P = 
0.026 and 0.014 respectively). Comparing males with females, haemoglobin was 
significantly lower in females (P = 0.000). 
Figure (3-17) compares means of blood concentrations of haemoglobin and glucose, 
sodium, potassium, calcium and magnesium between different groups according to 
ACT. Random blood concentrations of glucose of non-asthmatics were significantly 
lower compared with asthmatics, whether well controlled, poorly controlled or 
uncontrolled asthmatics (P < 0.01 for all). In contrast to poorly controlled asthmatics, 
calcium concentrations of non-asthmatics were significantly lower compared with 
both well controlled and uncontrolled asthmatics (P = 0.042 and 0.000 respectively). 
Testing for significant correlations between levels of glucose, haemoglobin and 
electrolytes and other studied variables revealed the following: 
In non-asthmatics 
− All forced expiratory volumes, forced expiratory flows, DAS and LF/HF 
correlated positively with haemoglobin concentration. Adjusting for MHR, LF 
Norm correlated positively while HF Norm correlated negatively with 
haemoglobin concentration.  
− LF Norm and LF/HF correlated negatively while LF Norm correlated positively 
with random blood glucose concentration. Adjusting for MHR, these significance 
findings remains the same. 
− All forced expiratory volumes correlated positively with potassium 
concentrations. 
− TP and VLF correlated negatively with calcium concentrations. 
− MHR correlated positively while MNN and VLF correlated negatively with 
magnesium concentrations. 
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Table (3-10): Comparisons of Blood Concentration of Haemoglobin [Hb], Glucose 
[RBG], Sodium [Na+], Potassium [K+], Calcium [Ca++] and Magnesium [Mg++] 
between Different Groups.  
Subjects and 
Patients   Gender 
[Hb] 
(g/dl) 
[RBG] 
(mg/dl) 
[Na+] 
(mmol/l) 
[K+] 
(mmol/l) 
[Ca++] 
(mg/dl) 
[Mg++] 
(mg/dl) 
Mean 11.62 93.32 140.04 4.13 9.1 1.63 
SD 
Female 
1.61 17.62 5.4 0.31 0.89 0.31 
Mean 14.75 93.93 139.32 4.19 8.52 1.55 
SD 
Male 
2.03 16.91 3.68 0.49 2.41 0.42 
Mean 13.19 93.63§ 139.68 4.16 8.83§ 1.59 
Non Asthmatics 
(Females = 28, 
Males = 28) 
SD 
Total 
2.41 17.11 4.59 0.4 1.78 0.37 
Mean 11.9 102.96 139.77 4.11 9.41 1.58 
SD 
Female 
1.87 10.98 4.03 0.45 1.2 0.41 
Mean 14.63 102.56 139.38 3.99 9.93 1.72 
SD 
Male 
1.41 10.93 4.44 0.29 0.84 0.28 
Mean 13.32 102.75 139.57 4.05 9.69 1.65 
Asthmatics 
(Females = 48, 
Males = 52) 
SD 
Total 
2.14 10.9 4.23 0.38 1.05 0.35 
Mean 12.16 106.67 139.54 4.11 9.56 1.53 
SD 
Female 
2.1 11.05 4.57 0.53 1 0.31 
Mean 14.8 104.03 139.03 3.98 9.9 1.69 
SD 
Male 
0.77 11.79 3.45 0.27 0.57 0.23 
Mean 13.61 105.23ψ 139.26 4.04 9.75ψ 1.62 
Asthmatics 
without 
Symptoms 
(Females = 24, 
Males = 29) 
SD 
Total 
2.01 11.42 3.96 0.41 0.8 0.28 
Mean 11.65 99.25 140 4.1 9.27 1.63 
SD 
Female 
1.6 9.78 3.49 0.37 1.37 0.49 
Mean 14.41 100.7 139.83 4 9.97 1.74 
SD 
Male 
1.95 9.67 5.49 0.32 1.1 0.33 
Mean 13 99.96€╣ 139.91 4.05 9.62 1.69 
Asthmatics with 
Symptoms 
(Females = 24, 
Males = 23) 
SD 
Total 
2.25 9.65 4.53 0.35 1.28 0.42 
§ Significant Mean Difference between Non-Asthmatics and Asthmatics 
ψ Significant Mean Difference between Non-Asthmatics and Asthmatics without Symptoms. 
€ Significant Mean Difference between Non-Asthmatics and Asthmatics with Symptoms. 
╣ Significant Mean Difference between Asthmatics with Symptoms and Asthmatics without Symptoms. 
 
In asthmatics 
− All forced expiratory volumes, PEFR, RMSSD, TP and HF Norm correlated 
positively with haemoglobin. Adjusting for MHR, these significance findings 
remains the same, except for HF Norm. Moreover, LF correlated positively with 
hemoglobin concentration. 
− FEV1%, FEV3%, FEV6% and FEV1/FEV6 correlated negatively with 
haemoglobin concentration. 
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− ACT score and DAS correlated positively with random blood glucose 
concentration. 
− FEV1%, FEV1/FEV6, FEF25% and DAS correlated negatively with sodium 
concentrations. 
− FEV6, FVC, TP and VLF correlated positively while FEV1/FEV6 correlated 
negatively with calcium concentrations. Adjusting for MHR, these significance 
findings remains the same. 
Figure (3-17): Comparisons of Means of (A) Blood Concentration of 
Haemoglobin, (B) Random Blood Glucose, Concentration of (C) Sodium, 
(D) Potassium, (E) Calcium and (F) Magnesium between Different 
Groups. 
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Figure (3-17): Continued. 
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For details of significant mean differences (means, standard deviations and P values) see 
appendix tables 7-13 and 7-14 
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CHAPTER FOUR 
DISCUSSION 
The discussion of the findings of the current study will be presented following the 
same sequence of the results chapter. New tables and figures will be introduced 
intended for proper interpretation of results and adjustment for confounding factors 
that may lead to spurious relationships. This is because confounding is a major threat 
to the validity of inferences made about causes and outcomes. 
1. Characteristics of Test and Control Groups 
The study involved 100 asthmatic patients and 56 apparently healthy subjects as a 
control group. Most of studied variables, particularly spirometric measurements, are 
related to gender, age and body size (Pellegrino et al 2005). Therefore, these 
parameters were matched in control and test groups (table 3-2). The mean ages of 
non-asthmatics (mean±SD = 25±4.6 years) were significantly lower compared with 
asthmatics (mean±SD = 29.5±5.3 years) (P = 0.000). However, the difference of the 
means of the two groups was not great, constituting only 4.5 years. This age 
difference is not expected to affect spirometric measurements after puberty spurt 
(Degroodt et al 1986 and Borsboom et al 1993). Therefore, comparison between 
spirometric measurements of control and test group is still valid in the studied age 
range (20 – 40 years old). 
Diastolic blood pressure was significantly higher in asthmatics (mean±SD = 80±10 
mmHg) compared with non-asthmatics (mean±SD = 75±10 mmHg) (P = 0.002). On 
the other side, systolic and mean arterial blood pressures were not significantly 
different in asthmatics and control groups (P = 0.267 and 0.116 respectively). These 
findings were also true when off-treatment asthmatics were compared with non-
asthmatics (table 7-16 and 7-17) indicating that high diastolic blood pressure in 
asthmatics is not attributable to hypertensive anti-asthma drug therapy. Furthermore, 
symptomatic patients, which were expected to be on β-2 agonist treatment 
(hypotensive agent), were found to have higher diastolic blood pressures compared 
with control group (P = 0.014). Stress hormones like cortisol and catecholamines, 
which may be increased in stressful conditions like asthma, are expected to increase 
both systolic and diastolic blood pressures alike (Kojima et al 1995, Nakada  et al 
1989 and McCrory et al 1982).  Therefore, a mechanism that predominantly increases 
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peripheral vascular resistance and consequently diastolic blood pressure should exist 
to explain these findings. 
Previous studies of vessels in asthmatics have focused on the pulmonary arteries 
(Saetta et al 1991) and the bronchial capacitance vessels in the bronchial mucosa 
(Carroll et al 1997). There is an old report on the larger bronchial arteries (Cudkowicz 
and Armstrong 1953) and almost no studies on systemic arteries of asthmatic patients. 
However, a recent study on abnormalities of the bronchial arteries in asthmatics may 
give a clue of systemic arteries and peripheral vascular resistance. Green et al (2006) 
described intimal thickening of bronchial arteries in cases of both fatal and non-fatal 
asthmatics. The described lesion was distinct from atherosclerosis and was not related 
to changes associated with cor pulmonale, which involves smooth muscle 
proliferation in both intima and media. 
Although these findings could be part of remodeling of airways compartments and not 
necessarily systemic process of all systemic arteries, the following suggestions 
deserve especial concern:  
1. Long term effects: 
According to Green et al the intimal lesions were not associated with inflammatory 
cells either within or adjacent to vessels showing the lesion. This finding when 
compared to another study, which showed that remodeling in the airway wall in 
patients with asthma is associated with infiltration and activation of inflammatory 
cells (Djukanovic et al 1992), it can be concluded that humeral inflammatory factor(s) 
cannot be ruled out as the cause of these permanent vascular lesions. This is because 
the intima is in closer contact with the circulating blood than the unaffected media. 
These findings suggest that similar intimal lesion may compromise the rest of arteries 
in systemic circulation but to a lesser extent (as humeral inflammatory factors will be 
diluted as they reach the general circulation). This could partially explain the mild 
increase in diastolic blood pressure secondary to the expected mild increase in the 
peripheral vascular resistance of asthmatic patients. 
2. Short term effects: 
Although the bronchial circulation has extensive collateral communications, it is 
likely that the arterial luminal narrowing observed by Green et al is physiologically 
significant. A major function of the airway circulation is to provide an essential route 
for clearance of smooth muscle bronchoconstrictor mediators. Csete et al (1991) 
tested the hypothesis that airway perfusion modifies the contractile response of airway 
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smooth muscle to allergen challenge by influencing the clearance of locally released 
spasmogens. This study proved that antigen-induced airway smooth muscle 
contraction in vivo was due to alterations in airway blood flow rather than to 
alterations in airway smooth muscle responsiveness to chemical mediators. This fact 
can also explain why the degree of response of bronchial smooth muscles to chemical 
mediators (marked bronchoconstriction) is far more than vascular smooth muscles 
(mild diastolic hypertension) i.e. because a relatively small amount of  chemical 
mediators (smooth muscles constrictors) will reach the general circulation.  
It is worth mentioning that the renin-angiotensin system was found to be activated in 
patients with asthma during severe acute attacks (Millar et al 1994). In addition, there 
is evidence of synergy in bronchoconstriction between Angiotensin II and some other 
bronchoconstrictors like methacholine (Millar et al 1995). The results of other studies 
indicate that endogenous angiotensin II promotes antigen-induced airway 
hyperresponsiveness and eosinophil accumulation by acting at type-1 receptors 
(Myou et al 2000). Angiotensin II is a potent vasoconstrictor and can therefore 
explain increased diastolic blood pressure discussed above.  
The mechanism of activation of renin-angiotensin system is uncertain. It is unclear 
whether high level of angiotensin II represents a pathological phenomenon or is a 
physiological response to asthma attack (Ramsay et al 1997). According to Ramsay et 
al study, plasma renin and angiotensin II correlated strongly, implying renin-
dependent angiotensin II formation. However, the study failed to demonstrate 
correlation between catecholamines, endothelin-1, histamine, serum angiotensin 
converting enzyme activity, total immunoglobulin E (as indicators of the severity of 
an asthma attack), renal function and renin or angiotensin II levels.  Interestingly, 
Ramsay et al also failed to demonstrate a relationship between blood pressure and 
renin or angiotensin II levels (Ramsay et al 1997). 
2. Classification of Patients 
Asthma severity was assessed by presence or absence of symptoms and spirometry at 
the time of examination. In addition, asthma control test (ACT) and NAEPP 
classification were used to assess asthma activity over the last 28 days prior to data 
collection. ACT score was higher while NAEPP class was lower in symptoms free 
compared with symptomatic asthmatic patients (P = 0.000 and 0.005 respectively). 
These findings give an impression that symptoms may be a good predictor of asthma 
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control. The self-reported symptoms of asthma seem to be an attractive measure of 
disease severity, and have been used to define severity in a variety of settings (Blanc 
et al. 1993). However, current symptoms are known to closely reflect the current level 
of control and compliance with medical treatment than the underlying severity of the 
disease (Apter et al 1994 and Juniper et al1990). 
In this study, it was clear that presence or absence of symptoms did not agree with 
asthma activity over the last month prior to examination. According to ACT, 41.5% of 
asymptomatic and 72.3% of symptomatic asthma patients were labeled uncontrolled. 
Figure (4-1) shows the distribution of NAEPP classes in symptomatic and 
asymptomatic asthmatic patients.  
Figure (4-1): Distribution of NAEPP Classes in Symptomatic and Asymptomatic 
Asthmatic Patients. 
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These findings can be explained by the results of Molly and others, which showed no 
agreement exist on clinical or epidemiologic parameters that could be used to classify 
patients according to disease severity (Molly et al 1999). This may be related in part 
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to confusion between the underlying mechanisms of the disease and current level of 
control. Asthma severity appears to be multidimensional rather than unidimensional, 
depending at least on three components, namely symptom intensity, airflow 
impairment, and management intensity (Bailey et al 1992). The level of control may 
show weak correlation with the underlying severity of disease. As an example, a 
patient with severe asthma taking daily steroids and exercising appropriate allergen 
avoidance may be well-controlled, while a noncompliant patient with mild to 
moderate disease may have more severe, disruptive symptoms.  
National Asthma Education and prevention Program (NAEP) guidelines characterize 
mild, moderate, and severe asthma according to frequency of symptoms; pulmonary 
function; school or work absences; degree of exercise tolerance; and health-care 
utilization (NAEP 2007). Despite the usefulness of these guidelines, they do not 
readily translate into a simple severity index that could be used in clinical and 
epidemiologic settings. In fact, the guidelines point out that, because of the highly 
variable nature of asthma, classification of patients into mild, moderate, and severe 
disease categories is necessarily imperfect, and that the categories may overlap. The 
problem is further complicated by the fact that an individual's underlying disease 
severity may vary over time. Investigators must therefore use caution when 
comparing groups of patients for whom severity categorization is based largely on 
symptomatology. This observation, that symptoms alone do not reflect disease 
severity, becomes even more important as health-care delivery moves closer to 
protocols/practice guidelines and "best treatment" programs that rely heavily on 
symptoms to guide subsequent treatment decisions. 
In this study ACT score correlated negatively, while NAEPP correlated positively 
with age implying that asthma severity increases with age. In spite of this, asthma 
duration was significantly higher in well controlled compared with both poorly 
controlled and uncontrolled asthmatic patients (P = 0.000 for both). This seems to 
contradict the hypothesis that airway remodeling is related to duration of asthma i.e. 
even when matched for severity, the airways of older asthmatic patients should show 
greater alterations than the airways of younger asthmatics. Based on histological 
analyses in individuals with fatal asthma, airway wall area has been reported to be 
increased from 50% to 300% compared with non-asthmatic control subjects and in 
individuals with non-fatal asthma increases from 10% to 100% (Kuwano et al 1993). 
However, all asthmatics, whether well controlled, poorly controlled or uncontrolled, 
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had long-standing history of asthma (mean±SD = 17.88±10.55, 8.93±6.97 and 
10.93±8.14 years respectively). Therefore, it seems that there was enough time for 
airways remodeling to take place for all categories of asthma patients. This suggests 
that factors other than asthma duration should contribute to the pathogenesis of severe 
asthma as proved by other studies (Lee et al 2007, Bai et al 2000, Wenzel et al 1999 
and James et al 1989). Longer asthma duration in well controlled compared with 
poorly controlled and uncontrolled patients could also be explained by the fact that 
asthmatics with longer history of asthma became more knowledgeable in dealing with 
asthma and therefore experience less attacks.  
3. Lung Function Parameters 
As expected (Sears 2007 and Lange et al 1998), all studied spirometric measurements 
are effective measures that can detect presence or absence of asthma (P ≤ 0.005 for 
all). This is especially true when symptomatic and uncontrolled asthmatics were 
compared with control group (table 7-14 A) and when symptomatic were compared 
with asymptomatic asthmatics. However, most of forced expiratory volumes, namely 
FEV3, FEV6 and FVC in symptoms free asthmatics and well controlled asthmatics, 
fail to show significant difference when compared with control group. This is also 
true when uncontrolled asthmatics were compared with poorly controlled or well 
controlled asthmatics. These Findings are comparable with previous studies (Sorkness 
et al 2008, Veen et al 2000 and Gibbons et al 1996). Sorkness et al partitioned airway 
obstruction into components of air trapping (indicated by FVC) and airflow limitation 
(indicated by FEV1%). They conclude that severe asthma had prominent air trapping, 
evident as reduced FVC over the entire range of FEV1%. That pattern was confirmed 
with measures of residual lung volume/total lung capacity in a subgroup of the same 
study. In contrast, mild asthma did not exhibit prominent air trapping, even at FEV1% 
< 75% predicted (Sorkness 2008). In addition, those with symptomatic asthma had a 
higher change in FVC than those with clinical remission following provocation with 
methacholine (Young et al 2006). Other studies comparing both closing volume or 
closing capacity in patients with mild asthma and normal subjects suggested increased 
values of these parameters in the former group, but the data did not reach statistical 
significance (King et al 1998). 
Unexpectedly, all forced expiratory volumes fail to show significant differences in 
well controlled asthmatics when compared with poorly controlled patients. Moreover, 
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all forced expiratory volumes, except FEV1, fail to show significant differences 
between uncontrolled asthmatics when compared with poorly controlled patients 
(table 7-14 A). This finding is comparable with the results of Veen et al (2000) study 
in which asthmatic patients with recurrent exacerbations (difficult-to-control asthma) 
were compared with another group of equally severe but stable asthma. Both vital 
capacities and residual volumes did not differ significantly in the two groups. It seems 
that forced expiratory volumes can poorly distinguish apparently healthy subjects 
from those with mild asthma, as well as, mild and severe forms of the disease. 
However, FVC can effectively differentiate between non-asthmatics and those with 
severe forms of asthma. 
FEV3 and FEV6 are expected to behave like FVC in mild asthmatic patients. This is 
because most of the air, if not all, will be expired in the first three seconds in those 
with uncompromised small airways. In severely obstructed patients, the total 
exhalation may last for up to 20 seconds or more, until the current end-of-test 
standards for accurately measured FVC are met (Miller 2005). This may be very 
demanding for both the patient and the technician. It was found that 6.64 s was 
sufficient to obtain 99% of FVC for spirograms with FEV1/FVC as low as 50%. 
Currently, research results confirm that the forced expiratory volume in six seconds 
can be used as a surrogate for forced vital capacity in detecting airways obstruction 
and restriction, although with some misclassification when compared to obtaining 
American Thoracic Society-acceptable manoeuvres of longer duration (Melbye et al 
2006 and Swanney 2000).  
In conclusion, for prediction of obstruction, it does not apparently matter much 
whether forced vital capacity or forced expiratory volume in six seconds are used. For 
prediction of restriction, they are equally poor (Pedersen 2006). In the present study 
FEV1% behave similar to FEV1/FEV6 (see below).  
Comparing severe asthma (i.e. those with poorly controlled and uncontrolled asthma) 
with mild asthma (i.e. well controlled asthmatic), FEV1%, FEV3%, FEV6%, 
FEV1/FEV6, FEF75%, FEF25%-75% and FEF75%-85% were significantly lower in 
patients with severe asthma (table 4-1). These findings are anticipated since the 
earliest change associated with airflow obstruction in small airways is believed to be a 
slowing in the terminal portion of the spirogram. This slowing of expiratory flow is 
most obviously reflected in a concave shape on the flow–volume curve (compare 
figure 3-3 with figure 3-4, 3-5 and 3-6). This is reflected in a proportionally greater 
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reduction in the flow measured after FEF75% or FEF25%-75% than in FEV1. As 
airway disease becomes more advanced the timed segments of the spirogram, such as 
the FEV1, will be reduced out of proportion to the reduction in FVC (Pellegrino 
2005).  
Table (4-1): Comparison of asthma parameters between mild and severe 
asthmatic patients.    
 
Mean of Patients 
with Mild Asthma 
(Well Controlled) 
Mean of Patients 
with Severe 
Asthma (Poorly 
Controlled and 
Uncontrolled) 
Significance of 
Mean Difference 
FEV1 2.51 2.20 0.161 
FEV3 3.10 2.92 0.403 
FEV6 3.22 3.09 0.452 
FVC 3.24 3.14 0.548 
FEV1% 77.65 69.77 0.011* 
FEV3% 95.72 92.38 0.019* 
FEV6% 95.72 92.38 0.019* 
FEV1/FEV6 0.78 0.71 0.014* 
PEFR 5.50 4.74 0.189 
FEF25% 4.62 3.76 0.091 
FEF50% 2.94 2.18 0.059 
FEF75% 1.33 0.88 0.020* 
FEF25%-75% 2.62 1.88 0.031* 
FEF75%-85% 1.05 0.64 0.008* 
ACT Score 21.08 13.08 0.000* 
NAEPP Class 1.64 2.64 0.000* 
Duration 16.60 9.89 0.029* 
DAS -0.24 -0.88 0.008* 
* Significant Mean Difference 
 
Testing for relationships between pulmonary function and anthropometry, most 
spirometric measurements correlate well with age, height, weight and body mass 
index. These findings are comparable with previous studies in this field (Pellegrino et 
al 2005, Miller et al 2005, Collins et al 1995). FEF25% correlated positively with 
weight and negatively with body mass index in non-asthmatics indicating that some 
spirometric measurements are more sensitive to body fat distribution (Bottai et al 
2002).  
3.1. Discrimination Analysis Score (DAS) 
In this research, 14 spirometric measurements were studied to evaluate pulmonary 
function of control and test groups. However, it is worth mentioning that limiting 
primary interpretation of spirograms to small number of spirometric measurements 
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avoids the problem of examining large number of measurements, a procedure leading 
to an inordinate number of "abnormal" tests, even among the healthiest groups in a 
population" (Knudson 1976). If one parameter is markedly abnormal, the entire flow-
volume curve is likely to be affected, but concordance of the parameters examined is 
not necessarily complete. For the latter reason, considerable caution must be exercised 
in attempting to use multiple parameters in defining abnormality, unless one applies 
more strict criteria for abnormality (Knudson 1976). Vedal and Crapo studied 
spirometry, diffusing capacity and lung volume tests of 251 healthy volunteers in 
order to determine the rate of false positive results of multiple pulmonary function 
tests. Each test had an approximately 5% false positive rate, defined as the percentage 
of normal subjects classified as abnormal by the tests. The percentage of subjects with 
at least one abnormal test rose substantially as the number of tests performed 
increased. When simple spirometry (FVC, FEV1, FEV1/FVC) was performed, 10% 
had at least one abnormal test; this rose to 24% when a complete battery of 14 tests 
was performed (Vedal and Crapo 1983). It should be noted, however, that additional 
parameters, such as the peak expiratory flow rate (PEFR) and maximum inspiratory 
flows, might assist in diagnosing extrathoracic airway obstruction. 
Therefore, in this study to avoid examining these 14 spirometric measurements 
simultaneously, they were condensed into one representative score. Discrimination 
analysis was used for this purpose. The representative score was called discrimination 
analysis score (DAS). Discrimination analysis is a statistical approach that can be 
used to analyze interrelationships among a large number of variables and to explain 
these variables in terms of their common underlying dimension. The statistical 
approach involves finding a way of condensing the information contained in a number 
of original variables into one dimension with minimum loss of information. 
Correlations between all spirometric measurements and DAS were found highly 
significant {P = 0.000 for all correlations} as shown in table 7-12C and figure 4-2. 
This confirms the fact that DAS can represent all spirometric measurements. Testing 
for significant correlations, DAS correlated positively with height and negatively with 
BMI in non-asthmatics giving results similar to other spirometric measurements. 
The relative importance of the studied spirometric measurements in predicting 
presence of asthma according to DAS is determined by standardized discriminant 
function coefficients shown in table 7-12A. FEV6 was found to be the most important 
discriminating spirometric measurement in DAS function but this is not necessarily 
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reflecting the importance of FEV6 per se in discriminating obstructive lung diseases 
(see ROC curves below). 
Figure (4-2):  Linear Curve Estimations showing the strength of relationship of DAS with some 
spirometric measurements. 
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The main use of discriminant analysis in statistics is to predict group membership 
from a set of predictors (in this study predictors were spirometric measurements). 
Accordingly, DAS can predict presence or absence of asthma. The cutoff point for 
DAS to predict presence of asthma was found to be 0.284 i.e. any subject whose DAS 
is less than 0.284 is most likely to be suffering from asthma.  
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Severity scores are most appropriately derived from studies that relate pulmonary 
function test values to independent indices of performance, such as ability to work in 
daily life, morbidity and prognosis (Anthonisen et al  1986 and Peto et al 1983). In the 
present study, DAS correlate very well with ACT score and NAEPP class (P = 0.000 
for both) implying that DAS can be used as a sensitive method for categorizing the 
severity of lung function impairment in asthmatics. In contrast to some spirometric 
measurement, DAS can efficiently demarcate apparently healthy subjects from those 
with mild asthma, as well as, mild from severe form of the disease (table 4-1). For 
further verification, accuracy of DAS was compared with FEV1% because it is the 
most widely used measurement by current authoritative spirometry guidelines (The 
American Thoracic Society (ATS), European Respiratory Society (ERS) and Third 
National Health and Nutrition Examination Survey (NHANES-III)) in categorizing 
obstructive lung diseases and assessing severity of lung diseases (Hansen et al 2007). 
Receiver Operating Characteristic curve (ROC curve) analysis was used for this 
purpose in this study.  
The ROC Curve procedure provides a useful way to evaluate the performance of 
classification schemes that categorize cases into one of two groups. It provides a 
graphical representation of the tradeoff between the false negative and false positive 
rates for every possible cut off. Equivalently, the ROC curve is the representation of 
the tradeoffs between sensitivity and specificity. The plot of the curves offers an 
excellent visual comparison of the models' performances, and the area under the 
curve gives the numbers to backup conclusions from the plot. This is because the 
further the curve lays above the reference line, the more accurate the test.  
Figure 4-3 shows that the area under ROC curve of DAS is higher compared with 
ROC curve of FEV1% with higher statistical significance and 95% confidence 
interval. However, FEV1% ROC curve is not far away from that of DAS implying 
that accuracy of FEV1%, although lower, is comparable with DAS. 
Conditional ratios (accuracy, Sensitivity, Specifity, positive predictive value and 
negative predictive value) of DAS were compared with those of FEV1% at different 
FEV1% cutoffs, namely 70%, 75% and 80%. This was done because there was 
considerable debates on whether to use fixed cutoff of FEV1% or FEV1% below the 
fifth percentile of the predicted value (Hansen et al 2007).  
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Figure (4-3): ROC curves of DAS and FEV1%. 
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95% Confidence Interval 
Variables Area Under the Curve 
Standard 
Error 
Statistical 
Significance Lower 
Bound 
Upper 
Bound 
DAS 0.93 0.02 2.77E-19 0.90 0.97 
FEV1% 0.89 0.03 3.76E-16 0.84 0.94  
 
Figure 4-4 compares conditional ratios of DAS and FEV1% at different cutoff of 
FEV1%. As expected, DAS have the highest accuracy, sensitivity and negative 
predictive value.  
Assessment of specifity and positive predictive value deserves special considerations. 
Referring back to ROC curve, a high-quality curve climbs rapidly towards upper left 
hand corner of the graph. This means that specifity will not change much with the 
increase in sensitivity. This is not true if ROC curve follows a diagonal path from the 
lower left hand corner to the upper right hand corner. This is because for every 
improvement in sensitivity is matched by a corresponding decline in the specifity. 
Figure 4-4 demonstrates that sensitivity increases markedly from 46% to 71% with 
only 7.24% decrease in specifity. As mentioned, this is expected from ROC curve in 
figure 4-3. 
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Figure (4-4): Conditional Ratios of DAS and Different Cutoff of FEV1%. 
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Based on findings of figure 4-4, it seems that the best cutoff for FEV1% to assess 
presence of asthma is 80%. At this cutoff of 80%, accuracy, sensitivity and negative 
predictive value are higher with analogous specifity and positive predictive value 
when compared with FEV1% at cutoff equal to 70%. 
DAS when compared with FEV1% (at the most accurate cutoff equal to 80%) as a 
predictive measurement for presence of asthma, is proved to be more sensitive, 
specific and accurate (appendix table 7-12D and 7-12E and figure 4-4). The P value 
of Chi-Square test was more significant for DAS (P = 9.80E-20) when compared with 
FEV1% (P = 1.89E-14). Both the positive predictive value (i.e. the proportion of 
disease positive out of whole test positive subjects) and the negative predictive value 
(i.e. the proportion of disease negative out of whole test negative subjects) were more 
in case of DAS test compared with FEV1% (appendix table 7-12D and 7-12E and 
figure 4). 
Using the same maneuvre, DAS was compared with other studied spirometric 
measurement as shown in figure 4-5 and table 4-2.  
As expected, the order of areas under the ROC curves of spirometric measurement 
and hence their efficiency in asthma diagnosis does not follow the order of 
standardized discriminant function coefficients of DAS function (appendix table 
12A). Actually, standardized discriminant function coefficients indicate the relative 
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importance of the studied spirometric measurements (in DAS function) in predicting 
presence of asthma but this is not necessarily reflecting the importance of their 
respective spirometric measurement per se in discriminating obstructive lung diseases. 
Possible explanation for dissociation of standardized discriminant function 
coefficients list from areas under ROC curve sequence is incomplete concordance of 
spirometric measurements in some instances. For examples:  
1. Both the FEV1 and FVC may decline with the progression of disease, and an 
FEV1/FVC of 0.5/1.0 indicates more impairment than one of 2.0/4.0, although the 
ratio of both is 50%.  
2. While the FEV1/FVC ratio should not only be used to determine the severity of an 
obstructive disorder, it may be of value when persons having constitutionally large 
lungs develop obstructive disease. In these cases, the FEV1/FVC ratio may be very 
low, when the FEV1 alone is within the mild category of obstruction.  
3. Sawyer et al (1998) found that using either FEV1 or PEFR often resulted in 
different severity classifications for the same patient. Overall, concordance in 
severity classification was demonstrated for the two measures in only 49.9% of 
paired samples.  
4. Other workers compared the negative predictive value of PEFR in relation to 
FEV1, and FEF25-75% at different levels of air trapping as determined by the 
RV/TLC. Thirty percent of patients with a normal PEFR value had an abnormal 
FEV1 or FEF25-75%. As air trapping increased, the ability of a normal PEFR to 
predict normal FEV1 and FEF25-75% readings fell from 83% to 53%. The 
negative predictive value was significantly lower for patients with RV/TLC ratio 
>30 compared with patients with RV/TLC <30 (Eid et al 2000). 
Discriminant function analysis consists of finding a transform that gives the 
maximum ratio of difference between a pair of groups. This is achieved by 
standardized discriminant function coefficients, which maximize the differences 
between the values of the dependent variables (spirometric measurements) and hence 
giving a score that can appropriately predict group membership. Therefore, 
standardized discriminant function coefficients depend mainly on heterogeneity 
(disconcordance) of dependent variables (spirometric measurements) but not their 
absolute importance (i.e. sensitivity and specifity). This explains the high-ceiling 
competence of DAS in discrimination. For example, standardized discriminant 
function coefficients of FEF75%, FEF25%-75% and FEF75%-85%, which are most 
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sensitive for early changes associated with obstructive lung diseases (Pellegrino 2005) 
as shown in table 4-2, are relatively lower compared with coefficients of the rest of 
spirometric measurements (appendix table 7-12A).  
On the other hand, ROC curves give graphical representation of sensitivity and 
specifity at different cutoffs and therefore they are admirable measures that can 
faithfully reflect accuracy of the parameter studied.  
The dependency of standardized discriminant function coefficients on disconcordance 
of spirometric measurements and ROC curves on sensitivity and specifity explain 
why FEV6 comes at the beginning of standardized discriminant function coefficients 
list and at the end of areas under the ROC curves sequence. 
 
Figure (4-5): ROC curves of DAS and other Spirometric Measurements. 
    (A) Forced Expiratory Volumes and Timed vital Capacity Ratios compared with DAS. 
    (B) Forced Expiratory Flows compared with DAS 
(A) 
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Figure (4-5): Continued 
(B) 
 
 
Table (4-2): Accuracy of DAS, Statistical Analysis of Areas Under ROC Curves Of 
DAS for accuracy and Other Spirometric Measurement in Descending Order. 
 
95% Confidence Interval 
Variables 
Area 
Under the 
Curve 
Standard 
Error 
Statistical 
Significance Lower Bound Upper Bound 
DAS 0.9339 0.019 2.77E-19 0.897 0.971 
FEF25%-75% (L/Sec) 0.9096 0.022 2.39E-17 0.866 0.953 
FEF75% (L/Sec) 0.9088 0.023 2.71E-17 0.865 0.953 
FEF75%-85% (L/Sec) 0.9067 0.023 3.96E-17 0.862 0.952 
FEF50% (L/Sec) 0.8955 0.024 2.77E-16 0.848 0.943 
FEV1% 0.8938 0.025 3.76E-16 0.844 0.943 
FEV1/FEV6 0.8937 0.025 3.81E-16 0.844 0.943 
FEF25% (L/Sec) 0.8632 0.029 5.71E-14 0.807 0.920 
FEV3% 0.8309 0.032 7.61E-12 0.768 0.893 
FEV6% 0.8309 0.032 7.61E-12 0.768 0.893 
PEFR (L/sec) 0.8266 0.034 1.41E-11 0.761 0.893 
FEV1 (L) 0.8088 0.034 1.66E-10 0.742 0.875 
FEV3 (L) 0.6904 0.042 8.14E-05 0.608 0.773 
FEV6 (L) 0.6476 0.044 0.002 0.560 0.735 
FVC (L) 0.6351 0.045 0.005 0.547 0.723 
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The order of the importance of spirometric measurement in asthma diagnosis as 
shown in table 4-2 further support what have been discussed before that: 
1. The earliest change associated with airflow obstruction in small airways is 
slowing in the terminal portion of the spirogram (Pellegrino 2005).  
2. FEV1/FEV6 can be used as a surrogate for FEV1/FVC in detecting airways 
obstruction (Melbye et al 2006 and Swanney 2000).  
3. Force expiratory volumes are the least accurate spirometric measurements in 
asthma diagnosis. This is because most forced expiratory volumes fail to 
demarcate apparently healthy subjects from those with mild asthma, as well as, 
mild from severe form of the disease (table 4-1). 
However, despite of the high-ceiling competence of DAS, it fails to show 100% 
sensitivity and specifity on asthma diagnosis. This may be attributed to the 
followings: 
1. Discriminant function analysis consists of finding a transform that gives the 
maximum ratio of difference between a pair of groups. This is achieved by 
standardized discriminant function coefficients, which depend mainly on 
disconcordance of spirometric measurements. Smoothing of this heterogeneity 
(disconcordance) is responsible for efficiency of in the discriminant function 
analysis. As DAS depends on many indicators, it is expected to hide the pitfalls in 
the misleading spirometric measurements. However, this does not necessarily 
denote that DAS sensitivity has not been affected. If DAS was derived from 
equally competent spirometric measurements, it should have been far more 
sensitive and accurate.  
2. Based on previous studies, it appears that there is seasonal variability in sensitivity 
of spirometry to asthma activity (Addo-Yobo et al 2002). This is especially true in 
exercise induced asthma (Koh et al 2002).  Seasonal variability in asthma activity 
is probably related to seasonal changes in the prevalence of asthma triggers. Major 
triggers of asthma activity include exposure to allergens (Helenius et al 1998 and 
Karjalainen et al1989), air pollutants (Perry 1983), low temperature (Rossi 1993), 
and viral infections (O’Brien et al 2004 and Mitchell et al 1976). This was proved 
by Goldberg et al (2005) when they demonstrate that sensitivity of exercise testing 
for asthma in adolescents is halved in the summer seasons.  
3. Asthma severity appears to be multidimensional and cannot be evaluated only by 
spirometry. Level of asthma control and management intensity must also be 
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considered (Bailey et al 1992). In addition, several studies have looked at the 
correlation between asthma symptoms and measures of lung function (Apter1994, 
Blanc 1993 and Bailey et al 1992) and failed to demonstrate complete correlation. 
Some have proposed that patients develop a perception of tolerance to their 
asthma symptoms, perceiving them less over time, and thus symptoms become a 
less accurate measure of disease severity. Some studies have also shown that both 
the heterogeneity of dyspnea perception in patients and the disparity in dyspnea 
perception between physicians and their patients. For example, Kikuchi et al 
(1994) asked whether dyspnea and chemosensitivity to hypoxia and hypercapnia 
are risk factors in fatal asthma attacks. Their results suggested that reduced 
chemosensitivity to hypoxia and blunted perception of dyspnea may predispose 
patients to fatal asthma attacks. Clinical investigators must therefore use caution 
when comparing groups of patients in whom severity categorization is largely 
based on relating spirometric measurements to symptoms.  
In conclusion, it seems more logical to use an index that considers the above-
mentioned considerations to obtain 100% accurate and reliable measure to predict 
asthma severity.  
4. Heart rate variability studies  
In physiological studies comparing HRV in different well-defined groups, the 
differences between underlying heart rate should also be properly acknowledged 
(Task Force of the ESC and NASPE 1996). Introduction of heart rate as a covariate in 
the statistical analysis of HRV is justified since heart rate, together with age, has been 
identified as a major determinant of heart rate variability (Kuch et al 2001, Kuo et al 
1999 and Sawyer et al 1998). In the present study, age was matched between control 
and test groups. In addition, age is not expected to affect HRV in 20-40 years old 
subjects (Kuo et al 1999). Therefore, only heart rate will be considered as a covariate 
in the statistical analysis of HRV.  
4.1. Effects of Gender and Age on HRV  
Testing for gender difference (after controlling for MHR) in short-term HRV (5-min) 
within studied groups revealed the following (tables 4-3 and 7-14 B): 
1. In non-asthmatics, all short-term HRV (5-min) time domain indices showed no 
gender difference. However, in the frequency domain, TP, LF and HF component 
were significantly higher in males.  
 105
2. In asthmatics, all short-term HRV (5-min) time domain indices are higher in 
males. This gender difference seems to be attributable to uncontrolled individual 
patients since controlled asthmatics showed no gender difference as regarding 
both time and frequency domain HRV indices (table 7-14 B). 
3. Comparing males with females of the whole sample (control and test groups), all 
short-term HRV (5-min) time domain indices, TP, VLF, LF and HF components 
of frequency domains were significantly higher in males except MHR, which was 
significantly higher in females.  
Table (4-3): Gender Differences of Short Term (5-min) HRV. 
 Whole Sample Non-Asthmatics Asthmatics 
 Female Mean 
Male 
Mean P1 P2 
Female
Mean 
Male 
Mean P1 P2 
Female 
Mean 
Male 
Mean P1 P2 
MHR 89.75 84.95 0.007  86.48 82.34 0.159  91.66 86.36 0.016  
MNN 676.5 721.0 0.003  701.9 744.2 0.105  661.7 708.5 0.010  
SDNN 76.65 107.85 0.006 0.002 64.44 90.62 0.086 0.089 83.78 117.13 0.028 0.014 
RMSSD 81.75 117.72 0.011 0.002 71.68 94.99 0.249 0.192 87.63 129.9 0.024 0.006 
TP 1892 3205 0.027 0.009 1108 2771 0.028 0.019 2350 3438 0.183 0.100 
VLF 380.4 871.2 0.012 0.011 263.8 893.23 0.078 0.081 448.4 859.3 0.077 0.074 
LF 593.9 949.5 0.047 0.017 319.7 820 0.014 0.009 753 1019 0.298 0.183 
HF 918.2 1385.0 0.12 0.034 524.5 1094 0.100 0.049 1147 1541 0.356 0.179 
LF Norm 51.71 50.24 0.596 0.663 49.89 55.46 0.234 0.213 52.77 47.42 0.120 0.154 
HF Norm 48.3 49.77 0.485 0.569 50.12 44.54 0.234 0.213 47.23 52.58 0.120 0.154 
LF/HF 1.41 1.66 0.452 0.337 1.35 1.65 0.329 0.247 1.44 1.67 0.606 0.522 
P1 = Not adjusted to MHR.  
P2 = adjusted to MHR. 
 
The study showed that none of the heart rate variability parameters was higher in 
women. Moreover, global autonomic activity (SDNN, RMSSD and TP) and 
especially VLF, LF and HF powers were higher in men. Raemakers et al (1998) 
hypothesized that there are gender differences in autonomic modulation making 
women at lower risk to develop cardiovascular diseases. Their results revealed higher 
SDNN, RMSSD and all frequency domain parameters, except for HF Norm, in men. 
However, following adjustment for MHR, SDNN showed no significant gender 
difference. Gender differences were confined to age categories of less than 40 years of 
age. Other studies of gender differences in autonomic regulation demonstrate that 
women have significantly greater HF spectral power than do age-matched men (Kuo 
et al 1999 and Rossy et al 1998). Indications of enhanced parasympathetic input to 
cardiac regulation appear to be greater in women even during periods of cardiac 
stress; i.e., in response to brief coronary occlusions (Airaksinen et al1998).  
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In the present study, the parasympathetic indices that showed gender difference 
(RMSSD and HF power) was higher in males. Although RMSSD and HF component 
significantly correlated with the other parasympathetic index HF Norm (CC = 0.612, 
P = 0.000 for RMSSD and CC = 0.487, P = 0.000 for HF component), the later fails to 
show gender difference. This was also true for LF Norm and LF/HF.  
The representation of LF and HF in normalized units emphasizes the controlled and 
balanced behavior of the two branches of the autonomic nervous system. Moreover, 
the normalization tends to minimize the effect of the changes in total power on the 
values of LF and HF components. For example, in the present study LF correlate 
positively with HF (CC = 0.947, P = 000) while LF Norm correlate negatively with 
HF Norm (CC = 0.986, P = 000). Therefore, Normalized LF and HF are better 
indicators of autonomic balance than absolute LF and HF powers. Nevertheless, 
normalized units should always be quoted with absolute values of the LF and HF 
power in order to describe completely the distribution of power in spectral 
components (Task Force of the ESC and NASPE 1996).  
Findings of present study potentiate implications of Umetani et al (1998) that gender 
difference in HRV is secondary to higher levels of parasympathetic activity in men in 
< 50 years old subjects. Umetani et al studied age and gender effects on the normal 
range of time domain heart rate variability (HRV) over nine decades in healthy 
subjects. Their results revealed at age <30 years, HRV for all measures was lower in 
female compared with male subjects. Gender differences decreased at age >30 years 
and disappeared at age >50 years. Umetani et al results are further supported by the 
fact that age range of present study (20-40 years old) shows no correlation between 
age and any of HRV indices (table 7-18 __ 7-21). In conclusion, previous studies 
examining gender differences in healthy populations report mixed findings possibly 
due to examining different age groups and a failure to control confounding factors 
that might affect cardiovascular control. 
Females have higher heart rate compared with males (P = 0.007 for MHR and P = 
0.003 for MNN). This finding is comparable with Agelink et al study, which proved 
that women up to the age of 55 years have a higher resting heart rate compared with 
men (Agelink et al 2001). LF component of HRV (an index of sympathetic activity) is 
lower in females compared with males (P = 0.047). Other studies of gender 
differences in autonomic regulation demonstrate significantly greater parasympathetic 
activity in women than do age-matched men (Kuo et al 1999 and Rossy et al 1998). 
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These facts confuse the understanding of high heart rate in females. This is because 
dominance of parasympathetic over sympathetic activity is expected to decrease, 
rather than increase, heart rate in females. The following may explain high heart rate 
in females: 
1. Blood pressure is relatively lower in females compared with males probably 
secondary to lower level of angiotensin II in the former (Xue B 2007) and 
therefore inhibition by baroceptors. However, Baroreflex responsiveness is proved 
to be attenuated in middle-aged women compared with men (Tanaka et al 2004 
and Huikuri1996). 
2. Sex hormones (Connor et al 2007 and Umetani et al 1998) and their effects e.g. 
low hemoglobin in females may explain high heart rate in females (see below). 
The mechanisms underlying the gender difference in cardiac autonomic function are 
obscure. Kuo et al propose that middle-aged women and men have a more dominant 
parasympathetic and sympathetic regulation of heart rate, respectively. The gender-
related difference in parasympathetic regulation diminishes after age 50 years, 
whereas a significant time delay for the disappearance of sympathetic dominance 
occurs in men (Kuo et al 1999). This indicates that the decline in autonomic balance 
exactly follows the expected decrement in sex hormones later in life (Umetani et al 
1998).  
A recent study explains gender difference in autonomic balance in a different way. 
Connor et al analyzed sex differences of monocyte intracellular expression of IL-6 
and its associations with reproductive hormones and autonomic mechanisms in 14 
matched pairs of men and women. Monocyte intracellular IL-6 production was 
repeatedly assessed over two circadian periods. Sympathetic balance was estimated by 
heart rate variability and the ratio of power in the low-frequency (LF) to high-
frequency (HF); vagal tone was indexed by the power of HF component. As compared 
to men, women showed greater monocyte expression of IL-6 across the circadian 
period. In addition, women showed lower sympathetic balance (LF/HF ratio), and 
greater levels of vagal tone (HF power). In women, but not men, sympathovagal 
balance was negatively associated with monocyte IL-6 expression, whereas vagal tone 
was positively associated with production of this cytokine. Levels of reproductive 
hormones were not related to monocyte IL-6 expression. The marked increase in 
monocyte expression of interleukin-6 in women has implications for understanding 
sex differences in risk of inflammatory disorders. Alternatively, it suggests that sex 
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differences in IL-6 expression may be a pathway to explain sex differences in 
sympathovagal balance or vagal tone or vice versa (Connor et al 2007). 
4.2. Relationship between Anthropometric Parameters and HRV  
As shown in tables 4-4 and 7-18 __ 7-21, most of short-term HRV measurements 
significantly correlate with weight, height and body mass index (BMI) as follows: 
1. Stature is associated with lower heart rates as indicated by correlations of MHR 
and MNN in both control and test groups, increased global autonomic activity 
(SDNN, RMSSD and TP) and especially LF and HF powers, low sympathetic (LF 
Norm) and high parasympathetic (RMSSD and HF Norm) activity in asthmatics.  
2. Increased weight is associated with low parasympathetic activity as indicated by 
correlations of RMSSD and HF Norm and high sympathetic activity as indicated 
by correlations of LF Norm and LF/HF in non-asthmatic.  
3. Increased BMI is associated with increased global autonomic activity (SDNN and 
RMSSD) in non-asthmatics, high sympathetic (LF Norm) and low 
parasympathetic (HF Norm) activity in asthmatics.  
All significant correlation coefficients are less than or equal to 0.33 (table 4-4) 
indicating weak correlations between anthropometric measurements and HRV. 
Previous studies in this field usually concentrate on autonomic regulation in obese 
subjects as a risk factor for arrhythmias and other cardiac alterations that accompany 
obesity (Arrone et al 1997and Hirsch et al 1991). The task force of the European 
society of cardiology and the North American society of pacing and electrophysiology 
suggested comprehensive investigations to obtain formulae of normal values of HRV 
in large normal populations based on age and gender without special consideration to 
anthropometry (Task Force of the ESC and NASPE 1996). This is probably justified 
by the weak correlations between anthropometry and HRV.  
As stated before, table 4-4 shows increased weight and BMI are associated with high 
sympathetic and low parasympathetic activity. Hirsch et al (1991) showed that a 10% 
body weight gain significantly decreased HRV, which was attributable to decreased 
parasympathetic activity, whereas a 10% weight loss had no effect. However, another 
study demonstrate that a 10% body weight gain reduced parasympathetic activity in 
non-obese subjects, while a 10% weight loss increased parasympathetic activity and 
decreased sympathetic activity in both obese and non-obese subjects. These findings 
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support the hypothesis that the autonomic nervous system tends to oppose weight 
change (Arrone et al 1997). 
Table (4-4): Correlations between Anthropometry and Short Term (5-min) HRV 
Non-Asthmatics Asthmatics 
 
Weight Height BMI Weight Height BMI 
  C1 C2 C1 C2 C1 C2 C1 C2 C1 C2 C1 C2 
MHR CC -0.04 - -0.26 - 0.05 - -0.03 - -0.24 - 0.09 - 
 Sig. 0.746 - 0.056 - 0.738 - 0.778 - 0.016 - 0.381 - 
MNN CC 0.03 - 0.26 - -0.06 - -0.01 - 0.25 - -0.13 - 
 Sig. 0.799 - 0.049 - 0.661 - 0.925 - 0.012 - 0.203 - 
SDNN CC -0.22 -0.26 0.18 0.19 -0.27 -0.31 0.06 0.07 0.27 0.29 -0.10 -0.09 
 Sig. 0.111 0.075 0.175 0.182 0.044 0.033 0.574 0.508 0.006 0.005 0.32 0.388 
RMSSD CC -0.25 -0.28 0.10 0.13 -0.28 -0.31 0.03 0.05 0.29 0.33 -0.13 -0.13 
 Sig. 0.062 0.048 0.474 0.386 0.040 0.03 0.732 0.631 0.003 0.001 0.197 0.224 
TP CC -0.16 -0.19 0.21 0.25 -0.23 -0.27 0.10 0.11 0.20 0.22 -0.02 -0.01 
 Sig. 0.229 0.182 0.112 0.087 0.083 0.065 0.336 0.279 0.044 0.035 0.831 0.933 
VLF CC -0.07 -0.10 0.21 0.23 -0.14 -0.16 0.12 0.14 0.15 0.13 0.04 0.06 
 Sig. 0.607 0.499 0.113 0.114 0.309 0.26 0.231 0.194 0.148 0.215 0.728 0.558 
LF CC -0.18 -0.19 0.20 0.24 -0.25 -0.26 0.08 0.09 0.19 0.21 -0.03 -0.03 
 Sig. 0.184 0.196 0.137 0.102 0.068 0.074 0.437 0.393 0.058 0.047 0.739 0.802 
HF CC -0.19 -0.23 0.13 0.17 -0.24 -0.28 0.08 0.09 0.20 0.23 -0.04 -0.04 
 Sig. 0.161 0.117 0.331 0.231 0.08 0.053 0.445 0.38 0.046 0.027 0.691 0.74 
LF Norm CC 0.25 0.32 0.08 0.16 0.22 0.26 0.08 0.08 -0.29 -0.27 0.22 0.20 
 Sig. 0.062 0.024 0.575 0.266 0.096 0.076 0.43 0.474 0.003 0.01 0.025 0.05 
HF Norm CC -0.25 -0.32 -0.08 -0.16 -0.22 -0.26 -0.07 -0.08 0.30 0.27 -0.22 -0.20 
 Sig. 0.062 0.024 0.574 0.266 0.096 0.076 0.482 0.474 0.003 0.01 0.028 0.05 
LF/HF CC 0.24 0.28 0.04 0.13 0.21 0.22 -0.02 -0.02 -0.12 -0.11 0.04 0.03 
 Sig. 0.078 0.05 0.758 0.388 0.114 0.13 0.877 0.817 0.249 0.312 0.681 0.798 
C1 = Correlation not adjusted to MHR. 
C2 = Correlation not adjusted to MHR. 
 
A disordered homeostatic mechanism may promote excessive storage of energy by 
decreasing sympathetic activity, while defending against weight gain by decreasing 
parasympathetic activity (Peterson et al 1988). In contrast, it has been reported that 
modest diet-induced weight gain elicits sympathetic neural activation in non-obese 
males (Gentile et al 2007). Masuo et al have reported that plasma norepinephrine 
concentrations increase following weight gain in men (Masuo et al 2003). The results 
of many studies consistently reveal higher muscle sympathetic nerve activity (MSNA) 
in obese compared with non-obese individuals (Alvarez 2002 and Gudbjornsdottir et 
al 1996). 
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The mechanism by which weight gain elicits sympathetic neural activation remains 
unclear. It was hypothesized that the increase in sympathetic nervous system activity 
with weight gain serves the homeostatic role of stimulating thermogenesis to prevent 
further weight gain Maintenance of a reduced or elevated body weight is associated 
with compensatory changes in energy expenditure, which oppose the maintenance of a 
body weight different from the ideal weight. These compensatory changes may 
account for the poor long-term efficacy of treatment of obesity (Leibel et al 1995) 
Landsberg postulated that a diet-induced increase in plasma insulin concentration was 
the primary mechanism mediating weight gain-induced sympathetic neural activation 
(Landsberg 2001). In contrast, the lack of an increase in plasma insulin concentrations 
in Gentile et al (2007) study precludes them from drawing the same conclusion. In an 
attempt to gain insight into other possible mechanisms of sympathetic activation, 
Gentile et al measured plasma concentrations of leptin and renin activity before and 
after weight gain. Although both increased significantly following weight gain, the 
changes were not correlated with the increases in muscle sympathetic nerve activity 
(MSNA). Future studies will be necessary to determine the mechanisms mediating 
sympathetic neural activation following weight gain.  
4.3. Relationship between Blood Pressure and HRV  
As shown in table 4-5 and tables 7-18 __ 7-21, most of short-term HRV measurements 
significantly correlate with blood pressures in non-asthmatics (especially following 
adjustment for MHR) as follows: 
1. High systolic blood pressure (SBP) is associated with high sympathetic (LF Norm 
and LF/HF) and low parasympathetic (HF Norm) activity. 
2. High diastolic blood pressure (DBP) is associated with depressed HRV (SDNN, 
RMSSD, TP, LF and HF), high sympathetic (LF Norm) and low parasympathetic 
(RMSSD and HF Norm) activity.  
3. High mean arterial blood pressure (MABP) is associated with depressed HRV 
(SDNN, RMSSD and HF), high sympathetic (LF Norm) and low parasympathetic 
(RMSSD and HF Norm) activity.  
Interestingly, none of the HRV parameters showed significant correlation with blood 
pressure in asthmatics (following adjustment for MHR). 
Most studies on relationships between blood pressure and autonomic nervous 
function, assessed by power spectral analysis of heart rate variability, used 
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conventional or clinic blood pressure measurements in selected subjects, which may 
have influenced the results. However, Fagard et al (2001) proved that the relationships 
between HRV and blood pressures were in general stronger for conventional blood 
pressures compared with 24-hour blood pressures monitering. For example, he found 
partial correlation coefficients of the relationships of the LF/HF ratios with systolic 
pressures were 0.12 (P ≤ 0.01) for conventional pressure and 0.02 (P not significant) 
for 24-hour blood pressure. 
Table (4-5): Correlations between Blood Pressures and Short Term (5-min) HRV 
Non-Asthmatics Asthmatics 
SBP DBP MABP SBP DBP MABP  
C1 C2 C1 C2 C1 C2 C1 C2 C1 C2 C1 C2 
MHR CC 0.10 - 0.04 - 0.08 - 0.08 - 0.04 - 0.06 - 
 Sig. 0.469 - 0.763 - 0.581 - 0.423 - 0.713 - 0.549 - 
MNN CC -0.11 - -0.02 - -0.07 - -0.09 - -0.04 - -0.07 - 
 Sig. 0.432 - 0.878 - 0.632 - 0.385 - 0.688 - 0.514 - 
SDNN CC -0.14 -0.18 -0.32 -0.37 -0.29 -0.35 -0.18 -0.16 -0.14 -0.10 -0.18 -0.14 
 Sig. 0.308 0.224 0.015 0.009 0.030 0.015 0.071 0.115 0.156 0.333 0.08 0.176 
RMSSD CC -0.14 -0.19 -0.32 -0.37 -0.29 -0.35 -0.19 -0.18 -0.15 -0.11 -0.19 -0.15 
 Sig. 0.31 0.191 0.016 0.009 0.031 0.013 0.055 0.079 0.138 0.311 0.065 0.143 
TP CC -0.07 -0.11 -0.27 -0.32 -0.22 -0.28 -0.17 -0.16 -0.13 -0.08 -0.16 -0.12 
 Sig. 0.634 0.461 0.042 0.025 0.104 0.054 0.084 0.128 0.197 0.451 0.104 0.235 
VLF CC 0.00 -0.02 -0.16 -0.20 -0.11 -0.15 -0.08 -0.05 -0.16 -0.12 -0.14 -0.10 
 Sig. 0.994 0.879 0.235 0.174 0.411 0.305 0.454 0.659 0.105 0.248 0.158 0.333 
LF CC -0.07 -0.09 -0.28 -0.31 -0.23 -0.26 -0.17 -0.16 -0.07 -0.02 -0.12 -0.09 
 Sig. 0.599 0.53 0.034 0.032 0.087 0.07 0.086 0.122 0.474 0.818 0.217 0.397 
HF CC -0.10 -0.16 -0.29 -0.35 -0.25 -0.33 -0.19 -0.19 -0.11 -0.07 -0.16 -0.13 
 Sig. 0.471 0.262 0.032 0.014 0.068 0.023 0.056 0.074 0.258 0.534 0.109 0.224 
LF Norm CC 0.22 0.33 0.25 0.34 0.28 0.40 0.08 0.07 0.19 0.18 0.17 0.15 
 Sig. 0.109 0.021 0.059 0.017 0.038 0.005 0.413 0.508 0.055 0.081 0.101 0.145 
HF Norm CC -0.22 -0.33 -0.25 -0.34 -0.28 -0.40 -0.15 -0.07 -0.21 -0.18 -0.21 -0.15 
 Sig. 0.109 0.021 0.059 0.017 0.038 0.005 0.13 0.508 0.035 0.081 0.037 0.145 
LF/HF CC 0.21 0.29 0.27 0.33 0.29 0.37 0.05 0.00 0.20 0.18 0.15 0.12 
 Sig. 0.127 0.045 0.042 0.021 0.032 0.009 0.622 0.987 0.05 0.08 0.127 0.244 
C1 = Correlation not adjusted to MHR. 
C2 = Correlation not adjusted to MHR. 
 
Previous studies have reported decreased HRV among hypertensives (Mussalo et al 
2001, Singh et al 1998 and Liao et al 1996). Not only hypertension was associated 
with decreased HRV but also the association between HRV and blood pressure was 
present across the full blood pressure range (Schroeder et al 2003, Lucini et al 2002 
and Fagard et al 2001). Individuals with low HRV at baseline were at an increased 
risk of developing hypertension over 9 years of follow-up, thus indicating that 
decreased HRV often precedes the development of hypertension (Schroeder et al 
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2003). According to these studies, there is disagreement about the association between 
normalized low-frequency power and hypertension (see below). However, they agree 
that individuals with hypertension have lower SDNN, LF and HF powers in absolute 
units. Most of these studies focused on frequency-domain measures, with fewer 
reporting on RMSSD (Liao et al 1996) or SDNN (Singh et al 1998).  
Comparing diastolic with systolic blood pressure, stronger associations between 
diastolic blood pressure and HRV parameter was very evident (table 4-5). Similar 
findings were obtained by Fagard et al (2001). In another study, the association 
between systolic blood pressure and SDNN was greatly attenuated by adjustment for 
age (Lucini et al 2002). This may explain the weaker associations between systolic 
blood pressure and HRV parameters in this study (age 20-40 years old). Schroeder et 
al (2003) show that the HRV-blood pressure association extends to low blood 
pressures and is stronger among lower blood pressures than among blood pressures in 
the hypertensive range. This finding is significant, because it shows that the 
association between blood pressure and HRV is continuous, without a marked 
threshold and with important effects even at relatively low blood pressures.  
Interestingly, there were no significant correlations between blood pressures and heart 
rate (table 4-5). Baroreceptor reflex is expected to provide a negative feedback on 
heart rate. However, since all subjects studied were normotensive (mean±SD of 
MABP = 88±10 in non-asthmatics and 90±9 in asthmatics), the threshold for the 
Baroreceptor reflex could have not been reached to elicit a response. This explanation 
agrees with Kollai et al study (1994)  on the relation between baroreflex sensitivity 
and cardiac vagal tone in humans. According to Kollai et al, 50 mmHg was 
considered as the minimum and 80 mmHg as the maximum threshold level for the 
integrated baroreflex.  
Another negative finding worth mentioning is that there was no single significant 
correlation between blood pressures and HRV parameters in asthmatic patients 
following adjustment for MHR. This is unexpected especially for diastolic blood 
pressure, which was significantly higher in asthmatics compared with non-asthmatics 
as discussed before. These findings may be a sign of functional impairment of the 
autonomic nervous system in asthmatic patients. Further studies are needed to 
determine possible underlying mechanisms beyond such findings. 
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4.4. Relationship between Pulmonary Ventilatory Function and HRV  
In non-asthmatics, high PEFR is associated with high VLF while high DAS is 
associated with high LF and HF components of HRV i.e. better ventilatory function is 
associated with better HRV (table 7-20). None of spirometric measurements, 
including DAS, has significant correlation with indicators of autonomic balance (LF 
Norm, HF Norm and LF/HF). This indicates that the autonomic discharge to the heart 
is not necessarily parallel to that of bronchial smooth muscles.  
Previous studies in this field are limited. Horváth et al tried to establish the relation 
between bronchial and cardiac vagal tone by correlating changes in airway resistance 
and in heart period (duration of cardiac cycle) in response to complete cholinergic 
blockade in healthy subjects. It was concluded that under resting conditions, vagal 
control of bronchial tone and heart period were not related in healthy subjects 
(Horváth et al 1995). The main mechanism by which action potentials are generated 
in parasympathetic neurons is reflex activation from peripherial receptors. Vagal 
activity regulating resting bronchomotor tone depends on reflexes arising from irritant 
airway receptors (Jammes et al 1979), while vagal activity to the heart is triggered by 
facilitatory inputs from arterial baroreceptors (Kollai et al 1994). Since these reflexes 
are functionally unrelated, it is likely that levels of bronchial and cardiac vagal 
activities are likewise unrelated. 
While in the healthy state the baseline levels of bronchial and cardiac parasympathetic 
activities do not seem to be related; it could not be excluded that in certain pathologic 
conditions, the two divisions are influenced in a similar fashion. Enhanced cholinergic 
influence to the airways has been established as a contributing factor to the 
development of bronchial asthma at least four decades ago (Simonsson et al 1967 and 
Molfino et al 1993). Hyperresponsiveness to cholinergic agonists is a common feature 
in asthma and is not limited to the airways, as local application of cholinergic agonists 
was shown to induce greater sweating (Kaliner 1976) and pupillary responses (Smith 
et al 1980) in asthmatics as compared with normal control subjects. Enhanced 
parasympathetic and depressed sympathetic activities in patients with mild asthma is 
demonstrated in the present study (table 4-7 and 4-8). 
Correlations between spirometric measurements and HRV before and after adjustment 
for heart rate were tested for significance (tables 7-19 __ 7-21) and revealed the 
followings: 
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1. All forced expiratory volumes, except FEV1, correlate significantly with most 
HRV parameters indicating that better ventilatory function is associated with 
increased HRV in asthmatics. However, these correlations are very weak (CC ≤ 
0.30 for all). Taking into consideration the strong significant correlation of forced 
expiratory volumes with height, which in turn has weak significant correlation 
with HRV, one may consider height as a confounding factor for the significant 
correlation between forced expiratory volumes and HRV parameters. Adjusting 
for height, in addition to heart rate, these significant correlations disappear (table 
4-6) indicating that there are no actual association between forced expiratory 
volumes and HRV. This is expected since the forced expiratory volumes are not 
so sensitive measures of ventilatory functions (as discussed earlier). If better 
ventilatory function is associated with better HRV in asthmatics, the significant 
correlations should appear first in the more sensitive measurements e.g. DAS, 
FEF25%-75% … ect (table 4-2). 
 
Table (4-6): Correlation of Forced Expiratory Volumes and HRV 
Measurements in Asthmatics Following Adjustment for Heart Rate and Height. 
 SDNN RMSSD TP VLF LF HF LF Norm 
HF 
Norm 
LF/H
F 
FEV1 CC 0.072 0.080 0.125 0.059 0.123 0.134 0.044 -0.04 -0.03 
 Sig. 0.481 0.432 0.219 0.562 0.226 0.189 0.665 0.665 0.702 
FEV3 CC 0.141 0.149 0.177 0.100 0.168 0.183 0.059 -0.05 -0.00 
 Sig. 0.165 0.142 0.082 0.329 0.097 0.071 0.565 0.565 0.986 
FEV6 CC 0.132 0.137 0.168 0.109 0.155 0.169 0.084 -0.08 0.036 
 Sig. 0.195 0.178 0.099 0.285 0.128 0.097 0.411 0.411 0.724 
FVC CC 0.134 0.139 0.179 0.116 0.166 0.180 0.104 -0.10 0.074 
 Sig. 0.187 0.173 0.078 0.254 0.103 0.076 0.311 0.311 0.471 
 
2. There are significant, but weak, correlation between both FEV3% and FEV6% 
and LF/HF (table 7-21). Higher sympathetic tone over parasympathetic (LF/HF) is 
associated with lower FEV3% and FEV6%. Dominance of sympathetic tone over 
parasympathetic (LF/HF) can be considered as a compensatory mechanism for the 
poor ventilatory functions (Woolcock 1969) and/or because of sympathomimetic 
therapy i.e. beta agonist used for treatment of asthma. These significant 
correlations are no longer there in off-treatment patients (CC = 0.023. P = 0.912 
for both FEV3% and FEV6%). 
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3. As shown in appendix tables 7-19B, higher heart rate (as indicated by MHR and 
MNN) is associated with poor ventilatory functions (as indicated by PEFR).  This 
is expected since asthma by itself is a known cause of tachycardia (McFadden 
2003). In addition, beta agonist used for treatment of asthma can also induce 
tachycardia. These significant correlations are no longer there in off-treatment 
patients (CC = -0.210, P = 0.302 for MHR and CC = -0.224, P = 0.272 for MNN). 
Interestingly, and the same as non-asthmatics, none of spirometric measurements, 
succeeds to achieve significant correlation with indicators of autonomic balance (LF 
Norm and HF Norm) in asthmatics. Definitely, this finding can not be explained by 
lack of relation between bronchial and cardiac autonomic balance in asthmatics. This 
is because previous studies, based on HRV, confirm increased vagal tone in 
asthmatics (Garrard et al 2005, Du et al 2001 and Kazuma et al 1997). However, these 
studies relied on comparison between healthy controls and asthmatics divided into 
groups according to the severity of asthma. The results were based on t-test and/or 
analysis of variance (ANOVA). None of these studies correlated HRV parameters 
with spirometric measurements. Lack of significant correlation between spirometric 
measurements and indicators of autonomic balance may be explained by the fact that 
narrowing of airways in asthmatics is multi-factorial, involving mucosal thickening, 
mucous plugs, airways remodeling, surfactant depletion, …ect, and not only due to 
bronchoconstriction (McFadden et al 2003 and Brusasco et al 2003). Even abnormal 
airways smooth muscles (ASM) behaviors can not be fully explained by high 
parasympathetic tone (Lim et al 1987). Mathematical modeling studies have 
demonstrated that, for a given degree of airway's smooth muscles shortening, the 
resistance increase would be far higher in a remodeled airway than in a normal 
healthy airway (James 1989). 
4.4.1. Effects of Asthma on HRV  
As shown in table 4-7, means of indicators of heart rate (MHR and MNN), global 
HRV (SDNN, RMSSD, TP, VLF, LF and HF) and parasympathetic tone (RMSSD 
and HF Norm) are higher in asthmatics compared with apparently healthy subjects. In 
contrast, sympathetic tone (LF Norm) was lower in asthmatics. However, only the 
heart rate achieved significant mean differences. None of the rest of HRV 
measurements was significantly different in asthmatics compared with apparently 
healthy subjects following adjustment for heart rate. This could be explained by the 
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evident variation in HRV measurements among asthmatics (see standard deviations 
and standard errors of the means in table 4-7). It is very clear that the HRV 
measurements changes in well controlled asthmatics are quite different compared with 
both poorly controlled and uncontrolled patients. This non-homogeneity makes the 
cohort including all asthmatics comparable with the control group.  
Table (4-7): Comparison of HRV measurements between Different Studied Groups. 
  MHR MNN SDNN RMSSD TP VLF LF HF LF Norm
HF 
Norm LF/HF
Mean 84.41 723.08 77.53 83.34 1940 578.54 569.87 809.27 52.67 47.33 1.5 
SD 10.95 97.32 57.02 75.07 2860.47 1335.39 770.1 1293.54 17.39 17.4 1.15 
Non 
Asthmatics 
SEM 1.46 13.01 7.62 10.03 382.25 178.45 102.91 172.86 2.32 2.33 0.15 
Mean 88.91 686.11 101.12 109.64 2916.37 662.11 891.96 1352.7 49.99 50.01 1.56 
SD 11.13 92.5 76.36 94.16 4084.96 1160.21 1267.82 2112.6 17.2 17.2 2.15 Asthmatics 
SEM 1.11 9.25 7.64 9.42 408.5 116.02 126.78 211.26 1.72 1.72 0.22 
Mean 91.39 665.28 110.22 128.48 3148.18 491.28 921.46 1676.62 41.01 58.99 0.94 
SD 10.85 78.65 68.85 97.98 3494.73 378.41 1110.57 2118.94 16.12 16.12 1.07 
Controlled 
Asthmatics 
SEM 2.63 19.08 16.70 23.76 847.60 91.78 269.35 513.92 3.91 3.91 0.26 
Mean 88.08 690.08 121.19 133.16 4316.41 729.77 1408.60 2178.03 47.52 52.48 1.19 
SD 9.97 82.00 79.42 97.58 5330.77 938.29 1730.07 2861.89 15.30 15.30 1.18 
Poorly 
Controlled 
Asthmatics SEM 1.92 15.78 15.28 18.78 1025.91 180.57 332.95 550.77 2.95 2.95 0.23 
Mean 88.55 690.52 88.68 92.59 2170.98 681.34 633.91 856.45 53.91 45.45 1.96 
SD 11.80 101.29 75.85 89.38 3391.95 1397.67 959.39 1495.99 17.41 17.45 2.65 
Uncontrolled 
Asthmatics 
SEM 1.58 13.54 10.14 11.94 453.27 186.77 128.20 199.91 2.33 2.33 0.35  
Non Asthmatics 
Vs 
Asthmatics 
Non-Asthmatics 
Vs 
Well Controlled 
Asthmatics 
Non-Asthmatics 
Vs 
Poorly Controlled 
Asthmatics 
Non-Asthmatics 
Vs 
Uncontrolled 
Asthmatics 
Well Controlled 
Asthmatics 
Vs 
Poorly Controlled 
Asthmatics 
Well Controlled 
Asthmatics 
Vs 
Uncontrolled 
Asthmatics 
Poorly Controlled 
Asthmatics 
Vs 
Uncontrolled 
Asthmatics 
 
P1  P2 P1 P2 P1 P2 P1 P2 P1 P2 P1 P2 P1 P2 
MHR 0.016 - 0.025  0.160  0.050  0.337  0.358  0.855  
MNN 0.022 - 0.029  0.138  0.070  0.398  0.337  0.984  
SDNN 0.045 0.065 0.092 0.121 0.008 0.011 0.398 0.459 0.611 0.581 0.265 0.287 0.048 0.047 
RMSSD 0.075 0.149 0.063 0.122 0.016 0.026 0.574 0.766 0.862 0.763 0.138 0.172 0.048 0.045 
TP 0.115 0.191 0.233 0.347 0.006 0.010 0.738 0.900 0.302 0.257 0.334 0.385 0.013 0.012 
VLF 0.695 0.66 0.798 0.825 0.601 0.592 0.659 0.646 0.533 0.543 0.578 0.589 0.867 0.869 
LF 0.086 0.145 0.246 0.362 0.001 0.002 0.756 0.917 0.151 0.125 0.343 0.394 0.003 0.003 
HF 0.082 0.179 0.086 0.180 0.002 0.003 0.891 0.854 0.373 0.292 0.104 0.137 0.002 0.002 
LF Norm 0.355 0.299 0.014 0.010 0.196 0.167 0.701 0.808 0.216 0.194 0.007 0.006 0.109 0.113 
HF Norm 0.425 0.346 0.014 0.009 0.196 0.162 0.558 0.677 0.216 0.190 0.004 0.004 0.079 0.081 
LF/HF 0.758 0.922 0.271 0.210 0.479 0.418 0.184 0.244 0.652 0.601 0.045 0.039 0.076 0.078 
* Significant Mean Difference, P1 = without Adjustment for MHR, P2 = Following Adjustment for MHR,  
 
Following adjustment for heart rate, Sympathetic tone (LF Norm) of well controlled 
asthmatics was significantly lower while parasympathetic tone (HF Norm) was 
significantly higher compared with both uncontrolled asthmatics and apparently 
healthy subjects. On the other hand, Global HRV (SDNN, RMSSD, TP, LF and HF) 
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was significantly higher in poorly controlled compared with both uncontrolled 
asthmatics and apparently healthy subjects. 
Comparing severe asthma (i.e. those with poorly controlled and uncontrolled asthma) 
with mild asthma (i.e. well controlled asthmatic), sympathetic (LF Norm) and 
parasympathetic (HF Norm) activities are significantly different (table 4-8). Thus, the 
autonomic balance of mild asthma seems to be different from the severe form of the 
disease. This finding is further supported by significantly lower sympathetic and 
higher parasympathetic activities in intermittent compared with persistent asthma 
(table 7-15). 
Table (4-8): Comparison of HRV parameters between mild and severe asthmatic patients. 
Non 
Asthmatics 
Vs 
Asthmatics 
Non 
Asthmatics 
Vs 
Mildly 
Asthmatic 
Non 
Asthmatics 
Vs 
Severely 
Asthmatic 
Mildly 
Asthmatic  
Vs 
Severely 
Asthmatic 
 
Mean of 
Non-
Asthma 
patients 
Mean of 
Patients with 
Mild 
Asthma 
Mean of 
Patients 
with 
Severe 
Asthma P1 P2 P1 P2 P1 P2 P1 P2 
MHR 88.91 89.38 88.75 0.016*  0.080  0.030*  0.984  
MNN 686.11 679.66 688.26 0.022*  0.079  0.045*  0.975  
SDNN 101.12 110.24 98.08 0.045* 0.065 0.035* 0.051 0.095 0.052 0.322 0.646 
RMSSD 109.64 125.14 104.48 0.075 0.149 0.028* 0.087 0.164 0.292 0.179 0.323 
TP 2916.37 3252.72 2804.25 0.115 0.191 0.096 0.205 0.179 0.281 0.133 0.617 
VLF 662.11 444.91 734.50 0.695 0.660 0.212 0.676 0.508 0.460 0.222 0.311 
LF 891.96 1022.14 848.57 0.086 0.145 0.102 0.139 0.141 0.240 0.366 0.517 
HF 1352.70 1745.65 1221.72 0.082 0.179 0.023* 0.074 0.173 0.369 0.061 0.235 
LF Norm 49.99 43.11 52.28 0.355 0.299 0.019* 0.017* 0.898 0.797 0.020* 0.020* 
HF Norm 50.01 56.89 47.72 0.425 0.346 0.019* 0.016* 0.977 0.899 0.015* 0.015* 
LF/HF 1.56 0.97 1.75 0.758 0.922 0.017* 0.195 0.371 0.482 0.012* 0.057 
* Significant Mean Difference, P1 = without Adjustment for MHR, P2 = Following Adjustment for MHR. 
 
Different behaviors of mild and severe asthma explain loss of correlations between 
indicators of autonomic balance and NAEPP classes. In addition, they explain the 
weak correlations between ACT states and both LF Norm, HF Norm and LF/HF 
(table 4-9). Previous studies, based on HRV, assessing changes of autonomic function 
are limited and usually compare healthy controls with asthmatics divided into groups 
according to the severity of asthma (Garrard et al 2005, Du et al 2001 and Kazuma et 
al 1997).  
In some asthmatic children, the circadian rhythm of parasympathetic nervous function 
disappeared, the parasympathetic nervous function was low in remission suggesting 
that the disorder of biologic rhythm is related to the pathogenesis of asthma (Kazuma 
et al 1998). The results of Garrard et al (2005) demonstrate lower sympathetic activity 
(LF Norm) in both asymptomatic and acute asthma subjects compared to controls 
without showing dominance of parasympathetic activity in these groups. Fujii et al  
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(2000) findings suggest that autonomic nervous activities, particularly vagal response 
after exercise, in asthmatic children is different from that in control children. LF and 
HF components of HRV were lowest in the severe asthma group in another study 
(Kazuma et al 1997). According to these studies, it seems that the autonomic control 
is not reproducible among asthmatics, probably due to interindividual variability. 
Importantly, the above-mentioned studies considered asthma severity at the time of 
the studies without special concern for asthma control. The findings of the current 
study, i.e. the autonomic balance of mild (well controlled and intermittent) asthma is 
different from severe (poorly controlled, uncontrolled and persistent) form of the 
disease, may explain part of interindividual variability of autonomic control among 
sufferers of asthma. 
 
Table (4-9): Correlations between Discriminant Analysis Score (DAS), NAEPP 
Class, ACT state, Normalized Low Frequency (LF Norm), Normalized High 
Frequency (HF Norm) and LF/HF Ratio in asthmatics. 
 
  DAS NAEPP Class 
ACT 
State 
LF 
Norm 
HF 
Norm LF/HF 
CC 1.000 -0.493 -0.259 0.004 -0.004 -0.091 
DAS 
Sig. . 0.000 ψ 0.009 ψ 0.969 0.969 0.370 
CC -0.493 1.000 0.518 0.133 -0.133 0.014 
NAEPP Class 
Sig. 0.000 ψ . 0.000 ψ 0.188 0.188 0.889 
CC -0.370 0.674 1.000 0.292 -0.309 0.204 
ACT State 
Sig. 0.000 ψ 0.000 ψ . 0.003 ψ 0.002 ψ 0.043 ψ 
ψ Significant Correlation 
N.B: 
• Patients were Graded 0-4 according to NAEPP Classification; 0 = Non Asthma, 1 = Mild 
Intermittent Asthma, 2 = Mild Persistent Asthma, 3 = Moderate Persistent Asthma, 4 = 
Severe Persistent Asthma. 
• Patients were Graded 0-3 according to ACT State; 0 = No Asthma, 1 = Controlled 
Asthma, 2 = Poorly controlled Asthma, 3 = Uncontrolled Asthma. 
• CC = Correlation Coefficient 
• Sig. = Significance of the Correlation 
 
One major difference between mild and severe asthma is the duration of contact of 
small airways to inflammatory mediators (Vignola et al 1998). This is especially true 
if one consider inadequate clearance of inflammatory mediators secondary to arterial 
luminal narrowing observed in bronchial circulation of uncontrolled/persistent asthma 
patients (Green et al 2006). All evidences suggest that the smooth muscle contractile 
apparatus of uncontrolled/persistent asthmatics is surrounded and bombarded by 
inflammatory mediators. There is evidence that link inflammatory mediators to 
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increased velocity of contraction and increased smooth muscle stiffness. The smooth 
muscle dysfunction may be one of the first mechanisms by which inflammatory 
mediators cause airway hyperresponsiveness, which could worsen over time as airway 
remodeling also makes a contribution (Fernandes 2003). Consequently, additional 
factors, on top of disordered autonomic control, are responsible for airway smooth 
muscle (ASM) dysfunction. Many studies showed differences in contractile force 
between normal and asthmatic ASM as follows: 
1. Fish and colleagues (1981) demonstrated that a deep inspiration (DI) to total lung 
capacity produced substantial and sustained bronchodilatation after constriction 
had been acutely induced in non-asthmatic subjects. This bronchodilatory effect is 
reduced in asthmatics. In some asthmatic subjects, DI can even exacerbate 
bronchoconstriction (Lim et al 1987). The importance of DI was further 
highlighted by the fact that a prolonged period in which DI is voluntarily 
prohibited significantly enhances airway responsiveness to methacholine in non-
asthmatic subjects (King et al 2001). These studies together suggest that DI is a 
key physiological mechanism of diminishing the effects of bronchoconstrictor 
stimuli. Prevention of DI alone can make healthy airways hyperresponsive in a 
manner similar to that of asthmatic subjects. In normal individuals, DI produce 
"plastic" deformation that keeps the airways well dilated. In asthmatics, "elastic" 
deformation takes place, which causes the airway smooth muscle to return to its 
original length after DI and therefore maintaining the narrowing of airways 
(Fernandes 2003). As an explanation for elastic deformation in asthmatic, it was 
anticipated that sensitization increases the quantity and activity of myosin light 
chain kinase (MLCK), an enzyme that phosphorylates the regulatory 20-kD light 
chain (LC20) of smooth muscle myosin, thereby increasing myosin ATPase 
activity (of the myosin heavy chain head) and increasing the actomyosin cycling 
rate thus maintaining the constriction of smooth muscle (Solway 2000). Another 
explanation for this phenomenon was proposed by Dulin et al (2003) who suggest 
a model in which abnormally long actin filaments might account for abnormally 
increased elasticity of contracted ASM in asthmatics. Both activation of MLCK 
and actin filaments elongation are supposed to be secondary to the effects of 
inflammatory mediators (Fernandes 2003). 
2. Pathological studies have documented an increased ASM mass in asthmatic 
airways, due to increase in myocyte number (hyperplasia) or size (hypertrophy) 
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(Bentley et al 2008). Among the possible causes for ASM proliferation are 
polypeptide growth factors, inflammatory mediators, and cytokines derived from 
several cells, such as epithelial cells, macrophages, and mast cells (Gerthoffer et al 
2002) which lead to:  
i. Airway narrowing, thus possibly accounting for the increase in airways 
hyperresponsiveness (AHR) (Lambert et al 1993).  
ii. Production of multiple cytokines, chemokines, and prostanoids (Gerthoffer et 
al 2002), which in turn would amplify the inflammatory process within the 
airway wall. Therefore, the increase in ASM mass in asthma may be regarded 
as a potential mechanism of AHR.  
3. For geometric reasons, a strong linear shortening of ASM would result in a 
complete airway closure (James et al 1989). However, for ASM shortening to 
happen, all non-contractile tissues arranged in parallel or in series with ASM must 
be stretched or compressed and deformed. This process absorbs part of the energy 
produced by ASM, thus limiting its shortening. The lung elastic recoil provides 
the major source of load against which the ASM has to shorten. To be effective 
against ASM shortening, the force exerted by lung parenchyma must be properly 
transmitted to the external wall of the airways and from here across all tissues 
separating it from ASM. Tissues softened by inflammatory changes may loose 
their ability to limit ASM shortening, especially at low lung volume (Lambert et al 
1997). Increased adventitial thickness was found to increase constriction by 
reducing parenchymal interdependence (Lambert et al 1993). In addition, fluid 
accumulation around the airways would uncouple them from lung parenchyma, 
thus possibly impeding the transmission of lung elastic recoil force to airways 
(Brusasco et al 2003).  
Based on (1) the finding of the current study, i.e. high parasympathetic and low 
sympathetic tones in mild but not in severe asthma and (2) the long-term effects of 
inflammatory mediators on ASM, one can conclude that the pathophysiology of ASM 
in Mild asthma may be different from severe form of the disease. In other wards, 
ASM dysfunction in mild asthmatics is mostly due to autonomic imbalance that favor 
bronchoconstriction while in severe asthma is essentially secondary to the long-term 
effects of inflammatory mediators on the contractile apparatus of ASM, airway's 
smooth muscle mass and decreased load against which the ASM has to shorten. 
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Testing for significant associations between asthma related parameters and HRV 
reveals the followings (table 7-21): 
1. As expected higher ACT score, which indicates better control of asthma, is 
associated with enhanced HF band of HRV (Kazuma et al 1997).  
2. Patients with longer asthma duration have lower sympathetic and higher 
parasympathetic tone. This does not contradict what is hypnotized above that 
pathophysiology of ASM in Mild asthma may be different from severe form of the 
disease. This is because well controlled, poorly controlled and uncontrolled 
asthmatic patients had long-standing history of asthma (mean±SD = 17.88±10.55, 
8.93±6.97 and 10.93±8.14 years respectively). Although, asthma duration was 
significantly higher in well controlled compared with both poorly controlled and 
uncontrolled asthmatic patients (P = 0.000 for both), it seems that there was 
enough time for inflammatory mediators to act in both controlled and uncontrolled 
asthmatic patients. This suggests that factors other than asthma duration contribute 
to the pathogenesis of ASM in uncontrolled severe asthma. Longer asthma 
duration in well controlled compared with both poorly controlled and uncontrolled 
patients could be explained by the fact that asthmatics with longer history of 
asthma became more knowledgeable in dealing with asthma e.g. avoidance of 
triggers, compliance with treatment protocols and therefore release of less 
quantities of inflammatory mediators. Other genetic, immunologic, and 
environmental factors may also contribute to the pathogenesis of ASM in severely 
asthmatic patients (Bracken et al 2002). 
5. Effects of Drug Therapy on studied Variables 
It is worth mentioning that the best approach to know the effect of drugs is to use 
paired rather than unpaired t-test. Unpaired t-test was used in this study because in 
contrast to paired t-test, it could be used in cross-sectional study designs. 
Drug therapy seemed to have no significant metabolic effects on studied groups, 
probably because most of these drugs were used in small doses and by inhalation 
route (Molema et al 1988, Yernault et al 1977 and Neville et al 1977). Little amounts 
will reach the general circulation and even then, it could easily be cleared or 
metabolized. Therefore, most of the findings in this study seemed to be associated 
with asthma itself rather than its treatments. As shown in appendix tables 7-16 and 7-
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17, comparing off-treatment asthmatics with non-asthmatics, it seems that the 
following is due to asthma and not to its treatment: 
a. Low spirometric measurement in asthmatics. 
b. High diastolic blood pressure in asthmatics (fully discussed earlier).  
c. High random blood glucose concentration in asthmatics (see below).  
Comparing off-treatment asthmatics with asthmatics taking beta agonists only, 
asthmatics taking steroid only and asthmatics taking both beta agonists and steroids 
reveals the following: 
a. Beta agonists therapy decreases diastolic blood pressure. 
b. Steroid therapy did not improve forced expiratory volumes. 
c. Combined beta agonists and steroids therapy did not improve FEV6 and FEV3. 
However, one cannot confirm b and c because the original pulmonary function (i.e. 
before therapy) is unknown. In addition, the compliance of patients to therapy has not 
been monitored. These unexpected findings (i.e. b and c) are good examples of the 
experimental error that can be avoided by the paired t-test. Therefore, paired t-test is 
the best to evaluate effects of therapy.  
Following adjustment for heart rate, global autonomic activity (SDNN, RMSSD and 
TP) and especially LF and HF powers are higher in asthmatics taking beta agonists 
only compared with non-asthmatics. This is not true when off-treatment asthmatics 
are compared with the control group implying that high HRV in the former 
comparison is secondary to the use of beta agonists therapy and not asthma itself 
(table 7-17). Knowing that 70.4% of asthmatics taking beta agonists only are males, 
one should consider gender as a covariate for the above comparison. Doing that, only 
LF power is higher in asthmatics taking beta agonists only compared with non-
asthmatics. 
In previous studies, acute salbutamol, terbutalin and fenoterol (beta agonists) 
inhalation showed increased adrenergic activity in asthmatic as indicated by LF 
and/or LF/HF (Eryonucu et al 2001 and Jartti et al 1997). Different results were 
obtained by Rossinen et al, who reported that commonly used doses of inhaled or 
nebulized salbutamol induced no acute myocardial ischaemia, arrhythmias or changes 
in HRV in patients with coronary artery disease and clinically stable asthma or chronic 
obstructive pulmonary disease (Rossinen et al 1998). This is further supported by 
another study that showed both formoterol and salmeterol (beta agonists) have no 
short-term effects on autonomic cardiovascular function in asthmatic adult patients 
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(Eryonucu et al 2005). The differences in the results of above studies remained to be 
explained. However, the differences of half-life of beta agonists and adaptation of 
cardiovascular adrenergic receptor to beta agonists may partly explain these variations 
(Jartti et al 1998). 
Interestingly, height of asthmatics taking beta agonists is significantly higher while 
that of asthmatics taking steroid only is  significantly lower compared with non-
asthmatics (table 7-16 and 7-17). Introducing gender as a covariate, height of 
asthmatics taking steroid only remain significantly lower compared with off-treatment 
asthmatics and control group implying that lower height in the former may be due to 
asthma and/or steroid therapy. On the other hand, comparing asthmatics taking steroid 
only with off-treatment asthmatics gives conclusions that delivered steroid therapy 
does not affect metabolic functions of asthmatics (as indicated by BMI, hemoglobin 
concentration and level of blood glucose and electrolytes). Whether these findings are 
true or secondary to experimental error of using unpaired t-test is questionable and 
need further randomized, double-blind, placebo-controlled studies. However, the 
above findings are expected in studied asthmatics since most of them tend to use 
steroid therapy through inhalation route. The present results regarding steroid therapy 
are comparable with at least two old studies on the endocrinometaholic effects of the 
steroid aerosol therapy evaluated in asthmatic patients (Molema et al 1988 and 
Yernault et al 1977). In Yernault et al study, nine patients had received no treatment 
with corticosteroids or ACTH for at least six months and were considered non-
corticodependent. Eleven patients had been treated with prednisolone for several 
months and were referred to as corticodependent. In this latter group, therapy with 
prednisolone was replaced by oral administration of betamethasone at least 48 hours 
before the investigation started. In the non-corticodependent group, aerosol 
administration of beclomethasone had no statistically significant effect on the results 
of the glucose tolerance test and the plasma levels of insulin; there was a slight 
decrease in basal levels of cortisol, but the response of the cortisol level to 
administration of ACTH remained quite normal. In corticodependent patients, after 
substitution of aerosol therapy with beclomethasone for the oral therapy with steroids, 
the depression of adrenal function disappeared, usually quickly (in less than one 
month), whereas the abnormalities in the results of the glucose tolerance test 
persisted. Thus, at the dosage used, the inhaled corticosteroid (ICS) might have minor 
systemic endocrinometabolic effects (Yernault et al 1977). 
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6. Relationship Between Blood Glucose Concentrations and 
studied Variables 
6.1. Effects of Sympathetic and Parasympathetic Activity on Blood Glucose 
Interestingly, high levels of blood glucose concentrations of non-asthmatics are 
associated with lower sympathetic (as indicated by LF Norm and LF/HF) and higher 
parasympathetic activity (HF Norm) as shown in table 7-20.  
The pancreatic islets are richly innervated by parasympathetic, sympathetic and 
sensory nerves. Several different neurotransmitters are stored within the terminals of 
these nerves, both the classical neurotransmitters, acetylcholine and noradrenaline, 
and several neuropeptides. The neuropeptides, vasoactive intestinal polypeptide, 
pituitary adenlyate cyclase activating polypeptide and gastrin releasing peptide are 
constituents of the parasympathetic nerves, whereas the neuropeptides galanin and 
neuropeptide Y are localised to sympathetic nerve terminals. Stimulation of the 
autonomic nerves and treatment with neurotransmitters affect islet hormone secretion. 
Thus, insulin secretion is stimulated by parasympathetic nerves or their 
neurotransmitters (D’Alessio 2001) and inhibited by sympathetic nerves or their 
neurotransmitters (Ahrén 2000). Release of insulin in response to exogenous glucose 
is normally modified by both sympathetic alpha-adrenergic inhibition and beta-
adrenergic excitation in some lamb species (Bloom and Edwards 1982). 
On the other hand, insulin is suggested to have direct effects on the cardiovascular 
system but these effects are not well described. Bellavere et al (1996) assessed the 
possible influence of insulin on autonomic control of heart function. Using power 
spectral analysis, results showed marked reductions of high frequency (HF) bands and 
an increased LF/HF ratio after insulin infusion in healthy subjects suggesting that 
insulin affects the cardiovascular system by reducing vagal influence on the heart and 
inducing a relative hypersympathetic tone. These findings are supported by Borne et 
al in another way. The outcome of Borne et al study shows reduction in cardiac vagal 
tone as indicated by the fall in R-R intervals during hyperinsulinemia in healthy 
subjects. Moreover, more than twofold increases in muscle sympathetic nerve 
activities (MSNA) were occurring concurrently with vagal hypotonia (Borne et al 
1999). However, both studies were done with Euglycaemic Clamp i.e. maintenance of 
a constant blood glucose level throughout the experiments. To determine whether 
insulin per se or insulin-induced stimulation of carbohydrate metabolism is the main 
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sympathetic excitatory stimulus, Vollenweider et al performed simultaneous 
microneurographic recordings of muscle sympathetic nerve activity, 
plethysmographic measurements of calf blood flow, and calorimetric determinations 
of carbohydrate oxidation rate. For a comparable rise in carbohydrate oxidation, 
insulin/glucose infusion that resulted in twofold greater increases in plasma insulin 
concentrations than did glucose infusion alone, evoked twofold greater increases in 
both muscle sympathetic nerve activity and calf blood flow. On the other hand, 
fructose infusion, which increased carbohydrate oxidation comparably, but had only a 
minor effect on insulinemia, did not stimulate either muscle sympathetic nerve 
activity or calf blood flow. These observations suggest that in humans 
hyperinsulinemia per se, rather than insulin-induced stimulation of carbohydrate 
metabolism, is the main mechanism that triggers both sympathetic activation and 
vasodilation in skeletal muscle (Vollenweider et al 1993).  
In conclusion, it is evident that release of insulin in response to exogenous glucose is 
normally modified by both sympathetics and parasympathetics, which are themselves 
acted upon by insulin in a negative feedback fashion. This presumed physiological 
control mechanism is probably inactive in asthmatics. This is because all significant 
correlation between blood glucose concentrations and indicators of autonomic 
balance, namely LF Norm, HF Norm and LF/HF, are lost in studied asthmatic patients 
(table 7-21). In other wards, there is no relationship between blood glucose 
concentrations and both sympathetic and parasympathetic activities. In favor of this 
suggestion are the relatively higher blood glucose concentrations of asthmatics as 
compared with the control group (P = 0.000).  
6.2. Modification of Antiasthmatic Medication 
Hyperglycemic effects of asthma treatments, namely beta agonists and steroids, are 
well documented in literature (Dawson et al 1995, Smith et al 1992 and Neville et al 
1977) and should not be ignored when comparing blood glucose concentrations of 
control groups with other asthma groups. Introducing asthma treatment i.e. beta 
agonists and steroids therapy as a covariate, blood glucose concentrations of well 
controlled asthmatics were significantly higher as compared with healthy subjects (P 
= 0.006). In contrast, the mean difference was not significant when the blood glucose 
concentrations of control group were compared with poorly controlled and 
uncontrolled asthmatics (P = 0.050 and 0.066 respectively). Thus, blood glucose 
concentrations of mild, but not severe, asthma patients differ from normal subjects. 
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This conclusion can explain the positive significant correlation between blood glucose 
concentrations and both ACT score and DAS in asthmatics (table 7-19). In addition, 
as reported earlier, autonomic balance in asthma subgroups shows high 
parasympathetic and low sympathetic tones in mild, but not severe, form of the 
disease. Bearing in mind actions of insulin per se on autonomic functions (diminished 
parasympathetic and enhanced sympathetic tones (Borne et al 1999 and Bellavere et 
al 1996), one can think of asthma control, autonomic balance, hyperglycemia 
secondary to insulin resistance to be closely connected. Importantly, insulin resistance 
is associated with aeroallergen sensitization and allergic asthma, but not non-allergic 
asthma (Husemoen et al 2008). Furthermore, Al-Shawwa et al hypothesize that the 
pro-inflammatory state of insulin resistance may contribute to the pathogenesis of 
asthma in obese patients (Al-Shawwa et al 2007). In addition, insulin sensitivity was 
increased in asthmatic patients as a result of improvements in respiratory function 
noted following proper treatment (Canis et al 2007). Based on these studies and 
findings of present study, insulin resistance is likely to be involved in the 
pathophysiology of disturbed autonomic nervous system in patients with mild asthma. 
7. Relationship Between Haemoglobin Concentrations and 
studied Variables 
Interestingly, most of spirometric measurements have significant positive correlation 
with haemoglobin concentrations in non-asthmatics signifying that better ventilatory 
functions are associated with adequate haemoglobin concentrations (table 7-18). 
Bearing in mind that both haemoglobin concentrations (CC = 0.532, P = 0.000) and 
spirometric measurements (table 7-19) correlate strongly and positively with height, 
one will expect positive correlation between spirometric measurements and 
haemoglobin concentrations in both asthmatics and control group. However, this 
pattern of association is incomplete in asthmatics because all forced expiratory 
volumes and PEFR correlate positively while all timed forced vital capacity ratios 
correlate negatively with haemoglobin concentrations. Possible explanation for this 
dissociation is the fact that in contrast to timed forced vital capacity ratios, forced 
expiratory volumes and PEFR are more sensitive to body size than ventilatory 
function of the lungs (see table 4-2 and correlations between height and force 
expiratory volumes and PEFR in table 7-19).  
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Since timed forced vital capacity ratios are more sensitive to poor ventilatory 
functions compared with forced expiratory volumes and PEFR, they are expected to 
be equally sensitive to chronic hypoxia. Taking into consideration that asthma-
induced hypoxia can encourage erythropoiesis (Scholz et al 1991); one can 
understand the negative correlation between timed forced vital capacity ratios and 
haemoglobin concentrations. 
As shown in table 7-20, high haemoglobin concentrations are associated with higher 
sympathetic (LF Norm and LF/HF) and lower parasympathetic activity (HF Norm) in 
apparently healthy subjects. These findings are comparable with previous reports in 
this field although results of such studies usually correlate autonomic function to 
erythropoietin concentrations rather than haemoglobin levels. Scholz et al suggest that 
the oxygen-sensing mechanism that controls renal erythropoietin production is 
primarily located in the kidney itself and Erythropoietin secretion is inversely 
correlated to renal oxygen supply (Scholz et al 1991). It was postulated that additional 
factors, such as neural and humoral, factors might contribute to the erythropoietin 
secretory response to hypoxia. This is because a comparison of the effects of renal 
artery constriction and anemia on the production of erythropoietin revealed higher 
hormone concentration in case of anaemia (Pagel et al 1988). In addition, renal 
ischemia in isolated perfused kidneys elicited a much weaker erythropoietin secretory 
response compared with systemic hypoxia in vivo (Pagel et al 1988).  
Numerous studies have investigated the role of renal nerves on erythropoietin 
secretion. Most of these studies were done in animal models and showed some 
contradictions. Eckardt et al (1992) conclude that renal nerve input plays no 
significant role in the control of the erythropoietin gene under both basal and 
stimulated (hypoxic) conditions. In contrast, Beynon (1977) reported reduced serum 
levels of Erythropoietin in the hypoxic animals immediately after cutting the 
splanchnic nerves. Zivny et al demonstrated that the changes in erythropoiesis after 
administration of metipranolol (beta antagonist) may be caused by reduction of 
erythropoietin production with a consequent reduction of the erythrocyte production 
rate (Zivny et al 1983). Moreover, combined renal denervation and beta-blockade 
were more effective than renal denervation alone in attenuating erythropoietin 
production during 5 hours of exposure to hypoxia (Fink and Fisher 1976). Biaggioni 
et al data support the hypothesis that the sympathetic nervous system stimulates 
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erythropoiesis in humans because anemia secondary to severe autonomic failure 
showed good response to erythropoietin therapy (Biaggioni et al 1994). 
A systemic factor related to sympathetic activation, which could modulate renal 
erythropoietin secretion, is the renin-angiotensin system. Studies in human volunteers 
demonstrated that elevation of plasma renin activity and thus angiotensin II levels, as 
well as intravenous infusion of angiotensin II, elevated erythropoietin concentrations 
in a dose-dependent manner. These effects were greatly reduced by administration of 
the angiotensin II receptor antagonist (Gossmann et al 2001). However, alteration of 
endogenous angiotensin II levels following high and low salt diet showed no effect on 
erythropoietin secretion in healthy volunteers implying that, at least in the 
physiological setting in healthy volunteers, increased concentrations of endogenous 
angiotensin II may not be a major factor of erythropoietin regulation. (Freudenthaler 
et al 2003).  
HRV improves in asthmatics with high haemoglobin concentrations as indicated by 
the significant positive correlations between haemoglobin and SDNN, RMSSD, TP 
and LF (table 7-21). These significant correlations are expected since anaemia is a 
recognized cause of low HRV (Nevruz et al 2007, Gehi et al 2005 and Sözen et al 
1998). Moreover, hemoglobin normalization improved the diminished HRV in 
patients with chronic kidney disease (Furuland et al 2008). On the other hand, there 
were no associations between haemoglobin concentrations indicators of autonomic 
balance in asthmatics (LF Norm, HF Norm and LF/HF). These findings further 
augment the view that autonomic nervous system may be disturbed in asthmatics. 
8. Relationship Between Electrolytes Levels and studied 
Variables 
8.1. Relationship between Electrolytes Levels and Ventilatory Functions 
Most previous studies on electrolyte disturbance in asthmatics have focused on 
asthma treatment as a contributing factor. This was especially true for Hypokalaemia 
(Whyte et al 1988 and Haalboom et al 1985), Hypocalcemia (Prince et al 1988 and 
Bos et al 1988) and hypomagnesaemia (Gustafson et al 1996 and Bos et al 1988). 
Therefore, asthma therapy, namely beta agonists and steroids, was introduced as a 
covariate when comparing serum electrolytes concentrations of asthmatics with 
control group (table 4-10) and correlating spirometric measurements with electrolytes 
concentrations (table 4-11). In spite of the significant positive correlation of 
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potassium and negative correlation of sodium with some spirometric measurements in 
asthmatics, none of these electrolytes showed significant mean differences when 
asthmatics are compared with control group. This is probably due to weakness of 
these correlations (correlation coefficients ≤ 0.230 for all significant correlations).  
Low electrolytes concentrations in asthma patients can be attributed to low intake 
(Britton et al 1994, Landon et al 1993 and Burney et al 1989) or secondary to asthma 
medication (Whyte et al 1988, Haalboom et al 1985, Prince et al 1988 and Bos et al 
1988 and Gustafson et al 1996). However, in the present study there is no difference 
of electrolytes concentrations between off and on-treatment asthmatics (table 7-17) 
implying that asthma medication has no significant effects on concentrations of 
electrolytes.   
Association between sodium intake and asthma has been reported in some previous 
studies (Carey et al 1993 and Burney et al 1989) but not others (Britton et al 1994 and 
Lieberman et al 1992). The findings of the present study are consistent with lack of 
agreement of these studies.  
Sodium concentrations showed no significant mean differences when asthmatics were 
compared with the control group, but elevated levels of sodium were associated with 
poor ventilatory function. The reverse was true for potassium in which high levels 
were associated with better pulmonary ventilation. Possible mechanisms that may 
lead to airway reactivity include direct effect of sodium and potassium on bronchial 
smooth muscle contractility (Chideckel et al 1987) as well as potential enhancement 
of the release of mast cell-derived inflammatory mediators, possibly through airway 
osmolarity changes (Mickleborough et al 2001 and Eggleston et al 1984).  
It is noteworthy that insulin resistance (Husemoen et al 2008) and high activity of 
renin-angiotensin system activity (Ramsay et al 1997 and Millar et al 1994) were both 
reported to coexist with asthma, and may well explain part of the lack of consistency 
of the results regarding sodium and potassium levels in asthmatics independently of 
dietary intake and asthma medication. However, studies in this field are scanty and 
the subject needs further exploration. 
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Table (4-10): Comparison of Serum Electrolytes Concentrations between 
Asthmatics and Control Groups Following Controlling for Drug Therapy. 
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S.[Na+] 139.230 139.821 -0.591 1.169 0.614 -2.900 1.718 
S.[K+] 4.196 4.023 0.173 0.104 0.100 -0.033 0.379 
S.[Ca++] 8.938 9.625 -0.687 0.374 0.068 -1.426 0.051 
S.[Mg++] 1.627 1.631 -0.004 0.097 0.965 -0.197 0.188 
 
Table (4-11): Correlations between Spirometric Measurements and Electrolytes 
Concentrations Following Controlling for Drug Therapy in asthmatic group. 
  S.[Na+] S.[K+] S.[Ca++] S.[Mg++] 
FEV1 CC -0.149 0.175 0.037 0.003 
 Sig. 0.076 0.036 0.975 0.665 
FEV3 CC -0.075 0.149 0.084 0.035 
 Sig. 0.374 0.077 0.320 0.676 
FEV6 CC -0.049 0.135 0.104 0.042 
 Sig. 0.563 0.108 0.217 0.621 
FVC CC -0.031 0.130 0.111 0.043 
 Sig. 0.712 0.122 0.189 0.612 
FEV1% CC -0.227 0.075 -0.132 -0.105 
 Sig. 0.006 0.370 0.117 0.214 
FEV3% CC -0.198 0.066 -0.113 -0.040 
 Sig. 0.018 0.437 0.179 0.632 
FEV6% CC -0.198 0.066 -0.113 -0.040 
 Sig. 0.018 0.437 0.179 0.632 
FEV1FEV6 CC -0.223 0.085 -0.117 -0.092 
 Sig. 0.008 0.313 0.164 0.273 
PEFR CC -0.157 0.141 -0.077 -0.028 
 Sig. 0.061 0.094 0.364 0.739 
FEF25% CC -0.191 0.154 -0.099 -0.033 
 Sig. 0.022 0.067 0.237 0.692 
FEF50% CC -0.142 0.170 -0.075 -0.056 
 Sig. 0.091 0.043 0.376 0.509 
FEF75% CC -0.186 0.159 0.014 -0.037 
 Sig. 0.026 0.057 0.868 0.665 
FEF25-75% CC -0.169 0.176 -0.056 -0.050 
 Sig. 0.044 0.036 0.504 0.551 
FEF85-75% CC -0.192 0.143 0.050 -0.023 
 Sig. 0.022 0.089 0.550 0.790 
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Interestingly, calcium concentrations were higher in asthmatics but did not achieve 
statistical significance. Although there was significant mean difference of calcium 
concentration between asthmatic and control group, it disappear on adjustment for 
treatment. As this study did not include blood pH or an estimate of ionized calcium, 
the above finding is difficult to discuss. However Hypocalcemia had been reported in 
healthy subjects following administration of IV ß2-agonists that cause an increase in 
the urinary excretion of calcium (Bos et al 1988). In acute asthma, an increase in 
urinary excretion of calcium has also been reported in asthmatic patients treated with 
IV aminophylline (Prince et al 1988). In patients with chronic asthma, the prevalence 
of hypocalcemia has not been evaluated. The findings of this study did not contradict 
previous studies, as none of asthmatic patients were receiving IV ß2-agonists or IV 
aminophylline during the measurement of their electrolytes concentrations.  
On the other hand, studies of asthma patients indicate that dietary magnesium intake 
and serum magnesium levels are lower than healthy controls (Britton et al 1994, 
Landon et al 1993 and Burney et al 1989). However, short-term magnesium 
supplementation trials to assess the effects of supplemental magnesium on lung 
function and symptoms among patients with asthma have had mixed results. High 
magnesium intake was associated with improvement in symptom scores, though not 
in measures of airflow or airway reactivity (Hill et al 1997).  
The evidence suggests that magnesium ions participate in numerous biochemical and 
physiologic processes that directly influence lung function and respiratory symptoms. 
The mechanisms for effects on lung function include alteration in smooth muscle 
function (Spivey et al 1990), immune function (Weglicki et al 1996) and oxidative 
stress (Dickens et al 1992). When magnesium is deficient, the action of calcium is 
enhanced and an excess of magnesium blocks calcium. These interactions are 
important to the respiratory patient because the intracellular influx of calcium causes 
bronchial smooth-muscle contraction (Landon et al 1993).  
In conclusion, it is important to remember that serum electrolyte levels, mainly 
magnesium and potassium, may not correctly reflect the intracellular status. Skeletal 
muscle biopsies of asthmatics had lower magnesium and potassium concentrations 
compared with healthy controls, both with and without oral beta 2-agonists therapy. 
Whether the findings are related to asthma pathophysiology or treatment remain for 
further investigations (Gustafson et al 1996). 
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8.2. Relationship between Serum Electrolytes Levels and Heart Rate Variability 
High TP and VLF are associated with increased calcium levels in asthmatics. In 
contrast, high TP and VLF are associated with lower calcium levels in non-asthmatics 
(table 7-20 and 7-21). Previous studies correlating electrolytes concentrations with 
HRV parameters are uncommon. The aims of these studies are usually to explore the 
relationships between heart rate variability parameters and electrolyte ion 
concentrations in certain diseases such as renal failure (Wen1 et al  2007and Tsai et al 
2002) and heart diseases (Bobkowski et al 2003) or as a result of certain interventions 
such as effects of dietary sodium (Jessica et al 2008). This is probably because 
electrolytes disturbance contribute to the genesis of ventricular arrhythmia and may 
explain sudden deaths associated with some diseases.  
Tsai and Chiu (2002) studied the relationship between 5-minute HRV and serum 
electrolytes concentrations in both pre- and post-dialysis. Results revealed that only 
calcium, among other electrolytes, is negatively correlated to heart rate (MNN) and 
parasympathetic tone (HF Norm) after hemodialysis but not before. However, in 
another study there were no correlations between calcium and HRV parameters after 
hemodialysis (Wen1 et al 2007) .  
Regarding magnesium, it shows only one significant correlation in which high VLF is 
associated with decreased magnesium levels in non-asthmatics. The effect of high-
dose intravenous magnesium infusion on time-domain HRV count had been 
investigated in patients with a first episode evolving anterior wall myocardial 
infarction. Patients who received magnesium infusion had higher HRV counts. 
However, no statistically significant differences regarding the clinical outcome or 
myocardial functional status were observed (Balli et al 1995). In addition, high 
parasympathetic and low sympathetic tones were associated with decreased serum 
magnesium concentration and higher prevalence of clinical symptoms in children with 
metal valve prolapse (Bobkowski et al 2003).  
None of the other studied electrolytes, namely sodium and potassium, achieved 
significant association with HRV parameters. Sodium and potassium concentrations 
are expected to modulate HRV because of their effect on the conduction system of the 
heart. Nevertheless, results of a recent study failed to demonstrate correlations 
between electrolytes, namely sodium, potassium, calcium and magnesium, and HRV 
parameters before and after hemodialysis (Wen1 et al 2007). The reasons, 
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implications and consequences of these, probably hidden, correlations remain to be 
explained by further research. 
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CAPTER FIVE 
CONCLUSIONS 
1. Characteristics of Test and Control Groups 
1.1. Diastolic blood pressure was elevated in asthmatics compared with non-
asthmatics  
1.2.  Presence or absence of symptoms did not agree with asthma control which draws 
attention to asthma classification criteria. 
1.3. Asthma severity increases with age, however, asthmatics with longer history 
experience less attacks suggesting that they became more knowledgeable in 
dealing with asthma.  
2. Lung Function Parameters 
2.1. All spirometric measurements studied are effective in asthma diagnosis, however, 
flows measured after FEF25% seem to be more sensitive to the severity of the 
disease.  
2.2. FEV1/FEV6 can be used as a substitute for FEV1/FVC in detecting airways 
obstruction.  
2.3. In this study, Forced expiratory volumes are the least accurate spirometric 
measurements in diagnosing asthma. 
2.4. DAS (Discrimination Analysis Score) is more sensitive, specific and accurate 
compared with other spirometric measurements, but like other indicators it fails 
to reach 100% sensitivity and specifity on asthma diagnosis. 
3. Heart rate variability studies  
3.1. Global autonomic activity (SDNN, RMSSD, TP, VLF, LF and HF) were higher 
in men compared with women.  
3.2. Stature is associated with lower heart rates, increased global autonomic activity, 
low sympathetic and high parasympathetic activity in asthmatics.  
3.3. Increased weight is associated with low parasympathetic and high sympathetic 
activity in non-asthmatics.  
3.4. Increased BMI is associated with increased global autonomic activity in non-
asthmatics, high sympathetic and low parasympathetic activity in asthmatics.  
3.5. High blood pressures are associated with high sympathetic and low 
parasympathetic activity in non-asthmatics. 
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3.6. High diastolic and mean arterial blood pressures are associated with depressed 
HRV in non-asthmatics.  
3.7. None of the HRV parameters showed significant correlations with blood 
pressures in asthmatics. 
3.8. In non-asthmatics, better ventilatory function is associated with better HRV. 
3.9. Autonomic discharge to the heart is not necessarily parallel to that of bronchial 
smooth muscles.  
3.10. Higher heart rate is associated with poor ventilatory functions. 
3.11. None of spirometric measurements achieves significant association with 
sympathetic or parasympathetic activity.  
3.12. The autonomic balance of mild asthma (showing high parasympathetic and 
low sympathetic activities) is different compared to the severe form of the disease 
(which showed normal parasympathetic and sympathetic activities). 
4. Effects of Drug Therapy on studied Variables 
4.1. Asthma drug therapy had no significant metabolic effects on asthmatics. 
4.2. LF power is higher in asthmatics taking beta agonists only compared with non-
asthmatics indicating sympathetic influence. 
5. Relationship Between Blood Glucose Concentrations and studied Variables 
5.1. High levels of blood glucose concentrations of non-asthmatics are associated 
with lower sympathetic and higher parasympathetic activities.  
5.2. In contrast to severe asthma patients, blood glucose concentrations of mild 
asthma patients were significantly higher as compared with apparently healthy 
subjects. 
6. Relationship between Hemoglobin Concentrations and studied Variables 
6.1. Better ventilatory functions are associated with good haemoglobin concentrations 
in non-asthmatics. 
6.2. In contrast to asthmatics, high haemoglobin concentrations are associated with 
higher sympathetic and lower parasympathetic activity in apparently healthy 
subjects.  
6.3. HRV improves in asthmatics with high haemoglobin concentrations. 
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7. Relationship between Electrolytes Concentrations and studied Variables 
7.1. None of studied electrolytes, namely sodium, potassium, calcium and 
magnesium, showed significant mean differences when asthmatics were 
compared with control group, yet high sodium and low potassium concentrations 
were associated with poor ventilatory function in asthmatics.  
7.2. High global HRV are associated with increased calcium levels in asthmatics. In 
contrast, it is associated with lower calcium levels in non-asthmatics. The 
significance of this finding will need more investigation. 
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CHAPTER SIX 
RECOMMENDATIONS 
1.1. Further studies are needed to identify possible causes of increased diastolic blood 
pressure in asthmatics. Research areas in this field include looking for evidences 
suggesting systemic arteries remodeling as result of chronic intimal contact with 
inflammatory mediators released from the lungs as well as searching for a 
common pathology that can explain bronchoconstriction and peripheral 
vasoconstriction simultaneously. 
1.2. Clinicians must use caution when comparing groups of patients for whom 
severity categorization is largely based on symptomatology. The observation, that 
symptoms alone do not reflect disease severity, becomes even more important as 
health-care delivery moves closer to protocols/practice guidelines and "best 
treatment" programs that rely heavily on symptoms to guide subsequent treatment 
decisions. 
1.3. Additional studies are desirable to develop more efficient discriminant analysis 
score (DAS) based on the most sensitive and specific spirometric measurements 
worked out by ROC curves. In addition, this score can be used as a part of a 
multidimensional scoring system, that also considers symptom and management 
intensity, for evaluating asthma severity.  
1.4. Many signs of functional impairment of the autonomic nervous system are noted 
in asthmatic patients. For example, lack of significant correlations between the 
following: (1) blood pressures and HRV parameters (2) blood glucose 
concentrations and both sympathetic and parasympathetic activities (3) blood 
pressure and blood glucose concentrations were relatively elevated in asthmatics 
compared with control group. Therefore, further research is required to determine 
the possible underlying mechanisms that explain functional deviations from 
normal in the autonomic nervous system of asthma patients. 
1.5. Better understanding could have been achieved for the present findings if 
hormonal assays for catecholamines, insulin, renin and angiotensin II and the 
levels of HbA1C were done. This is especially true regarding the relation between 
the presumed autonomic changes and blood pressure, electrolytes and glycaemic 
control. Therefore, more investigations are critical to determine whether 
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abnormalities in these parameters are pathological phenomena per se or merely 
physiological adjustments due to asthma attack and/or its treatments. 
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APPENDIX A 
 
Figure (7-1): Data Collection Sheet 
 
Name Code Number 
Age Gender Asthma Duration 
 
Past Medical History  
 
Asthma Control Test (ACT) Score 
 
Questions Single Best Answer Score 
VI. During the past 4 weeks, how much of 
the time did your asthma keep you 
from getting as much done at work, 
school or home? 
1. All of the time 
2. Most of the time 
3. Some of the time 
4. A little of the time 
5. None of the time 
 
VII. 
uring the past 4 weeks, how often have 
you had shortness of breath? 
1. More than once a day 
2. Once a day 
3. 3–6 times a week 
4. Once or twice a week 
5. Not at all 
 
VIII. 
uring the past 4 weeks, how often did 
your asthma symptoms (wheezing, 
coughing, shortness of breath, chest 
tightness or pain) wake you up at night 
or earlier than usual in the morning? 
1. Four or more times a week 
2. 2–3 times a week 
3. Once a week 
4. Once or twice per month 
5. Not at all 
 
IX. During the past 4 weeks how often have 
you used your nebulizer medication 
(such as salbutamol)? 
1. Three or more times a day 
2. Once or twice a day 
3. 2–3 times a week 
4. Once a week or less 
5. Not at all 
 
X. How would you rate your asthma 
control during the past 4 weeks? 
1. Not controlled at all 
2. Poorly controlled 
3. Somewhat controlled 
4. Well controlled 
5. Completely controlled 
 
Total score of asthma control test (out of 25)  
 
NAEPP Classification of Asthma Severity 
 
Asthma 
Classification 
Days 
Symptoms 
Nights 
Symptoms 
FEV1% NAEPP 
Score 
Severe persistent Continual  Frequent <60%  4 
Moderate persistent  Daily  ≥ 5times/month  60 % to 80% 3 
Mild persistent  >2 times /week  3-4 times/month ≥80% 2 
Mild intermittent ≤2 times /week  ≤ 2 times/month ≥80% 1  
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Figure (2-1): Continued 
Classification of Subjects/Patients 
 
Symptoms Classification ACT Classification NAEPP Classification 
(0) Non-Asthmatic 
(1) Symptoms-Free 
(2) Active Symptoms 
(0) Non-Asthmatic 
(1) Well Controlled Asthma 
(2) Poorly Controlled Asthma 
(3) Uncontrolled Asthma 
(0) Non-Asthmatic 
(1) Mild intermittent Asthma 
(2) Mild persistent Asthma  
(3) Moderate persistent Asthma 
(4) Severe persistent Asthma 
 
Drug Therapy 
 
Drugs  Specifications 
Beta Agonist 
VS 
Steroid 
(0) Off-treatment 
(1) Beta Agonist Only 
(2) Steroid Only 
(3) Combined Beta Agonist Steroid 
 
Antibiotics (0) No    (1) Yes  
Cough Syrups (0) No    (1) Yes  
Others (0) No    (1) Yes  
 
Examination 
 
Weight Height BMI 
SBP DBP MABP 
 
Laboratory Investigations 
 
[Hb] [RBG] [Na+] 
[K+] [Ca++] [Mg++] 
 
Pulmonary Function Tests 
 
FEV1  FEV3 FEV6 FVC 
FEV1% FEV3% , FEV6% FEV1/FEV6 
PEFR FEF25% FEF50% FEF75% 
FEF25%-75% FEF75 -85% 
 
Heart Rate Variability Studies 
 
MHR MNN SDNN RMSSD 
TP VLF LF HF 
LF Norm HF Norm LF/HF  
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APPENDIX B 
Table (7-1): Raw Data of Non-Asthmatics; Code, Gender, Age, Weight, 
Height, BMI, SBP, DBP, MABP, Hb, RBS, Na+, K+, Ca++ and Mg++ 
 
S.N Cod Gen Age Wt Ht BMI SBP DBP MABP Hb RBS Na+ K+ Ca++ Mg++ 
1 1 1 21 56 177 17.9 100 60 73.33 14.5 60 141 4.1 . . 
2 3 0 27 65.9 161.5 25.3 130 60 83.33 12.7 60 148 4.8 7.9 1.7 
3 5 0 28 92.7 162.5 35.1 122 82 95.33 12.1 67 161 4.5 8.5 2 
4 8 1 23 47.5 165.5 17.3 100 60 73.33 16.3 73 143 3.9 . 1 
5 9 1 21 53 167.5 18.9 110 70 83.33 15.1 93 141 4.3 2.4 0.8 
6 10 0 30 108.5 161 41.9 120 80 93.33 13.9 93 143 4.7 8 1.9 
7 11 0 33 71.5 155.5 29.6 120 80 93.33 10.9 67 142 4.4 8.2 1.9 
8 12 1 30 71.5 173 23.9 130 90 103.33 15.7 60 141 3.9 8.1 2.3 
9 13 0 20 105.5 148.5 47.8 130 105 113.33 15.1 107 144 4.1 8.3 1.9 
10 16 1 25 41.5 161 16 110 70 83.33 15.1 67 141 3.7 8.3 1.8 
11 17 1 29 73.8 168 26.1 124 70 88 9.7 73 146 4.2 8.2 2 
12 18 0 22 36.8 157.5 14.8 130 70 90 12.7 67 141 4 8.3 . 
13 19 0 21 63.7 158.5 25.4 135 75 95 11.5 73 136 3.9 8.2 1.1 
14 21 0 29 67 160.5 26 120 80 93.33 12.7 67 137 4.3 7.9 1.4 
15 22 0 21 73.4 160.5 28.5 105 70 81.67 12.1 73 139 4 7.7 1.5 
16 26 1 29 79.2 164.5 29.3 130 80 96.67 15 64 142 3.7 7.8 1.6 
17 28 0 25 62.5 154.5 26.2 110 65 80 11.9 100 139 3.9 8.5 1.8 
18 41 0 33 62.7 164.5 23.2 100 70 80 10.7 80 139 4.3 . 0.7 
19 47 1 21 66 169.5 23 100 80 86.67 22.5 122 143 3.3 8.1 1.6 
20 50 1 28 74.8 168 26.5 120 70 86.67 13.7 95 144 4.5 9 1.5 
21 51 1 29 64.5 173 21.6 120 80 93.33 16.5 109 136 4.4 8.5 1.5 
22 60 1 20 62.3 175 20.3 120 60 80 13.1 125 141 3.9 9.1 1.9 
23 59 1 27 73.1 168 25.9 110 75 86.67 13.6 100 132 5 8.6 1.3 
24 61 1 24 50.2 165 18.4 90 50 63.33 13.5 115 140 4 9.3 1.7 
25 58 1 27 68.9 171 23.6 110 70 83.33 15.1 95 137 3.4 8.9 1.7 
26 62 1 23 54.3 180.5 16.7 170 70 103.33 13.9 100 137 5.6 10.7 1.2 
27 70 1 23 71 174.5 23.3 130 80 96.67 16.5 100 140 4.4 . 0.7 
28 68 1 21 64 179.5 19.9 110 70 83.33 15.6 100 139 4.7 10.5 2.3 
29 69 1 22 83.5 184 24.7 120 80 93.33 15.1 95 146 4.7 . 0.8 
30 71 1 21 61.1 175 20 120 70 86.67 15.6 89 137 4.6 0.2 0.9 
31 72 1 20 60 175.5 19.5 110 70 83.33 13.9 100 133 4.4 7.8 1.4 
32 86 1 28 77.7 170 26.9 120 75 90 14.5 95 136 4.3 9.7 1.7 
33 85 1 28 62.3 169.5 21.7 110 70 83.33 14.2 100 138 4.1 10.3 1.6 
34 93 1 24 107.6 177 34.3 160 90 113.33 13.2 100 135 4.4 10.3 1.7 
35 92 1 21 89.1 177 28.4 130 90 103.33 14 98 136 4.3 10 1.9 
36 94 1 24 85 171.5 28.9 110 90 96.67 14.9 100 134 3.7 9.7 1.8 
37 118 0 30 61.4 160.2 23.9 120 80 93.33 12.4 100 139 4.1 8.9 1.6 
38 155 0 27 55.2 159.2 21.8 130 80 96.67 11.2 100 141 4.3 9.9 0.9 
39 154 0 21 63.2 161 24.4 110 80 90 9.9 110 135 3.7 9.4 1.5 
40 156 0 20 73 164 27.1 100 60 73.33 10.5 98 142 4.6 9.3 1.6 
41 157 0 20 68.7 157 27.9 110 70 83.33 10.3 110 139 4.3 9.8 1.6 
42 175 0 37 88 168 31.2 130 90 103.33 11.2 100 136 3.8 9.1 1.6 
43 176 0 25 57.3 156.3 23.5 120 80 93.33 8.9 110 140 3.6 9.1 1.6 
44 178 0 38 57.3 160.3 22.3 120 90 100 9 100 136 4 10.1 1.8 
45 207 0 20 63 166.5 22.7 120 80 93.33 8.3 89 135 4 9.9 2 
46 205 0 23 57 162.2 21.7 110 70 83.33 13.5 113 145 4.4 11.4 1.8 
47 208 0 20 62.5 168 22.1 120 70 86.67 12.1 115 134 3.9 10.2 1.8 
48 213 0 25 42.3 166 15.4 110 75 86.67 13.9 85 136 4.2 9.6 1.9 
49 209 0 20 47 158 18.8 120 80 93.33 11.5 100 136 3.6 9.9 1.7 
50 200 0 23 42.3 153.5 18 120 70 86.67 10.5 115 134 4.1 9.4 1.6 
51 212 0 20 45 152.2 19.4 110 70 83.33 10.3 115 141 3.9 9.6 1.6 
52 201 0 21 68 165.8 24.7 140 90 106.67 12.2 89 142 4 9.4 1.8 
53 215 0 25 55 161.2 21.2 110 80 90 13.3 110 141 4.1 9.2 1.6 
54 257 1 24 56.5 165.1 20.7 120 60 80 13.9 104 143 4 10 1.8 
55 260 1 35 58 174.4 19.1 110 70 83.33 15.1 98 139 4 9.7 1.7 
56 258 1 28 89.2 174.3 29.4 110 80 90 13.3 100 140 3.7 9.2 1.7 
Code for Gender (Gen): 0 = Female, 1 = Male. 
. = Missed Value 
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Table (7-2): Raw Data of Non-Asthmatics; FEV1, FEV3, FEV6, FVC, FEV1%, FEV3%, 
FEV6%, FEV1/FEV6, PEFR, FEF25%, FEF50%, FEF75%, FEF2575%, FEF8575% and DAS. 
 
S.N FEV1 FEV3 FEV6 FVC FEV1% 
FEV3
% 
FEV6
% 
FEV1/ 
1FEV6 PEFR 
FEF25
% 
FEF50
% 
FEF75
% 
FEF25
75% 
FEF85
75% DAS 
1 4.11 5.14 5.14 5.14 79.96 100 100 0.8 7.51 5.85 4.69 2.1 3.81 1.81 0.44 
2 2.58 2.73 2.73 2.73 94.51 100 100 0.95 7.07 6.2 6.26 2.31 4.83 1.53 1.40 
3 2.91 3.34 3.35 3.35 86.87 99.7 99.7 0.87 6.2 5.78 3.77 1.59 3.26 1.24 0.44 
4 3.24 3.72 3.72 3.72 87.1 100 100 0.87 8.22 6.28 3.61 1.77 3.31 1.51 1.34 
5 3.27 3.5 3.5 3.5 93.43 100 100 0.93 8.74 8.13 6.24 2.4 4.98 1.75 1.63 
6 2.51 2.93 2.96 2.97 84.51 98.65 98.65 0.85 6.11 6.09 3.23 1.13 3.79 0.83 0.67 
7 2.33 2.47 2.47 2.47 94.33 100 100 0.94 4.99 4.9 4.43 1.98 3.86 1.5 0.81 
8 3.84 4.29 4.47 4.47 85.91 95.97 95.97 0.86 8.89 8.82 6.85 2.09 5.24 1.21 1.10 
9 2.26 2.64 2.66 2.66 84.96 99.25 99.25 0.85 3.81 3.63 3.08 1.28 2.56 0.94 -0.26 
10 3.63 3.72 3.72 3.72 97.58 100 100 0.98 7.58 7.55 6.29 4.05 6.01 3.3 2.48 
11 3.22 3.56 3.59 3.59 89.69 99.16 99.16 0.9 8.32 7.62 4.86 2.03 4.23 1.49 1.33 
12 2.69 2.7 2.7 2.7 99.63 100 100 1 6.36 6 5.25 2.82 4.67 2.47 1.57 
13 3.01 3.11 3.11 3.11 96.78 100 100 0.97 6.2 6.09 4.95 2.41 4.29 1.99 1.39 
14 2.55 2.67 2.67 2.67 95.51 100 100 0.96 6.38 6.22 4.72 2.42 4.28 1.72 1.31 
15 2.86 3.07 3.07 3.07 93.16 100 100 0.93 5.22 5.2 4.49 2.37 4.16 1.78 1.18 
16 3.47 3.94 3.95 3.96 87.63 99.49 99.49 0.88 9.47 9.01 5.64 1.82 4.59 1.3 1.09 
17 2.24 2.38 2.38 2.38 94.12 100 100 0.94 7.2 7.15 4.54 1.84 3.94 1.3 0.81 
18 3.15 3.49 3.49 3.49 90.26 100 100 0.9 5.96 5.45 4.19 2.47 4.12 1.74 1.48 
19 3.58 3.92 3.92 3.92 91.33 100 100 0.91 7.63 7.44 6.26 2.39 4.95 1.81 1.29 
20 3.46 4.15 4.15 4.15 83.37 100 100 0.83 9.94 7.4 3.71 1.64 3.33 1.29 1.36 
21 4.07 4.71 4.71 4.71 86.41 100 100 0.86 7.71 7.69 4.85 2.29 4.3 1.9 0.88 
22 4.09 4.51 4.51 4.51 90.69 100 100 0.91 9.67 7.85 5.83 2.5 4.87 2.05 2.26 
23 3.7 4.11 4.2 4.22 87.68 97.39 97.39 0.88 8.02 7.63 6.14 2.26 5.17 1.42 1.62 
24 2.94 3.78 3.79 3.79 77.57 99.74 99.74 0.78 7.68 4.96 2.78 1.28 2.49 1 0.41 
25 2.73 3.33 3.33 3.33 81.98 100 100 0.82 7.81 5.85 2.82 1.22 2.52 0.97 0.48 
26 3.94 3.94 3.94 3.94 100 100 100 1 7.59 7.07 6.47 3.69 5.71 3.06 2.83 
27 4.59 5.23 5.24 5.24 87.6 99.81 99.81 0.88 9.64 9.33 6.23 2.77 5.6 1.97 1.95 
28 5.33 5.42 5.42 5.42 98.34 100 100 0.98 9.5 9.12 7.97 4.18 6.9 3.57 3.67 
29 4.41 5.2 5.22 5.22 84.48 99.62 99.62 0.84 8.98 8.54 5.41 2.26 4.76 1.68 1.20 
30 3.8 4.65 4.69 4.69 81.02 99.15 99.15 0.81 10.86 8.37 4.08 1.54 3.54 1.18 1.18 
31 3.97 4.39 4.39 4.39 90.43 100 100 0.9 8.39 7.52 5.62 2.43 4.79 2.04 1.74 
32 4.41 4.56 4.56 4.56 96.71 100 100 0.97 9.39 9.35 8.28 4.2 7.46 3.18 3.28 
33 3.95 4.34 4.34 4.34 91.01 100 100 0.91 7.02 6.72 4.94 3.2 5.06 2.35 2.19 
34 4.62 5.24 5.24 5.24 88.17 100 100 0.88 12.01 10.38 5.47 2.63 5.04 2.1 2.45 
35 4.29 4.39 4.39 4.39 97.72 100 100 1.27 10.25 10.04 8.33 4.34 7.45 3.37 2.55 
36 3.81 4.36 4.36 4.36 87.39 100 100 0.87 7.08 6.88 4.23 2.39 4 1.97 1.02 
37 2.41 2.78 2.78 2.78 86.69 100 100 0.87 5.1 4.36 3.89 1.32 3.11 0.85 0.31 
38 2.86 3.09 3.09 3.09 92.56 100 100 0.93 5.36 5.32 4.64 2.02 4.09 1.52 1.00 
39 2.76 3.06 3.06 3.06 90.2 100 100 0.9 6.92 6.35 3.67 1.81 3.35 1.39 0.87 
40 3 3.73 3.78 3.78 79.37 98.68 98.68 0.79 6.08 5 3 1.36 2.75 0.97 0.06 
41 2.47 3.17 3.23 3.23 76.47 98.14 98.14 0.76 6.11 4.23 2.35 1 2.04 0.77 -0.21 
42 3.02 3.22 3.22 3.22 93.79 100 100 0.94 6.78 6.77 6.03 2.52 5.08 1.66 1.49 
43 1.9 2.01 2.02 2.02 94.06 99.5 99.5 0.94 6 5.96 3.7 1.5 3.17 1.04 0.42 
44 2.27 2.47 2.48 2.48 91.53 99.6 99.6 0.92 6.83 6.32 2.98 1.7 3.07 1.22 0.87 
45 2.94 2.97 2.97 2.97 98.99 100 100 0.99 7.41 6.59 5.22 2.65 4.75 2.3 2.02 
46 3.63 3.95 3.95 3.95 91.9 100 100 0.92 7.11 7.08 5.91 2.46 4.84 1.89 1.34 
47 2.57 2.6 2.6 2.6 98.85 100 100 0.99 6.3 6.29 4.12 2.17 3.94 1.75 1.37 
48 2.56 2.58 2.58 2.58 99.22 100 100 0.99 4.26 4.25 3.72 2.81 3.6 2.47 1.14 
49 2.68 2.82 2.82 2.82 95.04 100 100 0.95 6.23 6.17 4 1.85 3.55 1.51 0.93 
50 2.54 2.72 2.72 2.72 93.38 100 100 0.93 4.33 4.28 3.08 2.09 3.06 1.62 0.79 
51 2.33 2.46 2.46 2.46 94.72 100 100 0.95 4.17 4.12 3.01 1.73 2.84 1.48 0.53 
52 2.77 3.12 3.21 3.21 86.29 97.2 97.2 0.86 7.51 7.39 4.71 1.35 3.68 0.9 0.35 
53 2.69 3.04 3.04 3.04 88.49 100 100 0.88 5.52 5.42 3.56 1.65 3.18 1.26 0.39 
54 3.74 4.2 4.2 4.2 89.05 100 100 0.89 8.17 6.77 5.21 2.36 4.65 1.72 1.96 
55 3.49 3.53 3.53 3.53 98.87 100 100 0.99 8.52 8.51 6.77 3.49 6.14 2.83 2.44 
56 3.28 3.54 3.58 3.59 91.36 98.61 98.61 0.92 8.51 8.05 6.55 2.41 5.37 1.62 1.69 
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Table (7-3): Raw Data of Non-Asthmatics;  MHR, MNN, SDNN, RMSSD, TP, 
VLF, LF, HF, LF Norm, HF Norm, LF/HF, Sympathetic (Sym) and 
Parasympathetic (P.Sym) Activity. 
 
S.N MHR MNN SDNN RMSSD TP VLF LF HF LF Norm 
HF 
Norm LF/HF Sym. P.Sym 
1 73.1 820.7 63.9 66 1262.2 342.6 552.9 366.7 60.1 39.9 1.5 2 2 
2 82.5 727 33.8 33.4 245.3 133.6 64.8 46.9 58 42 1.4 2 2 
3 88.7 676.5 42.6 33.1 985.7 485.8 372.9 127 74.6 25.4 2.9 2 2 
4 73.6 814.8 92.6 93.1 2902.2 233.2 1706.1 963 63.9 36.1 1.8 3 3 
5 72.9 823.6 47.4 46.9 720.3 355.3 239.5 125.5 65.6 34.4 1.9 2 2 
6 91.6 655.2 31.2 31 112.6 82.1 13.9 16.6 45.6 54.4 0.8 1 1 
7 70.4 852.2 54.4 54.7 693.9 245.7 294.2 154 65.6 34.4 1.9 2 2 
8 108.1 555.1 18.5 22.2 60.1 33.2 19.4 7.5 72.1 27.9 2.6 1 1 
9 89.9 667 56.1 45.5 785 293.6 336.1 155.2 68.4 31.6 2.2 2 2 
10 97.8 613.4 24.3 16.5 174.2 99.7 59.5 15.1 79.8 20.2 3.9 2 1 
11 86.5 693.7 28.8 28.3 173.4 53.6 57.4 62.5 47.8 52.2 0.9 2 2 
12 86.9 690.5 43.5 52.8 426 71.9 148.1 206.1 41.8 58.2 0.7 2 2 
13 98.1 611.3 28.4 25.1 252.1 98.7 124.9 28.5 81.4 18.6 4.4 2 1 
14 76.8 781.3 36.7 36 302.7 226.4 57.7 18.6 75.6 24.4 3.1 2 1 
15 84.1 713.4 186 263.9 3612 696.2 541.4 2374.4 18.6 81.6 0.2 3 3 
16 80.2 748.4 41.4 16.9 221.6 114.9 79.3 27.4 74.3 25.7 2.9 2 2 
17 80.5 745.2 42 54 399.7 65.3 52 282.4 15.5 84.5 0.2 2 2 
18 77.6 773.5 45.9 28.2 820.5 634.9 138 47.6 74.4 25.6 2.9 2 2 
19 96.4 622.6 39.3 38.9 425.1 295.9 107.1 22 83 17 4.9 2 1 
20 84.4 710.7 49.9 28.4 718.5 507.8 136.8 73.9 64.9 35.1 1.9 2 2 
21 98.9 607.2 23.8 33.6 95.4 22.4 29 33.9 53.5 46.5 1.2 1 2 
22 80.7 743.4 176.5 201.1 4819.8 852.8 1220.3 2746.7 30.8 69.2 0.4 2 3 
23 82.3 729.2 64.7 51.7 818.1 263 355.7 199.3 64.1 35.9 1.8 2 2 
24 76 789.9 98.4 100.7 1705.4 145 542.9 1017.4 34.8 65.2 0.5 2 3 
25 71.6 837.7 184 174.2 6169.6 1835.7 1988.9 2345 45.9 54.1 0.8 3 3 
26 78.7 762.2 88.7 92.4 1392.2 422 671.7 298.5 69.2 30.8 2.2 2 2 
27 75.6 793.3 151.8 166.7 7261.5 2095.8 2244.3 2921.4 43.4 56.6 0.8 3 3 
28 70.7 849 59.5 51.1 903.8 409.5 270.3 224 54.7 45.3 1.2 3 3 
29 76.2 787.8 51.1 48.1 762.3 106.9 181.7 473.7 27.7 72.3 0.4 3 3 
30 81.2 739.1 225.7 208.6 13522 9578.6 1648 2295.5 41.8 58.2 0.7 2 3 
31 66.1 907.9 169.6 177.6 4138.1 1102.7 1104.4 1931.4 36.4 63.6 0.6 2 3 
32 105 571.4 201.7 290.3 9525.7 1119.2 2919.6 5486.8 34.7 65.3 0.5 3 3 
33 70.3 853.3 63.5 43.8 785.8 541.1 152.6 92.1 62.3 37.7 1.7 2 2 
34 88.8 675.9 47.6 16.7 426.9 242.7 145.4 38.8 79 21 3.8 2 2 
35 74.1 809.9 28.6 31.2 166.1 34.3 56.6 75.2 43 57 0.8 2 2 
36 59.3 1011 81.7 86.6 1455.7 254.4 744.7 456.6 62 38 1.6 2 2 
37 71.9 834.7 73.5 86 691.2 208.7 154.5 328 32 68 0.5 2 2 
38 63.3 947.5 61.4 67.3 1066.1 187.6 435.8 442.7 49.6 50.4 1 2 2 
39 93.1 644.6 41.6 44.2 436.7 190.9 155.5 90.3 63.3 36.7 1.7 2 2 
40 91.1 658.5 38 34.7 433.1 128.1 180 124.9 59 41 1.4 2 2 
41 92.6 647.6 59.1 66 789.3 212.4 247 329.9 42.8 57.2 0.7 2 2 
42 84.8 707.8 53.1 43.1 693 189.7 232.3 271 46.2 53.8 0.9 2 2 
43 86.8 690.9 42.4 45.5 499.8 125.5 190 184.3 50.8 49.2 1 2 2 
44 87.3 687.1 29 35 129.4 32.7 30.9 65.8 32 68 0.5 2 2 
45 90.3 664.4 126.7 142.4 2406.3 381.7 720.5 1304 35.6 64.4 0.6 2 2 
46 93.9 639 50.2 36.1 562 272.4 161.9 127.7 55.9 44.1 1.3 2 2 
47 100.4 597.8 42.8 46.8 498.1 164.3 176 157.8 52.7 47.3 1.1 2 2 
48 88.1 681.4 148.6 173.5 3845.1 533 1122.3 2189.7 33.9 66.1 0.5 2 3 
49 95.5 628.2 27.6 34 136.3 23.4 49.7 63.2 44 56 0.8 2 2 
50 99.6 602.1 185.6 257.9 7173.7 1098.7 1998.5 4076.5 32.9 67.1 0.5 3 3 
51 96.3 623.1 114 127.6 1259.3 240.7 341.1 677.5 33.5 66.5 0.5 2 2 
52 80.1 748.7 37.9 35.5 420.3 156.4 204.4 59.5 77.5 22.5 3.4 2 2 
53 79.2 757.5 72.3 73.8 1351.8 207.6 408.4 735.9 35.7 64.3 0.6 2 2 
54 103.5 579.8 185.9 272.9 9713.9 2929.2 3170.5 4614.1 40.7 59.3 0.7 3 3 
55 90.7 661.3 186.6 230.2 6643 611.6 2365.9 3665.6 39.2 60.8 0.6 3 3 
56 82.7 725.9 41.9 25 650 407.3 189.4 53.3 78.1 21.9 3.6 2 2 
 
Code for Sympathetic Activity (Sym): 1 = Low Sympathetic Tone, 2 = Normal Sympathetic Tone, 3 = High Sympathetic Tone. 
Code for Parasympathetic Activity (P.Sym): 1 = Low Parasympathetic Tone, 2 = Normal Parasympathetic Tone, 3 = High Parasympathetic 
Tone. 
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Table (7-4): Raw Data  of Asthmatics without Symptoms; Code, Gender, 
Age, Weight, Height, BMI, SBP, DBP, MABP, Hb, RBS, Na+, K+, Ca++ 
and Mg++ 
S.N Cod Gen Age Wt Ht BMI SBP DBP MABP Hb RBS Na+ K+ Ca++ Mg++ 
57 52 0 32 75 156.5 30.6 110 80 90 15.5 131 143 3.3 10.7 1.7 
58 55 1 27 63.2 175.5 20.5 105 85 91.67 17.1 90 142 3.9 9.9 1.6 
59 56 1 34 54.5 174.5 17.9 90 70 76.67 15.1 87 132 3.6 9 1.8 
60 64 1 30 59.7 176.5 19.2 110 70 83.33 14.1 105 144 4.6 10.7 2 
61 65 1 30 89 198 22.7 120 80 93.33 14.5 94 136 4.5 9.4 1.7 
62 67 0 21 57.4 170 19.9 100 60 73.33 13.7 98 134 4.9 9.9 . 
63 78 1 35 73.5 176.5 23.6 110 70 83.33 15.1 105 146 3.8 10.6 1.6 
64 77 1 32 67 177.5 21.3 120 90 100 15.6 98 143 4.4 10 1.6 
65 73 1 27 48.8 172.5 16.4 120 90 100 14.9 95 138 3.9 . 0.8 
66 75 1 25 75.7 176 24.4 100 70 80 15.1 98 139 4.4 10.3 1.9 
67 76 1 37 58.5 158.5 23.3 120 70 86.67 14.9 110 135 3.9 9.3 1.8 
68 74 0 35 56 167 20.1 140 90 106.67 14.2 100 133 4.9 9.8 1.8 
69 82 1 22 77.7 179 24.3 110 90 96.67 15.9 89 143 3.7 10.1 1.5 
70 88 1 36 77.5 177.5 24.6 115 75 88.33 14.9 125 133 3.7 9.4 1.7 
71 87 0 35 88.6 172 29.9 120 90 100 13.5 115 135 3.9 8.6 1.6 
72 84 1 30 67.7 166.5 24.4 110 65 80 15 110 136 4 10 1.5 
73 89 1 36 84.5 184 25 110 80 90 15.4 110 140 3.5 10 1.8 
74 90 0 28 117.8 162.5 44.6 140 100 113.33 12.3 115 139 3.6 8.4 1.6 
75 91 0 35 88 152 38.1 105 80 88.33 13.9 95 140 4 9 1.5 
76 95 1 32 51 163 19.2 110 70 83.33 13.9 125 136 4.1 9 1.7 
77 100 1 27 71.2 177.5 22.6 110 80 90 13.7 100 135 3.9 9.8 1.9 
78 112 0 21 48 161.5 18.4 120 70 86.67 7.9 89 142 3.5 9.5 1.5 
79 115 0 30 60.9 146 28.6 130 80 96.67 9 110 140 3.6 9.1 1.5 
80 111 1 35 72 173.5 23.9 100 80 86.67 15.1 115 139 3.9 10.3 1.6 
81 133 0 25 57.5 161 22.2 120 90 100 14.1 100 146 4.5 12.8 1.9 
82 131 1 28 58 178 18.3 130 90 103.33 14.5 123 142 3.9 10.2 1.6 
83 138 0 36 73.5 164 27.3 140 80 100 11.2 110 137 4.2 8.7 1.6 
84 137 0 22 58.5 168.5 20.6 100 70 80 13.9 118 136 4 8.6 1.6 
85 139 0 26 52 160.5 20.2 120 70 86.67 11 120 134 4.1 8.6 1.6 
86 151 0 24 49 150.5 21.6 100 80 86.67 12.1 100 136 4.6 8.8 1.6 
87 153 1 30 64.3 171.5 21.9 120 70 86.67 15.1 85 139 3.9 8.3 1.5 
88 150 1 26 56.8 175 18.5 120 80 93.33 14.9 89 139 4.1 9.1 1.8 
89 158 0 20 57.5 157.7 23.1 130 80 96.67 8 120 137 4.1 9.5 1.5 
90 177 0 29 48 152 20.8 110 70 83.33 9.5 89 144 3.7 9.4 1.5 
91 174 0 30 64.9 154.8 27.1 140 100 113.33 14 115 144 3.9 9.4 1.1 
92 170 0 35 54.1 151 23.7 110 70 83.33 13.5 98 147 5 . 0.6 
93 172 0 25 68 154.5 28.5 130 100 110 12 110 136 3.9 9.3 1.5 
94 171 1 38 80.5 164.2 29.9 140 90 106.67 14.3 118 143 4 9.7 1.6 
95 211 1 20 76.5 178 24.1 150 80 103.33 14.8 100 143 3.8 10.3 1.7 
96 218 0 27 60.9 154.3 25.6 130 80 96.67 11 95 140 3.9 10 1.7 
97 217 1 27 62.5 178 19.7 110 80 90 15.1 120 139 4 10.2 1.9 
98 220 0 20 70.6 151.6 30.7 120 90 100 12.1 100 150 5.5 . 0.8 
99 219 0 31 53.5 155.2 22.2 80 60 66.67 10.1 121 143 3.8 9.7 1.6 
100 253 1 40 86 165.5 31.4 130 100 110 14.9 110 140 4.4 10.5 1.6 
101 250 1 28 91.5 178.6 28.7 110 80 90 14.5 115 139 4.1 10.3 1.7 
102 254 1 28 76.5 165.7 27.9 130 90 103.33 13.5 100 135 3.9 9.9 1.8 
103 252 1 37 55.4 170.5 19.1 120 100 106.67 15.4 93 139 4.1 10.5 1.7 
104 255 1 25 57.5 165.3 21 110 70 83.33 13.2 98 141 3.6 10 1.7 
105 300 1 25 57.4 169 20.1 110 70 83.33 13.9 110 136 4 9.9 1.8 
106 304 0 24 46.3 154.7 19.3 110 85 93.33 14 108 136 4 9.2 1.6 
107 303 1 31 63.7 174.5 20.9 110 85 93.33 14.8 100 140 3.9 10.4 2.2 
108 371 0 31 71 160.7 27.5 120 90 100 11.5 100 136 3.7 11 1.8 
109 378 0 37 63.2 161 24.4 110 80 90 13.9 103 141 4.1 10.3 1.9 
 
Code for Gender (Gen): 0 = Female, 1 = Male. 
. = Missed Value 
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Table (7-5): Raw Data of Asthmatics without Symptoms; FEV1, FEV3, FEV6, FVC, FEV1%, 
FEV3%, FEV6%, FEV1/FEV6, PEFR, FEF25%, FEF50%, FEF75%, FEF2575%, FEF8575% 
and DAS. 
S.N FEV1 FEV3 FEV6 FVC FEV1% 
FEV3
% 
FEV6
% 
FEV1/ 
1FEV6 PEFR 
FEF25
% 
FEF50
% 
FEF75
% 
FEF25
75% 
FEF85
75% DAS 
57 2.56 2.9 2.94 2.94 87.07 98.64 98.64 0.87 4.36 3.71 4 1.54 3.11 1.09 0.33 
58 2.89 4.18 4.47 4.47 64.65 93.51 93.51 0.65 6.65 4.05 2.1 0.81 1.79 0.65 -1.37 
59 3.09 3.66 3.66 3.66 84.43 100 100 0.84 5.72 5.37 3.2 1.74 3.06 1.46 0.25 
60 3.9 5.53 5.69 5.69 68.54 97.19 97.19 0.69 8.63 5.67 3.07 1.44 2.75 1.18 -0.73 
61 3.88 4.98 5.05 5.05 76.83 98.61 98.61 0.77 6.54 5.75 3.92 1.58 3.41 1.3 -0.32 
62 2.84 3.59 3.6 3.6 78.89 99.72 99.72 0.79 4.69 4.34 2.85 1.28 2.62 1 -0.52 
63 3.67 4.83 5.22 5.26 69.77 91.83 91.83 0.7 8.17 6.52 3.04 1 2.49 0.7 -0.86 
64 2.91 4 4.17 4.17 69.78 95.92 95.92 0.7 6.37 4.51 2.46 0.94 2.07 0.76 -1.01 
65 2.55 2.97 3.08 3.08 82.79 96.43 96.43 0.83 6.55 6.53 3.68 0.98 2.87 0.65 -0.25 
66 3.33 4.85 4.91 4.91 67.82 98.78 98.78 0.68 6.62 5.17 2.56 1.25 2.33 1.04 -1.58 
67 2.33 2.95 3.02 3.02 77.15 97.68 97.68 0.77 5.38 4.05 2.21 0.97 1.95 0.67 -0.35 
68 2.23 2.63 2.67 2.67 83.52 98.5 98.5 0.84 4.97 4.87 3.39 0.99 2.51 0.69 -0.54 
69 3.7 5.33 5.73 5.75 64.35 92.7 92.7 0.65 7.72 5.27 2.61 1.19 2.34 0.88 -1.56 
70 2.85 3.99 4.26 4.28 66.59 93.22 93.22 0.67 6.57 3.79 2.14 0.95 1.96 0.72 -0.76 
71 2.5 3.45 3.6 3.6 69.44 95.83 95.83 0.69 4.98 3.44 2 0.94 1.83 0.71 -1.06 
72 1.51 2.34 2.73 2.77 54.51 84.48 84.48 0.55 4.17 1.73 0.9 0.38 0.76 0.29 -1.51 
73 3.62 4.86 5.08 5.08 71.26 95.67 95.67 0.71 7.05 5.82 3.22 1.19 2.67 0.88 -1.02 
74 2.6 3.01 3.15 3.17 82.02 94.95 94.95 0.83 5.34 5.22 3.2 1.09 2.74 0.71 -0.03 
75 2.51 2.82 2.83 2.83 88.69 99.65 99.65 0.89 7.46 7.2 4.07 1.4 3.44 0.98 0.46 
76 3.05 3.45 3.45 3.45 88.41 100 100 0.88 5.74 5.37 4.58 1.85 3.74 1.4 0.65 
77 4.29 5.44 5.44 5.44 78.86 100 100 0.79 6.54 6.37 4.79 2.02 4.1 1.46 -0.04 
78 2.65 2.75 2.75 2.75 96.36 100 100 0.96 6.03 5.96 5.08 2.04 4.08 1.59 1.00 
79 2.02 2.44 2.64 2.65 76.23 92.08 92.08 0.77 5.2 4.57 2.18 0.61 1.66 0.38 -0.66 
80 3.09 4.11 4.44 4.45 69.44 92.36 92.36 0.7 6.12 6.11 2.52 0.77 2.07 0.57 -1.80 
81 1.16 1.84 2.16 2.26 51.33 81.42 81.42 0.54 2.19 1.31 0.65 0.25 0.58 0.18 -1.86 
82 3.42 4.38 4.38 4.38 78.08 100 100 0.78 7.63 5.16 3.04 1.77 2.9 1.54 0.50 
83 1.87 2.3 2.47 2.47 75.71 93.12 93.12 0.76 5.58 3.93 1.71 0.52 1.46 0.33 -0.26 
84 2.25 2.64 2.64 2.64 85.23 100 100 0.85 5.06 4.92 2.76 1.16 2.44 0.84 -0.22 
85 2.48 2.69 2.7 2.7 91.85 99.63 99.63 0.92 5.57 5.11 4.35 1.81 3.74 1.27 0.90 
86 2.68 2.88 2.88 2.88 93.06 100 100 0.93 5.76 5.74 4.95 2.11 4.29 1.42 1.08 
87 1.83 2.63 3.03 3.2 57.19 82.19 82.19 0.6 4.85 2.19 1.04 0.36 0.85 0.25 -0.85 
88 2.42 3.56 4.02 4.02 60.2 88.56 88.56 0.6 5.15 3.07 1.64 0.6 1.35 0.46 -1.94 
89 2.52 2.57 2.57 2.57 98.05 100 100 0.98 6.98 6.93 5.08 2.88 4.74 2.39 1.43 
90 2.54 2.84 2.84 2.84 89.44 100 100 0.89 5.62 5.59 3.24 1.57 3.05 1.2 0.42 
91 2.65 2.78 2.78 2.78 95.32 100 100 0.95 5.88 5.87 5 2.37 4.53 1.66 1.38 
92 1.67 2.27 2.39 2.39 69.87 94.98 94.98 0.7 3.97 2.74 1.4 0.48 1.16 0.39 -1.22 
93 2.43 2.58 2.58 2.58 94.19 100 100 0.94 5.62 5.62 4.37 1.83 3.77 1.36 0.79 
94 1.94 2.7 2.79 2.79 69.53 96.77 96.77 0.7 4.64 2.64 1.57 0.65 1.39 0.53 -0.95 
95 4.5 4.52 4.52 4.52 99.56 100 100 1 11.22 10.58 10.06 4.9 8.56 4.05 3.77 
96 2.16 2.67 2.72 2.72 79.41 98.16 98.16 0.79 3.82 3.7 2.32 0.95 2 0.65 -0.77 
97 3.68 4.44 4.44 4.44 82.88 100 100 0.83 8.7 6.61 3.61 1.94 3.45 1.58 1.22 
98 2.66 2.85 2.85 2.85 93.33 100 100 0.93 5.34 4.87 4.82 2.23 4.11 1.61 1.16 
99 2.53 3.01 3.07 3.07 82.41 98.05 98.05 0.82 5.16 4.71 2.59 1.31 2.4 1.1 -0.18 
100 3.49 4.27 4.42 4.45 78.43 95.96 95.96 0.79 7.63 6.42 3.65 1.39 3.13 0.96 0.31 
101 2.18 3.1 3.34 3.34 65.27 92.81 92.81 0.65 4.18 3.02 1.69 0.65 1.44 0.49 -1.67 
102 1.13 1.46 1.5 1.5 75.33 97.33 97.33 0.75 3 2.66 0.98 0.38 0.89 0.28 -1.31 
103 2.09 3 3.41 3.52 59.38 85.23 85.23 0.61 5.05 2.92 1.27 0.37 1.05 0.33 -1.37 
104 2.07 2.53 2.6 2.6 79.62 97.31 97.31 0.8 4.69 4.46 2.23 0.77 1.92 0.58 -0.75 
105 2.54 3.72 4.18 4.18 60.77 89 89 0.61 6.09 3.4 1.54 0.69 1.42 0.51 -1.57 
106 2.47 2.98 3.01 3.01 82.06 99 99 0.82 4.78 4.75 2.9 1.09 2.53 0.82 -0.45 
107 2.22 2.81 2.96 2.96 75 94.93 94.93 0.75 4.5 4.23 2.15 0.68 1.79 0.51 -1.07 
108 2.42 2.85 2.9 2.9 83.45 98.28 98.28 0.83 5.88 5.48 2.64 1.1 2.47 0.82 -0.03 
109 2.01 2.96 3.36 3.49 57.59 84.81 84.81 0.6 4.22 2.46 1.27 0.42 1.03 0.32 -1.65 
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Table (7-6): Raw Data - Asthmatics without Symptoms;  MHR, MNN, SDNN, 
RMSSD, TP, VLF, LF, HF, LF Norm, HF Norm, LF/HF, Sympathetic (Sym) 
and Parasympathetic (P.Sym) Activity. 
 
S.N MHR MNN SDNN RMSSD TP VLF LF HF LF Norm 
HF 
Norm LF/HF Sym. P.Sym 
57 98.8 607.2 23.8 33.6 95.4 22.4 39 33.9 53.5 46.5 1.2 1 2 
58 76.5 784.8 81.9 82.7 538.8 123.9 152 262.9 36.6 63.4 0.6 2 2 
59 68.6 874.4 48.7 59 186.3 32 30.2 124 19.6 80.4 0.2 1 2 
60 56.6 1060.7 70.5 68.9 874.8 266.6 354.4 293.8 54.7 45.3 1.2 2 2 
61 87.3 687.6 223.7 227 7331.3 3275.1 1464.5 2591.6 36.1 63.9 0.6 2 3 
62 99.9 600.7 232.5 303.2 14127.9 2916 3943.1 7268.9 35.2 64.8 0.5 3 3 
63 84.6 709.5 261.3 273.1 19093.6 3818.5 6092.6 9182.6 39.9 60.1 0.7 2 3 
64 93.3 643.3 215.6 266.9 8735.6 1007.8 3054.4 4673.4 39.5 60.5 0.7 3 3 
65 97.8 613.7 46.5 51.3 511.4 123.2 171.2 217 44.1 55.9 0.8 3 3 
66 109.4 548.3 192.5 261.5 5926.6 438.9 1464.2 4023.4 26.7 73.3 0.4 2 3 
67 94.1 637.5 178.5 199.7 4365.7 645.8 1255.2 1464.7 33.7 66.3 0.5 3 3 
68 89.6 669.8 53 58.9 349 100.3 106.1 142.6 42.7 57.3 0.7 2 2 
69 87.7 684.5 106.7 114.8 1969.1 226.2 845.9 897.1 48.5 51.5 0.9 2 2 
70 73.5 816.2 150.2 156.4 2950.8 575.4 764 1611.4 32.2 67.8 0.5 2 3 
71 84.3 711.8 295.6 348.6 15811.2 681.7 5151.5 9978 34 66 0.5 3 3 
72 80.9 741.8 55.3 46.5 778.3 117.6 404.9 255.8 61.3 38.7 1.6 2 2 
73 86.1 696.7 77.1 66.2 1165.3 287.6 364 513.7 41.5 58.5 0.7 2 2 
74 92.6 647.7 193.1 168.3 8381.3 1888.8 2399.4 4093.1 37 63 0.6 3 3 
75 80.4 745.9 41 31.7 464.1 186.2 171 106.9 61.5 38.5 1.6 2 2 
76 85.9 698.3 52.8 58.6 847.3 195.9 282.5 368.9 43.4 56.6 0.8 2 2 
77 85.9 698.3 44.3 29.9 680.6 260 362 58.6 86.1 13.9 6.2 2 2 
78 71.7 836.9 52.7 46.8 537.6 161.4 245.1 131.1 65.2 34.8 1.9 2 2 
79 102.2 587.3 35.2 23.7 544 310.3 193.5 40.2 82.8 17.2 4.8 2 2 
80 90.8 660.6 41 39.4 406.5 109.7 267.4 29.4 90.1 9.9 9.1 2 2 
81 93.3 643 213 253 9370.3 2097.9 3367.4 3905 46.3 53.7 0.9 3 3 
82 106.2 565.1 195.6 268.6 7346.6 454.6 2942.4 3949.5 42.7 57.3 0.7 3 3 
83 95.2 629.9 40.6 42.7 273.5 58.7 146.3 68.5 68.1 31.9 2.1 2 2 
84 84.3 712.1 129.7 129.6 2123.7 374.8 672.8 1076 38.5 61.5 0.6 2 2 
85 110.2 544.5 52.6 68.9 259.6 76.5 120.1 63.1 65.6 34.4 1.9 2 2 
86 84.7 708.1 48.1 30.1 892.3 530.8 248.3 113.1 68.7 31.3 2.2 2 2 
87 91.8 653.4 19.2 15.8 129.9 20.4 62.9 46.6 57.4 42.6 1.3 2 2 
88 65.5 916.4 76 86.7 653 66.6 165.6 420.8 28.2 71.8 0.4 2 2 
89 91.7 654.4 42.3 48.9 448 124.7 58.5 264.9 18.1 81.9 0.2 2 2 
90 87.8 683.6 39.5 32.4 519.9 246.8 170.1 103 62.3 37.7 1.7 2 2 
91 99.8 601.3 33.6 27.5 158.7 61.1 69.6 28 71.3 28.7 2.5 2 2 
92 92.5 648.6 47.1 53.6 379.2 75.1 167.8 136.3 55.2 44.8 1.2 2 2 
93 90.3 664.6 40.9 43.9 267 122.2 74 70.8 51.1 48.9 1 2 2 
94 91.4 656.4 37.5 30.7 383.1 107.7 184.6 90.9 67 33 2 2 2 
95 78.6 763.5 72.8 52.9 1542.1 782.6 398.5 361 52.5 47.5 1.1 2 2 
96 94.3 636.2 170.7 201.2 4640.3 1137.5 885.5 2617.2 25.3 74.7 0.3 2 3 
97 105.4 569.2 187.3 272.9 6389.4 899.9 1254.4 4235.2 22.8 77.2 0.3 2 3 
98 99.9 600.6 49 32.4 371.7 177.6 109.8 84.3 56.6 43.4 1.3 2 2 
99 85.9 698.2 231.5 258.4 12394.3 1234.1 3851.9 7308.4 34.5 65.5 0.5 3 3 
100 80.2 748.4 65.1 44.1 1460.5 757.5 442.4 260.6 62.9 37.1 1.7 2 2 
101 85.6 700.6 50 48.9 432.4 97 272 63.4 81.1 18.9 4.3 2 2 
102 107.2 559.4 202.7 296.1 6655.3 412.5 2313 3929.8 37.1 62.9 0.6 3 3 
103 61.2 980.2 38.8 41.5 111.4 66.8 18.9 25.6 42.5 57.5 0.7 1 2 
104 79.4 755.8 61.1 72.7 436.1 62.5 175.8 197.8 47.1 52.9 0.9 2 2 
105 85.6 700.8 307 356.6 7083.1 4249.6 703 2130.5 24.8 75.2 0.3 2 3 
106 92 651.9 201 220.8 9408.8 1263.8 3674.2 4470.8 45.1 54.9 0.8 3 3 
107 88.4 678.9 200.1 199.5 6863.3 695.2 3123 3045.1 50.6 49.4 1 3 3 
108 92.6 647.9 22.3 13.2 169.6 39.1 107.3 23.2 82.2 17.8 4.6 2 1 
109 100.8 595 38.4 25.6 552.6 242.6 217 93.1 70 30 2.3 2 2 
 
Code for Sympathetic Activity (Sym): 1 = Low Sympathetic Tone, 2 = Normal Sympathetic Tone, 3 = High Sympathetic Tone. 
Code for Parasympathetic Activity (P.Sym): 1 = Low Parasympathetic Tone, 2 = Normal Parasympathetic Tone, 3 = High Parasympathetic 
Tone. 
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Table (7-7): Raw Data - Asthmatics without Symptoms; ACT score, 
ACT state, NAEPP Class, Duration of asthma and Therapy 
S.N ACT score 
ACT 
state NAEPP Dur B S B±S A.B C.S O 
57 11 3 2 5 1 1 3 1 1 0 
58 14 3 3 20 1 0 1 0 1 0 
59 9 3 3 2 0 1 2 0 1 0 
60 14 3 2 4 1 0 1 0 0 0 
61 13 3 3 7 1 1 3 1 1 0 
62 17 2 2 16 1 1 3 0 0 0 
63 18 2 2 6 0 0 0 0 0 0 
64 10 3 2 14 1 0 1 0 0 0 
65 13 3 3 15 1 0 1 1 1 0 
66 14 3 2 4 1 0 1 0 0 0 
67 20 1 2 4 1 1 3 0 0 0 
68 13 3 2 2 1 0 1 0 0 0 
69 16 2 2 4 0 0 0 0 0 0 
70 22 1 2 33 1 0 1 0 0 0 
71 19 2 2 30 1 0 1 0 0 0 
72 14 2 3 20 0 0 0 0 0 0 
73 25 1 2 30 0 0 0 0 0 0 
74 17 2 2 6 1 0 1 0 0 1 
75 14 3 3 11 0 0 0 0 0 0 
76 23 1 1 2 0 0 0 0 1 0 
77 18 2 2 11 1 0 1 0 0 0 
78 18 2 2 4 0 1 2 0 0 0 
79 22 1 2 7 1 1 3 1 0 0 
80 14 3 3 4 0 0 0 1 0 0 
81 16 2 2 9 1 1 3 0 0 0 
82 21 1 2 16 0 0 0 0 0 0 
83 10 3 3 4 1 1 3 0 0 0 
84 19 2 1 20 0 0 0 0 0 0 
85 18 2 2 4 0 0 0 0 0 1 
86 17 2 1 2 0 0 0 0 0 0 
87 13 3 4 14 1 0 1 0 0 0 
88 16 2 2 3 1 1 3 0 0 0 
89 24 1 1 15 0 0 0 0 0 0 
90 22 1 1 27 0 0 0 0 0 0 
91 13 3 3 2 1 1 3 1 0 0 
92 19 2 2 5 0 1 2 0 0 1 
93 19 2 1 2 0 1 2 0 0 1 
94 17 2 2 10 1 0 1 0 0 0 
95 20 1 1 4 1 1 3 0 0 0 
96 18 2 2 12 1 1 3 1 0 0 
97 23 1 1 20 0 0 0 0 0 0 
98 23 1 1 20 0 0 0 0 0 0 
99 25 1 1 26 0 0 0 0 0 0 
100 14 3 2 11 0 0 0 0 0 0 
101 15 3 3 4 0 0 0 0 0 0 
102 13 3 3 17 1 1 3 0 0 0 
103 11 3 4 4 0 1 2 0 0 0 
104 20 1 2 2 1 1 3 0 0 0 
105 9 3 3 23 1 0 1 1 1 0 
106 17 2 2 9 1 0 1 0 0 0 
107 19 2 3 2 1 0 1 0 0 0 
108 14 3 2 3 1 1 3 0 1 0 
109 13 3 4 37 1 1 3 0 0 0 
 
Code for ACT State: 1 = Controlled Asthmatic Patient, 2 = Uncontrolled Asthmatic Patient. 
Code for NAEPP Classification (NAEPP): 0 = No Asthma, 1 = Mild Intermittent Asthma, 2 = Mild Persistent Asthma, 3 = Moderate 
Persistent Asthma, 4 = Severe Persistent Asthma. 
Code for Taking Beta Agonists Therapy (B): 0 = Not Taking Beta Agonists Therapy, 1 = Taking Beta Agonists Therapy. 
Code for Taking Steroids Therapy (S): 0 = Not Taking Steroids Therapy, 1 = Taking Steroids Therapy. 
Code for Taking Beta Agonists ± Steroids Therapy (B±S): 0 = Not Taking Beta Agonists or Steroids Therapy, 1 = Taking Beta 
Agonists Therapy Only, 2 = Taking Steroids Therapy Only, 3 = Taking both Beta Agonists and Steroids Therapy. 
Code for Taking Antibiotics Therapy (A.B): 0 = Not Taking Antibiotics Therapy, 1 = Taking Antibiotics Therapy. 
Code for Taking Cough Syrup Therapy (C.S): 0 = Not Taking Cough Syrup Therapy, 1 = Taking Cough Syrup Therapy.  
Code for Taking Other Therapies (O): 0 = Not Taking Other Therapies, 1 = Taking Other Therapies. 
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Table (7-8): Raw Data  of Asthmatics with; Code, Gender, Age, Weight, 
Height, BMI, SBP, DBP, MABP, Hb, RBS, Na+, K+, Ca++ and Mg++ 
S.N Cod Gen Age Wt Ht BMI SBP DBP MABP Hb RBS Na+ K+ Ca++ Mg++ 
110 36 0 27 71.6 161 27.6 100 60 73.33 12 105 140 4.6 8.3 1.6 
111 35 1 33 48.5 170.5 16.7 80 50 60 15 89 159 3.8 8.6 1.5 
112 38 0 29 67 149.5 30 110 70 83.33 12.5 93 138 3.9 7.4 1.5 
113 39 0 23 49.5 169.5 17.2 100 80 86.67 10.7 80 135 4.9 8 1.4 
114 40 0 21 42.5 160.5 16.5 100 80 86.67 10.2 73 141 3.9 8.3 1.5 
115 42 0 20 72 161 27.8 110 70 83.33 11.2 100 136 4.2 6.7 0.8 
116 45 1 27 52 166 18.9 100 70 80 15 81 144 3.4 . 0.5 
117 46 1 30 54 188.5 15.2 120 70 86.67 16.8 91 139 3.5 9.1 1.7 
118 57 1 27 55.5 171.5 18.9 105 80 88.33 15.6 87 145 4 9.4 1.7 
119 63 0 33 80.5 158.5 32 130 80 96.67 14.1 88 143 4.4 6.2 1.1 
120 66 1 20 60.2 170.5 20.7 110 80 90 16.5 105 132 4.8 9.9 2.1 
121 80 0 35 59.5 160.5 23.1 120 90 100 13.2 110 146 3.9 8.1 1.5 
122 81 0 27 66.5 158.5 26.5 110 70 83.33 12 100 143 3.5 9.9 1.4 
123 83 1 34 63.3 180.5 19.4 120 90 100 15 95 144 3.9 9.6 1.5 
124 101 0 35 86.7 166 31.5 110 80 90 14.9 98 142 3.9 10 1.7 
125 102 1 27 54 162 20.6 110 90 96.67 15.1 114 137 4 10.4 1.6 
126 113 0 32 85 159.5 33.4 120 80 93.33 12 100 141 3.6 10.3 1.5 
127 114 0 39 61.3 161.5 23.5 160 90 113.33 9.9 110 143 4 10.1 1.6 
128 117 0 32 84.5 162.3 32.1 120 80 93.33 11.3 89 133 4 9.6 1.5 
129 116 0 34 80 158.5 31.8 125 90 101.67 10.9 103 139 4.3 9.7 1.9 
130 110 0 35 105.2 167 37.7 130 90 103.33 14 100 138 3.7 10.6 2.1 
131 132 0 25 62.5 155.2 25.9 110 80 90 9.4 110 149 4.9 . 0.2 
132 130 1 29 48.3 160 18.9 130 90 103.33 15.1 105 138 4.3 9.8 1.9 
133 134 1 35 68.2 175.5 22.1 110 70 83.33 14.9 85 139 4.1 10.1 1.6 
134 152 1 21 57.9 167.2 20.7 125 90 101.67 13 115 140 4 9.2 1.6 
135 173 0 20 63.1 160.5 24.5 100 70 80 9.9 95 142 3.8 8.4 1.5 
136 174 1 33 64 169 22.4 120 90 100 15.9 110 136 4 9.1 1.8 
137 203 0 27 67.3 158.3 26.9 120 90 100 9.9 100 138 3.9 9.6 2.1 
138 210 0 23 65.5 167.8 23.3 120 90 100 11 104 137 4 10.4 2.2 
139 214 0 33 78.3 156.3 32.1 120 90 100 11.1 113 139 4.4 9.4 1.5 
140 251 1 38 66.8 168 23.7 130 80 96.67 15.1 100 136 4.3 10.1 1.8 
141 256 1 34 66.7 173 22.3 110 70 83.33 15.2 95 139 4 10 1.6 
142 261 1 32 93.5 177.5 29.7 120 80 93.33 13.3 105 133 4.3 9.9 1.9 
143 301 0 30 66 161.5 25.3 120 90 100 13.5 98 137 4.1 10.4 1.9 
144 302 1 30 77.7 175.4 25.3 120 80 93.33 15.1 100 141 3.9 9.4 1.8 
145 305 1 39 71 164.1 26.4 110 80 90 14.3 103 139 4 10.1 1.9 
146 306 1 23 75 172.1 25.3 90 80 83.33 15.1 105 139 3.6 10.6 2.3 
147 321 1 35 75 178 23.7 120 65 83.33 8.9 100 139 4.2 9.3 1.8 
148 320 1 30 72.2 168.2 25.5 110 80 90 14.2 103 134 4 9.7 1.8 
149 322 1 24 96 163.2 36 100 70 80 15.1 118 145 4.5 14.3 2.1 
150 323 1 38 52.4 169 18.3 120 80 93.33 13.5 110 136 4 10.7 1.8 
151 324 1 32 70 174.5 23 120 80 93.33 8.9 100 140 3.6 10.3 1.9 
152 325 0 26 75.7 156 31.1 130 90 103.33 12.5 105 141 4.5 11.6 2.2 
153 372 0 29 42.5 158.7 16.9 120 80 93.33 9.5 113 141 3.9 10.1 2.3 
154 370 0 23 53.5 158.3 21.3 120 100 106.67 13.6 95 139 3.9 10.8 1.9 
155 374 1 34 78 185.3 22.7 110 80 90 14.9 100 142 3.7 9.8 1.9 
156 379 0 30 43.1 152.5 18.5 100 70 80 10.2 100 139 4.3 9.4 2.3 
 
Code for Gender (Gen): 0 = Female, 1 = Male. 
. = Missed Value 
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Table (7-9): Raw Data of Asthmatics with Symptoms; FEV1, FEV3, FEV6, FVC, FEV1%, 
FEV3%, FEV6%, FEV1/FEV6, PEFR, FEF25%, FEF50%, FEF75%, FEF2575%, FEF8575% 
and DAS. 
S.N FEV1 FEV3 FEV6 FVC FEV1% 
FEV3
% 
FEV6
% 
FEV1/ 
1FEV6 PEFR 
FEF25
% 
FEF50
% 
FEF75
% 
FEF25
75% 
FEF85
75% DAS 
110 2.45 2.98 3.1 3.1 79.03 96.13 96.13 0.79 5.5 7.57 4.95 2.19 4.71 0.77 -0.25 
111 1.26 2.1 2.57 2.85 44.21 73.68 73.68 0.49 2.21 1.27 0.61 0.24 0.52 0.18 -1.99 
112 2.29 2.66 2.66 2.66 86.09 100 100 0.86 5.03 4.53 2.64 1.31 2.44 1 0.05 
113 2.89 3.38 3.38 3.38 85.5 100 100 0.86 6.65 5.94 3.25 1.44 2.95 1.23 0.34 
114 1.59 1.97 2.03 2.03 78.33 97.04 97.04 0.78 3.33 3.23 1.67 0.62 1.43 0.42 -1.04 
115 2.26 2.7 2.87 2.87 78.75 94.08 94.08 0.79 3.69 3.37 2.57 0.96 2.13 0.84 -0.66 
116 2.16 3.15 3.46 3.47 62.25 90.78 90.78 0.62 3.11 3.08 1.58 0.66 1.39 0.47 -2.43 
117 1.94 2.4 2.42 2.42 80.17 99.17 99.17 0.8 5.23 4.31 1.19 0.71 1.78 0.57 -0.15 
118 2.12 3.3 3.38 3.99 53.13 82.71 82.71 0.63 3.14 2.53 1.25 0.48 1.07 0.36 -1.38 
119 1.28 1.89 2.07 2.07 61.84 91.3 91.3 0.62 2.45 1.59 0.99 0.37 0.81 0.28 -1.81 
120 2.85 3.28 3.36 3.36 84.82 97.62 97.62 0.85 6.98 7.77 3.76 1.33 3.12 0.98 -0.30 
121 1.2 1.6 1.73 1.76 68.18 90.91 90.91 0.69 3.17 2.08 0.91 0.3 0.75 0.22 -1.03 
122 1.72 2.34 2.53 2.56 67.19 91.41 91.41 0.68 3.18 2.59 1.34 0.56 1.18 0.37 -1.40 
123 2.54 3.91 4.38 4.44 57.21 88.06 88.06 0.58 5.39 2.78 1.73 0.71 1.39 0.57 -2.11 
124 1.19 1.75 1.88 1.88 63.3 93.09 93.09 0.63 2.82 1.35 0.88 0.41 0.79 0.31 -1.40 
125 0.82 1.55 2.05 2.62 31.3 59.16 59.16 0.4 1.57 0.65 0.35 0.14 0.28 0.13 -1.27 
126 0.89 1.38 1.53 1.53 58.17 90.2 90.2 0.58 1.66 1.15 0.56 0.25 0.51 0.21 -1.96 
127 0.74 1.17 1.42 1.49 49.66 78.52 78.52 0.52 1.44 0.79 0.4 0.16 0.32 0.14 -1.50 
128 1.83 2.25 2.29 2.29 79.91 98.25 98.25 0.8 5.37 4.34 1.84 0.67 1.66 0.47 -0.43 
129 2.34 2.51 2.51 2.51 93.23 100 100 0.93 5.76 5.6 3.37 1.81 3.53 1.32 1.02 
130 1.31 2 2.22 2.23 58.74 89.69 89.69 0.59 2.2 1.65 0.89 0.4 0.79 0.3 -2.11 
131 1.61 2.84 2.84 2.84 56.69 100 100 0.57 2.28 1.75 1.24 0.85 1.23 0.68 -3.05 
132 1.08 1.81 2.09 2.14 50.47 84.58 84.58 0.52 2.66 1.14 0.69 0.33 0.59 0.24 -1.88 
133 1.39 2.47 3 3.24 42.9 76.23 76.23 0.46 2.8 1.3 0.72 0.34 0.68 0.24 -2.40 
134 1.6 2.39 2.62 2.65 60.38 90.19 90.19 0.61 2.69 1.79 1.18 0.49 1 0.35 -1.92 
135 1.49 1.75 1.76 1.76 84.66 99.43 99.43 0.85 2.99 2.68 1.81 0.76 1.55 0.6 -0.73 
136 3.35 4.14 4.25 4.25 78.82 97.41 97.41 0.79 8.54 6.16 3.45 1.37 2.98 0.97 0.70 
137 1.45 2.19 2.45 2.46 58.94 89.02 89.02 0.59 2.83 1.59 1.01 0.39 0.84 0.32 -1.86 
138 1.68 2.37 2.63 2.72 61.76 87.13 87.13 0.64 3.25 2.45 1.11 0.39 0.94 0.27 -1.53 
139 2.38 3.14 3.51 3.6 66.11 87.22 87.22 0.68 4.15 4.09 1.88 0.47 1.43 0.32 -1.71 
140 1.08 1.74 2.11 2.26 47.79 76.99 76.99 0.51 3.05 1.08 0.5 0.21 0.46 0.17 -1.24 
141 2.66 3.53 3.53 3.53 75.35 100 100 0.75 5.97 4.02 2.39 1.21 2.17 0.97 -0.32 
142 3.19 3.73 3.78 3.78 84.39 98.68 98.68 0.84 7.41 7.17 4.42 1.51 3.76 0.97 0.50 
143 2.06 2.56 2.73 2.74 75.18 93.43 93.43 0.75 5.55 4.38 2.04 0.63 1.61 0.43 -0.55 
144 1.61 2.9 3.55 3.78 42.59 76.72 76.72 0.45 2.84 1.54 0.9 0.38 0.81 0.31 -3.13 
145 1.7 2.57 2.82 2.82 60.28 91.13 91.13 0.6 4.67 1.88 1.17 0.51 1.03 0.41 -1.23 
146 1.08 1.66 1.88 1.89 57.14 87.83 87.83 0.57 2.46 1.24 0.7 0.27 0.61 0.23 -1.68 
147 0.73 1.03 1.2 1.3 56.15 79.23 79.23 0.61 1.95 1.04 0.38 0.12 0.29 0.1 -0.87 
148 2.63 3.37 3.4 3.4 77.35 99.12 99.12 0.77 4.46 4.44 2.48 1.21 2.34 0.97 -0.90 
149 3.32 4.32 4.32 4.32 76.85 100 100 0.77 6.37 5.24 3.34 1.36 2.86 1.02 -0.34 
150 2.68 3.77 4.23 4.37 61.33 86.27 86.27 0.63 7.14 3.84 1.73 0.6 1.34 0.45 -0.86 
151 3 4.07 4.07 4.07 73.71 100 100 0.74 5.44 5.44 2.56 1.27 2.43 1.02 -1.33 
152 2.48 2.99 3.02 3.02 82.12 99.01 99.01 0.82 5.54 5.34 2.62 1.17 2.39 0.89 -0.35 
153 1.85 2.44 2.54 2.54 72.83 96.06 96.06 0.73 4.34 2.91 1.65 0.66 1.4 0.47 -0.83 
154 0.64 1.17 1.52 1.6 40 73.13 73.13 0.42 1.18 0.58 0.32 0.15 0.3 0.13 -1.81 
155 2.29 3.12 3.62 4.13 55.45 75.54 75.54 0.63 4.99 3.27 1.15 0.27 0.78 0.18 -0.80 
156 0.68 0.94 0.94 0.94 72.34 100 100 0.72 0.96 0.89 0.61 0.37 0.57 0.31 -1.90 
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Table (7-10): Raw Data - Asthmatics with Symptoms;  MHR, MNN, SDNN, 
RMSSD, TP, VLF, LF, HF, LF Norm, HF Norm, LF/HF, Sympathetic (Sym) 
and Parasympathetic (P.Sym) Activity. 
S.N MHR MNN SDNN RMSSD TP VLF LF HF LF Norm 
HF 
Norm LF/HF Sym. P.Sym 
110 95.7 627.1 21.8 25.8 101.2 58.2 25.3 17.7 58.8 41.2 1.4 1 1 
111 89.9 667.3 95.4 102.1 739.4 344.2 196.6 198.6 49.8 50.2 1 2 2 
112 91.7 654.6 50.9 51 774.2 211.5 261.7 301 46.5 53.5 0.9 2 2 
113 84.1 713.1 102.9 117.9 1105 204.5 221.5 678.9 24.6 75.4 0.3 2 2 
114 103.2 581.6 27 25.4 448 120.5 53.7 28.2 65.6 34.4 1.9 2 1 
115 74.8 802.3 63 66.5 996.9 378.4 231.8 386.6 37.5 62.5 0.6 2 2 
116 80.2 747.9 178.9 180.6 2951.3 1342 733.9 875.5 45.6 54.4 0.8 2 3 
117 82.7 725.6 40.5 42.2 385.9 192.7 67.7 125.5 35 65 0.5 2 2 
118 81.5 735.9 236.6 267.2 11375 1512.5 3517.9 6344.7 35.7 64.3 0.6 3 3 
119 91.2 658 46.3 46.1 354.5 121.4 138 95.2 59.2 40.8 1.5 2 2 
120 108.7 552 188.3 277.2 6000.8 402.8 2020.6 3577.3 36.1 63.9 0.6 3 3 
121 90.7 661.5 167.1 195.8 5150.2 1144.4 1338 2667.8 33.4 66.6 0.5 3 3 
122 89.9 667.3 97.1 85.1 937.9 396.9 309.9 231.2 57.3 42.7 1.3 2 2 
123 72.9 823.1 75.3 114.8 283.3 77.5 64.6 141.2 31.4 68.6 0.5 2 2 
124 82.5 727.6 66.7 66.2 1331.3 223.3 380.2 727.9 34.3 65.7 0.5 2 2 
125 83.5 718.2 30 23.4 242.7 71.9 159.3 11.6 93.2 6.8 13.7 2 1 
126 109.9 546 23.8 22.6 135.9 79.8 35 21.1 62.4 37.6 1.7 2 1 
127 98.8 607.4 47 32.5 370.1 193.3 129.8 47.1 37.4 26.6 2.8 2 2 
128 94.5 635.1 29.7 27.8 250.3 197.5 19.4 33.4 36.7 63.3 0.6 1 2 
129 77.7 772.3 28 28 232.1 136.3 73.8 21.9 77.1 22.9 3.4 2 2 
130 90.4 663.4 99.2 137.3 347.5 103.3 119.3 124.9 48.8 51.2 1 2 2 
131 75.1 798.6 60.1 51.3 1152 289.6 534.7 327.7 62 38 1.6 2 2 
132 88.3 679.8 127.6 124.3 2945.3 316.5 717.6 1911.2 27.3 72.7 0.4 2 3 
133 109.6 547.5 187.4 287.7 6532 685.6 1572.1 4274.3 26.9 73.1 0.4 3 3 
134 97.8 613.4 36.5 17.1 392.4 68.2 301.4 22.8 93 7 13.2 1 1 
135 92.2 651.1 185.3 219.1 7318.9 1060.3 2130.2 4128.5 34 66 0.5 3 3 
136 84.8 707.9 29.4 27.3 111.4 144.1 92 92.7 49.8 50.2 1 2 2 
137 103.6 579.3 24 23 194.6 79.7 78.5 36.5 68.2 31.8 2.1 2 2 
138 80.1 749 180.1 187.5 4493.1 558.7 2049.8 1884.6 52.1 47.9 1.1 3 3 
139 83.6 717.9 57 32.9 1140.9 346.3 655 139.6 82.4 17.6 4.7 2 2 
140 91.2 657.7 258.5 224.1 12007.9 7622.6 1550.3 2834.9 35.4 64.6 0.5 3 3 
141 91.7 654.3 226.5 248.6 11754.5 2484.3 4628.5 4641.6 49.9 50.1 1 3 3 
142 84.7 708.4 85.3 94.6 881.8 169.3 384.4 328.1 53.9 46.1 1.2 2 2 
143 100.4 597.8 29.8 26.2 108.9 32 47.1 29.9 61.2 38.8 1.6 2 2 
144 92.7 647.2 54.1 58.6 741.4 128.4 246.8 366.1 40.3 59.7 0.7 2 2 
145 95.5 628.5 59.6 38.3 1307.5 144.6 712.1 450.8 61.2 38.8 1.6 2 2 
146 100.5 597.1 170.1 192.6 6174.9 1271.1 1982.9 2920.8 40.4 59.6 0.7 3 3 
147 88.5 678.1 42.9 48.5 393.9 46.1 156.8 191 45.1 54.9 0.8 2 2 
148 73.5 816.2 51.6 44.1 616.2 315.3 221.1 79.8 73.5 26.5 2.8 2 2 
149 79.7 753.2 230.4 254.6 11869.9 5468 2491.9 3910 38.9 61.1 0.6 3 3 
150 77.9 770.5 63.2 57.1 425.6 220.6 95.2 109.8 46.4 53.6 0.9 2 2 
151 70.5 851.3 190.1 176.6 1883.8 835.7 526.3 521.8 50.2 49.8 1 2 2 
152 79.2 757.4 71.2 59.3 1417 424.7 642.5 349.9 64.7 35.3 1.8 2 2 
153 79.4 756.1 62.5 59.4 1096.3 447.3 234.9 414.1 36.2 63.8 0.6 2 2 
154 100.7 595.8 33.8 38.1 202.3 17.1 111.9 73.3 60.4 39.6 1.5 2 2 
155 79 759.7 72.5 67.7 2741.1 645.4 1180.8 914.9 56.3 43.7 1.3 2 1 
156 115.7 518.4 119.8 84.3 859.8 568.7 178.2 112.9 61.2 38.8 1.6 2 2 
 
Code for Sympathetic Activity (Sym): 1 = Low Sympathetic Tone, 2 = Normal Sympathetic Tone, 3 = High Sympathetic Tone. 
Code for Parasympathetic Activity (P.Sym): 1 = Low Parasympathetic Tone, 2 = Normal Parasympathetic Tone, 3 = High Parasympathetic 
Tone. 
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Table (7-11): Raw Data - Asthmatics with Symptoms; ACT score, ACT 
state, NAEPP Class, Duration of asthma and Therapy  
S.N ACT score 
ACT 
state NAEPP Dur B S B±S A.B C.S O 
110 13 3 2 7 1 0 1 1 1 0 
111 9 3 4 13 1 1 3 0 0 0 
112 17 2 2 10 0 0 0 0 0 0 
113 22 1 1 23 0 0 0 1 1 0 
114 13 3 2 20 0 1 2 1 0 0 
115 19 2 2 12 1 0 1 0 0 0 
116 7 3 2 11 1 1 3 1 1 0 
117 20 1 1 25 1 1 3 1 1 0 
118 9 3 3 9 0 1 2 1 0 0 
119 9 3 2 10 1 1 3 0 0 0 
120 16 2 2 3 1 0 1 0 0 0 
121 10 3 3 20 1 1 3 1 0 0 
122 11 3 2 7 0 0 0 0 0 0 
123 13 3 3 18 0 0 0 0 0 0 
124 12 3 3 12 1 0 1 1 0 0 
125 15 3 2 10 0 0 0 0 0 0 
126 9 3 4 17 1 1 3 0 1 0 
127 6 3 4 17 1 1 3 0 0 1 
128 8 3 3 15 1 1 3 0 0 0 
129 12 3 3 5 1 0 1 1 1 0 
130 6 3 4 7 1 1 3 0 0 0 
131 12 3 3 2 1 1 3 1 0 0 
132 17 2 3 4 1 0 1 0 0 0 
133 22 1 2 30 1 1 3 0 0 0 
134 15 3 2 4 1 0 1 0 0 0 
135 18 2 1 6 1 1 3 0 0 0 
136 13 3 3 3 1 0 1 1 0 0 
137 11 3 3 8 1 0 1 1 0 0 
138 13 3 3 3 1 1 3 1 1 0 
139 11 3 3 12 1 1 3 1 0 0 
140 14 3 3 12 1 1 3 0 1 0 
141 13 3 2 25 1 1 3 0 0 0 
142 16 2 2 5 0 0 0 1 0 1 
143 9 3 3 3 1 1 3 0 0 0 
144 19 2 3 20 1 1 3 0 0 0 
145 9 3 3 27 1 1 3 0 0 0 
146 21 1 2 20 0 0 0 0 0 0 
147 13 3 4 32 1 0 1 1 0 1 
148 19 2 2 20 0 0 0 1 1 0 
149 14 3 3 3 1 1 3 1 0 0 
150 16 2 2 6 1 1 3 0 0 0 
151 14 3 3 8 1 1 3 1 0 0 
152 13 3 2 20 1 1 3 0 0 0 
153 12 3 2 13 1 1 3 0 0 1 
154 9 3 4 3 1 1 3 1 0 0 
155 12 3 4 2 1 0 1 0 0 0 
156 11 3 3 7 1 0 1 1 0 0 
 
Code for ACT State: 1 = Controlled Asthmatic Patient, 2 = Uncontrolled Asthmatic Patient. 
Code for NAEPP Classification (NAEPP): 0 = No Asthma, 1 = Mild Intermittent Asthma, 2 = Mild Persistent Asthma, 3 = Moderate 
Persistent Asthma, 4 = Severe Persistent Asthma. 
Code for Taking Beta Agonists Therapy (B): 0 = Not Taking Beta Agonists Therapy, 1 = Taking Beta Agonists Therapy. 
Code for Taking Steroids Therapy (S): 0 = Not Taking Steroids Therapy, 1 = Taking Steroids Therapy. 
Code for Taking Beta Agonists ± Steroids Therapy (B±S): 0 = Not Taking Beta Agonists or Steroids Therapy, 1 = Taking Beta 
Agonists Therapy Only, 2 = Taking Steroids Therapy Only, 3 = Taking both Beta Agonists and Steroids Therapy. 
Code for Taking Antibiotics Therapy (A.B): 0 = Not Taking Antibiotics Therapy, 1 = Taking Antibiotics Therapy. 
Code for Taking Cough Syrup Therapy (C.S): 0 = Not Taking Cough Syrup Therapy, 1 = Taking Cough Syrup Therapy. 
Code for Taking Other Therapies (O): 0 = Not Taking Other Therapies, 1 = Taking Other Therapies. 
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APPENDIX C 
Table (7-12): Discriminant Analysis of Spirometric Indices According to Presence of Asthma 
(A) 
Standardized Canonical Discriminant Function 
Coefficients  
FEV6 (L) -3.42635 
FEV1 (L) 2.072851 
FEF25%-75% (L/Sec) 0.979686 
FEV3 (L) 0.897951 
PEFR (L/sec) 0.88807 
FEF25% (L/Sec) -0.86232 
FVC (L) 0.705001 
FEF50% (L/Sec) -0.66032 
FEV1% 0.584239 
FEV3% -0.51316 
FEF75%-85% (L/Sec) -0.38974 
FEF75% (L/Sec) 0.357051 
FEV1/FEV6 -0.30805 
 
 
(B) 
Canonical Discriminant Function Coefficients 
(Unstandardized coefficients) 
FEV1 (L) 2.581247 
FEV3 (L) 0.947458 
FEV6 (L) -3.59972 
FVC (L) 0.741176 
FEV1% 0.048703 
FEV3% -0.08066 
FEV1/FEV6 -2.65372 
PEFR (L/sec) 0.479868 
FEF25% (L/Sec) -0.47014 
FEF50% (L/Sec) -0.44485 
FEF75% (L/Sec) 0.483335 
FEF25%-75% (L/Sec) 0.769923 
FEF75%-85% (L/Sec) -0.6501 
(Constant) 4.405138  
(C) 
Correlations between Spirometric Indices and Standardized Canonical Discriminant Function Scores (DAS) 
 Pearson Correlation Significance (2-tailed) 
FEV1 (L) 0.718 0.000 
FEV3 (L) 0.433 0.000 
FEV6 (L) 0.335 0.000 
FVC (L) 0.308 0.000 
FEV1% 0.865 0.000 
FEV3% 0.629 0.000 
FEV6% 0.629 0.000 
FEV1/FEV6 0.878 0.000 
PEFR (L/Sec) 0.763 0.000 
FEF25% (L/Sec) 0.843 0.000 
FEF50% (L/Sec) 0.905 0.000 
FEF75% (L/Sec) 0.914 0.000 
FEF25%-75% (L/Sec) 0.924 0.000 
FEF75%-85% (L/Sec) 0.894 0.000  
 
 
FEV1% * Presence of Asthma Crosstabulation  DAS * Presence of Asthma Crosstabulation 
 Presence of Asthma Total   Presence of Asthma Total (D) 
 Asthmatics Non Asthmatics   
(E) 
 Asthmatics Non Asthmatics  
FEV1<80% 71 4 75  DAS<0.284 81 3 84 
FEV1% 
FEV!≥80% 29 52 81  
DAS 
DAS≥0.284 19 53 72 
Total 100 56 156  Total 100 56 156 
Sig. of Chi-Square Test 1.89E-14  Sig. of Chi-Square Test 9.80E-20 
Sensitivity 71.00%  Sensitivity 81.00% 
Specifity 92.86%  Specifity 94.00% 
Positive Predictive Value 94.67%  Positive Predictive Value 96.43% 
Negative Predictive Value 64.20%  Negative Predictive Value 73.61% 
Accuracy 78.85%  Accuracy 86.54%  
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Table (7-13): Means (M) and standard Deviations (SD) of Studied Variables of Different Groups 
Non 
Asthmatics Asthmatics 
Asthmatics 
without 
Symptoms 
Asthmatics 
with 
Symptoms 
Controlled 
Asthmatics 
Poorly 
Controlled 
Asthmatics 
Uncontrolled 
Asthmatics  
M SD M SD M SD M SD M SD M SD M SD 
Age 25.00 4.61 29.50 5.30 29.38 5.30 29.64 5.35 28.35 5.82 27.41 5.53 30.86 4.67 
Wt 66.39 15.90 66.68 13.97 66.38 13.96 67.01 14.13 62.54 10.93 66.22 16.16 68.16 13.62 
Ht 166.04 7.81 166.28 9.56 166.79 10.56 165.71 8.37 167.67 12.60 165.16 9.15 166.40 8.81 
BMI 24.14 6.06 24.23 5.32 23.96 5.18 24.53 5.51 22.38 3.95 24.26 5.61 24.77 5.49 
SBP 118.32 13.69 115.80 13.25 116.70 13.66 114.79 12.85 114.41 16.19 115.93 11.18 116.16 13.42 
DBP 75.04 9.98 80.20 10.02 80.47 10.39 79.89 9.70 76.18 7.81 80.00 9.90 81.52 10.48 
MABP 89.46 9.61 92.07 10.00 92.55 10.30 91.52 9.73 88.92 9.11 91.97 9.49 93.07 10.45 
Hb 13.19 2.41 13.32 2.14 13.61 2.01 13.00 2.25 13.11 2.67 13.30 1.92 13.40 2.09 
RBG 93.63 17.11 102.75 10.90 105.23 11.42 99.96 9.65 106.59 14.66 103.07 8.96 101.43 10.35 
Na+ 139.68 4.59 139.57 4.23 139.26 3.96 139.91 4.53 139.71 4.07 138.41 4.19 140.09 4.26 
K+ 4.16 0.40 4.05 0.38 4.04 0.41 4.05 0.35 3.96 0.52 4.09 0.38 4.05 0.33 
Ca++ 8.83 1.78 9.69 1.05 9.75 0.80 9.62 1.28 9.62 0.65 9.43 1.16 9.83 1.08 
Mg++ 1.59 0.37 1.65 0.35 1.62 0.28 1.69 0.42 1.64 0.30 1.63 0.33 1.66 0.38 
FEV1 3.24 0.75 2.28 0.83 2.65 0.72 1.86 0.75 2.65 0.86 2.45 0.73 2.08 0.83 
FEV3 3.58 0.86 2.96 1.00 3.34 0.96 2.54 0.87 3.22 0.92 3.11 0.93 2.81 1.04 
FEV6 3.60 0.86 3.12 1.00 3.47 0.99 2.73 0.87 3.32 0.90 3.26 0.98 3.00 1.03 
FVC 3.60 0.86 3.16 1.00 3.49 0.99 2.80 0.89 3.33 0.90 3.28 0.99 3.06 1.03 
FEV1% 90.51 5.91 71.74 14.30 77.00 11.99 65.80 14.47 79.34 14.28 75.62 13.79 67.55 13.25 
FEV3% 99.64 0.80 93.21 7.91 95.76 4.99 90.34 9.52 96.31 6.25 95.00 6.33 91.41 8.63 
FEV6% 99.64 0.80 93.21 7.91 95.76 4.99 90.34 9.52 96.31 6.25 95.00 6.33 91.41 8.63 
FEV1/FEV6 0.91 0.08 0.72 0.13 0.77 0.12 0.67 0.13 0.80 0.14 0.76 0.13 0.69 0.12 
PEFR 7.33 1.75 4.93 1.91 5.78 1.53 3.97 1.84 6.02 2.05 5.10 1.56 4.51 1.90 
FEF25% 6.74 1.58 3.98 1.96 4.76 1.62 3.09 1.96 5.02 2.10 4.35 1.72 3.49 1.90 
FEF50% 4.87 1.43 2.37 1.52 2.99 1.56 1.68 1.13 3.23 2.18 2.73 1.29 1.94 1.22 
FEF75% 2.26 0.78 0.99 0.71 1.25 0.78 0.70 0.49 1.51 1.12 1.09 0.53 0.78 0.54 
FEF25%-75% 4.29 1.18 2.07 1.32 2.58 1.34 1.49 1.03 2.89 1.84 2.35 1.09 1.68 1.09 
FEF75%-85% 1.73 0.67 0.74 0.56 0.95 0.64 0.51 0.33 1.20 0.93 0.81 0.38 0.57 0.38 
ACT Score 25.00 0.00 15.08 4.48 16.72 4.19 13.23 4.11 22.06 1.64 17.59 1.15 11.75 2.31 
NAEPP Class 0.00 0.00 2.39 0.84 2.17 0.80 2.64 0.82 1.47 0.51 1.96 0.52 2.88 0.69 
Duration 0.00 0.00 11.57 8.75 11.09 9.33 12.11 8.11 17.88 10.55 8.93 6.97 10.93 8.14 
DAS 1.29 0.82 -0.72 1.09 -0.35 1.10 -1.15 0.92 0.09 1.40 -0.62 0.99 -1.02 0.89 
MHR 84.41 10.95 88.91 11.13 88.68 11.48 89.16 10.83 91.39 10.85 88.08 9.97 88.55 11.80 
MNN 723.08 97.32 686.11 92.50 689.27 102.40 682.54 80.84 665.28 78.65 690.08 82.00 690.52 101.29 
SDNN 77.53 57.02 101.12 76.36 107.30 82.65 94.14 68.80 110.22 68.85 121.19 79.42 88.68 75.85 
RMSSD 83.34 75.07 109.64 94.16 118.60 103.52 99.54 82.29 128.48 97.98 133.16 97.58 92.59 89.38 
TP 1940.00 2860.47 2916.37 4084.96 3365.82 4570.75 2409.54 3435.28 3148.18 3494.73 4316.41 5330.77 2170.98 3391.95 
VLF 578.54 1335.39 662.11 1160.21 647.31 965.92 678.79 1357.13 491.28 378.41 729.77 938.29 681.34 1397.67 
LF 569.87 770.10 891.96 1267.82 1048.59 1464.87 715.34 986.65 921.46 1110.57 1408.60 1730.07 633.91 959.39 
HF 809.27 1293.54 1352.70 2112.60 1651.80 2480.36 1015.42 1559.28 1676.62 2118.94 2178.03 2861.89 856.45 1495.99 
LF Norm 52.67 17.39 49.99 17.20 49.46 17.91 50.58 16.55 41.01 16.12 47.52 15.30 53.91 17.41 
HF Norm 47.33 17.40 49.65 17.31 50.54 17.91 48.65 16.76 58.99 16.12 52.48 15.30 45.45 17.45 
LF/HF 1.50 1.15 1.58 2.16 1.45 1.63 1.73 2.64 0.94 1.07 1.19 1.18 1.96 2.65 
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Table (7-14 A): Significance of Mean Difference between Different Groups   
 
 
Non Asthmatics 
Vs 
Asthmatics 
Non Asthmatics 
Vs 
Asthmatics without 
Symptoms 
Non Asthmatics 
Vs 
Asthmatics with 
Symptoms 
Asthmatics without 
Symptoms 
Vs 
Asthmatics with 
Symptoms 
Age 0.000* 0.000* 0.000* 0.807 
Wt 0.911 0.997 0.835 0.824 
Ht 0.864 0.673 0.838 0.571 
BMI 0.932 0.863 0.736 0.596 
SBP 0.267 0.537 0.180 0.473 
DBP 0.002* 0.006* 0.014* 0.774 
MABP 0.116 0.110 0.284 0.611 
Hb 0.718 0.324 0.687 0.161 
RBG 0.000* 0.000* 0.026* 0.015* 
Na+ 0.884 0.614 0.794 0.449 
K+ 0.101 0.149 0.162 0.900 
Ca++ 0.002* 0.001* 0.014* 0.552 
Mg++ 0.311 0.636 0.217 0.340 
FEV1 0.000* 0.000* 0.000* 0.000* 
FEV3 0.000* 0.160 0.000* 0.000* 
FEV6 0.002* 0.490 0.000* 0.000* 
FVC 0.005* 0.534 0.000* 0.000* 
FEV1% 0.000* 0.000* 0.000* 0.000* 
FEV3% 0.000* 0.000* 0.000* 0.000* 
FEV6% 0.000* 0.000* 0.000* 0.000* 
FEV1/FEV6 0.000* 0.000* 0.000* 0.000* 
PEFR 0.000* 0.000* 0.000* 0.000* 
FEF25% 0.000*  0.000* 0.000* 0.000* 
FEF50% 0.000* 0.000* 0.000* 0.000* 
FEF75% 0.000* 0.000* 0.000* 0.000* 
FEF25%-75% 0.000* 0.000* 0.000* 0.000* 
FEF75%-85% 0.000* 0.000* 0.000* 0.000* 
ACT Score 0.000* 0.000* 0.000* 0.000* 
NAEPP Class 0.000* 0.000* 0.000* 0.005* 
Duration 0.000* 0.000* 0.000* 0.563 
DAS 0.000* 0.000* 0.000* 0.000* 
MHR 0.016* 0.049* 0.030* 0.833 
MNN 0.022* 0.081 0.023* 0.715 
SDNN 0.045* 0.030* 0.191 0.393 
RMSSD 0.075 0.043* 0.303 0.315 
TP 0.115 0.052 0.458 0.245 
VLF 0.695 0.758 0.708 0.895 
LF 0.086 0.034* 0.413 0.191 
HF 0.082 0.027* 0.472 0.133 
LF Norm 0.355 0.345 0.534 0.746 
HF Norm 0.425 0.345 0.696 0.588 
LF/HF 0.758 0.851 0.579 0.528 
Significance of Mean Difference after Adjustment for MHR 
SDNN 0.065 0.039 0.286 0.346 
RMSSD 0.149 0.072 0.527 0.265 
TP 0.191 0.076 0.680 0.189 
VLF 0.660 0.748 0.659 0.896 
LF 0.145 0.045 0.662 0.130 
HF 0.179 0.043 0.834 0.079 
LF Norm 0.299 0.291 0.475 0.757 
HF Norm 0.346 0.282 0.605 0.599 
LF/HF 0.922 0.786 0.633 0.459 
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Table (7-14 A) Continued. 
 
 
Non-Asthmatics 
Vs 
Well Controlled 
Asthmatics 
Non-Asthmatics 
Vs 
Poorly Controlled 
Asthmatics 
Non-Asthmatics 
Vs 
Uncontrolled 
Asthmatics 
Well Controlled 
Asthmatics 
Vs 
Poorly Controlled 
Asthmatics 
Well Controlled 
Asthmatics 
Vs 
Uncontrolled 
Asthmatics 
Poorly Controlled 
Asthmatics 
Vs 
Uncontrolled 
Asthmatics 
Age 0.015 0.039 0.000 0.537 0.069 0.003 
Wt 0.345 0.960 0.527 0.420 0.170 0.575 
Ht 0.514 0.677 0.832 0.369 0.612 0.557 
BMI 0.255 0.930 0.553 0.278 0.123 0.695 
SBP 0.297 0.450 0.398 0.717 0.640 0.941 
DBP 0.679 0.035 0.001 0.216 0.054 0.516 
MABP 0.843 0.278 0.055 0.318 0.131 0.637 
Hb 0.906 0.834 0.621 0.791 0.648 0.850 
RBG 0.001 0.003 0.003 0.400 0.168 0.602 
Na+ 0.982 0.214 0.618 0.337 0.751 0.101 
K+ 0.071 0.494 0.156 0.271 0.401 0.642 
Ca++ 0.042 0.063 0.000 0.669 0.587 0.225 
Mg++ 0.644 0.596 0.275 0.995 0.772 0.729 
FEV1 0.008 0.000 0.000 0.412 0.010 0.047 
FEV3 0.166 0.034 0.000 0.709 0.120 0.178 
FEV6 0.291 0.134 0.001 0.847 0.227 0.241 
FVC 0.320 0.161 0.003 0.862 0.293 0.310 
FEV1% 0.001 0.000 0.000 0.295 0.000 0.003 
FEV3% 0.054 0.002 0.000 0.495 0.005 0.014 
FEV6% 0.054 0.002 0.000 0.495 0.005 0.014 
FEV1/FEV6 0.000 0.000 0.000 0.301 0.001 0.005 
PEFR 0.010 0.000 0.000 0.101 0.003 0.165 
FEF25% 0.001 0.000 0.000 0.227 0.002 0.040 
FEF50% 0.000 0.000 0.000 0.262 0.001 0.020 
FEF75% 0.000 0.000 0.000 0.060 0.000 0.064 
FEF25%-75% 0.000 0.000 0.000 0.152 0.000 0.022 
FEF75%-85% 0.001 0.000 0.000 0.030 0.000 0.083 
ACT Score 0.000 0.000 0.000 0.000 0.000 0.000 
NAEPP Class 0.000 0.000 0.000 0.002 0.000 0.000 
Duration 0.000 0.000 0.000 0.000 0.000 0.200 
DAS 0.000 0.000 0.000 0.017 0.000 0.074 
MHR 0.025 0.160 0.050 0.337 0.358 0.855 
MNN 0.029 0.138 0.070 0.398 0.337 0.984 
SDNN 0.092 0.008 0.398 0.611 0.265 0.048 
RMSSD 0.063 0.016 0.574 0.862 0.138 0.048 
TP 0.233 0.006 0.738 0.302 0.334 0.013 
VLF 0.798 0.601 0.659 0.533 0.578 0.867 
LF 0.246 0.001 0.756 0.151 0.343 0.003 
HF 0.086 0.002 0.891 0.373 0.104 0.002 
LF Norm 0.014 0.196 0.701 0.216 0.007 0.109 
HF Norm 0.014 0.196 0.558 0.216 0.004 0.079 
LF/HF 0.271 0.479 0.184 0.652 0.045 0.076 
Significance of Mean Difference after Adjustment for MHR 
 
SDNN 0.121 0.011 0.459 0.581 0.287 0.047 
RMSSD 0.122 0.026 0.766 0.763 0.172 0.045 
TP 0.347 0.010 0.900 0.257 0.385 0.012 
VLF 0.825 0.592 0.646 0.543 0.589 0.869 
LF 0.362 0.002 0.917 0.125 0.394 0.003 
HF 0.180 0.003 0.854 0.292 0.137 0.002 
LF Norm 0.010 0.167 0.808 0.194 0.006 0.113 
HF Norm 0.009 0.162 0.677 0.190 0.004 0.081 
LF/HF 0.210 0.418 0.244 0.601 0.039 0.078 
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Table (7-14 B): Significance of Mean Difference between Males and Females.   
 
Whole Sample Non-Asthmatics All Asthmatics  
Female 
Mean Male Mean Sig. 
Female 
Mean Male Mean Sig. 
Female 
Mean Male Mean Sig. 
Age 27.25 28.49 0.161 25.14 24.86 0.819 28.48 30.44 0.064 
Wt 65.6 67.5 0.424 64.87 67.91 0.479 66.03 67.28 0.662 
Ht 159.51 172.55 0.000 160.16 171.92 0.000 159.13 172.88 0.000 
BMI 25.81 22.67 0.000 25.35 22.94 0.138 26.07 22.52 0.001 
SBP 117.92 115.55 0.271 118.64 118 0.863 117.5 114.23 0.223 
DBP 79.7 77.06 0.11 76.86 73.21 0.174 81.35 79.13 0.272 
MABP 92.44 89.89 0.109 90.79 88.14 0.308 93.4 90.83 0.204 
Hb 11.8 14.67 0.000 11.62 14.75 0.000 11.9 14.63 0.000 
RBG 99.41 99.54 0.955 93.32 93.93 0.896 102.96 102.56 0.855 
Na+ 139.87 139.36 0.47 140.04 139.32 0.566 139.77 139.38 0.649 
K+ 4.11 4.06 0.367 4.13 4.19 0.580 4.11 3.99 0.117 
Ca++ 9.3 9.47 0.449 9.1 8.52 0.272 9.41 9.93 0.016 
Mg++ 1.6 1.66 0.286 1.63 1.55 0.467 1.58 1.72 0.062 
FEV1 2.25 2.98 0.000 2.66 3.82 0.000 2.01 2.52 0.002 
FEV3 2.64 3.7 0.000 2.9 4.26 0.000 2.48 3.4 0.000 
FEV6 2.71 3.85 0.000 2.91 4.28 0.000 2.59 3.62 0.000 
FVC 2.72 3.89 0.000 2.91 4.28 0.000 2.6 3.68 0.000 
FEV1% 81.96 75.16 0.004 91.65 89.37 0.152 76.31 67.51 0.002 
FEV3% 96.74 94.36 0.034 99.67 99.61 0.770 95.04 91.53 0.026 
FEV6% 96.74 94.36 0.034 99.67 99.61 0.770 95.04 91.53 0.026 
FEV1/FEV6 0.82 0.76 0.011 0.92 0.9 0.547 0.77 0.69 0.002 
PEFR 4.96 6.58 0.000 5.98 8.68 0.000 4.37 5.44 0.004 
FEF25% 4.53 5.39 0.017 5.66 7.81 0.000 3.86 4.09 0.575 
FEF50% 3.08 3.45 0.226 4.16 5.58 0.000 2.45 2.3 0.638 
FEF75% 1.37 1.52 0.316 1.95 2.56 0.003 1.03 0.96 0.645 
FEF25%-75% 2.72 3.01 0.277 3.71 4.87 0.000 2.14 2 0.616 
FEF75%-85% 1.02 1.17 0.204 1.49 1.98 0.005 0.75 0.74 0.965 
ACT Score 18.47 18.8 0.735 25 25 NO 14.67 15.46 0.381 
NAEPP Class 1.45 1.61 0.44 0.00 0.00 NO 2.29 2.48 0.265 
Duration 7.07 7.75 0.633 0.00 0.00 NO 11.19 11.92 0.675 
DAS -0.03 0.03 0.77 0.87 1.71 0.000 -0.56 -0.87 0.159 
MHR 89.75 84.95 0.007 86.48 82.34 0.159 91.66 86.36 0.016 
MNN 676.58 721.04 0.003 701.93 744.22 0.105 661.79 708.56 0.010 
0.006 0.086 0.028 SDNN 76.65 107.85 0.002 
64.44 90.62 
0.089 
83.78 117.13 
0.014 
0.011 0.249 0.024 RMSSD 81.75 117.72 0.002 
71.68 94.99 
0.192 
87.63 129.97 
0.006 
0.027 0.028 0.183 TP 1892.63 3205.46 0.009 
1108.11 2771.89 
0.019 
2350.28 3438.91 
0.100 
0.012 0.078 0.077 VLF 380.42 871.21 0.011 
263.86 893.23 
0.081 
448.42 859.36 
0.074 
0.047 0.014 0.298 LF 593.98 949.58 0.017 
319.74 820 
0.009 
753.95 1019.36 
0.183 
0.12 0.100 0.356 HF 918.24 1385.04 0.034 524.5 1094.03 0.049 1147.92 1541.73 0.179 
0.596 0.234 0.120 LF Norm 51.71 50.24 0.663 49.89 55.46 0.213 52.77 47.42 0.154 
0.485 0.234 0.120 HF Norm 48.3 49.77 0.569 50.12 44.54 0.213 47.23 52.58 0.154 
0.452 0.329 0.606 LF/HF 1.41 1.66 0.337 1.35 1.65 0.247 1.44 1.67 0.522 
NO = T-test can not be calculated because standard deviation equal to zero. 
Significances in italic do not consider adjustment for MHR. 
Significances in bold consider adjustment for MHR. 
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Table (7-14 B): Continued. 
Well Controlled Asthmatics Poorly Controlled Asthmatics Uncontrolled Asthmatics 
 Female 
Mean 
Male 
Mean Sig. 
Female 
Mean 
Male 
Mean Sig. 
Female 
Mean 
Male 
Mean Sig. 
Age 25.50 29.91 0.131 25.47 29.83 0.044 30.81 30.90 0.948 
Wt 56.67 65.75 0.080 64.01 68.98 0.422 69.23 67.15 0.575 
Ht 155.33 174.40 0.001 159.47 172.28 0.000 159.79 172.56 0.000 
BMI 23.77 21.62 0.375 25.12 23.18 0.358 27.11 22.59 0.002 
SBP 111.67 115.91 0.654 114.67 117.50 0.512 120.37 112.24 0.023 
DBP 76.67 75.91 0.875 78.33 82.08 0.338 84.07 79.14 0.076 
MABP 88.34 89.24 0.875 90.44 93.89 0.359 96.17 90.17 0.030 
Hb 9.90 14.86 0.000 12.17 14.70 0.000 12.20 14.51 0.000 
RBG 103.33 108.36 0.546 103.60 102.42 0.734 102.52 100.41 0.452 
Na+ 141.50 138.73 0.284 138.47 138.33 0.937 140.11 140.07 0.971 
K+ 4.27 3.79 0.069 4.12 4.06 0.669 4.07 4.03 0.726 
Ca++ 9.14 9.84 0.085 9.01 9.93 0.036 9.68 9.97 0.335 
Mg++ 1.38 1.77 0.021 1.47 1.83 0.004 1.68 1.65 0.750 
FEV1 2.53 2.72 0.669 2.26 2.69 0.131 1.76 2.38 0.004 
FEV3 2.85 3.42 0.228 2.70 3.63 0.007 2.29 3.30 0.000 
FEV6 2.89 3.55 0.155 2.76 3.88 0.002 2.42 3.53 0.000 
FVC 2.89 3.57 0.139 2.77 3.92 0.001 2.44 3.63 0.000 
FEV1% 87.49 74.89 0.040 81.55 68.22 0.011 70.92 64.42 0.067 
FEV3% 98.36 95.19 0.236 97.15 92.32 0.059 93.13 89.82 0.148 
FEV6% 98.36 95.19 0.236 97.15 92.32 0.059 93.13 89.82 0.148 
FEV1/FEV6 0.88 0.75 0.038 0.82 0.69 0.009 0.71 0.66 0.101 
PEFR 5.83 6.13 0.715 4.63 5.68 0.082 3.90 5.08 0.018 
FEF25% 5.44 4.79 0.463 4.23 4.50 0.709 3.31 3.65 0.518 
FEF50% 3.53 3.06 0.624 2.92 2.48 0.390 1.94 1.94 0.998 
FEF75% 1.67 1.42 0.628 1.20 0.96 0.238 0.78 0.79 0.992 
FEF25%-75% 3.15 2.75 0.620 2.53 2.12 0.347 1.69 1.67 0.946 
FEF75%-85% 1.32 1.13 0.667 0.89 0.71 0.205 0.54 0.61 0.498 
ACT Score 23.00 21.55 0.063 17.87 17.25 0.187 11.04 12.41 0.025 
NAEPP Class 1.17 1.64 0.059 1.73 2.25 0.007 2.85 2.90 0.811 
Duration 19.67 16.91 0.573 9.80 7.83 0.468 10.07 11.72 0.453 
DAS 0.42 -0.09 0.407 -0.25 -1.08 0.029 -0.96 -1.08 0.615 
MHR 91.93 91.09 0.866 89.92 85.78 0.300 92.57 84.81 0.012 
MNN 656.20 670.23 0.694 674.27 709.84 0.285 656.10 722.57 0.012 
0.288 0.442 0.002 
SDNN 83.40 124.85 
0.220 
131.75 108.00 
0.621 
57.21 117.97 
0.002 
0.190 0.412 0.002 
RMSSD 85.62 151.86 
0.125 
146.97 115.88 
0.641 
55.10 127.49 
0.001 
0.686 0.455 0.003 
TP 2563.82 3466.92 
0.573 
5019.28 3437.82 
0.594 
820.04 3428.74 
0.002 
0.432 0.424 0.019 
VLF 383.00 550.34 
0.384 
865.11 560.59 
0.530 
231.46 1100.20 
0.023 
0.735 0.596 0.010 
LF 767.55 1005.41 
0.641 
1571.53 1204.95 
0.744 
296.71 947.86 
0.007 
0.762 0.415 0.005 
HF 1413.28 1820.25 
0.663 
2582.63 1672.28 
0.557 
291.89 1382.07 
0.002 
0.316 0.513 0.079 
LF Norm 46.48 38.02 
O.336 
45.68 49.82 
0.550 
58.10 50.00 
0.159 
0.316 0.513 0.040 
HF Norm 53.52 61.98 
0.336 
54.32 50.18 
0.550 
40.57 50.00 
0101 
0.134 0.311 0.633 
LF/HF 1.47 0.65 
0.148 
0.96 1.48 
0.311 
1.79 2.13 
0.461 
Significances in italic do not consider adjustment for MHR. 
Significances in bold consider adjustment for MHR. 
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Table (7-15): Significance of Mean Difference of LF Norm and HF Norm 
between Different NAEPP Classes 
 
Dependent Variable NAEPP(I) Class Vs NAEPP Class(J) 
Significance 
Without 
adjustment 
for MHR 
Significance 
With 
adjustment 
for MHR 
Mild Intermittent Asthma 0.040* 0.036* 
Mild Persistent Asthma 0.677 0.601 
Moderate Persistent Asthma 0.599 0.555 
No Asthma 
Severe Persistent Asthma 0.955 0.973 
No Asthma 0.040* 0.036* 
Mild Persistent Asthma 0.081 0.083 
Moderate Persistent Asthma 0.116 0.113 
Mild Intermittent Asthma 
Severe Persistent Asthma 0.121 0.128 
No Asthma 0.677 0.601 
Mild Intermittent Asthma 0.081 0.083 
Moderate Persistent Asthma 0.886 0.913 
Mild Persistent Asthma 
Severe Persistent Asthma 0.769 0.787 
No Asthma 0.599 0.555 
Mild Intermittent Asthma 0.116 0.113 
Mild Persistent Asthma 0.886 0.913 
Moderate Persistent 
Asthma 
Severe Persistent Asthma 0.707 0.742 
No Asthma 0.955 0.973 
Mild Intermittent Asthma 0.121 0.128 
Mild Persistent Asthma 0.769 0.787 
LF Norm 
 
Severe Persistent Asthma 
Moderate Persistent Asthma 0.707 0.742 
Mild Intermittent Asthma 0.040* 0.035* 
Mild Persistent Asthma 0.678 0.587 
Moderate Persistent Asthma 0.600 0.547 
No Asthma 
Severe Persistent Asthma 0.954 0.583 
No Asthma 0.040* 0.035* 
Mild Persistent Asthma 0.081 0.084 
Moderate Persistent Asthma 0.116 0.113 
Mild Intermittent Asthma 
Severe Persistent Asthma 0.121 0.045 
No Asthma 0.678 0.587 
Mild Intermittent Asthma 0.081 0.084 
Moderate Persistent Asthma 0.886 0.918 
Mild Persistent Asthma 
Severe Persistent Asthma 0.769 0.390 
No Asthma 0.600 0.547 
Mild Intermittent Asthma 0.116 0.113 
Mild Persistent Asthma 0.886 0.918 
Moderate Persistent 
Asthma 
Severe Persistent Asthma 0.707 0.372 
No Asthma 0.954 0.583 
Mild Intermittent Asthma 0.121 0.045 
Mild Persistent Asthma 0.769 0.390 
HF Norm 
Severe Persistent Asthma 
Moderate Persistent Asthma 0.707 0.372 
 
* Significant Mean Difference 
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Table (7-16): Means (M) and Standard Deviations (SD) of Studied Variables of 
Different Groups according to Drug Taken 
Non 
Asthmatics Asthmatics 
Asthmatic 
Not Taking 
Beta Agonist 
or Steroid 
Asthmatic 
Taking Beta 
Agonist only 
Asthmatic 
Taking 
Steroid only 
Asthmatic 
Taking both 
Beta Agonist 
and Steroid 
 
M SD M SD M SD M SD M SD M SD 
Age 25.00 4.61 29.50 5.30 30.23 5.24 29.93 4.52 29.71 6.24 28.70 5.73 
Wt 66.39 15.90 66.68 13.97 68.20 14.03 68.31 15.35 62.90 11.46 65.25 13.56 
Ht 166.04 7.81 166.28 9.56 167.12 8.70 171.18 11.09 157.13 5.83 164.03 7.68 
BMI 24.14 6.06 24.23 5.32 24.65 5.99 23.37 5.23 25.44 3.96 24.32 5.22 
SBP 118.32 13.69 115.80 13.25 117.88 10.88 111.30 14.05 114.29 7.87 117.75 14.41 
DBP 75.04 9.98 80.20 10.02 80.38 8.82 76.11 9.44 77.14 7.56 83.38 10.65 
MABP 89.46 9.61 92.07 10.00 92.88 8.15 87.84 10.26 89.52 5.59 94.83 10.70 
Hb 13.19 2.41 13.32 2.14 13.64 2.13 13.77 2.10 12.61 2.86 12.93 2.00 
RBG 93.63 17.11 102.75 10.90 102.19 11.39 102.81 13.00 106.14 9.91 102.48 9.40 
Na+ 139.68 4.59 139.57 4.23 138.88 3.70 141.19 4.79 140.71 5.44 138.73 3.70 
K+ 4.16 0.40 4.05 0.38 4.01 0.35 4.00 0.38 4.24 0.49 4.07 0.38 
Ca++ 8.83 1.78 9.69 1.05 9.39 0.94 9.93 1.09 9.32 1.16 9.74 1.05 
Mg++ 1.59 0.37 1.65 0.35 1.59 0.37 1.73 0.22 1.27 0.62 1.71 0.32 
FEV1 3.24 0.75 2.28 0.83 2.37 0.72 2.46 0.90 1.78 0.64 2.19 0.86 
FEV3 3.58 0.86 2.96 1.00 3.09 0.75 3.27 1.15 2.37 0.54 2.77 1.02 
FEV6 3.60 0.86 3.12 1.00 3.31 0.78 3.43 1.15 2.49 0.41 2.91 1.01 
FVC 3.60 0.86 3.16 1.00 3.34 0.79 3.50 1.15 2.57 0.36 2.93 1.00 
FEV1% 90.51 5.91 71.74 14.30 71.18 14.44 70.24 12.32 68.92 21.63 73.60 14.33 
FEV3% 99.64 0.80 93.21 7.91 92.58 6.28 93.55 7.97 92.13 14.79 93.59 7.54 
FEV6% 99.64 0.80 93.21 7.91 92.58 6.28 93.55 7.97 92.13 14.79 93.59 7.54 
FEV1/FEV6 0.91 0.08 0.72 0.13 0.72 0.14 0.71 0.11 0.70 0.19 0.74 0.14 
PEFR 7.33 1.75 4.93 1.91 5.21 1.95 5.14 2.03 4.00 1.92 4.76 1.79 
FEF25% 6.74 1.58 3.98 1.96 4.21 2.24 3.98 1.78 3.14 2.18 3.97 1.89 
FEF50% 4.87 1.43 2.37 1.52 2.56 1.95 2.21 1.15 1.97 1.57 2.43 1.44 
FEF75% 2.26 0.78 0.99 0.71 1.02 0.94 0.93 0.50 1.01 0.91 1.01 0.66 
FEF25%-75% 4.29 1.18 2.07 1.32 2.17 1.66 1.95 0.98 1.80 1.48 2.13 1.28 
FEF75%-85% 1.73 0.67 0.74 0.56 0.78 0.77 0.72 0.41 0.80 0.76 0.72 0.46 
ACT Score 25.00 0.00 15.08 4.48 14.77 4.63 15.70 4.90 17.00 4.40 14.53 4.13 
NAEPP Class 0.00 0.00 2.39 0.84 2.46 0.76 2.37 0.88 2.14 0.69 2.40 0.90 
Duration 0.00 0.00 11.57 8.75 12.19 8.25 12.26 9.83 8.29 4.72 11.28 8.96 
DAS 1.29 0.82 -0.72 1.09 -0.83 1.40 -0.83 0.87 -0.83 1.40 -0.56 0.95 
MHR 84.41 10.95 88.91 11.13 86.14 11.03 89.53 12.80 87.30 7.05 90.57 10.53 
MNN 723.08 97.32 686.11 92.50 707.66 91.18 684.30 106.07 691.36 59.13 672.41 88.55 
SDNN 77.53 57.02 101.12 76.36 93.05 74.67 119.42 80.68 67.94 50.18 99.81 77.62 
RMSSD 83.34 75.07 109.64 94.16 104.77 98.15 131.91 99.17 70.59 58.35 104.62 92.69 
TP 1940.00 2860.47 2916.37 4084.96 2556.85 4214.65 4076.94 5181.21 1241.87 1435.61 2659.70 3342.01 
VLF 578.54 1335.39 662.11 1160.21 448.95 617.78 869.49 1347.27 234.56 198.65 735.49 1363.01 
LF 569.87 770.10 891.96 1267.82 810.02 1305.53 1277.76 1637.69 402.49 407.73 770.47 1004.21 
HF 809.27 1293.54 1352.70 2112.60 1297.88 2486.17 1931.16 2604.82 462.01 494.61 1153.75 1545.79 
LF Norm 52.67 17.39 49.99 17.20 52.68 18.11 49.31 16.49 49.00 24.40 48.86 16.18 
HF Norm 47.33 17.40 49.65 17.31 47.32 18.11 50.69 16.49 51.00 24.40 50.24 16.52 
LF/HF 1.50 1.15 1.58 2.16 1.73 1.94 1.56 2.46 2.66 4.89 1.31 1.17 
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Table (7-16): continued 
Non 
Asthmatics Asthmatics 
Asthmatic 
Not Taking 
Antibiotic 
Asthmatic 
Taking 
Antibiotic 
Asthmatic 
Not Taking 
Syrup 
Asthmatic 
Taking Syrup  
M SD M SD M SD M SD M SD M SD 
Age 25.00 4.61 29.50 5.30 29.24 5.34 29.61 5.32 29.24 5.34 28.70 5.73 
Wt 66.39 15.90 66.68 13.97 64.49 12.54 67.57 14.50 64.49 12.54 65.25 13.56 
Ht 166.04 7.81 166.28 9.56 164.80 7.71 166.89 10.21 164.80 7.71 164.03 7.68 
BMI 24.14 6.06 24.23 5.32 23.77 4.50 24.42 5.64 23.77 4.50 24.32 5.22 
SBP 118.32 13.69 115.80 13.25 115.69 13.07 115.85 13.42 115.69 13.07 117.75 14.41 
DBP 75.04 9.98 80.20 10.02 80.00 9.64 80.28 10.24 80.00 9.64 83.38 10.65 
MABP 89.46 9.61 92.07 10.00 91.90 10.27 92.14 9.96 91.90 10.27 94.83 10.70 
Hb 13.19 2.41 13.32 2.14 12.83 2.10 13.52 2.13 12.83 2.10 12.93 2.00 
RBG 93.63 17.11 102.75 10.90 104.83 11.82 101.90 10.47 104.83 11.82 102.48 9.40 
Na+ 139.68 4.59 139.57 4.23 139.28 3.88 139.69 4.38 139.28 3.88 138.73 3.70 
K+ 4.16 0.40 4.05 0.38 4.05 0.36 4.04 0.39 4.05 0.36 4.07 0.38 
Ca++ 8.83 1.78 9.69 1.05 9.83 1.16 9.62 1.00 9.83 1.16 9.74 1.05 
Mg++ 1.59 0.37 1.65 0.35 1.71 0.32 1.63 0.36 1.71 0.32 1.71 0.32 
FEV1 3.24 0.75 2.28 0.83 2.28 0.80 2.28 0.85 2.28 0.80 2.19 0.86 
FEV3 3.58 0.86 2.96 1.00 2.93 0.98 2.97 1.01 2.93 0.98 2.77 1.02 
FEV6 3.60 0.86 3.12 1.00 3.08 1.00 3.14 1.01 3.08 1.00 2.91 1.01 
FVC 3.60 0.86 3.16 1.00 3.11 1.00 3.19 1.00 3.11 1.00 2.93 1.00 
FEV1% 90.51 5.91 71.74 14.30 73.80 12.98 70.89 14.81 73.80 12.98 73.60 14.33 
FEV3% 99.64 0.80 93.21 7.91 94.37 6.79 92.74 8.33 94.37 6.79 93.59 7.54 
FEV6% 99.64 0.80 93.21 7.91 94.37 6.79 92.74 8.33 94.37 6.79 93.59 7.54 
FEV1/FEV6 0.91 0.08 0.72 0.13 0.74 0.12 0.72 0.14 0.74 0.12 0.74 0.14 
PEFR 7.33 1.75 4.93 1.91 5.00 1.76 4.90 1.97 5.00 1.76 4.76 1.79 
FEF25% 6.74 1.58 3.98 1.96 4.11 1.86 3.93 2.02 4.11 1.86 3.97 1.89 
FEF50% 4.87 1.43 2.37 1.52 2.47 1.41 2.33 1.56 2.47 1.41 2.43 1.44 
FEF75% 2.26 0.78 0.99 0.71 1.04 0.69 0.97 0.73 1.04 0.69 1.01 0.66 
FEF25%-75% 4.29 1.18 2.07 1.32 2.16 1.28 2.03 1.34 2.16 1.28 2.13 1.28 
FEF75%-85% 1.73 0.67 0.74 0.56 0.75 0.51 0.74 0.58 0.75 0.51 0.72 0.46 
ACT Score 25.00 0.00 15.08 4.48 14.90 4.25 15.15 4.61 14.90 4.25 14.53 4.13 
NAEPP Class 0.00 0.00 2.39 0.84 2.38 0.73 2.39 0.89 2.38 0.73 2.40 0.90 
Duration 0.00 0.00 11.57 8.75 10.07 8.86 12.18 8.69 10.07 8.86 11.28 8.96 
DAS 1.29 0.82 -0.72 1.09 -0.67 1.04 -0.75 1.11 -0.67 1.04 -0.56 0.95 
MHR 84.41 10.95 88.91 11.13 90.56 10.66 88.23 11.32 90.56 10.66 90.57 10.53 
MNN 723.08 97.32 686.11 92.50 672.07 84.39 691.85 95.58 672.07 84.39 672.41 88.55 
SDNN 77.53 57.02 101.12 76.36 99.45 85.71 101.80 72.84 99.45 85.71 99.81 77.62 
RMSSD 83.34 75.07 109.64 94.16 104.69 97.77 111.66 93.28 104.69 97.77 104.62 92.69 
TP 1940.00 2860.47 2916.37 4084.96 2681.46 3976.30 3012.31 4152.52 2681.46 3976.30 2659.70 3342.01 
VLF 578.54 1335.39 662.11 1160.21 875.51 1789.65 574.94 772.05 875.51 1789.65 735.49 1363.01 
LF 569.87 770.10 891.96 1267.82 706.76 1027.74 967.61 1353.06 706.76 1027.74 770.47 1004.21 
HF 809.27 1293.54 1352.70 2112.60 1099.20 1797.22 1456.25 2232.17 1099.20 1797.22 1153.75 1545.79 
LF Norm 52.67 17.39 49.99 17.20 50.60 18.22 49.74 16.90 50.60 18.22 48.86 16.18 
HF Norm 47.33 17.40 49.65 17.31 49.40 18.22 49.75 17.06 49.40 18.22 50.24 16.52 
LF/HF 1.50 1.15 1.58 2.16 1.72 2.55 1.52 1.99 1.72 2.55 1.31 1.17 
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Table (7-17): Significance of Mean Difference between Different Groups according to Drug Taken 
 
 
Non 
Asthmatics 
Vs 
Asthmatics 
Not Taking 
Beta Agonists 
or Steroids 
Non 
Asthmatics 
Vs 
Asthmatics 
Taking Beta 
Agonists Only 
Non 
Asthmatics 
Vs 
Asthmatics 
Taking 
Steroids Only 
Non 
Asthmatics 
Vs 
Asthmatics 
Taking Both 
Beta Agonists 
or Steroids 
Asthmatics 
Not Taking 
Beta Agonists 
or Steroids 
Vs 
Asthmatics 
Taking Beta 
Agonists Only 
Asthmatics 
Not Taking 
Beta Agonists 
or Steroids 
Vs 
Asthmatics 
Taking 
Steroids Only 
Asthmatics 
Not Taking 
Beta Agonists 
or Steroids 
Vs 
Asthmatics 
Taking Both 
Beta Agonists 
or Steroids 
Asthmatics 
Not Taking 
Antibiotics 
Vs 
Asthmatics 
Taking 
Antibiotics 
Asthmatics 
Not Taking 
Cough Syrup 
Vs 
Asthmatics 
Taking Cough 
Syrup 
Age 0.000* 0.000* 0.060 0.001* 0.341 0.877 0.193 0.758 0.066 
Wt 0.520 0.505 0.425 0.705 0.661 0.344 0.338 0.292 0.001 
Ht 0.389 0.033* 0.007* 0.214 0.972 0.007* 0.112 0.269 0.086 
BMI 0.757 0.606 0.336 0.880 0.182 0.582 0.969 0.546 0.078 
SBP 0.963 0.032* 0.383 0.845 0.460 0.301 0.924 0.958 0.238 
DBP 0.015* 0.495 0.570 0.000* 0.048* 0.319 0.273 0.897 0.425 
MABP 0.066 0.577 0.834 0.013* 0.103 0.206 0.531 0.915 0.183 
Hb 0.183 0.146 0.759 0.576 0.065 0.365 0.152 0.144 0.575 
RBG 0.023* 0.005* 0.016* 0.004* 0.624 0.479 0.720 0.252 0.524 
Na+ 0.555 0.116 0.676 0.264 0.894 0.643 0.838 0.643 0.283 
K+ 0.074 0.095 0.965 0.270 0.068 0.251 0.506 0.922 0.190 
Ca++ 0.078 0.000* 0.429 0.003* 0.993 0.931 0.156 0.410 0.072 
Mg++ 0.694 0.372 0.113 0.100 0.078 0.236 0.102 0.292 0.122 
FEV1 0.000* 0.000* 0.000* 0.000* 0.187 0.036* 0.240 0.993 0.918 
FEV3 0.032* 0.162 0.001* 0.000* 0.650 0.028* 0.092 0.858 0.545 
FEV6 0.250 0.406 0.001* 0.001* 0.689 0.012* 0.042* 0.803 0.465 
FVC 0.329 0.687 0.002* 0.001* 0.838 0.020* 0.044* 0.740 0.427 
FEV1% 0.000* 0.000* 0.003* 0.000* 0.682 1.000 0.454 0.335 0.107 
FEV3% 0.000* 0.000* 0.029* 0.000* 0.915 0.199 0.310 0.314 0.269 
FEV6% 0.000* 0.000* 0.029* 0.000* 0.317 0.199 0.310 0.314 0.269 
FEV1/FEV6 0.000* 0.000* 0.003* 0.000* 0.317 0.947 0.400 0.371 0.112 
PEFR 0.000* 0.000* 0.001* 0.000* 0.702 0.140 0.390 0.789 0.878 
FEF25% 0.000* 0.000* 0.001* 0.000* 0.817 0.252 0.865 0.669 0.526 
FEF50% 0.000* 0.000* 0.000* 0.000* 0.845 0.390 0.875 0.665 0.389 
FEF75% 0.000* 0.000* 0.002* 0.000* 0.831 1.000 0.703 0.687 0.463 
FEF25%-75% 0.000* 0.000* 0.000* 0.000* 0.824 0.441 0.694 0.667 0.425 
FEF75%-85% 0.000* 0.000* 0.002* 0.000* 0.972 1.000 0.834 0.935 0.826 
ACT Score 0.000* 0.000* 0.000* 0.000* 0.762 0.279 0.802 0.789 0.681 
NAEPP Class 0.000* 0.000* 0.000* 0.000* 0.829 0.336 0.726 0.930 0.133 
Duration 0.000* 0.000* 0.000* 0.000* 0.885 0.279 0.473 0.281 0.486 
DAS 0.000* 0.000* 0.001* 0.000* 0.569 0.826 0.138 0.739 0.344 
MHR 0.537 0.096 0.388 0.007* 0.302 0.597 0.086 0.336 0.118 
MNN 0.537 0.096 0.394 0.009* 0.294 0.597 0.084 0.311 0.135 
SDNN 0.354 0.021* 0.983 0.108 0.220 0.481 0.969 0.897 0.722 
RMSSD 0.394 0.023* 0.776 0.218 0.262 0.843 0.948 0.744 0.858 
TP 0.952 0.143 0.948 0.273 0.278 0.930 0.990 0.711 0.884 
VLF 0.712 0.390 0.400 0.576 0.413 0.538 0.564 0.242 0.082 
LF 0.482 0.059 0.810 0.293 0.286 0.758 0.865 0.299 0.934 
HF 0.672 0.079 0.759 0.239 0.337 0.860 1.000 0.405 0.814 
LF Norm 0.850 0.361 0.505 0.273 0.600 0.692 0.559 0.828 0.861 
HF Norm 0.850 0.361 0.505 0.408 0.600 0.692 0.689 0.930 0.788 
LF/HF 0.909 0.352 0.463 0.424 0.556 0.580 0.594 0.703 0.830 
Significance of Mean Difference after Adjustment for MHR 
SDNN 0.366 0.016* 0.714 0.165 0.189 0.396 0.751 0.831 0.639 
RMSSD 0.345 0.038* 0.654 0.422 0.328 0.343 0.831 0.630 0.684 
TP 0.521 0.025* 0.592 0.503 0.165 0.388 0.966 0.637 0.758 
VLF 0.673 0.292 0.500 0.495 0.205 0.689 0.336 0.238 0.320 
LF 0.396 0.013* 0.661 0.546 0.156 0.376 0.772 0.301 0.945 
HF 0.312 0.025* 0.565 0.644 0.285 0.269 0.574 0.358 0.985 
LF Norm 0.968 0.350 0.571 0.231 0.441 0.609 0.336 0.872 0.783 
HF Norm 0.964 0.342 0.569 0.329 0.436 0.609 0.440 0.872 0.783 
LF/HF 0.631 0.984 0.136 0.482 0.666 0.254 0.301 0.656 0.790 
 
* Significant Mean Difference 
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Table (7-18): Correlations between Variables of Non-Asthmatics (A). 
 
  Age Wt Ht BMI SBP DBP MABP Hb RBG Na+ K+ Ca++ Mg++ 
FEV1 CC -0.15 0.18 0.83 -0.15 0.13 -0.06 0.02 0.56 0.03 -0.10 0.30 0.04 -0.10 
 Sig. 0.281 0.180 0.000* 0.262 0.356 0.637 0.912 0.000* 0.846 0.485 0.022* 0.803 0.454 
FEV3 CC -0.16 0.23 0.82 -0.09 0.04 -0.10 -0.05 0.57 0.04 -0.03 0.30 -0.04 -0.16 
 Sig. 0.237 0.082 0.000* 0.495 0.755 0.448 0.707 0.000* 0.791 0.825 0.027* 0.785 0.238 
FEV6 CC -0.16 0.24 0.82 -0.09 0.05 -0.09 -0.04 0.57 0.03 -0.03 0.30 -0.04 -0.16 
 Sig. 0.245 0.074 0.000* 0.526 0.738 0.486 0.748 0.000* 0.828 0.837 0.026* 0.757 0.260 
FVC CC -0.16 0.24 0.82 -0.09 0.05 -0.09 -0.04 0.57 0.03 -0.03 0.30 -0.04 -0.16 
 Sig. 0.247 0.073 0.000* 0.531 0.739 0.488 0.748 0.000* 0.828 0.835 0.026* 0.756 0.260 
FEV1% CC 0.05 -0.30 -0.07 -0.28 0.26 0.08 0.18 -0.15 -0.07 -0.24 -0.04 0.22 0.14 
 Sig. 0.734 0.023* 0.586 0.033* 0.050 0.538 0.177 0.286 0.607 0.072 0.751 0.127 0.323 
FEV3% CC -0.06 -0.26 -0.04 -0.25 -0.09 -0.25 -0.22 0.01 0.14 -0.07 -0.10 0.11 -0.19 
 Sig. 0.672 0.050 0.784 0.065 0.496 0.064 0.109 0.970 0.312 0.623 0.456 0.444 0.162 
FEV6% CC -0.06 -0.26 -0.04 -0.25 -0.09 -0.25 -0.22 0.01 0.14 -0.07 -0.10 0.11 -0.19 
 Sig. 0.672 0.050 0.784 0.065 0.496 0.064 0.109 0.970 0.312 0.623 0.456 0.444 0.162 
FEV1/FEV6 CC -0.01 -0.13 0.03 -0.17 0.27 0.17 0.24 -0.09 -0.05 -0.24 -0.01 0.22 0.17 
 Sig. 0.937 0.328 0.799 0.218 0.045* 0.215 0.070 0.495 0.738 0.077 0.933 0.127 0.222 
PEFR CC -0.04 0.25 0.76 -0.07 0.21 -0.07 0.05 0.42 -0.03 -0.06 0.15 -0.20 -0.08 
 Sig. 0.788 0.061 0.000* 0.594 0.125 0.588 0.728 0.001* 0.844 0.646 0.280 0.152 0.546 
FEF25% CC 0.05 0.29 0.72 -0.02 0.30 0.14 0.24 0.43 -0.05 -0.10 0.12 -0.12 -0.03 
 Sig. 0.740 0.028* 0.000* 0.874 0.022* 0.288 0.069 0.001* 0.724 0.444 0.361 0.403 0.839 
FEF50% CC 0.05 0.12 0.57 -0.11 0.27 0.08 0.18 0.40 -0.14 -0.08 0.18 0.02 0.06 
 Sig. 0.740 0.376 0.000* 0.402 0.045* 0.553 0.175 0.002* 0.295 0.573 0.173 0.885 0.668 
FEF75% CC 0.00 -0.10 0.47 -0.29 0.18 -0.02 0.07 0.27 -0.09 -0.25 0.18 0.21 0.06 
 Sig. 0.981 0.463 0.000* 0.029* 0.180 0.869 0.604 0.046* 0.526 0.064 0.173 0.136 0.669 
FEF25%-75% CC 0.08 0.13 0.57 -0.11 0.26 0.07 0.17 0.37 -0.12 -0.15 0.21 0.09 0.05 
 Sig. 0.547 0.356 0.000* 0.407 0.056 0.584 0.200 0.005* 0.387 0.269 0.118 0.539 0.715 
FEF75%-85% CC -0.10 -0.18 0.45 -0.35 0.16 -0.08 0.02 0.26 -0.06 -0.26 0.17 0.23 0.08 
 Sig. 0.472 0.197 0.000* 0.007* 0.249 0.580 0.872 0.056 0.643 0.055 0.212 0.102 0.545 
DAS CC 0.03 -0.03 0.57 -0.27 0.25 -0.12 0.04 0.27 -0.03 -0.25 0.24 0.13 0.01 
 Sig. 0.847 0.827 0.000* 0.045* 0.064 0.388 0.786 0.048* 0.845 0.067 0.076 0.351 0.960 
MHR CC -0.04 -0.04 -0.26 0.05 0.10 0.04 0.08 -0.08 0.10 0.03 -0.17 0.12 0.31 
 Sig. 0.781 0.746 0.056 0.738 0.469 0.763 0.581 0.575 0.486 0.825 0.206 0.392 0.021* 
MNN CC 0.03 0.03 0.26 -0.06 -0.11 -0.02 -0.07 0.11 -0.08 -0.07 0.14 -0.10 -0.29 
 Sig. 0.823 0.799 0.049* 0.661 0.432 0.878 0.632 0.440 0.546 0.624 0.306 0.498 0.031* 
SDNN CC -0.15 -0.22 0.18 -0.27 -0.14 -0.32 -0.29 0.12 0.20 -0.24 0.00 -0.16 -0.13 
 Sig. 0.260 0.111 0.175 0.044* 0.308 0.015* 0.030* 0.382 0.132 0.074 0.980 0.268 0.363 
RMSSD CC -0.14 -0.25 0.10 -0.28 -0.14 -0.32 -0.29 0.07 0.20 -0.23 -0.03 -0.07 -0.06 
 Sig. 0.299 0.062 0.474 0.040* 0.310 0.016* 0.031* 0.630 0.146 0.084 0.809 0.602 0.653 
TP CC -0.09 -0.16 0.21 -0.23 -0.07 -0.27 -0.22 0.20 0.13 -0.17 0.03 -0.31 -0.19 
 Sig. 0.492 0.229 0.112 0.083 0.634 0.042* 0.104 0.136 0.323 0.223 0.833 0.026* 0.159 
VLF CC -0.13 -0.07 0.21 -0.14 0.00 -0.16 -0.11 0.20 0.03 -0.09 0.12 -0.62 -0.29 
 Sig. 0.331 0.607 0.113 0.309 0.994 0.235 0.411 0.142 0.822 0.517 0.365 0.000* 0.036* 
LF CC -0.04 -0.18 0.20 -0.25 -0.07 -0.28 -0.23 0.22 0.14 -0.13 -0.03 -0.02 -0.13 
 Sig. 0.779 0.184 0.137 0.068 0.599 0.034* 0.087 0.106 0.292 0.327 0.823 0.878 0.335 
HF CC -0.05 -0.19 0.13 -0.24 -0.10 -0.29 -0.25 0.11 0.19 -0.18 -0.05 -0.01 -0.05 
 Sig. 0.708 0.161 0.331 0.080 0.471 0.032* 0.068 0.399 0.164 0.173 0.710 0.933 0.738 
LF Norm CC 0.07 0.25 0.08 0.22 0.22 0.25 0.28 0.26 -0.32 0.19 0.01 -0.06 -0.05 
 Sig. 0.633 0.062 0.575 0.096 0.109 0.059 0.038* 0.057 0.015* 0.154 0.963 0.662 0.699 
HF Norm CC -0.07 -0.25 -0.08 -0.22 -0.22 -0.25 -0.28 -0.26 0.32 -0.19 -0.01 0.06 0.05 
 Sig. 0.633 0.062 0.574 0.096 0.109 0.059 0.038* 0.057 0.016* 0.154 0.962 0.663 0.699 
LF/HF CC 0.03 0.24 0.04 0.21 0.21 0.27 0.29 0.30 -0.29 0.17 -0.12 -0.07 -0.05 
 Sig. 0.841 0.078 0.758 0.114 0.127 0.042* 0.032* 0.027* 0.029* 0.207 0.362 0.615 0.695 
 
* Significant Correlation 
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Table (7-18): Correlations between Variables of Non-Asthmatics (B). 
 
  MHR MNN SDNN RMSSD TP VLF LF HF LF Norm 
HF 
Norm LF/HF 
FEV1 CC -0.13 0.17 0.17 0.12 0.24 0.20 0.25 0.20 0.15 -0.15 0.12 
 Sig. 0.322 0.214 0.202 0.373 0.070 0.148 0.066 0.141 0.285 0.285 0.373 
FEV3 CC -0.17 0.20 0.17 0.10 0.26 0.26 0.24 0.17 0.14 -0.14 0.10 
 Sig. 0.199 0.133 0.200 0.462 0.052 0.052 0.073 0.202 0.307 0.307 0.467 
FEV6 CC -0.16 0.19 0.17 0.09 0.26 0.26 0.23 0.17 0.15 -0.15 0.11 
 Sig. 0.225 0.151 0.221 0.496 0.057 0.052 0.082 0.220 0.282 0.282 0.440 
FVC CC -0.16 0.19 0.17 0.09 0.26 0.26 0.23 0.17 0.15 -0.15 0.11 
 Sig. 0.225 0.151 0.222 0.499 0.057 0.052 0.082 0.222 0.280 0.280 0.438 
FEV1% CC 0.14 -0.13 0.01 0.09 -0.06 -0.22 0.00 0.09 -0.05 0.05 0.02 
 Sig. 0.294 0.324 0.950 0.501 0.647 0.098 0.971 0.528 0.713 0.713 0.885 
FEV3% CC -0.22 0.22 0.23 0.23 0.14 0.00 0.19 0.20 -0.24 0.24 -0.20 
 Sig. 0.101 0.108 0.094 0.089 0.301 0.990 0.162 0.134 0.075 0.075 0.149 
FEV6% CC -0.22 0.22 0.23 0.23 0.14 0.00 0.19 0.20 -0.24 0.24 -0.20 
 Sig. 0.101 0.108 0.094 0.089 0.301 0.990 0.162 0.134 0.075 0.075 0.149 
FEV1/FEV6 CC 0.05 -0.05 -0.06 0.02 -0.09 -0.20 -0.04 0.03 -0.08 0.08 -0.02 
 Sig. 0.721 0.734 0.684 0.883 0.499 0.135 0.753 0.846 0.577 0.577 0.855 
PEFR CC -0.10 0.09 0.11 0.03 0.26 0.32 0.20 0.13 0.14 -0.14 0.14 
 Sig. 0.448 0.489 0.404 0.848 0.057 0.017 0.141 0.349 0.307 0.306 0.318 
FEF25% CC -0.02 0.03 0.00 -0.04 0.14 0.16 0.11 0.08 0.18 -0.18 0.20 
 Sig. 0.892 0.854 0.975 0.747 0.296 0.235 0.405 0.556 0.193 0.193 0.142 
FEF50% CC 0.00 0.02 0.01 0.03 0.07 -0.04 0.11 0.12 0.17 -0.17 0.20 
 Sig. 0.990 0.894 0.968 0.813 0.627 0.789 0.437 0.360 0.199 0.199 0.137 
FEF75% CC 0.01 0.02 0.13 0.17 0.13 -0.06 0.19 0.23 0.06 -0.06 0.08 
 Sig. 0.947 0.898 0.344 0.212 0.354 0.641 0.152 0.086 0.685 0.685 0.535 
FEF25%-75% CC 0.01 0.01 0.05 0.08 0.10 -0.03 0.15 0.18 0.12 -0.12 0.15 
 Sig. 0.931 0.933 0.722 0.549 0.443 0.809 0.262 0.187 0.380 0.381 0.278 
FEF75%-85% CC 0.00 0.03 0.17 0.20 0.14 -0.06 0.21 0.24 0.02 -0.02 0.04 
 Sig. 0.990 0.835 0.215 0.140 0.320 0.663 0.125 0.079 0.909 0.909 0.748 
DAS CC -0.01 0.03 0.22 0.22 0.24 0.08 0.28 0.29 0.06 -0.06 0.08 
 Sig. 0.935 0.843 0.104 0.103 0.077 0.565 0.035* 0.030* 0.662 0.662 0.555 
 
* Significant Correlation 
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Table (7-19): Correlations between Variables of Asthmatics (A). 
 
  Age Wt Ht BMI SBP DBP MABP Hb RBG Na+ K+ Ca++ Mg++ 
FEV1 CC -0.11 0.16 0.39 -0.05 -0.07 -0.03 -0.05 0.24 0.16 -0.13 0.06 0.11 0.02 
 Sig. 0.293 0.123 0.000* 0.627 0.478 0.735 0.589 0.017* 0.123 0.214 0.571 0.302 0.848 
FEV3 CC -0.02 0.18 0.53 -0.10 -0.14 -0.05 -0.09 0.37 0.11 -0.05 0.05 0.18 0.04 
 Sig. 0.868 0.074 0.000* 0.311 0.154 0.643 0.348 0.000* 0.293 0.616 0.639 0.073 0.677 
FEV6 CC 0.03 0.18 0.58 -0.12 -0.15 -0.04 -0.09 0.43 0.09 -0.02 0.02 0.20 0.05 
 Sig. 0.787 0.068 0.000* 0.228 0.147 0.712 0.375 0.000* 0.391 0.809 0.830 0.047* 0.606 
FVC CC 0.04 0.17 0.60 -0.14 -0.16 -0.04 -0.09 0.45 0.07 0.00 0.01 0.21 0.06 
 Sig. 0.692 0.085 0.000* 0.162 0.119 0.710 0.350 0.000* 0.473 0.972 0.889 0.041* 0.560 
FEV1% CC -0.28 -0.01 -0.23 0.12 0.06 -0.03 0.00 -0.28 0.15 -0.23 0.07 -0.20 -0.10 
 Sig. 0.005* 0.940 0.023* 0.228 0.548 0.746 0.961 0.005* 0.133 0.023* 0.468 0.057 0.349 
FEV3% CC -0.22 0.05 -0.13 0.12 -0.03 -0.07 -0.06 -0.20 0.13 -0.19 0.12 -0.12 -0.09 
 Sig. 0.025* 0.622 0.191 0.220 0.746 0.470 0.531 0.043* 0.211 0.062 0.245 0.254 0.370 
FEV6% CC -0.22 0.05 -0.13 0.12 -0.03 -0.07 -0.06 -0.20 0.13 -0.19 0.12 -0.12 -0.09 
 Sig. 0.025* 0.622 0.191 0.220 0.746 0.470 0.531 0.043* 0.211 0.062 0.245 0.254 0.370 
FEV1/FEV6 CC -0.28 -0.02 -0.22 0.11 0.06 -0.03 0.00 -0.28 0.15 -0.22 0.08 -0.20 -0.09 
 Sig. 0.004* 0.848 0.026* 0.281 0.541 0.740 0.962 0.004* 0.145 0.031* 0.450 0.049* 0.359 
PEFR CC -0.03 0.12 0.32 -0.04 0.06 0.01 0.03 0.22 0.17 -0.18 0.05 0.09 0.05 
 Sig. 0.785 0.228 0.001* 0.699 0.577 0.906 0.745 0.026* 0.100 0.076 0.627 0.388 0.614 
FEF25% CC -0.20 0.10 0.13 0.04 0.02 -0.01 0.00 0.02 0.13 -0.21 0.09 0.00 -0.01 
 Sig. 0.048* 0.310 0.192 0.680 0.822 0.896 0.991 0.847 0.189 0.037* 0.386 0.979 0.889 
FEF50% CC -0.30 0.07 0.01 0.07 0.11 0.00 0.05 -0.05 0.18 -0.13 0.12 -0.05 -0.09 
 Sig. 0.003* 0.497 0.941 0.519 0.288 0.991 0.645 0.617 0.070 0.212 0.232 0.663 0.367 
FEF75% CC -0.33 0.03 0.01 0.03 0.10 -0.04 0.01 -0.09 0.18 -0.08 0.11 -0.04 -0.09 
 Sig. 0.001* 0.767 0.950 0.779 0.342 0.677 0.888 0.388 0.067 0.430 0.274 0.709 0.381 
FEF25%-75% CC -0.31 0.07 0.02 0.06 0.09 -0.02 0.03 -0.06 0.18 -0.13 0.12 -0.05 -0.09 
 Sig. 0.002* 0.512 0.882 0.545 0.361 0.848 0.784 0.549 0.081 0.194 0.236 0.609 0.399 
FEF75%-85% CC -0.34 0.01 0.05 -0.02 0.11 -0.03 0.03 -0.08 0.17 -0.07 0.08 -0.01 -0.08 
 Sig. 0.001* 0.944 0.598 0.859 0.293 0.752 0.801 0.452 0.097 0.488 0.413 0.921 0.436 
ACTScore CC -0.27 -0.11 0.04 -0.13 -0.11 -0.17 -0.16 -0.06 0.26 -0.12 0.03 -0.08 -0.03 
 Sig. 0.007* 0.287 0.668 0.189 0.292 0.087 0.107 0.558 0.009* 0.244 0.800 0.417 0.732 
NAEPP Class CC 0.41 0.20 0.12 0.13 0.10 0.15 0.15 0.11 -0.16 0.11 -0.11 0.17 0.15 
 Sig. 0.000* 0.045 0.222 0.201 0.306 0.129 0.143 0.265 0.106 0.287 0.275 0.109 0.145 
Duration CC 0.18 0.02 0.15 -0.06 -0.14 -0.19 -0.19 0.00 -0.05 0.01 -0.09 -0.09 -0.03 
 Sig. 0.068 0.852 0.125 0.561 0.156 0.056 0.057 0.994 0.639 0.907 0.390 0.362 0.796 
DAS CC -0.19 -0.01 -0.10 0.05 0.19 0.02 0.10 -0.13 0.22 -0.20 0.06 -0.11 0.00 
 Sig. 0.058 0.903 0.300 0.593 0.056 0.816 0.321 0.185 0.030* 0.049* 0.575 0.292 0.963 
MHR CC -0.10 -0.03 -0.24 0.09 0.08 0.04 0.06 -0.08 0.09 -0.05 0.06 -0.04 0.04 
 Sig. 0.299 0.778 0.016* 0.381 0.423 0.713 0.549 0.421 0.385 0.640 0.552 0.698 0.659 
MNN CC 0.09 -0.01 0.25 -0.13 -0.09 -0.04 -0.07 0.08 -0.10 0.04 -0.04 0.06 -0.01 
 Sig. 0.348 0.925 0.012* 0.203 0.385 0.688 0.514 0.440 0.313 0.679 0.703 0.558 0.908 
SDNN CC -0.09 0.06 0.27 -0.10 -0.18 -0.14 -0.18 0.21 0.06 0.00 0.03 0.20 0.18 
 Sig. 0.350 0.574 0.006* 0.320 0.071 0.156 0.080 0.035* 0.573 0.977 0.754 0.053 0.080 
RMSSD CC -0.12 0.03 0.29 -0.13 -0.19 -0.15 -0.19 0.24 0.05 -0.03 0.05 0.19 0.18 
 Sig. 0.220 0.732 0.003* 0.197 0.055 0.138 0.065 0.016* 0.653 0.761 0.621 0.063 0.081 
TP CC -0.05 0.10 0.20 -0.02 -0.17 -0.13 -0.16 0.20 0.10 0.03 0.06 0.21 0.14 
 Sig. 0.591 0.336 0.044* 0.831 0.084 0.197 0.104 0.041* 0.336 0.747 0.528 0.037* 0.164 
VLF CC -0.01 0.12 0.15 0.04 -0.08 -0.16 -0.14 0.17 0.04 0.03 0.11 0.30 0.12 
 Sig. 0.921 0.231 0.148 0.728 0.454 0.105 0.158 0.092 0.670 0.763 0.255 0.003* 0.230 
LF CC -0.06 0.08 0.19 -0.03 -0.17 -0.07 -0.12 0.19 0.10 0.06 0.03 0.20 0.13 
 Sig. 0.580 0.437 0.058 0.739 0.086 0.474 0.217 0.055 0.318 0.576 0.751 0.058 0.190 
HF CC -0.07 0.08 0.20 -0.04 -0.19 -0.11 -0.16 0.18 0.10 0.02 0.04 0.13 0.12 
 Sig. 0.472 0.445 0.046* 0.691 0.056 0.258 0.109 0.067 0.321 0.860 0.670 0.197 0.229 
LF Norm CC 0.04 0.08 -0.29 0.22 0.08 0.19 0.17 -0.19 0.13 0.08 0.00 0.05 -0.06 
 Sig. 0.661 0.430 0.003* 0.025* 0.413 0.055 0.101 0.065 0.209 0.451 0.988 0.603 0.524 
HF Norm CC -0.08 -0.07 0.30 -0.22 -0.15 -0.21 -0.21 0.22 -0.14 -0.09 0.00 -0.06 0.07 
 Sig. 0.419 0.482 0.003* 0.028* 0.130 0.035* 0.037* 0.029* 0.165 0.359 0.968 0.549 0.507 
LF/HF CC -0.03 -0.02 -0.12 0.04 0.05 0.20 0.15 -0.07 0.21 -0.04 -0.04 0.06 -0.03 
 Sig. 0.735 0.877 0.249 0.681 0.622 0.050 0.127 0.517 0.035 0.695 0.716 0.596 0.805 
 
* Significant Correlation 
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Table (7-19): Correlations between Variables of Asthmatics (B). 
 
  MHR MNN SDNN RMSSD TP VLF LF HF 
LF 
Norm 
HF 
Norm LF/HF 
FEV1 CC -0.30 0.30 0.14 0.13 0.15 0.10 0.15 0.15 -0.08 0.11 -0.10 
 Sig. 0.002* 0.002* 0.176 0.188 0.130 0.302 0.141 0.140 0.455 0.259 0.314 
FEV3 CC -0.35 0.37 0.22 0.22 0.21 0.15 0.20 0.20 -0.11 0.15 -0.08 
 Sig. 0.000* 0.000* 0.028* 0.031* 0.037* 0.130 0.048* 0.045* 0.280 0.147 0.405 
FEV6 CC -0.37 0.38 0.22 0.21 0.20 0.16 0.19 0.19 -0.10 0.14 -0.06 
 Sig. 0.000* 0.000* 0.028* 0.033* 0.042* 0.107 0.059 0.056 0.301 0.166 0.563 
FVC CC -0.38 0.39 0.22 0.22 0.21 0.17 0.20 0.20 -0.10 0.13 -0.03 
 Sig. 0.000* 0.000* 0.025* 0.030* 0.034* 0.093 0.048* 0.046* 0.339 0.193 0.748 
FEV1% CC 0.00 -0.01 -0.10 -0.09 -0.06 -0.11 -0.04 -0.04 -0.01 0.04 -0.18 
 Sig. 0.985 0.905 0.321 0.372 0.560 0.295 0.713 0.725 0.948 0.700 0.080 
FEV3% CC -0.01 0.02 0.03 0.04 0.03 -0.06 0.05 0.05 -0.08 0.12 -0.26 
 Sig. 0.912 0.839 0.749 0.680 0.804 0.523 0.630 0.606 0.414 0.230 0.008* 
FEV6% CC -0.01 0.02 0.03 0.04 0.03 -0.06 0.05 0.05 -0.08 0.12 -0.26 
 Sig. 0.912 0.839 0.749 0.680 0.804 0.523 0.630 0.606 0.414 0.230 0.008* 
FEV1/FEV6 CC -0.01 -0.01 -0.10 -0.09 -0.05 -0.10 -0.03 -0.03 0.00 0.03 -0.16 
 Sig. 0.938 0.955 0.310 0.354 0.593 0.312 0.751 0.761 0.992 0.758 0.117 
PEFR CC -0.26 0.26 0.04 0.05 0.07 0.05 0.06 0.07 -0.11 0.14 -0.16 
 Sig. 0.009* 0.008* 0.690 0.617 0.489 0.649 0.523 0.486 0.295 0.154 0.104 
FEF25% CC -0.16 0.15 -0.02 -0.01 0.02 -0.02 0.03 0.03 0.00 0.04 -0.09 
 Sig. 0.113 0.136 0.829 0.897 0.855 0.855 0.768 0.781 0.977 0.715 0.371 
FEF50% CC -0.11 0.10 -0.10 -0.10 -0.05 -0.04 -0.05 -0.05 0.04 -0.01 -0.08 
 Sig. 0.276 0.326 0.328 0.328 0.631 0.723 0.648 0.650 0.726 0.938 0.448 
FEF75% CC -0.11 0.10 -0.07 -0.06 -0.04 -0.03 -0.04 -0.03 -0.02 0.04 -0.10 
 Sig. 0.292 0.304 0.492 0.534 0.723 0.737 0.689 0.797 0.856 0.673 0.330 
FEF25%-
75% CC -0.11 0.10 -0.09 -0.08 -0.04 -0.03 -0.04 -0.04 0.02 0.01 -0.09 
 Sig. 0.265 0.307 0.384 0.402 0.684 0.739 0.679 0.727 0.857 0.923 0.391 
FEF75%-
85% CC -0.13 0.14 -0.03 -0.03 -0.01 -0.02 -0.02 0.00 -0.07 0.09 -0.11 
 Sig. 0.186 0.177 0.744 0.801 0.916 0.850 0.871 0.996 0.516 0.384 0.267 
ACTScore CC 0.01 -0.02 0.13 0.15 0.17 -0.01 0.18 0.22 -0.17 0.21 -0.07 
 Sig. 0.947 0.835 0.200 0.147 0.094 0.908 0.081 0.027* 0.094 0.036 0.509 
NAEPP Class CC 0.01 0.01 -0.12 -0.13 -0.14 0.01 -0.15 -0.19 0.13 -0.17 0.03 
 Sig. 0.947 0.884 0.243 0.190 0.165 0.925 0.149 0.063 0.188 0.087 0.738 
Duration CC 0.11 -0.13 0.16 0.18 0.15 0.04 0.13 0.19 -0.23 0.22 -0.16 
 Sig. 0.273 0.201 0.107 0.073 0.138 0.680 0.199 0.055 0.020* 0.030* 0.109 
DAS CC -0.03 0.01 -0.14 -0.14 -0.05 -0.04 -0.06 -0.05 0.00 0.01 -0.10 
 Sig. 0.747 0.895 0.158 0.175 0.591 0.697 0.567 0.619 0.969 0.912 0.332 
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Table (7-20): Correlations between Variables of Non-Asthmatics after 
Controlling for MHR 
  SDNN RMSSD TP VLF LF HF LF Norm 
HF 
Norm LF/HF 
Age CC -0.152 -0.126 -0.080 -0.149 0.005 -0.023 0.012 -0.013 -0.029 
 Sig. 0.298 0.388 0.587 0.307 0.972 0.876 0.933 0.932 0.843 
Wt CC -0.257 -0.284 -0.194 -0.099 -0.188 -0.227 0.322 -0.322 0.281 
 Sig. 0.075 0.048 0.182 0.499 0.196 0.117 0.024 0.024 0.050 
Ht CC 0.194 0.127 0.247 0.229 0.237 0.174 0.162 -0.162 0.126 
 Sig. 0.182 0.386 0.087 0.114 0.102 0.231 0.266 0.266 0.388 
BMI CC -0.306 -0.311 -0.266 -0.164 -0.257 -0.278 0.256 -0.256 0.220 
 Sig. 0.033 0.030 0.065 0.260 0.074 0.053 0.076 0.076 0.130 
SBP CC -0.177 -0.190 -0.108 -0.022 -0.092 -0.164 0.328 -0.328 0.288 
 Sig. 0.224 0.191 0.461 0.879 0.530 0.262 0.021 0.021 0.045 
DBP CC -0.371 -0.369 -0.320 -0.197 -0.307 -0.350 0.340 -0.340 0.328 
 Sig. 0.009 0.009 0.025 0.174 0.032 0.014 0.017 0.017 0.021 
MABP CC -0.346 -0.351 -0.277 -0.150 -0.261 -0.325 0.396 -0.396 0.369 
 Sig. 0.015 0.013 0.054 0.305 0.070 0.023 0.005 0.005 0.009 
Hb CC 0.083 0.034 0.164 0.196 0.144 0.078 0.324 -0.324 0.376 
 Sig. 0.569 0.817 0.261 0.178 0.322 0.596 0.023 0.023 0.008 
RBG CC 0.189 0.178 -0.047 0.002 0.163 0.162 -0.331 0.331 -0.327 
 Sig. 0.194 0.222 0.747 0.987 0.264 0.267 0.020 0.020 0.022 
Na+ CC -0.243 -0.242 0.113 -0.076 -0.172 -0.211 0.241 -0.241 0.205 
 Sig. 0.093 0.093 0.442 0.602 0.236 0.146 0.096 0.096 0.158 
K+ CC -0.007 -0.016 -0.180 0.116 -0.005 -0.032 0.054 -0.055 -0.092 
 Sig. 0.960 0.911 0.215 0.427 0.971 0.827     0.710 0.710 0.529 
Ca++ CC -0.161 -0.091 -0.335 -0.627 -0.044 -0.042 -0.073 0.072 -0.093 
 Sig. 0.268 0.535 0.018 0.000 0.762 0.773 0.620 0.621 0.524 
Mg++ CC -0.135 -0.107 -0.209 -0.332 -0.081 -0.061 -0.093 0.093 -0.110 
 Sig. 0.355 0.463 0.150 0.020 0.580 0.678 0.526 0.527 0.451 
FEV1 CC 0.154 0.114 -0.209 0.183 0.222 0.189 0.218 -0.218 0.191 
 Sig. 0.291 0.435 0.150 0.209 0.125 0.195 0.132 0.132 0.188 
FEV3 CC 0.161 0.098 0.224 0.267 0.217 0.170 0.221 -0.221 0.180 
 Sig. 0.269 0.502 0.122 0.064 0.134 0.243 0.127 0.127 0.217 
FEV6 CC 0.152 0.088 0.254 0.267 0.208 0.159 0.229 -0.229 0.185 
 Sig. 0.297 0.546 0.078 0.064 0.152 0.274 0.113 0.113 0.202 
FVC CC 0.152 0.088 0.247 0.267 0.207 0.159 0.230 -0.230 0.186 
 Sig. 0.299 0.550 0.087 0.064 0.153 0.276 0.112 0.112 0.201 
FEV1% CC 0.026 0.100 0.246 -0.237 0.043 0.096 -0.052 0.052 0.012 
 Sig. 0.858 0.494 0.088 0.102 0.768 0.512 0.725 0.725 0.934 
FEV3% CC 0.240 0.270 -0.057 -0.001 0.230 0.271 -0.264 0.264 -0.188 
 Sig. 0.097 0.061 0.699 0.995 0.112 0.060 0.067 0.067 0.197 
FEV6% CC 0.240 0.270 0.175 -0.001 0.230 0.271 -0.264 0.264 -0.188 
 Sig. 0.097 0.061 0.231 0.995     0.112 0.060 0.067 0.067 0.197 
FEV1/FEV6 CC -0.050 0.025 -0.084 -0.212 -0.009 0.042 -0.077 0.077 -0.026 
 Sig. 0.731 0.864 0.568 0.144 0.951 0.773 0.601 0.601 0.861 
PEFR CC 0.078 -0.001 0.231 0.310 0.155 0.102 0.201 -0.201 0.198 
 Sig. 0.593 0.995 0.110 0.030 0.287 0.485 0.167 0.166 0.173 
FEF25% CC -0.052 -0.090 0.093 0.138 0.061 0.024 0.269 -0.269 0.274 
 Sig. 0.724 0.539 0.527 0.345 0.676 0.870 0.062 0.062 0.057 
FEF50% CC -0.013 0.015 0.044 -0.058 0.104 0.105 0.234 -0.234 0.251 
 Sig. 0.930 0.921 0.763 0.691 0.476 0.474 0.106 0.106 0.082 
FEF75% CC 0.131 0.172 0.122 -0.078 0.214 0.235 0.077 -0.077 0.103 
 Sig. 0.369 0.237 0.403 0.593 0.140 0.104 0.598 0.598 0.482 
FEF25%-75% CC 0.032 0.066 0.080 -0.058 0.150 0.158 0.172 -0.172 0.188 
 Sig. 0.829 0.653 0.586 0.691 0.303 0.277 0.239 0.239 0.196 
FEF75%-85% CC 0.180 0.210 0.145 -0.063 0.235 0.255 0.035 0.035 0.066 
 Sig. 0.215 0.147 0.321 0.668 0.104 0.077 0.813 0.813 0.653 
DAS CC 0.209 0.215 0.227 0.062 0.285 0.288 0.076 -0.076 0.094 
 Sig. 0.149 0.137 0.117 0.673 0.047 0.044 0.602 0.602 0.521 
* Significant Correlation 
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Table (7-21): Correlations between Variables of Asthmatics after Controlling 
for MHR 
  SDNN RMSSD TP VLF LF HF LF Norm 
HF 
Norm LF/HF 
Age CC -0.073 -0.100 -0.014 0.017 -0.022 -0.031 0.047 -0.047 -0.063 
  Sig. 0.485 0.342 0.893 0.874 0.837 0.766 0.653 0.653 0.546 
Wt CC 0.070 0.050 0.114 0.136 0.090 0.092 0.075 -0.075 -0.024 
  Sig. 0.508 0.631 0.279 0.194 0.393 0.380 0.474 0.474 0.817 
Ht CC 0.291 0.334 0.219 0.130 0.207 0.230 -0.266 0.266 -0.106 
  Sig. 0.005 0.001 0.035 0.215 0.047 0.027 0.010 0.010 0.312 
BMI CC -0.091 -0.127 -0.009 0.062 -0.026 -0.035 0.204 -0.204 0.027 
  Sig. 0.388 0.224 0.933 0.558 0.802 0.740 0.050 0.050 0.798 
SBP CC -0.164 -0.183 -0.159 -0.046 -0.162 -0.186 0.070 -0.070 0.002 
  Sig. 0.115 0.079 0.128 0.659 0.122 0.074 0.508 0.508 0.987 
DBP CC -0.101 -0.106 -0.079 -0.121 -0.024 -0.065 0.182 -0.182 0.182 
  Sig. 0.333 0.311 0.451 0.248 0.818 0.534 0.081 0.081 0.080 
MABP CC -0.142 -0.153 -0.124 -0.102 -0.089 -0.127 0.152 -0.152 0.122 
  Sig. 0.176 0.143 0.235 0.333 0.397 0.224 0.145 0.145 0.244 
Hb CC 0.214 0.254 0.220 0.164 0.209 0.204 -0.163 0.163 -0.039 
  Sig. 0.040 0.014 0.034 0.117 0.044 0.050 0.119 0.119 0.712 
RBG CC 0.076 0.055 0.103 0.065 0.101 0.099 0.110 -0.110 0.193 
  Sig. 0.469 0.604 0.325 0.535 0.335 0.344 0.295 0.295 0.064 
Na+ CC 0.057 0.041 0.122 0.084 0.140 0.111 0.042 -0.042 -0.049 
  Sig. 0.586 0.699 0.243 0.426 0.181 0.290 0.689 0.689 0.640 
K+ CC 0.081 0.095 0.062 0.146 0.022 0.028 -0.034 0.034 -0.028 
  Sig. 0.441 0.363 0.552 0.163 0.835 0.793 0.750 0.750 0.789 
Ca++ CC 0.203 0.201 0.223 0.304 0.201 0.141 0.060 -0.060 0.055 
  Sig. 0.051 0.054 0.032 0.003 0.053 0.179 0.568 0.568 0.603 
Mg++ CC 0.191 0.174 0.103 0.134 0.097 0.063 -0.052 0.052 -0.079 
  Sig. 0.067 0.096 0.327 0.202 0.354 0.546 0.621 0.621 0.451 
FEV1 CC 0.165 0.186 0.182 0.090 0.179 0.193 -0.038 0.038 -0.066 
 Sig. 0.114 0.074 0.080 0.389 0.086 0.063 0.716 0.716 0.531 
FEV3 CC 0.257 0.283 0.250 0.140 0.238 0.261 -0.076 0.076 -0.047 
 Sig. 0.013 0.006 0.016 0.180 0.022 0.012 0.471 0.471 0.656 
FEV6 CC 0.258 0.284 0.250 0.153 0.234 0.257 -0.069 0.069 -0.020 
 Sig. 0.013 0.006 0.016 0.143 0.024 0.013 0.512 0.512 0.848 
FVC CC 0.264 0.291 0.262 0.161 0.246 0.269 -0.060 0.060 0.008 
 Sig. 0.010 0.005 0.011 0.123 0.018 0.009 0.569 0.569 0.939 
FEV1% CC -0.095 -0.085 -0.065 -0.112 -0.039 -0.041 0.004 -0.004 -0.157 
 Sig. 0.367 0.418 0.536 0.284 0.713 0.694 0.967 0.967 0.132 
FEV3% CC 0.040 0.050 0.019 -0.073 0.044 0.048 -0.085 0.085 -0.240 
 Sig. 0.702 0.634 0.860 0.486 0.673 0.651 0.418 0.418 0.021 
FEV6% CC 0.040 0.050 0.019 -0.073 0.044 0.048 -0.085 0.085 -0.240 
 Sig. 0.702 0.634 0.860 0.486 0.673 0.651 0.418 0.418 0.021 
FEV1/FEV6 CC -0.096 -0.087 -0.059 -0.109 -0.032 -0.035 0.014 -0.014 -0.139 
 Sig. 0.362 0.410 0.576 0.300 0.758 0.739 0.894 0.894 0.183 
PEFR CC 0.081 0.113 0.111 0.050 0.104 0.123 -0.077 0.077 -0.140 
 Sig. 0.442 0.283 0.288 0.632 0.321 0.242 0.463 0.463 0.181 
FEF25% CC -0.003 0.018 0.037 -0.024 0.050 0.054 0.028 -0.028 -0.062 
 Sig. 0.978 0.862 0.726 0.820 0.632 0.608 0.790 0.790 0.554 
FEF50% CC -0.084 -0.075 -0.039 -0.040 -0.034 -0.032 0.056 -0.056 -0.053 
 Sig. 0.425 0.477 0.714 0.707 0.746 0.763 0.594 0.594 0.613 
FEF75% CC -0.059 -0.042 -0.032 -0.041 -0.035 -0.017 -0.008 0.008 -0.081 
 Sig. 0.574 0.689 0.765 0.694 0.740 0.874 0.936 0.936 0.443 
FEF25%-75% CC -0.076 -0.063 -0.035 -0.041 -0.034 -0.025 0.037 -0.037 -0.064 
 Sig. 0.469 0.546 0.737 0.699 0.746 0.814 0.722 0.722 0.543 
FEF75%-85% CC -0.020 0.000 -0.005 -0.028 -0.010 0.013 -0.056 0.056 -0.095 
 Sig. 0.848 0.997 0.965 0.789 0.928 0.901 0.594 0.594 0.367 
ACTScore CC 0.167 0.185 0.188 -0.003 0.193 0.244 -0.182 0.182 -0.048 
 Sig. 0.110 0.076 0.071 0.978 0.064 0.019 0.080 0.080 0.646 
NAEPP Class CC -0.120 -0.140 -0.146 0.020 -0.154 -0.200 0.135 -0.135 0.008 
 Sig. 0.254 0.180 0.162 0.853 0.142 0.055 0.198 0.198 0.938 
Duration CC 0.153 0.167 0.136 0.034 0.117 0.178 -0.234 0.234 -0.173 
 Sig. 0.142 0.109 0.194 0.746 0.263 0.087 0.024 0.024 0.098 
DAS CC -0.134 -0.126 -0.055 -0.039 -0.057 -0.053 0.022 -0.022 -0.093 
 Sig. 0.202 0.228 0.601 0.712 0.590 0.617 0.833 0.833 0.375 
Significant Correlation 
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